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Abstract 
 
Therapeutic antibodies are highly versatile macromolecules that can be engineered to 
bind and inhibit a target with high specificity.  Unfortunately, the cell membrane is 
impenetrable to antibody reagents, thus limiting their use almost entirely to 
extracellular targets.  Expanding the application of therapeutic antibodies to 
intracellular targets is an exciting concept that could have a huge impact on how 
intracellular protein-protein interactions involved in diseases can be modulated.  The 
modification of therapeutic antibodies with Cell Penetrating Peptides (CPPs) can 
enable cellular penetration, however, no general approach to modifying antibodies 
with CPPs has been developed that allows for systematic optimisation of both the in 
vivo and cell penetrating properties. 
In this study, neutralising single-chain variable fragment antibodies (scFvs) have been 
isolated from naïve scFv libraries using antibody phage display that are specific to the 
model intracellular targets Bcl-2 and Bcl-xL.  Lead scFvs showed potent inhibition of 
these proteins in an in vitro assay with IC50 values of <10 nM being calculated, which 
is superior to the small molecule Bcl-2/xL inhibitor ABT-737.  The lead anti-Bcl-xL 
scFv was conjugated to the CPPs octa-arginine, HIV Tat49-57 or Antp52-58.  These 
peptides were synthesised to possess either an N-isobutyryl cysteinyl or N-
maleimidopropionyl moiety and a C-terminal lysine residue, allowing for site-specific 
conjugation to an unpaired cysteine residue introduced to the scFv construct and 
regioselective introduction of 5-carboxyfluorescein to the CPP, respectively.  Live-cell 
confocal microscopy showed that the scFv-octa-arginine conjugate possessed superior 
cell entry capabilities compared to the scFv-Tat49-57 and scFv-Antp52-58 conjugates.  
Further studies using a panel of cancer cell lines are required to determine if the anti-
Bcl-xL scFv-octa-arginine conjugate can induce apoptosis through inhibition of 
cellular Bcl-xL. 
Additonally, a novel approach to controlling the cell penetrating properties of the CPP 
octa-arginine has been developed.  It was demonstrated that carbamate protection of 
octa-arginine¶Vguanidine functionality effectively inhibited its cell entry capabilities.  
Moreover, esterase-labile acyloxymethyl carbonyl (AM) protecting groups were 
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utilised to protect the guanidine functionality of octa-arginine, inhibiting its cell entry 
capabilities.  In a HPLC based assay it was demonstrated that the AM protected octa-
arginine was deprotected by pig liver esterase, suggesting that in vivo deprotection 
could be achieved by serum esterases.  The controlled unmasking of octa-arginine is 
predicted to increase its circulation time and reduce non-specific tissue uptake in vivo, 
potentially making this CPP more suitable for in vivo applications.  
The methodologies utilised for the preparation of scFv-CPP conjugates and developed 
for the controlled unmasking of octa-arginine in this study will allow for optimisation 
of the cell penetrating and in vivo properties of this promising class of macromolecular 
therapeutic, thus providing a gate-way to unlocking the immense potential of 
therapeutic intracellular antibodies. 
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Introduction 
 
Antibodies are extremely versatile molecules that can be engineered to be highly 
specific for a particular target.  These properties have made them one of the most 
successful classes of macromolecular drugs.  Unfortunately, the large size of 
antibodies restricts their application to extracellular targets.  Thus, expanding the 
application of therapeutic antibodies to target intracellular protein-protein interactions 
(PPIs) is undoubtedly an exciting concept.   
The major goal of this project is to obtain insight into how antibodies can be modified 
to possess cell entry capabilities whilst possessing therapeutically suitable in vivo 
properties.  These are two essential criteria for the successful application of 
therapeutic antibodies to target intracellular PPIs.  In this chapter, the different 
approaches currently available for inhibiting intracellular protein interactions will be 
discussed, with particular emphasis on the application of therapeutic antibodies to 
achieve this goal.        
 
1.1 Inhibiting protein-protein interactions 
PPIs are pivotal in almost every biological process, the deregulation or disruption of a 
protein interaction is often the underlying cause in a variety of diseases, including 
many cancers.1  Some well characterised pathways, for example, the intrinsic 
apoptotic pathway and p53-regulated apoptosis are known to be deregulated through 
aberrant protein interactions, resulting in cancer formation.2-3  Viruses also rely on 
protein interactions with host proteins for viral infectivity and replication.4  For 
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example, members of the papillomavirus and herpesvirus family are able to deregulate 
the cell cycle through virus-host protein interactions, which often results in benign 
growths, but can also lead to cancer formation.4  It therefore comes as no surprise that 
PPIs are of huge interest to the medicinal chemist. The inhibition of a PPI can be 
achieved using a range of different molecules, for example, small organic molecules, 
peptides, peptidomimetics and protein therapeutics.   
The surfaces involved in a PPI are generally large (1500-3000 Å2) and hydrophobic in 
nature.5  This makes the design of selective small molecule inhibitors a challenging 
task .  Furthermore, this often means that potent small molecule inhibitors are also 
hydrophobic, which can cause significant solubility and aggregation problems.6  With 
the development of high-throughput screening (HTS), in silico screening and 
molecular modelling, it is now possible to rationally design molecules to selectively 
inhibit a PPI.  Nevertheless, this is still a time consuming and challenging process due 
to the nature of the protein surfaces involved.7  
Two different alternatives to small molecule inhibitors are therapeutic proteins and 
peptides and the exploitation of RNA interference (RNAi).  Both methods work at 
GLIIHUHQWFHOOXODUOHYHOV51$LFDQEHDUWLILFLDOO\LQGXFHGWRVSHFLILFDOO\µNQRFN-RXW¶D
SURWHLQ¶V IXQFWLRQ E\ activating RNA-induced silencing complex (RISC) mediated 
degradation of the target cellular mRNA.8  In contrast, therapeutic macromolecules 
can be used to inhibit a target protein at the post-translational level (Figure 1-1).9 
 
Figure 1-1: The inhibition of a target protein using RNAi, macromolecular therapeutics or small 
molecules.  RNAi using siRNA inhibits a protein¶s function by activating RISC mediated mRNA 
degradation of the target protein mRNA UHVXOWLQJ LQ D FRPSOHWH IXQFWLRQDO µNQRFN-RXW¶  ,Q FRQWUDVW, 
small molecule and macromolecular inhibitors act at the protein level. 
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The inhibition of protein expression using RNAi can be achieved using short-
interfering RNA (siRNA) 8 or short hairpin RNA (shRNA).10  The use of siRNA to 
transiently knockout the expression of a target protein has proven a very effective tool 
in functional genomics.11  Furthermore, siRNA has shown potential as a therapeutic 
entity when administered locally for the treatment of eye and lung diseases.12 
Recently, safety concerns have been raised over the therapeutic application of RNAi 
regarding innate immune responses, and off-target non-specific interactions.13  
Moreover, the major obstacle associated with siRNA is intracellular delivery, due to 
the hydrophilic and anionic nature of RNA making the cell membrane impenetrable.14  
It should be noted that intracellular delivery is also a problem associated with many 
protein based therapeutics.  Extensive research in this area offers promise in 
overcoming some of these problems.   
Macromolecules, such as proteins and peptides can also be used to inhibit intracellular 
targets.  The size and complexity of a macromolecule allows for the design of 
inhibitors that closely resemble the native protein interaction and occupy large areas of 
an active-site.15  Effective inhibitors can be designed by firstly identifying the region 
of a protein that is involved in the interaction of interest, based on this region, it is then 
possible to design highly selective peptides and peptidomimetics.15 
The application of antibodies and other recombinant proteins to target cell surface 
receptors and other extracellular targets has been very successful.16  By either 
µHYROXWLRQDU\¶RUUDWLRQDOPHWKRGVDQWLERGLHVFDQEHHQJLQeered to be highly selective 
for a chosen target.  It is also possible to engineer antibodies that are specific to 
particular protein conformations 17-18 and post-translational modifications.19  Using 
antibody reagents to modulate a PPI would allow for highly specific and transient  
modulation of a target, which is in contrast to the functional knock-out achieved using 
RNAi.9   
However, the non-trivial challenge associated with using antibodies to inhibit an 
intracellular target is intracellular delivery.  The cell membrane is highly regulated and 
effectively impenetrable to large polar molecules, such as proteins and DNA.  Thus, 
the application of therapeutic antibodies is almost exclusively restricted to 
extracellular targets.  The development of effective methods to address such molecules 
to intracellular targets in vitro and in vivo is an area of intense research.   
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1.2 Therapeutic antibodies 
Antibodies are part of the vertebrate immune system and are structurally related 
proteins that bind with high specificity to foreign molecules (antigens) marking them 
for destruction.20 
It is possible to isolate antibodies possessing high selectivity to a particular molecule.  
The simplest approach to achieve this is by immunisation of an animal with the 
molecule of interest invoking an immune response.  Antibodies can then be isolated 
IURPWKHKRVW¶VEORRGSODVPD20  This method allows for the isolation of a mixture of 
antibodies i.e. polyclonal antibodies, which recognise different regions (epitopes) of 
the antigen.20  Polyclonal antibodies are extremely useful for diagnostic purposes, for 
example, in western blotting or HTS.  However, they are limited in their use as 
therapeutic agents because of the inherent variability between immunisation batches 
thus making them difficult to standardise.21  The therapeutic potential of antibodies 
was only realised following the development of technology for the isolation of a single 
antibody species, specific for one epitope, referred to as a monoclonal antibody 
(mAb). 
The versatility and function of an antibody is derived from its molecular structure.  
There are five different classes of antibody isotypes, defined by their heavy chain.  
These are: IgA, IgD, IgE, IgG and IgM, the most abundant isoform in humans being 
the IgG.22 The IgG is composed of two heavy chains (50 kDa) and two light chains (25 
kDa) giving a molecule of 150 kDa.    
In 1959, Porter et al. showed that the digestion of an IgG with the plant protease 
papain resulted in three distinct antibody fragments.23  One fragment is the fragment 
crystalline (Fc) region, which is responsible for the initiation of the complement 
system and antibody-dependant cell-mediated cytotoxicity 24, and the other two 
identical fragments are responsible for antigen binding, referred to as the Fragment 
Antigen Binding (Fab) region.  The Fab region can be further deconstructed into the 
variable domain (Fv domain), which is the minimum required fragment for antigen 
recognition (Figure 1-2).22 
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Figure 1-2:  Antibody structure; the antibody isotype IgG is a 150 kDa protein comprised of constant 
(C) and variable (V) regions.  These regions are divided up into variable heavy (VH), constant heavy 
(CH, CH2 and CH3), variable light (VL) and constant light (CL) chains.  The Fab fragment is composed of 
a constant light (CL), constant heavy (CH), variable (VL) and a variable heavy (VH) chain.  The Fv 
fragment is composed of one VH and VL region are responsible for antigen recognition. 
 
The two heavy chains of an IgG are linked to each other and also to a light chain by 
interdomain disulfide bonds.  The two heavy and light chains are also further divided 
into constant (C) and variable (V) regions.  Each heavy chain is folded to form four 
distinct domains (VH, CH, CH2 and CH3) and the light chain folds to form two domains 
(CL and VL).  The variable regions (VH and VL) are further divided into three hyper-
variable regions, commonly referred to as complementarity determining regions 
(CDRs), which are inter-dispersed with framework regions.  The six CDRs are 
responsible for the antigen specificity of an antibody.22 
 
1.2.1 Antibody Engineering  
In 1975, Kohler and Milstein reported the development of a technique capable of 
producing cell lines that secrete mAbs.25  This technique, referred to as hybridoma 
SS
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technology involves the fusion of immunised spleen cells with mouse myeloma cells, 
resulting in an immortalised cell line secreting antibodies of a defined specificity.25 
Mouse mAbs found limited use as therapeutic agents due to an immunogenic response 
in humans, resulting in human anti-mouse antibodies (HAMA response).26  In an 
attempt to reduce immunogenicity, mouse variable domains were introduced to a 
human constant region to produce a chimaeric antibody.27  A further improvement was 
achieved by grafting mouse CDR regions, selected by hybridoma technology, to an 
antibody variable fragment framework of human origin affording a humanised 
antibody fragment.28 
IQ:LQWHU¶VJURXSGHVFULEHGWKHDSSOLFDWLRQRIILODPHQWRXV0SKDJHIRUWKHin 
vitro presentation and selection of µIXOO\¶human antibodies.29  Antibody libraries of 
naïve or immune origin (ideally containing 109-1011 clones) can be cloned into the 
phage genome next to a phage coat protein gene.  As a result, the antibody is displayed 
on the surface of the phage particle as a fusion with the coat protein.30  This links the 
antibody genotype with the phenotype allowing for the selection and recovery of 
antigen specific antibodies.  Subsequent infection of E. coli amplifies the selected 
phage, generating a new library containing antigen specific antibodies.  Finally, 
screening of enriched libraries can allow for the isolation of human mAbs of high 
affinity and specificity for an antigen.29-31  Subsequently, other in vitro display 
techniques, such as ribosome display and yeast surface display have also proven to be 
effective tools for antibody engineering.32 
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Figure 1-3: In vitro and in vivo selection of antibodies.   
 
The development of in vitro display technologies has made it possible to rapidly 
isolate antibodies of therapeutic potential to almost any target.  Additionally, in vitro 
display allows greater control over selection conditions, such as antigen concentration, 
pH, salt concentration and temperature.32  Alteration of these parameters can allow 
identification of antibodies that are specific to certain antigen conformation, or 
particular epitopes that would not be accessible using in vivo selection.32  The 
selection of antibodies specific to non-immunogenic molecules and post-translational 
protein modifications is also possible.19  
The ease of obtaining the antibody-encoding DNA after in vitro selection has made it 
possible to engineer new recombinant antibody formats with new properties.  The 
most notable modification to an antibody fragment is the engineering of the single 
chain variable fragment (scFv).  The isolated Fv domain is relatively unstable, but can 
be stabilised by linking the VH and VL domains with a 10-15 amino acid polypeptide, 
generally (Gly4-Ser)3.33  This stabilised Fv fragment is commonly referred to as a 
scFv.  
The scFv can be further modified by altering the length of the polypeptide linker.  
Reducing the linker length to approximately five amino acids can result in the two 
domains being too close to pair.  Consequently, the VL and VH domains pair with 
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another scFv to form a dimer, which is often referred to as a diabody.34  Further 
reduction of the polypeptide linker to less than five residues results in the formation of 
triabodies 35 and even tetrabodies 36 (Figure 1-4).   
 
Figure 1-4:  The different antibody formats formed by reducing the polypeptide linker between the VH 
and VL domain.  The smallest is the scFv (~ 28 kDa).  Reduction of the polypeptide linker to 5 amino 
acids results in the formation of a diabody (~ 50 kDa).  Further reduction to < 5 amino acids results in 
triabody (~ 75 kDa) and tetrabody (~ 100 kDa) formation. 
 
These multivalent fragments possess greater avidity for an antigen over the scFv.37  
There has been a wide variety of antibody formats developed, both multivalent and 
multispecific, based on the Fv and Fab domains.  Unfortunately, the detailed 
discussion of the many antibody formats is outside the scope of this chapter (see 
review by Holliger et al. (2005) 38). 
The in vivo distribution of an antibody and fragments thereof vary with size and 
antigen affinity.  For example, the larger IgG and Fab fragments are retained in tumour 
tissue to a greater extent than the smaller fragments.  However, with decreasing 
antibody fragment size the tumour penetration increases and the retention is more 
specific.39  Thus, the intermediate-sized antibody formats, such as diabodies and 
triabodies, possess the most desirable in vivo properties.39-40 
In addition to the different antibody formats, in vitro selection techniques also allow 
for engineering of antibodies that possess significantly greater affinity for an antigen 
than is possible to select using in vivo selection.  This can be achieved by generating a 
new library based on an antibody previously selected against an antigen by 
Diabody
(~ 50 kDa)
scFv
(~ 28 kDa)
Triabody
(~ 75 kDa)
Tetrabody
(~ 100 kDa)
Polypeptide linker
VL
VH
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randomised mutagenesis of the CDR regions.  From this synthetic library it is then 
possible to select new scFv with higher affinity for the antigen.  Using this approach, 
antibodies with affinities in the pM range have been developed.41  Notably, Boder et 
al. (2000) reported the selection of an anti-fluorescein scFv with a Kd of 48 fM.42  This 
was achieved by screening a synthetic scFv yeast surface display library of 105-107 
scFv based on an anti-fluorescein scFv with a Kd of  310 pM.42  
The unique molecular structure and the techniques available for the isolation and 
engineering of antibodies make them extremely versatile molecules.  In vitro selection 
makes it possible to isolate antibodies with the desired specificity within weeks.30  
Additionally, further modifications can afford antibodies of remarkable affinity with 
properties tailored for the specific application.  Consequently, expanding the 
application of antibodies to intracellular targets is unsurprisingly of huge interest. 
 
1.3 Targeting intracellular protein-protein interactions 
with antibodies  
The plasma membrane of a eukaryotic cell tightly regulates the influx and efflux of 
bioactive molecules. Large hydrophobic molecules are unable to efficiently enter cells 
through passive diffusion, thus requiring alternative means of entry.  For this reason, 
antibodies that are specific for intracellular antigens require delivery across the cell 
membrane. 
There are two distinct approaches to address antibodies to intracellular targets.  One 
method is the intracellular delivery of DNA encoding for an antibody fragment, 
IROORZHGE\SURWHLQH[SUHVVLRQXVLQJWKHKRVW¶VFHOOXODUPDFKLQHU\43  The alternative 
approach is the delivery of an antibody fragment across the cell membrane and into the 
cytoplasm using delivery vectors.43  Figure 1-5 illustrates the different approaches for 
the cytoplasmic delivery of an antibody reagent.      
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Figure 1-5: The different approaches to target antibody fragments to intracellular compartments.  There 
are two distinct methods, one is the delivery of DNA encoding for an antibody fragment into the cell.  
Once inside the cell, the DNA is transcribed and translated by the cellular machinery either in the 
cytoplasm or in the endoplasmic reticulum.  The second approach is by intracellular delivery of an 
antibody molecule to the cytoplasm either via direct cellular penetration or endocytosis, of which the 
former often results in entrapment in cellular vesicles.  This can be achieved by using delivery vectors 
such as, Cell Penetrating Peptides (CPPs), cationic polymers or by receptor-mediated endocytosis. 
 
 
Intracellularly expressed recombinant antibody molecules are often referred to as 
µ,ntrabodies¶whereas an intracellularly delivered antibody molecule is referred to as a 
µ7UDQVERG\¶43   The aim of both approaches is to efficiently target an antibody 
molecule to the correct cellular compartment for binding to the target antigen.   
Many interesting therapeutic targets for intracellular antibodies are located in the 
cytoplasm.  However, antibody internalisation mediated by delivery vectors such as, 
cell penetrating peptides (CPPs), cationic polymers or by receptor-mediated 
endocytosis often result in entrapment of the antibody molecule in the endosomal 
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compartment.74  The antibody molecule is then destined for degradation in the 
lysosome unless it is released into the cytoplasm by rupturing of the endosome.   
Antibody fragments targeted to the cytoplasm via gene delivery are presented by 
equally challenging obstacles such as, protein expression levels and correct folding in 
the reducing cytoplasmic environment.43  Without correct folding the antibody 
fragment is unlikely to bind the target antigen. 
Methods for addressing antibody reagents to intracellular compartments employing the 
intrabody and transbody approaches, together with techniques to overcome some of 
the many obsticales involved with these approaches are discussed in more detail 
below.  
 
1.3.1 Intrabodies 
In 1988, Carlson and co-workers reported the first example of an intrabody by 
expressing an antibody specific for alcohol dehydrogenase I (ADH I) in 
Saccharomyces cerevisiae.  This approach successfully inhibited ADH I activity.44  
Marasco et al. (1993) were the first to utilise intrabodies in mammalian cells by 
expressing a monoclonal antibody specific for the CD4 binding region of the human 
immunodeficiency virus type 1 (HIV-1) envelope protein in the endoplasmic reticulum 
of COS cells.45  Research has since continued to explore intrabodies for both 
therapeutic and diagnostic application. 
Although the concept of intrabodies seems simple, there are many challenges 
presented by the cellular barriers and the reducing intracellular milieu.  Many 
antibodies rely on intrachain disulfide bond for correct folding and activity.46  
Intrabodies that are targeted to the endoplasmic reticulum have the benefit of 
molecular chaperones and a favourable redox environment for correct folding.47  
However, cytosolic intrabodies offer the greatest potential for the inhibition of 
intracellular PPIs.  Unfortunately, the reducing cellular environment can cause 
antibody insolubility, instability and folding issues.47   
Recent studies have focused on engineering antibody fragments so that intrachain 
disulfides are not required for correct folding.48  Intracellular selection techniques have 
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also been developed that allow identification of scFv that can fold correctly in the 
reducing cellular environment.  The most notably example of this approach is 
Intracellular Antibody Capture Technology (IACT).49  This method is based on the 
yeast-two hybrid system and allows for selection based on successful scFv expression, 
folding and antigen binding in the intracellular environment of yeast.  The successful 
formation of the scFv/antigen complex results in the activation of a reporter gene and 
subsequent identification of the functional scFv.49-50  
IACT has proven effective in identifying intrabodies when used as a secondary 
screening technique for scFv libraries selected using antibody phage display.50  Further 
development of IACT focussed on screening naïve single domain antibody (Dab) 
libraries.  Unfortunately, this was limited by the low transformation efficiency of 
yeast, hence only small library sizes could be accessed.51  Third generation IACT 
(ICA3) circumvents this problem by repeated cycles of library screening and CDR 
randomisation to generate new sub-libraries.52  Thus, ICA3 may prove to be a powerful 
tool for the selection of high affinity functional intrabodies. 
Another recent development in the area of intrabodies is the design of an intrabody 
phage display library.  Philibert et al. (2007) created a scFv library based on a scFv 
scaffold developed for cytoplasmic expression.53  Using this library they were able to 
isolate scFv specific for the papilloma virus protein E6.  Impressively, these scFvs 
were expressed in the cytoplasm of E. coli in yields of ~0.5 g/L.  The transfection of 
HeLa cells with an expression plasmid containing the scFv-GFP construct afforded 
soluble expression of the scFv-GFP fusion in the cytoplasm of HeLa cells.53  This 
approach holds great promise for the selection and application of functional scFvs able 
to inhibit intracellular PPIs.  
However, even with an antibody that is intracellularly stable, the significant challenge 
of efficiently and specifically delivering recombinant DNA to target cells in vivo still 
remains.  There have been a variety of non-viral and viral based DNA delivery 
systems described.54 Unfortunately, many of the current non-viral vectors are 
relatively inefficient at delivering DNA to target cells and in several clinical studies 
viral vectors have been reported to induce immune responses and have been linked to 
the development of a leukaemia-like syndrome. 55-57 
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1.3.2 Transbodies 
A possible solution to the stability and delivery problems associated with intrabodies 
is the intracellular delivery of antibody fragments.  Heng et al. (2005) coined the 
SKUDVH µ7UDQVERGLHV¶ IRU DQ DQWLERG\ WKDW is modified to enable cellular 
internalisation.43 
Transbodies are expressed and purified using standard protein expression systems, 
such as Escherichia coli (E. coli) allowing for correct folding and characterisation of 
the protein before administration.  Furthermore, the intradomain disulfide bonds in the 
folded VH and VL domains of the Fv domain provide stability and are often essential 
for antigen-binding 46, once folded these disulfide bonds are buried and unsolvated 
making them relatively stable to reducing agents.58  This circumvents the protein 
stability and folding problems that are associated with intrabodies.43 
The major benefit of transbodies is that no genetic modification to the target cells is 
required, avoiding the problems associated with gene delivery.  Additionally, 
transbodies would possess a limited half-life, unlike gene therapy.  The major obstacle 
however, is the intracellular delivery of antibodies.    
Recently, receptor-mediated delivery of an antibody fragment has been demonstrated.  
Rizk et al. (2009) described the cellular internalisation of an anti-actin Fab fragment 
mediated by the neurokinin-1 receptor (NK1R).  This receptor is not only 
overexpressed in some aggressive brain tumours, but also breast and colon 
carcinomas.59  An unpaired cysteine residue introduced to the Fab fragment allowed 
for the conjugation of the NK1R ligand substance P 1 by a thioether bond.  The 
conjugated Fab was internalised by cells expressing the NK1R receptor, subsequently 
enabling the Fab to bind to actin.60 
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Although, receptor-mediated endocytosis shows great potential for the intracellular 
delivery of macromolecules it is limited to cells that overexpress a particular receptor.  
The amount of protein delivered into the cell is also limited by the number of receptors 
available. 
An alternative and extensively investigated method for intracellular delivery of 
macromolecules is RIIHUHGE\DFODVVRISHSWLGHRIWHQUHIHUUHGWRDVµ&HOO3HQHWUDWLQJ
3HSWLGHV¶ &33V  7KH XVH RI &33V KDV VKRZed great promise for the delivery of 
macromolecules, including antibody reagents into cells.  By conjugation of a CPP to a 
protein or the expression of a CPP fusion protein, it is possible to internalise a protein 
that otherwise would not be able to traverse the cellular membrane.61  Table 1-1 shows 
a selection of studies that have reported the successful intracellular delivery of 
antibody fragments using CPPs. 
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Table 1-1: Examples of Transbodies  
Antibody-CPP 
construct CPP sequence Description Reference 
scFv-Tat44-57 
conjugate CGISYGRKKRRQRRR 
In vivo study.  Anti-ED-B 
scFv ± a marker for tumour 
neovasculature. 
Niesner et al. (2002) 62 
scFv-Tat47-57 
fusion YGRKKRRQRRR 
In vitro study. Intracellular 
delivery of anti-Bcl-2 scFv.  
The inhibition of Bcl-2 
induces apoptosis in cancer 
cell lines relying on Bcl-2 
overexpression for survival.   
Cohen-Saidon et al. 
(2003) 63 
scFv-Tat47-57 
fusion YGRKKRRQRRR 
Anti-morphine scFv. 
In vivo study assessing the 
delivery of scFv-Tat across 
blood brain barrier 
Nakajima et al. (2004) 64 
scFv-Antp41-58 
fusion FlRQIKIWFQNRRMKWKK 
Intracellular delivery of an 
anti-myc scFv ± mutated c-
myc is implicit in some 
cancers.  Inhibition induces 
apoptosis in some cell lines. 
Avignolo et al. (2008) 65 
scFv-Antp43-58 
fusion QIKIWFQNRRMKWKK 
In vitro study. scFv specific 
for Matrix Protein (M1) of 
Influenza A 
Poungpair et al. (2010) 66 
scFv-MTS fusion KGEGAAVLLPVLLAAPG 
In vitro study. Anti-Akt 
kinase scFv ± Akt is 
involved in cell survival and 
proliferation 
Shin et al. (2005) 67 
scFv-MTS 
conjugate KGEGAAVLLPVLLAAPG 
In vitro study. anti-Ricin A-
chain scFv ± intracellular 
delivery neutralised the 
ricin toxin   
Wu et al. (2010) 68 
Fab-Tat48-60 ,  
HIV-1 REV34-50 
and Antp43-58 
conjugate 
HIV-1 Rev34-50: 
RQARRNRRRRWRERQR 
 
Non-specific Fab ± in vivo 
study comparing the 
biodistribution of Fab-CPP 
fragments in rats 
Kamayama et al. (2006)69 
)DE¶2-Tat37-72 
conjugate 
37CFITKALGISYGRKKRRQ- 
RRRPPQGSQTHQVSLSKQ72 
In vitro study. Anti-Tetanus 
toxin antibody fragment, 
intracellular delivery 
neutralising the toxin in 
chromaffin cells. 
Stein et al. (1999) 70 
IgG-Polyarginine 
conjugate R68 
In vitro study. Anti-cyclin 
D mAb.  Intracellular 
delivery inhibited cell cycle 
progression 
Chen et al. (2006) 71 
IgG-Tat44-60 
conjugate GRKKRRQRRRPPQGYG 
In vitro and in vivo study.  
Radio- labelled anti-
p21WAF/CIP-2 mAb labelled 
with Tat.  Intracellular 
delivery inhibited G1-S 
phase cell cycle arrest by 
EGF 
Hu et al. (2007) 72 
 
Table 1-1 shows some promising examples of transbodies, antibodies have been 
delivered into a number of cell lines using CPPs for a variety of different targets.  For 
example, an anti-WHWDQXV WR[LQ )DE¶2 fragment was successfully delivered into 
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chromaffin cells neutralising the toxin.70  There are also examples of transbodies being 
used to inhibit protein interactions implicated in cancer formation.  The anti-apoptotic 
protein Bcl-2 that is overexpressed in a number of cancer cells was successfully 
inhibited using a neutralising anti-Bcl-2 scFv Tat fusion protein.63 
However, there are still relatively few examples of antibodies being used for 
intracellular targets.  Additionally, the reported use of transbodies is largely focused 
on in vitro delivery, with very few studies utilising transbodies in vivo.  Unfortunately, 
the current examples of transbodies, in general, apply different approaches to achieve 
intracellular delivery, making it difficult to determine the specific requirement for 
effective intracellular delivery of an antibody reagent.  There are a large number of 
variables that should be considered when designing a transbody, such as the size of the 
antibody fragment, the CPP and the nature of the antibody construct (i.e. fusion 
protein or conjugate).70,73  Thus, a general and systematic approach for the 
construction and application of transbodies is required.74   
 
1.4 Cell penetrating peptides  
The discovery and subsequent application of the many CPPs was sparked by two 
major discoveries.  The first was in 1988 when Frankel et al. (1988) reported that the 
protein HIV transactivator of transcription (Tat) was able to directly penetrate cells, 
activating its target gene involved in HIV infectivity.75  In a later study, Joliot et al. 
(1991) demonstrated that the 60 amino acid homeodomain of the Antennapedia 
protein of Drosophila was also able to translocate across cell membranes.76  Detailed 
studies into these two proteins resulted in the discovery of the minimum peptide 
sequences responsible for cell penetration, referred to as Tat 77 and Penetratin$QWS-
UHVSHFWLYHO\ 
However, the most significant finding was the ability of these peptides to internalise 
an attached cargo that otherwise was unable to penetrate cells.61  Peptides possessing 
these properties are now commonly referred to as CPPs.  This led to extensive 
research focusing on the potential applications of CPPs and other peptides that may 
possess similar properties. 
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To date, there are >100 reported peptides with cell penetrating capabilities.80  Almost 
all CPPs are cationic, adopt amphipathic structures and are rich in lysine and arginine 
residues.81  CPPs are usually <30 amino acids and possess a net positive charge at 
physiological pH.82 
CPPs can be divided into three groups based on the primary structure, these are 
primary amphipathic (paCPPs), secondary amphipathic (saCPPs) and non-amphipathic 
(naCPPs).83  A selection of CPPs is shown in Table 1-2. 
 
Table 1-2: A selection of cell penetrating peptides  
 
# Name* Amino acid sequence Reference 
 
paCPPs 
  
2 Transportan GWTLNSAGYLLGKINLKALAALAKKIL Pooga et al. (1998) 84 
3 Pep-1 KETWWETWWTEWSQPKKKRKV Morris et al. (2001) 85 
4 MPG GALFLGFLGAAGSTMGAWSQPKSKRKV Morris et al. (1999) 86 
 
   
 
saCPPs 
  
5 Antp43-58 RQIKIWFQNRRMKWKK Derossi et al. (1996) 79 
6 KLAL KLALKLALKALKAALKLA Oehlke et al. (1998) 87 
7 pVEC LLIILRRRIRKQAHAHSK Elmquist et al. (2001) 88 
 
   
 
naCPPs 
  
8 Octa-Arginine  RRRRRRRR Wender et al. (2000) 89 
9 HIV Tat47-57 YGRKKRRQRRR Vives et al. (1994) 77 
10 HIV Tat49-57 RKKRRQRRR Vives et al. (1997) 90 
*Divided into groups based on primary structure; primary amphipathic (paCPPs), secondary 
amphipathic (saCPPs) and non-amphipathic (naCPPs). 
 
The paCPPs are generally >20 amino acids and are composed of sequential 
hydrophobic and hydrophilic amino acids.82  Peptide internalisation occurs by both 
endocytosis and direct translocation across the membrane.83  
The saCPPs are commonly used for the delivery of proteins and are generally shorter 
than the paCPPs.  Again, these peptides possess amphipathicity but are predicted to 
only form this secondary structure when interacting with the phospholipid bilayer.91  
The naCPPs are generally the shortest CPPs and are able to penetrate cells solely 
based on their cationic features.92-93 
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Amphipathicity is an important property of peptides that possess cell penetrating 
capabilities. Amphipathicity is often presented in Į-helical or ȕ-structures by spatial 
separation of hydrophobic and hydrophilic amino acid residues for example 
tryptophan and arginine, respectively.82  The strong amphipathicity of phospholipid 
membranes explains this important requirement of CPPs to favourably interact with 
cell membranes.81  Several mechanisms have been described such as the pore 
formation, inverted micelle and carpet-like models.81-82  Common to all of these 
models is the requirement for amphipathicity, which allows for the interaction of the 
hydrophobic residues of a peptide with the lipid components of a membrane and the 
hydrophilic residues with the charged components.81-82  This interaction may then 
disrupt the integrity of the membrane allowing for the peptide to directly penetrate into 
the cell in an energy independent process. 
There have been a number of examples of peptides that internalise into cells but 
possess properties different to the majority of CPPs.  A recent example is the non-
cationic peptide p18 (50LSTAADMQGVVTDGMASG67) 11.  This peptide is derived 
from the protein Azurin.94  Similarly, Crespo et al. (2003) reported that the non-
cationic peptide FAM-(Pro)14-OH 12 was able to internalise into cells.95  
Unfortunately, there are no further examples of these two peptides being used as 
CPPs.  The use of a non-cationic CPP could potentially avoid some of the problems 
associated with using a polycationic peptide in vivo.  Further studies into these two 
peptides may shed light on their ability to deliver attached cargo into cells. In 
complete contrast to the cationic CPPs, Martin et al. (2011) recently reported the 
design of an anionic CPP called  SAP(E) (VELPPP)3  13.96  This peptide showed 
internalisation into a number of cell lines, however, with less efficiency than Tat and 
Antp.96  Nonetheless, this peptide still offers an interesting alternative to the cationic 
CPPs. 
An alternative to using peptides for intracellular delivery is the use of small molecule 
mimics of CPPs.  Okuyama et al. (2007) describe the use of a biphenyl scaffold for the 
display of guanidine moieties in an attempt to mimic the cationic Į-helix of many 
&33V7KLVPROHFXOHZDVQDPHGµVPDOO-PROHFXOHFDUULHU¶60R&14.97 
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The SMoC 14 when conjugated to the 25 kDa protein geminin enabled the 
internalisation of the protein into a variety of cell lines.  SMoCs offer a simple and 
protease resistant alternative to CPPs.97-98  However, a study comparing the efficiency 
of SMoCs with commonly used CPPs, together with the use of different sized cargos 
has yet to be reported. 
 
1.4.1 Mechanism of CPP internalisation  
Many early studies using fixed cells demonstrate CPP internalisation at 4 qC 
suggesting internalisation via an energy independent route.79,90,93  However, Richard et 
al. (2003) suggested that fixing cells actually perturbs the cell membrane resulting in 
artifactual results and overestimation of peptide internalisation.99  More recent studies 
using live cells show minimal, if any, uptake at 4 qC but uptake principally at 37 qC.99  
Confocal microscopy of live cells treated with a fluorescently labelled CPP often 
shows localisation of the peptide in cellular vesicles, suggesting an energy dependant 
route is taken.99-100 
Additionally, internalisation of cationic peptides such as Tat and polyarginine appears 
to be dependent on interactions with anionic cell surface proteoglycans such as 
heparan sulfate proteoglycans (HSPG).  The electrostatic interaction of arginine and 
lysine residues with HSPG draws the CPP into close proximity to the cell 
membrane.101  This interaction may then promote signalling cascades leading to 
activation of the protein Rac, which then promotes F-actin reorganisation, an essential 
step in lamellipodia formation and macropinocytosis.102-103 
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Endocytic uptake of CPPs is now generally accepted as the primary mechanism for 
CPP internalisation.  However, the exact route is still unclear and it is likely that a 
variety of endocytic pathways are used by CPPs, for example, caveolae mediated 
clathrin mediated endocytosis, clathrin and caveolin independent endocytosis and 
macropinocytosis.104-106 Additionally, there are some examples of arginine rich 
peptides internalising via energy independent routes using live cells.107  Overall, the 
exact mechanism of internalisation is likely to be dependent on cell type, CPP 
concentration, the CPP properties and the attached cargo.108,101 
In support of the endocytic uptake mechanism is the entrapment of CPPs and the 
attached cargo in cellular vesicles.  Tünnemann et al. (2006) showed that the 
destination of Tat was dependant on the size of the attached cargo.  Small cargo (<50 
amino acids), were able to escape the endosomes and localise in the cytoplasm.  
However, with increasing size (>50 amino acids) the amount of cargo in the 
endosomes increased.73   
Importantly, many biologically active molecules require delivery to the cytosolic 
compartment for activity.  Direct penetration of amphipathic peptides by disruption of 
the phospholipid membrane leads to the delivery of an attached cargo directly to the 
cytosol.82  However, endocytic uptake involves encapsulation of the CPP and attached 
cargo in cellular vesicles.99  Initially after internalisation the CPP will be contained in 
the early endosomes.74  Unless the endosome is disrupted, allowing for release of the 
contents into the cytoplasm, the CPP and cargo are destined for the late endosomes 
and eventually lysosomes where degradation will occur.74   
There have been a number of peptides and polymers that have been demonstrated to 
display endosomolytic properties. Table 1-3 shows a selection of molecules that 
display endosomolytic properties. 
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Table 1-3: A selection of endosomolytic agents 
 
# Endosomolytic agents Reference 
 
  
 
Polymer based 
 
15 poly(propylacrylic acid) Cheung et al. (2001)109 
16 poly(acrylic acid) Philippova et al. (1997)110 
17 poly(ethyleneimine) Alexis et al. (2006) 17 
 
  
 
Peptide based 
 
18 HA2; GLFGAIAGFIEGGWTGNIDGWYG Wadia et al. (2004)111 
19 H5WYG; GLFHAIAHFIHGGWHGLIGGWGYG Pichon et al. (2001) 112 
20 10HIS; HHHHHHHHHH Lo et al. (2008) 113 
21 43E; LAELLAELLAEL Ohmori et al. (1997) 114 
   
Many of the peptide based endosomolytic agents mimic the mechanisms used by 
viruses to escape the endosomes.  Indeed, HA2 18 and H5WYG 19 are derived from 
the influenza virus.111-112  These virus derived peptides change conformation in the 
low pH of the endosome to form a hydrophobic, amphipathic Į-helix.  The peptide 
then inserts into the membrane disrupting the endosome,  ultimately leading to the 
release of the contents into the cytoplasm.115  Alternatively, the histidine rich peptides 
and endosomolytic polymers disrupt the HQGRVRPH PHPEUDQH E\ D µSURWRQ VSRQJH¶
effect.113  Once in the acidic environment of the endosome, the secondary and tertiary 
amines of the endosomolytic agent are protonated.  This results in an influx of chloride 
ions, increasing the ionic concentration, and leading to osmotic swelling and rupturing 
of the endosomes.116   
A number of the endosomolytic peptides have been used to increase the cytoplasmic 
delivery of HIV Tat-protein conjugates and DNA/Tat complexes.  For example, Wadia 
et al. (2004) demonstrated that co-treatment of a fibroblast cell line with a Tat49-57-
HA2 fusion peptide and a Tat-Cre fusion protein significantly enhanced endosomal 
release of the Tat-Cre compared to when the Tat-Cre was used alone.111  Similarly, Lo 
et al. (2008) demonstrated that a Tat49-57-10His/DNA complex displayed 
approximately 7000 fold greater DNA transfection efficiency compared to a Tat49-
57/DNA complex, this is presumably a result of increased release of the DNA from 
cellular vesicles.113  
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The nature of the CPP-cargo linkage also appears to be influential on the intracellular 
delivery and cellular localisation of the cargo.  Several studies have suggested that the 
biological effect of CPP-cargo conjugates is enhanced by the use of a reversible 
linkage.  For example, Stein et al. (1999) showed that an anti-WHWDQXV WR[LQ )DE¶2 
conjugated to Tat37-72 via a disulfide bond neutralised the toxin in chromaffin cells to a 
greatHUH[WHQWWKDQWKHWKLRHWKHUOLQNHG)DE¶2-Tat conjugate.70  Similarly, Chen et al. 
(2001) demonstrated that the İPKC inhibitor ȥİRACK reversibly conjugated to R7 via 
a disulfide linkage significantly reduced ischemia-induced cell damage, whereas the 
thioether linked ȥİRACK-R7 conjugate had no significant effect.117  These reports 
suggest that intracellular release of the CPP is important for the desired activity of the 
cargo, presumably to reduce interference of the CPP with the cargo or altering its co-
localisation within the cell.118  However, there are also many examples of non-
reversible CPP-protein conjugates being successful used to induce biological 
responses, thus the influence of the CPP-cargo linkage is possibly cargo and CPP 
dependent.  
Understanding the processes of CPP internalisation is important for the effective 
application of CPPs for the intracellular delivery of macromolecules.  The choice of 
CPP, application of endosomolytic peptides, and the nature of the CPP-cargo 
conjugation are all important factors that should be considered to ensure that a CPP-
cargo conjugate induce the desired biological effect.  
  
1.4.2 The application of CPPs in vivo 
A number of in vivo pharmacological studies using diseased mouse models show 
promise for CPP mediated delivery of therapeutic cargo.  However, there are few 
studies that address the pharmacokinetics (PK), ADME (absorption, distribution, 
metabolism and elimination) and the safety of CPPs, thus making it difficult to assess 
the therapeutic potential of protein-CPP conjugates.  
The study by Lee et al. (2001) is one of a few that address the PK properties of a 
protein-CPP conjugate.119  In this study, a radiolabeled Tat48-58-biotin/streptavidin 
(SA) complex was intravenously (i.v.) administered to rats.  The percentage injected 
dose per gram of target tissue (% ID/g) calculated for the Tat48-58-biotin/SA complex 
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suggested a modest increase in uptake of SA  by the brain, liver, kidney, heart and 
lung relative to the native SA .  Additionally, the authors reported that the Tat48-58-
biotin/SA complex possessed increased membrane permeability compared to the 
native SA.  This resulted in rapid blood clearance, thus having a negative effect on 
%ID/g and suggesting uptake by peripheral tissues.119  
A few studies have also addressed the tissue distribution of protein-CPP conjugates, 
giving further insight into the effect of CPP conjugation on the in vivo properties of an 
attached protein.  One example by Schwarze et al. (1999) reported widespread tissue 
GLVWULEXWLRQ LQ PLFH RI D  N'D ȕ-galactosidase-Tat47-57 fusion protein.120  
Interestingly, enzyme activity was observed in brain tissue suggesting transport across 
the blood-brain barrier.  However, a study by Kameyama et al. (2006) showed less 
widespread distribution of a 125I labelled Fab fragment (polyclonal Fab mixture) 
conjugated with Tat48-60, HIV-1 Rev34-50 or Antp43-58.  This study showed that tissue 
distribution may also be dependent on the CPP used.  For example, the highest levels 
of radioactivity for the 125I labelled Fab-Tat48-60 conjugate were observed in the liver 
and spleen, whereas for Fab-Antp43-58 and Fab-HIV-1 Rev34-50 conjugates this was in 
the liver, spleen and adrenal gland.  For the unconjugated 125I labelled Fab, 
radioactivity was seen in the thyroid gland, gastrointestinal contents, renal cortex and 
skin.69 
Niesner et al. (2002), using a mouse tumour model, observed lower tumour retention 
of an scFv specific for the ED-B domain of fibronectin conjugated  to Tat44-57, 
compared to the unconjugated scFv.  However, increased retention in the liver, spleen 
and kidney was observed.62  |Fibronectin is overexpressed and present in higher 
quantities in the extracellular matrix associated with tumour vasculature, 121  therefore 
the decrease in tumour retention of the scFv upon Tat44-57 conjugation is presumably a 
result of faster blood clearance and non-specific tissue uptake of the conjugate. 
The findings of the aforementioned studies were recently supported by Sarko et al. 
(2010).  In this study, the biodistribution in mice of 10 different 111In or 68Ga 
radiolabelled CPPs was determined.  The authors reported rapid clearance from 
circulation (four hours after injection, <1% ID/g was in circulation) and non-specific 
uptake into almost all organs.122 
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The non-specific tissue uptake of CPP conjugates may explain why relatively large 
doses (mg/kg) are required to obtain a biological response.  These high doses may 
result in toxicity issues caused by the CPP.119  For example, the CPP octa-arginine has 
been shown to be a potent inhibitor of the proteasome and the enzyme Furin.123-124  A 
number of other CPPs, such as Antp and Tat have also shown cellular toxicity at high 
doses.125-127  Thus, a high dose coupled with the non-specific tissue uptake of a CPP 
FRXOGLQFUHDVHµRII-WDUJHW¶ELRORJLFDOHIIHFWV 
Local delivery may overcome some of the problems associated with CPPs in vivo.  
This was illustrated by Rothbard et al. (2000) reporting that topical administration of 
cyclosporine-polyarginine (R7) significantly reduced skin inflammation in a mouse 
model of dermatitis.128  Notably, Chen et al.  GHYHORSHG DQ HIIHFWLYH 3.&į
inhibitor for the treatment of ischemia/reperfusion injury by conjugation of the cell 
LPSHUPHDEOH3.&įSHSWLGHLQKLELWRUįV1-1 to Tat47-57 22.129 
 
 
Figure 1-6: The cell permeable 3.&įSHSWLGHLQKLELWRUįV1-1-Tat47-57 conjugate 22.  
 
 
Several studies have demonstrated that 22 reduces cardiac damage in a porcine model 
of acute myocardial infarction (AMI) after intracoronary injection.130-131  Furthermore, 
22 is currently in phase II clinical trials to assesses its safety and efficacy for the 
reduction of infarct size in AMI patients.132-133 
Further in vivo tissue distribution, PK and toxicity studies will provide greater 
understanding of the PK and clearance mechanisms of protein-CPP conjugates.  PK 
studies investigating the effect of CPP conjugation to antibody fragments will also 
provide insight into the therapeutic potential of transbodies and on how CPPs may be 
modified to optimise PK properties of an antibody-CPP conjugate. 
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1.4.3 Modulation of CPP in vivo properties 
Recently, several approaches have been reported to reduce the non-specific uptake of 
CPPs by targeted delivery or targeted activation of CPP internalisation.  A number of 
interesting examples are discussed in this section. 
Tan et al. (2006) described the targeted delivery of Tat47-58 to breast cancer cells 
overexpressing the receptor ErbB2.  This was achieved by conjugation of an anti-
ErbB2 peptide to the C-terminus of Tat47-58 to afford the chimeric peptide 23.  This 
peptide showed greater uptake into cells overexpressing ErbB2 than cell expressing 
lower levels both in vitro and in vivo.134  Myrberg et al. (2008) describe a similar 
approach using a tumour-homing peptide that was identified from a phage display 
library.135  7KLVµWXPRXU-KRPLQJ¶&3324 was composed of the CPP p-VEC, linked to 
a cyclic tumour specific peptide.  This peptide showed in vivo tumour-homing 
properties and greater uptake into breast tumours than pVEC alone.  This group later 
published another breast tumour-homing CPP 25, which consists of a linear tumour 
targeting peptide conjugated to pVEC.136 
 
 
 
 
Figure 1-7: ([DPSOHVRIFKLPHULFµtumour-homing¶ cell penetrating peptides 
 
The targeting of CPPs to specific tissues is a promising approach, however this may 
not significantly reduce non-specific tissue uptake due to the cationic charge of the 
CPP.  In the context of the tissue targeting approach, an alternative is the targeted 
activation of a CPP.  
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Recently, Zhang et al. (2011) described the design and synthesis of an acid-activated 
CPP based on the CPP Transportan-10 26.137  This was achieved by replacing the 
lysine residues contained in Transportan-10 with histidine residues to afford the 
peptide TH 27.  At pH 7.4, TH 27 is uncharged and unable to internalise into cells.  
However, in a slightly acidic environment (pH <6.5) the imidazole side chains of the 
histidine residues are protonated resulting in a net positive charge allowing for peptide 
internalisation.  This acid-activated CPP may preferentially enter cancer cells in the 
acidic environment of a hypoxic tumour. 
  
 
 
 
In 2003, the Tsein group described an elegant approach to targeting CPP activation 
with a PRGLILHG&33UHIHUUHGWRDVDQµ$FWLYDWDEOH&HOO3HQHWUDWLQJ3HSWLGH¶$&33
28.138  This peptide consisted of a fluorescein labelled nona-arginine connected via a 
cleavable linker to nona-glutamate.  This formed a peptide hairpin that was unable to 
internalise into cells, the nona-arginine was then released from the hairpin upon 
cleavage of the linker by a protease.  After separation of the cleaved peptide, the nona-
arginine was able to internalise into cells (Figure 1-8). 
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Figure 1-8: The activatable CPP (ACPP) 28 consists of nona-arginine linked to nona-glutamine via a 
proteolytic linker cleavable by the proteases MMP-2.  In the uncleaved ACP is unable to penetrate cells.  
The peptide is cleaved by matrix metalloproteinases-2 (MMP-2), which is over-expressed by several 
types of cancer cells.  Cleavage results in the dissociation of the nona-glutamine peptide 30 from the 
nona-arginine 29, thus allowing the nona-arginine 29 to internalise into the cancer cell. 
 
 
The anionic and cationic peptides of ACPP 28 were linked together with the 
recognition sequence for matrix metalloproteinases-2 (MMP-2), an enzyme which is 
overexpressed by a variety of tumours and plays an important part in tumour invasion 
and metastasis.139  Using a mouse xenograft model, the ACPP was shown to localise in 
a MMP-2 positive tumour to a greater extent than an ACPP containing a scrambled 
linker.138  Additionally, Aguilera et al. (2009) demonstrated that i.v. injection of nona-
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arginine in healthy mice resulted in localisation primarily around the injection site, 
which eventually re-distributed to the liver.  In contrast, the ACPP was distributed 
uniformly in all tissues.140  However, a recent study using a dual isotope labelled 
MMP-2 cleavable ACPP, allowing for discrimination between the uncleaved and 
cleaved peptide after i.v. administration in mice, demonstrated that activation of the 
ACPP was tumour-independent.  The authors also suggested that tumour uptake of the 
ACPP is not a result of tumour specific activation but an effect of the increased 
SHUPHDELOLW\DQGWLVVXHUHWHQWLRQRIWKHDFWLYDWHG&33DQGWKHµOHDN\¶YDVFXODWXUHRID
tumour.141 
Another interesting approach for the targeted activation of CPP intracellular delivery 
is based on tissue targeting using antibodies.  In 2001, Liang et al. described a prodrug 
system for tissue specific delivery.142  7KLV GHOLYHU\ V\VWHP FDOOHG µ$77(0376¶
(antibody targeted, [protamine] triggered, electrically modified pro-drug strategy) 
involves a tissue targeting component conjugated to heparin, for example a tissue 
specific antibody-heparin conjugate, and a drug component modified with a cationic 
peptide.  The two components form an antibody-heparin/drug-peptide conjugate.142-143  
This approach was successfully utilised for the site-specific delivery of plasminogen 
activators (tPA) by using an anti-¿EULQ,J*WRWDUJHWEORRGFORWV8SRQDGPLQLVWUDWLRQ
of protamine, an FDA approved antidote for heparin, the tPA was released from the 
complex by protamine displacing the cationic peptide to form a protamine/heparin 
complex.  Interestingly, Kwon et al. (2008) applied the core principle of ATTEMPTS 
to Tat mediated intracellular delivery of macromolecules.144  The authors 
demonstrated that Tat mediated internalisation of the enzyme Asparaginase (E.C. 
3.5.1.1, ASNase) could be inhibited by forming an ASNase-Tat/heparin complex.  The 
addition of protamine then released the ASNase-Tat allowing for intracellular delivery 
of the enzyme (Figure 1-9).144-145   
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Figure 1-9:  The principle of targeted CPP mediated delivery using the ATTEMPTS approach i) the 
targeting antibody-heparin conjugate is administered as a complex with the CPP-cargo conjugate ii) 
protamine is then administered and competes with the CPP-cargo for binding to heparin, resulting in the 
displacement of the CPP-cargo at the target site iii) the released CPP-cargo is then free to internalise 
into the cell.144   
 
This proof-of-principle study illustrates that the core concept of ATTEMPTS can be 
used to target the Tat-mediated intracellular delivery of macromolecules.  This concept 
would allow for site-specific activation of TAT-cargo conjugate, reducing the non-
specific interactions of CPPs seen in vivo.  To date, the in vivo application of this 
system has not been reported, nevertheless, this novel approach to tissue targeting of a 
CPP-cargo conjugate looks promising. 
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A novel and simple alternative to the aforementioned approaches would be to 
individually mask the cationic side-chains of a CPP with hydrolytically or catalytically 
labile protecting groups.  This could be achieved by using established prodrug 
moieties used for the masking of amines and guanidine functional groups.146-147  A 
generic approach to CPP activation based on peptide deprotection by hydrolysis or 
serum esterase activity could increase circulation time allowing for higher organ 
uptake and lower uptake by peripheral tissues.  This concept will be explored in detail 
later in this thesis. 
 
1.5 Making Transbodies 
The approach taken for the preparation of an antibody-CPP is an important step for the 
successful use of the transbody.  Any limitation in the ability to produce useful 
quantities of active transbodies could significantly hinder the optimisation stages.  
Furthermore, the many variables that can influence the cellular penetration of a CPP 
and attached cargo must also be taken into account.  
The preparation of a transbody is generally achieved either by genetic fusion of a CPP 
to an antibody fragment to allow for expression of an antibody-CPP fusion protein, or 
by chemical conjugation of a CPP to give an antibody-CPP conjugate (see Table 1-1). 
Synthetic IgGs and antibody fragments are generally produced by expression in a 
biological system.  The expression system used is extremely important and often a 
limiting factor for the preparation of antibody reagents.  The expression of IgGs is 
most suited to mammalian expression systems.  The size, complexity and mammalian 
origin of IgGs make them difficult to express in bacterial systems.  The expression of 
IgGs in Chinese Hamster Ovary cells (CHO) is now a well-established method.148 
In contrast, the relative simplicity of antibody fragments, e.g. scFv, makes bacterial 
systems most convenient for expression.  E. coli is the most commonly used system 
because of its well characterised genetics and relatively low cost.  There are many 
approaches for the expression of scFv in E. coli.  The expression of an antibody 
fragment in the reducing environment of the E. coli cytoplasm often results in the 
formation of inclusion bodies.  However, refolding of proteins from isolated inclusion 
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bodies is possible.149  Alternatively, the use of engineered E. coli strains that possess 
an oxidising cytoplasmic environment and overexpressed molecular chaperones have 
been shown to increase the expression of antibody fragments.150  Often the favoured 
approach is directing scFv to the oxidising periplasmic space by addition of a leader 
sequence such as, PelB to the N-terminus of the protein construct.  Using this 
approach, yields in the range of 0.2-20 mg/L culture of active scFv can be 
achieved.151-152  However, expression yields have been shown to be related to primary 
sequence, thus meaning expression levels often vary between different scFvs.153 
The vast majority of CPP fusion proteins have been expressed in E. coli systems.  
Recently, the development of a mammalian system for the expression of CPP fusion 
proteins has also been described.154-155  However, Shaw et al. (2008) noted that with 
increasing cationic charge of the CPP the yield and secretion of the CPP fusion protein 
was greatly reduced.155 Therefore, this approach may be less suitable for the highly 
cationic CPPs, such as poly-arginine and Tat.   
Although there are many examples of CPP fusion proteins, this approach limits the 
range of CPP modifications that are possible.  For example, regioselective labelling of 
a CPP with fluorescent probes or the incorporation of non-canonical amino acids 
would be difficult to achieve. 
 
1.5.1 Chemical conjugation of CPPs to antibodies 
Chemical conjugation offers an attractive alternative to fusion proteins.  However, an 
inherent difficulty associated with chemical conjugation is the control of stoichiometry 
and site of conjugation.  These are important variables that must be controlled to avoid 
any detrimental effects to protein activity.  The İ-amine of lysine residues is frequently 
used for the conjugation of fluorescent probes.156  However, the abundance of lysine 
residues in many proteins makes site-specific conjugation difficult.    
An interesting approach to achieve site-specific modification of proteins was 
developed by Mao et al. (2004).  The authors described the application of the 
transpeptidase Sortase A (SrtA) for the site-specific ligation of a selection of peptides 
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to Green Fluorescent Protein (GFP).157  Scheme 1-1 illustrates the protein-peptide 
ligation catalysed by SrtA.  
 
Scheme 1-1: Sortase A catalysed protein-peptide conjugation 
 
 
SrtA catalysed ligation is achieved by introduction of the recognition sequence 
LPETGXn to the protein and GGG to the peptide.  SrtA can then catalyse the 
formation of an amide bond between these two substrates, and expelling GXn.157  
Interestingly, SrtA was able to catalyse the ligation of ((?)-peptides, synthetic branched 
peptides and small molecules possessing the SrtA recognition sequence to the C-
terminus of a recombinant protein.157 
Alternatively, site-specific protein modifications can be achieved by introducing 
chemically modified amino acids as bioorthogonal handles to a protein.  In principle, 
the two reactive components are required to be mutually reactive to each other but 
inert to the remaining functional groups present in the protein.158  By using an E. coli 
methionine auxotroph, amino acids possessing bioorthogonal moieties, such as alkenes 
and azides, have been incorporated into proteins.159  Functional groups can also be 
introduced by chemical or enzymatic methods.158   
One of the most promising functional groups for protein-peptide conjugation is the 
azide moiety.  The reaction of an azide with an alkyne moiety in the presence of Cu(I) 
by a Huisgen-[3+2]-cycloaddition results in the formation of a non-reversible 1,2,3-
triazole linkage.158  Recently, copper-free strain-promoted alkyne-azide cycloaddition 
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has also been described for the modification of proteins, thus avoiding the use of 
copper (Figure 1-10).160  
 
Figure 1-10: Protein-peptide conjugation by either Cu(I) catalysed Huisgen-[3+2]-cycloaddition or 
copper-free strain-promoted alkyne-azide cycloaddition.    
 
 
An established approach for the site-specific modification of proteins is achieved by 
the introduction of an unpaired cysteine to the protein construct.  The cysteine residue 
can then be modified using thiol reactive groups.   Generally, native cysteine residues 
are involved in disulfide bonds and buried within the centre of the protein, thus 
making it possible to site-specifically label an unpaired cysteine residue.  Commonly 
used thiol reactive groups for protein-peptide conjugation are illustrated in Figure 1-
11. 
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Figure 1-11: A selection of thiol reactive groups commonly used for protein-peptide conjugation.  These 
include the maleimido 31, iodoacetyl 32, free thiol 33 pyridyl disulfide 34 moeities. 
 
 
The thiol-reactive maleimido 31 and iodoacetyl 32 groups are commonly employed 
for thiol-specific peptide-protein conjugation.161  In slightly alkaline conditions (pH 
7.5-9.0) a thiol reacts with the iodoacetyl moiety via a SN2 reaction to form a thioether 
bond.  At lower pH the iodoacetyl group are able to react with imidazolyl, methionine 
and primary amines.161  In contrast, the maleimido moiety reacts with a thiol in 
slightly acidic conditions (pH 5-7).  The reaction of a thiol with the unsaturated imide 
of a maleimido moiety via a Michael addition forms a thioether bond.  At more 
alkaline pH, reactivity towards primary amines increases.161  
The maleimido group is a well-established thiol reactive group for protein-peptide and 
protein-protein conjugation.  There are a number of hetrobifunctional cross-linking 
reagents possessing maleimido moieties that are commercially available.  Two 
established heterobifunctional reagents for protein conjugation are succinimidyl-4-N-
(maleimidomethyl)cyclohexane-1-carboxylate (SMCC) 35 and the water soluble 
sulfo-SMCC derivative 36.156  These two reagents have found wide application for the 
preparation of protein-protein and protein-peptide conjugates.  The NHS ester moiety 
can be used to react with primary amines of a protein, allowing for conjugation of a 
sulfhydryl to the maleimido moiety (Scheme 1-2). 
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Scheme 1-2:  Protein modification using succinimidyl-4-N-(maleimidomethyl)cyclohexane-1-
carboxylate (SMCC) 36. 
 
 
 
 
Alternatively, a robust method for protein-peptide conjugation is the application of 
maleimido functional peptides.  This approach allows for easy characterisation of the 
maleimido functional group introduced to the peptide and purification using HPLC.  
This can be difficult if the maleimido moiety is introduced to the protein.  
There have been a number of approaches described for the synthesis of maleimido 
functional peptides.162-164  A simple and robust approach using Fmoc solid-phase 
peptide synthesis (Fmoc SPPS) is described by Hansen et al. (1998).163  The authors 
described the introduction of 6-maleimidohexanoic acid 37 to the N-terminus of a 
peptide by carboxyl activation of acid with the coupling reagent HOBt and N,Nƍ-
diisopropylcarbodiimide (DIC).163  Cleavage of the peptide from the resin is then 
achieved using TFA and the scavenger triisopropylsilane (TIPS) to afford the desired 
N-maleimido peptide in high purity (Scheme 1-3). This approach provides a 
maleimido functionalised peptide that can then be conjugated to a protein possessing 
an unpaired cysteine residue.   
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Scheme 1-3: Synthesis of maleimido functionalised peptides.163 
 
 
 
 
The maleimido moiety, although utilised extensively for site-specific protein-peptide 
conjugation, is limited by the irreversible nature of the conjugation.  Furthermore, 
there are only two sites that can be functionalised, the nitrogen and the unsaturated 
imide, thus limiting the conjugation to only two components.  
Recently, Tedaldi et al. (2009) and Smith et al. (2010) reported the development and 
application of mono-bromomaleimide 38 and di-bromomaleimide 39 as a reversible 
and selective reagent for the modification of sulfhydryls.165-166  These maleimide 
derivatives allow for both reversible and non-reversible protein-peptide conjugation 
and possess three points of functionalisation (Figure 1-12).  
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Figure 1-12: Modification of a protein using either mono-bromomaleimide 38 or di-bromomaleimide 39 
allowing for conjugation of a second molecule that possesses a sulfhydryl moiety to the protein.  The 
reaction can be reversed using the reducing agents TCEP, 2-mercaptoethanol or glutathione.  
 
  
Both bromomaleimides 38 and 39 present a versatile alternative to the established 
maleimido moiety.  The ability to reverse the conjugation using reducing agents 
allows for regeneration of the starting unconjugated protein.  In a cellular context, this 
may also allow for dissociation of the conjugate in the reducing intracellular 
environment.166  
Alternatively, conjugation via a disulfide bond between an unpaired cysteine residue 
and a peptide possessing a sulfhydryl allows for reversible protein-peptide 
conjugation.  Disulfide bonds can be formed by oxidation of two thiols without the use 
of any activating agents.  The disadvantage of this approach is the generation of 
homodimers.  To overcome this, disulfide exchange functional groups can be used 
such as, pyridyl disulfides.161-167  An established method to achieve this is using 2-
dithiodipyridine 40.  Initially, the free sulfhydryl of one of the components (i.e. the 
peptide) is activated with 40 in a disulfide exchange eliminating 2-mercaptopyridine 
41 and forming the pyridyl disulfide intermediate.  This mixed disulfide is then 
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susceptible to further disulfide exchange with another sulfhydryl-containing molecule.  
The addition of the second component (i.e. protein) possessing a sulfhydryl will then 
furnish the desired conjugate via a disulfide linkage (Scheme 1-4). 
  
Scheme 1-4: Protein-peptide conjugation using 2-dithiodipyridine 40 via a mixed disulfide mechanism.  
 
 
The stability of a disulfide linkage can also be increased by using hindered disulfide 
bonds, which can alter the rate of conjugate dissociation in vivo.  Thorpe et al. (1987) 
demonstrated this by developing the heterobifunctional cross-linking reagent 4-
succinimidyloxycarbonyl-Į-methyl-Į-(2-pyridyldithio)toluene (SMPT) 42 for the 
preparation of immunotoxin conjugates.168  The immunoconjugate possessing the 
hindered disulfide linkage 43 possessed an in vivo half-life of 22 h, which was 
approximately twice as long as an unhindered disulfide 44.  The use of similarly 
hindered disulfide linkages may also be important for the in vivo application of 
antibody-CPP disulfide linked conjugates. 
 
 
 
The chemical conjugation of a CPP offers greater flexibility for modification to the 
CPP and also the nature of the protein-CPP conjugation compared to CPP fusion 
proteins.  Furthermore, it is important to consider the variables that are involved when 
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utilising CPPs for intracellular delivery of proteins.  Thus, utilisation of the 
appropriate techniques to prepare antibody-CPP conjugates is paramount to the 
successful therapeutic application of transbodies.   
 
1.6 Research aims and objectives 
Transbodies hold the potential for the modulation of almost any intracellular target.  
This thesis aims to develop a systematic approach to modifying antibody reagents to 
enable the cell penetration and inhibition of an intracellular protein-protein interaction.   
As discussed in this chapter there are a number of obstacles associated with using 
CPPs for the delivery of antibodies and antibody fragments into cells.  There are three 
key requirements that need to be addressed for transbodies to be successfully used as 
therapeutic molecules: 
  
i) Efficient intracellular delivery of attached antibody fragment. 
ii) Delivery of the antibody fragment into the correct cellular compartment 
allowing for target inhibition. 
iii) An antibody-CPP conjugate possessing in vivo properties that allow for 
therapeutic quantities to reach target tissues. 
 
The intracellular delivery of antibody fragments can be achieved using CPPs, 
however, endosomal entrapment is an inherent issue in this delivery approach.  
Additionally, the cationic charge of a CPP is required for activity but is also 
responsible for the non-specific, wide-spread tissue uptake seen in vivo, thus rendering 
CPP-mediated cargo delivery unsuitable for many therapeutic applications. 
It is the major goal of this project to address some of these issues, to obtain insight into 
how antibody fragments can be modified with CPPs to possess cell penetrating 
capabilities, whilst possessing suitable in vivo properties.  This thesis focuses on 
developing methodologies for systematic modification of antibody fragments. 
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The objectives of this thesis are; 
 
1. Isolation of scFvs that inhibit a model intracellular protein-protein interaction. 
 It is proposed that by screening a naïve scFv library using antibody 
phage display it will be possible to identify scFvs that are specific and 
neutralising to the anti-apoptotic protein Bcl-2. 
2. Investigate the use of CPPs to achieve intracellular delivery of neutralising 
anti-Bcl-2 scFvs into the cytoplasm to induce a biological response. 
 Develop a systematic approach for the comparison of different CPPs 
and for the optimisation of scFv internalisation. 
 Develop methodology to allow for the robust and reproducible 
production of a panel of scFv-CPP conjugates. 
3. Investigate novel methods to modify the properties of cationic CPPs to 
improve in vivo properties. 
 Inhibit the internalisation of a CPP by protecting individual 
guanidinium moieties.   
 Develop a protection strategy for the guanidinium moieties of a CPP 
that can be catalytically/hydrolytically removed, allowing for controlled 
release of CPP activity. 
 
The first stage of this study is the isolation of single chain variable fragments (scFv) 
that are specific and neutralising towards the anti-apoptotic protein Bcl-2, which is 
involved in the intrinsic apoptotic pathway.  Overexpression of Bcl-2 is associated 
with a variety of cancers.  Moreover, Bcl-2 is a well-characterised protein with a 
number of small molecule Bcl-2 inhibitors being reported.  Bcl-2 inhibits the onset of 
apoptosis by forming heterodimers with pro-apoptotic members of the intrinsic 
apoptotic pathway.  It is this clinically relevant, but well characterised protein-protein 
interaction that will be the model therapeutic target in this project. 
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Following the initial phase of this project, the main aim is to develop a systematic 
approach to modifying anti-Bcl-2 scFvs to possess cell penetrating capabilities using 
CPPs.  Concurrent, development of a novel approach to modulate the in vivo 
properties and cellular internalisation of a CPP is also undertaken.   
Thus, it is anticipated that this thesis will provide a general approach for the 
modification of a scFv to enable cellular penetration and inhibition of an intracellular 
PPI, whilst retaining therapeutically desirable in vivo properties.  
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2  
 
 
Isolation of neutralising single chain 
antibodies specific to Bcl-2 
 
The first stage of this study is the isolation of single chain variable fragments (scFvs) 
that are specific and neutralising towards a model intracellular protein-protein 
interaction.  It was proposed that the anti-apoptotic protein Bcl-2 would be an ideal 
model target due its clinical relevance, extensive characterisation and the availability 
of small molecule Bcl-2 inhibitors, which will allow comparison of neutralising anti-
Bcl-2 scFv with established data.   
 
2.1 Bcl-2 - The model target  
Apoptosis, or programmed cell death is vital for tissue homeostasis and protection 
from cytotoxic insults.  Apoptosis is regulated by two main signalling cascades; the 
extrinsic and intrinsic apoptosis pathways.  The extrinsic pathway is activated by 
ligand binding to cell surface receptors in the tumour necrosis factor (TNF) receptor 
family.  This activates caspase- ZKLFK WKHQ DFWLYDWHV WKH GRZQVWUHDP µHIIHFWRU
FDVSDVHV¶FDVSDVH-3, -6 and -7.169  These caspases initiate cellular destruction, which 
eventually leads to apoptosis.169  The intrinsic pathway is activated by developmental 
cues and cytotoxic insults, such as DNA damage and growth factor deprivation.  This 
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pathway is regulated by members of the Bcl-2 protein family.169-170  The deregulation 
of the intrinsic apoptosis pathway is a critical step in tumour development.2  
Bcl-2 is the founding member of the Bcl-2 family.  All Bcl-2 family members have 
one of four regions of homology with Bcl-2, termed the Bcl-2 homology domains 
(BH1-4).169  There are three subtypes of the Bcl-2 family, the pro-apoptotic, anti-
apoptotic and the BH3-only proteins.169-170  The pro-apoptotic proteins BAX, BAK 
and BOK induce mitochondrial outer membrane permeabilisation resulting in the 
release of cytochrome c and subsequent activation of apoptosis.  Figure 2-1 illustrates 
the extrinsic and intrinsic apoptosis pathways. 
 
 
 
  
Figure 2-1: The intrinsic and extrinsic apoptosis pathways.  In healthy cells Bcl-2/xL forms a 
heterodimer with BAX or BAK stopping the activation of apoptosis.  Activation of the BH3-only 
proteins by cellular stress leads to displacement of Bcl-2/xL from the dimer allowing for BAX or BAK 
to initiate the onset of apoptosis.  Overexpression of Bcl-2/xL deregulates this pathway.  Bcl-2/xL 
inhibitors act by inhibiting Bcl-2/xL heterodimer formation with BAX and BAK.  The figure is 
modified from Youle et al. (2008).170  
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Heterodimerisation between the pro-apoptotic proteins and the anti-apoptotic proteins, 
such as Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bcl-B and A1, stops the pro-apoptotic proteins 
activating apoptosis.169-170  It is the balance between heterodimer and free pro-
apoptotic protein that determines activation of apoptosis.169-170  A further level of 
control is provided by the BH3-only proteins, such as BAD, BIK, BID, HRK, BIM, 
BMF, NOXA and PUMA.  Upon cytotoxic insult the expression and post-translational 
modification of the BH3-proteins is up-regulated, allowing binding to the anti-
apoptotic proteins and competing with the pro-apoptotic proteins.  This results in an 
increase in free pro-apoptotic proteins and subsequent activation of apoptosis.  
The BH1, 2 and 3 domains of the anti-apoptotic proteins fold into a globular domain 
forming a hydrophobic groove displayed on the surface of the protein.  The 
DPSKLSKLOLFĮ-helical BH3 region of the pro-apoptotic and BH3-only proteins fit into 
this groove.171  Figure 2-2 shows the crystal structure of Bcl-xL in complex with the 
BH3 region of the pro-apoptotic protein BAK. 
 
Figure 2-2:  Surface representation of the BAK BH3/ Bcl-xL interaction, modified from Ji et al. 
(2006).172 
 
BAK BH3
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The overexpression of the anti-apoptotic proteins is a critical step in tumour 
development.  Overexpression inhibits the onset of apoptosis allowing for the survival 
of cells possessing other oncogenic mutations.2  Bcl-2 and Bcl-xL are overexpressed 
in a wide range of cancers, for example follicular lymphoma, leukaemia, lung and 
breast cancer.169-170  
The importance of Bcl-2 and Bcl-xL in tumour development has led to extensive 
research into the design of Bcl-2 and Bcl-xL inhibitors that induce apoptosis in cancer 
cells relying on overexpression of Bcl-2/xL for survival.  The hydrophobic groove of 
Bcl-2 and Bcl-xL is often the target for the rational design of small molecule inhibitors 
and BH3 peptide mimetics.  A number of small molecule Bcl-2 inhibitors have been 
developed, for example HA14-1 45 173, BH3I-2s 46 174, and TW-37 47.175  One of the 
most promising Bcl-2 inhibitors is ABT-737 48 and the next generation bioavailable 
derivative ABT-263 49, which is currently in phase I clinical trials.176-177  
 
 
BH3 peptides have also been used to inhibit Bcl-2 and Bcl-xL.  The application of 
BH3 peptides has mostly been limited to diagnostic purposes in studies investigating 
key members of the intrinsic apoptosis pathway.  However, there are several examples 
of BH3 peptides being developed for therapeutic purposes.  Notably, Walensky et al. 
(2004) reported a novel approach to using BH3 peptides for inhibition of Bcl-xL by 
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deYHORSLQJDµVWDSOHG¶%+KHOL[that displayed improved stability and affinity to Bcl-
xL.178  The stapled BH3 helix also possessed cell penetrating capabilities.178-179  The 
use of CPPs to mediate the intracellular delivery of BH3 peptides has also been 
reported.180-181 
The role of Bcl-2 and Bcl-xL in deregulating the intrinsic apoptotic pathway is well 
characterised, and a number of small molecule Bcl-2/xL inhibitors have been reported.  
Thus, it is expected that scFv that bind to Bcl-2 and/or Bcl-xL and inhibit dimer 
formation with the pro-apoptotic proteins will induce apoptosis in the same manner as 
the small molecule Bcl-2/xL inhibitors.  
 
2.2 Isolation of anti-Bcl-2 and Bcl-xL scFv using antibody phage 
display 
It was predicted that by screening naïve scFv phage display libraries for scFv specific 
for Bcl-2 and Bcl-xL it would be possible to identify scFvs that inhibit Bcl-2 and Bcl-
xL binding to the pro-apoptotic proteins.   
Phage display has proven to be a powerful technique for the isolation of antibodies.   
The introduction of scFv-encoding DNA to the N-terminal region of a phage coat 
protein gene results in the expression of a scFv-coat protein fusion, resulting in 
presentation of the scFv on the surface of the phage particle.182  This effectively links 
the genotype with the phenotype of the antibody fragment.  Using this approach, 
antibody libraries of naïve or immune origin (ideally containing 109-1011 clones) can 
be cloned into the phage genome to afford an antibody phage display library.183   
Commonly, M13 filamentous bacteriophage is used for antibody phage display.30  
This bacteriophage infects E. coli and replicates using the host DNA replication 
machinery.  The phage genome is a single-stranded DNA molecule of approximately 
6,400 nucleotides and consists of 11 genes, 5 of which are coat proteins.30  Each phage 
particle comprises of approximately 2700 copies of the major coat protein pVIII, and 5 
copies each of coat proteins pIII, pVI, pVII and pIX, which form the tips of the phage 
particle.30  Insertion of scFv-encoding DNA to the N-terminal region of the pIII gene 
results in the scFv being expressed as a fusion with the coat protein (Figure 2-3).30  
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Figure 2-3: M13 phage structure; the phage particle consists of 5 coat proteins, pIII, pVI, pVII, pVIII 
and pIX.  The sub-cloning of scFv-encoding DNA upstream of the pIII gene results in the presentation 
of the scFv on the surface of the phage particle upon assembly as a pIII-scFv fusion protein. 
 
For the generation of a scFv phage library, the application of a phagemid is generally 
favoured.  A phagemid is a plasmid that contains an f1 origin of replication, phage 
coat protein gene and antibiotic resistance gene.30  E. coli containing a phagemid 
requires infection with a helper phage to supply the phage genes required for phage 
assembly and packaging of the phagemid within the phage particle.30  The application 
of phagemids for scFv phage display allows for a large scFv phage display library to 
be created.30,184     
Many techniques used for probing scFv libraries involve the immobilisation of the 
target antigen, thus allowing for isolation of the antigen/phage complexes from the 
non-specific scFv-phage contained in the library.  An established selection technique 
is soluble selection using streptavidin coated magnetic beads and biotinylated 
antigen.31  Figure 2-4 outlines the principle of soluble selection of scFv from a phage 
display library. 
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Figure 2-4:  Process of soluble selection of scFv using a naive phage display library  
 
It was proposed that neutralising anti-Bcl-2 and anti-Bcl-xL scFv could be identified 
by soluble selection of anti-Bcl-2 and anti-Bcl-xL scFv from a naïve scFv phage 
display library, followed by screening of the enriched libraries using a competition 
assay for the Bcl-2/xL interaction with a BH3 peptide.   
Additionally, the screening of naïve libraries for scFv that are cross-selective to both 
Bcl-2 and Bcl-xL was investigated.  For a scFv to be cross-selective for Bcl-2 and Bcl-
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xL an epitope common to both proteins is required.  Table 2-1 shows the homology 
between the BH regions of Bcl-2 and Bcl-xL.  
 
Table 2-1: The sequence line-up of human Bcl-2 and human Bcl-xL, BH1-4 domains. The homology 
for BH1, 2, 3 and 4 were calculated as 95, 81.8, 53.3 and 57.1 % respectively. 
 
Bcl-2/xL conserved region Amino acid sequence % Homology 
   
BH1 Bcl-2:   ELFRDGVNWGRIVAFFSFGC 
95% 
 Bcl-xL:  ELFRDGVNWGRIVAFFEFGC 
   
BH2 Bcl-2:  WIQDNGGWDAF 
88% 
 Bcl-xL: WIQENGGWDTF 
   
BH3 Bcl-2:   VHLTLRQAGDDFSRR 
53% 
 Bcl-xL:  VKQALREAGDEFELR 
   
BH4 Bcl-2:   DNREIVMKYIHYKLSQRGYEW 
57% 
 Bcl-xL: SNRELVVDFLSYKLSQKGYSW 
 
 
The high degree of homology in the BH regions increases the possibility of isolating 
cross-selective anti-Bcl-2/xL scFv.  Furthermore, as the BH regions are involved in 
heterodimer formation, it is possible that binding to these regions will inhibit Bcl-2 
and Bcl-xL activity. 
 
2.2.1 Selection of anti-Bcl-2 and anti-Bcl-xL scFvs 
The first step in the soluble selection of anti-Bcl-2/xL scFvs was the biotinylation of 
Bcl-2 and Bcl-xL, thus allowing for immobilisation to streptavidin coated magnetic 
beads.  The biotinylation of Bcl-2 and Bcl-xL is outlined in Scheme 2-1. 
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Scheme 2-1: Biotinylation of Bcl-2 and Bcl-xL using sulfosuccinimidyl-6-(biotinamido) hexanoate 50.  
 
 
A 4x molar excess of sulfosuccinimidyl-6-(biotinamido) hexanoate 50 was added to 
either Bcl-xL or Bcl-2 at rt.  After 1 h the reaction was analysed using MALDI-TOF 
MS (Figure 2-5). 
 
 
Figure 2-5:  MALDI-TOF MS of the [M+2H]2+ species of a) Bcl-2, b) Bcl-xL, c) Bcl-2-(biotin) and d) 
Bcl-xL-(biotin).  
 
 
The successful biotinylation of Bcl-2 was confirmed by MALDI-TOF MS with four 
major peaks being detected at m/z 12145.9, 12315.6, 12483.7 and 12654.8 (Figure 2-5, 
c).  These peaks correspond to the [M+2H]2+ species for the Bcl-2, Bcl-2-(biotin), Bcl-
12285.5
12455.3
12625.5
d) Biotinylated Bcl-xL
12115.2.8
12483.7
12654.812145.9
b) Biotinylated Bcl-2
12314.6
a) Bcl-2 c) Bcl-xL
d cl-2-(nBiotin) ) Bcl-xL-(n iotin)
12106.8
a) Bcl-2
12148.0
c) Bcl-xL
In
te
n
si
ty
/ 
A
.U
In
te
n
si
ty
/ 
A
.U
cl-2 b  cl-xL
c) Bcl-2-(biotin) d) Bcl-x -(biotin)
  
51 
2-(2x biotin) and Bcl-2-(3x biotin) conjugates, respectively.  Similarly, MALDI-TOF 
MS of the Bcl-xL biotinylation reaction mixture revealed four major peaks at m/z 
12115.2, 12285.5, 1245543 and 12625.5, assigned as the [M+2H]2+ species for Bcl-
xL, Bcl-xL-(biotin), Bcl-xL-(2x biotin) and Bcl-xL-(3x biotin) conjugates, 
respectively (Figure 2-5, d).  The purification of Bcl-2 and Bcl-xL from the reaction 
mixture was achieved by size exclusion using Sephadex G-25 (PD-10, GE 
Healthcare).   
To ensure that the Bcl-2 and Bcl-xL structure was unaffected by biotinylation, a 
binding enzyme-linked immunosorbent assay (ELISA) using three commercial anti-
Bcl-2 and anti-Bcl-xL antibodies was performed.  Additionally, the ability of 
biotinylated Bcl-2 and Bcl-xL to bind to the BH3 region of BID was determined using 
a phage binding ELISA with phage displaying BID BH3 (data shown in Appendix I).  
The biotinylated Bcl-2 and Bcl-xL successfully bound to BID BH3 and was also 
recognised by the commercial anti-Bcl-2 and anti-Bcl-xL antibodies, thus suggesting 
that the integrity of the proteins was retained.  
The next step in isolating anti-Bcl-2/xL scFvs was the soluble selection of scFvs from 
three naïve scFv phagemid libraries (MedImmune, U.K) contained in the phagemid 
pCANTAB6.185  This phagemid is approximately 4.5 kb and contains the phage coat 
protein pIII gene and an Ampicillin resistance gene.  The scFv-encoding DNA is 
cloned at the N-terminal region of the pIII gene. The selection approach that was 
employed to enrich the naïve libraries with specific and cross-selective anti-Bcl-2 and 
anti-Bcl-xL scFv is outlined in Figure 2-6. 
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Figure 2-6:  Selection pathways for soluble selection of anti-Bcl-2 and anti-Bcl-xL scFv from the naïve 
scFv phagemid libraries; DP47 (Lib 1), BMV (Lib 2) and CS (Lib 3).  The predicted outcome of the 
soluble selections is scFv specific for Bcl-xL and Bcl-2 and also scFv that are cross-selective for both 
antigens. 
 
It was predicted that by alternating the selection antigen with each round it would be 
possible to select cross-selective anti-Bcl-2/xL scFvs.  After each selection round, a 
representative population (~96 clones) of phage were screened for binding to Bcl-2 
and Bcl-xL using a phage binding ELISA.  Additionally, selected scFv were also 
screened against insulin and streptavidin to identify non-specific scFv.  Figure 2-7 
illustrates the increase in Bcl-2 and Bcl-xL specific scFv after four rounds of phage 
selection for the Bcl-2, Bcl-xL and the cross-selective Bcl-2/xL libraries. 
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Figure 2-7:  Phage binding ELISA of a representative population of phage isolated after four rounds of 
phage selection against either Bcl-2 or Bcl-xL.  The binding of phage displaying scFv to Bcl-2, Bcl-xL 
and the negative controls; biotinylated insulin and streptavidin is shown. Phage libraries were selected 
against a) Bcl-2, b) Bcl-xL, and also selected against both c-d) Bcl-2 and Bcl-xL. 
 
 
The percentage of scFvs specific for Bcl-2 and Bcl-xL present in the libraries 
increased throughout the selection rounds, ranging from 2-10% in round 1 to 85-100% 
in round 4 (Figure 2-7, a and b).  However, the number of non-specific binders to 
insulin and streptavidin also increased throughout rounds, with the majority of 
libraries showing non-specific binders at the level of 15-25% in round 4.  The cross-
selective libraries contained approximately 70-100% cross-selective scFv after four 
rounds of selection (Figure 2-7, c and d). 
DNA sequencing of the enriched libraries after each selection round allowed for 
determination of the scFv sequence diversity.  Of the six CDRs the VH CDR3 is often 
the most variable in a scFv population 186, thus only the VH CDR3 amino acid 
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sequence was taken into account.  It is desirable to obtain an enriched library that has a 
high VH CDR3 diversity together with a high percentage of antigen specific scFvs, 
thus increasing the likelihood of isolating scFvs with the desired properties and 
antigen affinity.  Table 2-2 shows the diversity of the VH CDR3 amino acid sequences 
for each library selected against Bcl-2 and Bcl-xL as the selection rounds progressed. 
 
Table 2-2: The percentage amino acid sequence diversity of the VH CDR3 for a representative 
population (~96 clones) of scFv present in each library after four rounds of selection against either Bcl-
2, Bcl-xL or both proteins  
 
Library Number % Sequence Diversity of VH CDR3 
  R1 R2 R3 R4 
1 83 n.d. 65 19 
2 100 73 60 29 
3 90 70 56 43 
4 87 50 38 22 
5 90 88 62 41 
6 92 83 66 60 
7 83 75 63 35 
8 100 43 8 3 
9 90 73 65 43 
10 87 77 72 35 
11 90 58 56 3 
12 92 83 63 30 
13 90 58 56 3 
14 87 77 72 35 
15 92 83 63 30 
 
 
The selection of scFvs specific for Bcl-2, Bcl-xL or cross-selective to both proteins 
was successful with libraries containing anti-Bcl-2, anti-Bcl-xL and cross-selective 
scFv being obtained.  Additionally, high sequence diversity was maintained 
throughout four rounds of selection, thus increasing the possibility of isolating scFv 
that have high affinity and are neutralising towards Bcl-2 and Bcl-xL.   
 
2.3 Identification of scFv neutralisating towards Bcl-2 and Bcl-xL 
A representative population from each of the round 4 libraries were selected for 
screening in a functional assay to identify scFv that inhibit Bcl-2 and Bcl-xL binding 
to the BH3 region of BID.  
 Decrease in scFv VH CDR3 amino acid 
sequence diversity 
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The first step for the functional screening of the scFv libraries was the development of 
a high-throughput assay.  An established technique for high-throughput screening of 
scFv phagemid libraries is the use of crude scFvs expressed in the periplasm of E. 
coli.187, 31  However, as the scFvs are used without purification it is possible that potent 
scFv with low expression levels could be overlooked.  Therefore, the functional assay 
is required to be highly sensitive to inhibitors. 
It was proposed that an amplified luminescent proximity homogeneous assay (Alpha 
screen®) could be used to identify scFv that inhibit Bcl-2 and Bcl-xL activity.  The 
principle of this assay is based on a donor bead containing the photosensitiser 
phthalocyanine and acceptor bead containing a thioxene derivative.188  The donor bead 
coverts ambient oxygen to 1O2 upon excitation at 680 nm, the 1O2 then transfers 
energy to the acceptor bead, which then emits light at 520-620 nm.  This energy 
transfer only occurs when the two beads are in close proximity (< 200 nm).188  The 
assay developed in this project utilises streptavidin coated donor beads, allowing for 
binding of biotinylated Bcl-2 or Bcl-xL and anti-flag antibody coated acceptor beads, 
allowing for binding of BID BH3-flag peptide 51. 
 
 
The interaction of 51 with the hydrophobic groove on the surface of Bcl-2 or Bcl-xL 
draws the two beads into close proximity allowing for energy transfer between the 
beads and subsequent detection of the protein interaction.  A scFv that binds to Bcl-
2/xL but does not inhibit this interaction will not be detected.  Whereas a neutralising 
scFv will inhibit the formation of the BH3/Bcl-2 complex inhibiting the emission 
signal from the acceptor bead.  Figure 2-8 illustrates the principle of the Bcl-2/xL 
Alpha screen assay. 
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Figure 2-8: Bcl-2 and Bcl-xL Alpha screen assay set up, binding of Bcl-2 to BH3 results in a signal at 
520-620 nm, addition of an anti Bcl-2 scFv to the assay may inhibit this interaction resulting in loss of 
signal. 
 
Initial range finding studies were performed to determine the ideal concentration of 
Bcl-2/xL and BH3-flag required for a suitable signal to background ratio. The 
concentration of Bcl-2, Bcl-xL and BID BH3-flag 51 that were used in the assay are 
shown in Table 2-3. 
 
a) No binding of scFv
b) Binding of scFv ʹ no inhibition of Bcl-2/xL
c) Binding of scFv ʹ inhibition of Bcl-2/xL
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Table 2-3: The assay concentrations of biotinylated Bcl-2, Bcl-xL and BH3-flag used in the Alpha 
screen competition assays. 
 
 
Biotinylated Bcl-2/xL, nM BH3-flag, nM 
Bcl-xL assay 1.95 0.49 
Bcl-2 assay 7.8 7.8 
   
 
Figure 2-9 shows a homologous competitive binding experiment for the competition 
of unlabelled BID BH3 (without flag-tag) for the Bcl-2 and Bcl-xL interaction with 
BH3-flag.   
 
 
  BH3-flag, IC50 nM 
Bcl-xL assay 10  ± 3 
Bcl-2 assay 293 ± 5 
 
Figure 2-9: Alpha screen sensitivity assay, the Bcl-2 and Bcl-xL interaction with BH3-flag was 
inhibited using unlabelled BH3 peptide (without flag-tag) to generate an inhibition curve, giving insight 
into the assay sensitivity.  Each inhibition curve shows the range bars for the duplicate assay points.  
Each experiment was also performed at n=3, allowing for the determination of the IC50 values. 
 
The IC50 value of the unlabelled BH3 is approximately 10 ± 3 nM in the Bcl-xL assay 
and 293 ± 5 nM in the Bcl-2 assay.  Reported Kd values for Bcl-xL and Bcl-2 binding 
to BID BH3 are in the range of 2-12 nM and 200-270 nM, respectively.178, 189-190  The 
lower affinity of Bcl-2 for BID BH3 also explains the higher concentrations of Bcl-2 
and BH3-flag that are required to obtain a suitable assay signal.  However, the higher 
concentration of Bcl-2 used in the assay could lead to potent inhibitors that have low 
expression being overlooked in the high-throughput screen.  For this reason a 
Dissociation-Enhanced Lanthanide Fluorescent Immunoassay (DELFIA) assay 
adapted from the assay described by Rega et al. (2007) was investigated as an 
alternative format to screen anti-Bcl-2 scFv libraries.191  The heterogeneous nature of 
this assay allows for the addition of larger quantities of crude cell lysate without 
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affecting the final assay signal reading.  Figure 2-10 illustrates the principle of the Bcl-
2 DELFIA assay. 
 
Figure 2-10: Bcl-2 DELFIA assay.  Biotinylated BID BH3 was coated onto a streptavidin coated 96-
well microtitre plates.  Bcl-2 and the crude scFv are then added to each well.  Finally, the addition of 
anti-histidine detection antibody labelled with Eu3+ allowed for detection of Bcl-2 binding to BH3 
through emission at 615 nm. Washing was introduced between steps.  ScFv that inhibit this interaction 
result in signal inhibition as a result of scFv/Bcl-2 complexes being removed from the well during the 
washing step.  Figure modified from Rega et al. (2007).191 
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The scFvs were expressed from pCANTAB6 in E. coli and directed to the periplasm.  
The addition of a sucrose rich buffer was used to disrupt the bacteria membrane 
releasing the scFv into the supernatant.  Supernatants were then used in each assay 
without purification.  For both assays, total binding and non-specific binding control 
was used to calculate the total specific binding of Bcl-2 and BH3-flag of each well.       
Using the Alpha screen assay, 384 individual colonies from the Bcl-xL (Lib 7-9), and 
cross selective (Lib 10-15) libraries were screened.  Assay wells with a signal that 
corresponded to <30% of the total binding signal for the Bcl-xL/BH3-flag interaction 
were classified as positive hits.  Using the DELFIA assay, 288 colonies from Bcl-2 
libraries (Lib 4-6) were screened.  Inhibitors of the BID BH3/Bcl-2 interaction were 
identified by a signal that was <5% of the total specific binding signal.  Table 2-4 
shows the number of positive hits for scFv neutralising to Bcl-2 or Bcl-xL binding to 
BH3.  Additionally, DNA sequencing of each scFv clone screened in the functional 
assay allowed for identification of unique scFvs neutralising towards Bcl-2 and Bcl-
xL. 
 
Table 2-4:  Positive hits identified from the high-throughput assays for the inhibition of Bcl-2 or Bcl-xL 
binding to BID BH3. 
 
Selection Antigen Library Positive hits Unique sequences 
Bcl-xL 7-9 101 22 
Bcl-xL/2 10-15 347 34 
Bcl-2 4-6 92 44 
 
 
The highest number of unique positive hits was seen from Bcl-2 selection libraries 
(Lib 4-6).  The lowest number of positive hits was from the Bcl-xL selection libraries 
(Lib 7-9).  The high-throughput screen successfully identified a number of scFvs that 
inhibit the binding of Bcl-2 and Bcl-xL to BID BH3.  
  
2.3.1 Profiling of positive hits 
A total of 40 unique scFvs identified as inhibitors of Bcl-2 or Bcl-xL in the high-
throughput screens were expressed on a small-scale in E. coli TG1 and purified using 
His-tag affinity purification by the high-throughput expression team at MedImmune 
(U.K) using the method described by Vaughan et al. (1996).31  The purified scFvs 
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were then used in the Alpha screen assay to calculate the IC50 values for inhibition of 
the Bcl-2 and Bcl-xL interaction with BID BH3-flag.  In the first instance, scFvs were 
screened in either the Bcl-2 or Bcl-xL assay dependant on the antigen used to select 
the scFv (i.e. Bcl-xL, Bcl-2 or cross-selective libraries).  The most potent scFvs were 
then also screened in both the Bcl-2 and Bcl-xL assays to confirm antigen specificity 
(Table 2-5).  
 
 
Table 2-5: IC50 values for anti-Bcl-2 and anti-Bcl-xL scFvs, identified using either an Alpha screen or 
DELFIA high-throughput assay.  IC50 values are calculated for the inhibition of either the Bcl-2 or Bcl-
xL interaction with BID BH3.  The full amino acid sequences of the scFvs are shown in Appendix III.  
 
 
scFv # 
IC50, nM 
 VH CDR3 amino acid sequence Bcl-xL Bcl-2 
19 1191 nd DGLQFDIDAFDM 
20 1044 nd ENSNYDAFDI 
21 53 - ENSKYDY 
22 21 - TGEYSGYDTSGVEL 
23 1150 nd VAGDTPIDY 
24 2 - DATTAPFYYYMDV 
25 327 nd ATGDPSGYNWFDP 
26 157 nd DCSSVGCYTSLDY 
28 58 nd DMIRLDWGDLSIDNWFDP 
29 173 nd DFGNWNYYYYYYYGMDV 
30 73 nd DSWGAGGVDAFDV 
31 683 nd QDRYGSGTSCYYEXYFDV 
32 123 nd DRLEWLGINYYYGMDV 
68 94 nd GVSGFTLPFDS 
69 50 - ASYQHFDWSPLGVDS 
70 23 - ETGYYDAFDL 
73 480 nd ENSEYDSVDMDS 
74 1787 nd DLNYDFWSGSGMDV 
42 - 11 DPLSLYPYFDS 
43 nd 220 WDYSSAFDI 
44 - 2 DLWELLLADAFDI 
45 - 6 SKFLWFGGRNYFDP 
46 nd 832 LGTSGWPFYYHYYMDV 
49 - 4 PSYDYWSAYPQRNYFYHGMDV 
53 - 24 SRHMSDFWGSYLLPSGFFDV 
54 - 23 IDCIGDFCDASGSSSFDY 
55 - 5 EDCGGTTCLGADS 
56 - 50 ESQHIVGAAYLDP 
57 - 47 DQWLAPFDYDS 
59 - 72 HSGSGWYDHYFDH 
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60 - 16 GVSATYYEPYYFDF 
61 2 18 ALSQTYWGFFPTYFDS 
65 13 190 DSNTFWRGFWGYYFNV 
67 22 14 SGSSSWYRPDDAFDI 
77 6 85 VSKWDRPGYLDY 
          nd; not determined, (-) no inhibition 
 
 
A number of scFvs were isolated that showed potent inhibition of Bcl-2 and Bcl-xL.  
Additionally, four cross-selective scFvs were identified that inhibited both Bcl-2 and 
Bcl-xL (scFv53, 65, 67 and 77).  Notably, a high number of scFvs with IC50 values of 
<10 nM were identified from the Bcl-2 selection libraries with scFv44, 45, 49 and 55 
showing the most potent inhibition of Bcl-2 binding to BID BH3. 
Unfortunately, upon closer inspection of scFv67, the most potent cross-selective 
inhibitor of Bcl-2 and Bcl-xL, it became apparent that there was an amber stop codon 
present in the VH domain.  This was supressed in the TG1 E.coli, however, expression 
of scFv67 in other E. coli strains or in mammalian cells will result in a truncated scFv.  
Thus, for scFv67 to be utilised in further studies this amber stop codon must be 
removed using site-directed mutagenesis.     
The small molecule Bcl-2/xL inhibitor ABT-737 was also screened in both the Bcl-xL 
and Bcl-2 Alpha screen assays to determine the IC50 values (Figure 2-11). 
 
IC50, µM 
Bcl-2 Bcl-xL 
0.5 ± 0.2 1.2 ± 0.3 
 
Figure 2-11: ABT-737 inhibition of the Bcl-2 and Bcl-xL interaction with BH3-flag, determined using 
an Alpha screen competition assay.  Each inhibition curve shows the range bars for the duplicate assay 
points.  Each experiment was also performed at n=3, allowing for the determination of the IC50 values. 
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The IC50 value for ABT-737 inhibition of Bcl-2 and Bcl-xL binding to BID BH3-flag 
was calculated as 0.5 ± 0.2 µM and 1.2 ± 0.3 µM, respectively.  Thus, a number of the 
isolated scFv are significantly more potent inhibitors of both Bcl-2 and Bcl-xL than 
this small molecule inhibitor. 
 
2.3.2 Binding of scFv in reducing environment  
An important requirement for isolated scFv is the ability to bind to Bcl-2 and Bcl-xL 
in the reducing intracellular environment of a cell.  Intracellular reduced glutathione 
52 is responsible for reducing non-native disulfide bonds and preventing the folding of 
proteins in the cytosol, thus deactivating proteins that should not be in that cellular 
compartment.192  The concentration of reduced glutathione in the cytosol can be as 
high as 10 mM.192  Reduced glutathione reduces a disulfide bond by a mixed disulfide 
mechanism shown in shown in Scheme 2-2.  
 
Scheme 2-2: Mechanism of disulfide bond reduction by reduced glutathione 52.167  
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To assess the stability of the isolated scFvs in a reducing environment a model system 
was developed.  This was based on a binding ELISA, involving a pre-incubation step 
of the scFv with reduced glutathione at 37 oC.  After this incubation step, the ability of 
the scFvs to bind to Bcl-2 and Bcl-xL was determined.  Figure 2-12 shows the results 
from this ELISA for the most potent scFvs isolated, scFv24, 44 and 77. 
 
Figure 2-12:  The percentage total binding of scFv24 and 77 to Bcl-xL, and scFv44 to Bcl-2 after 
incubation at 37 oC with increasing concentrations of reduced glutathione.  The binding of scFv was 
also assessed using the non-specific antigen streptavidin to ensure that non-specific binding of the scFv 
did not increase.  Total percentage binding is calculated relative to the total binding of a fresh sample of 
scFv. 
 
Figure 2-13 shows the scFv binding to Bcl-2 and Bcl-xL as a percentage of the total 
binding of a fresh sample of scFv that had not been incubated at 37 oC or in the 
presence of glutathione.  Incubation of scFv24, 44 and 77 at 37 oC for 24 h with 
reduced glutathione at concentrations of 0, 2.5, 5, 10 and 20 mM had minimal 
influence on the scFv binding to Bcl-2 and Bcl-xL.  The scFv incubated at 37 oC for 
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24 h without glutathione showed approximately 95% total binding, thus the scFvs are 
stable at 37 oC.  Incubation with increasing glutathione concentrations reduced the 
binding of the scFv to approximately 80-95% total binding.  Therefore, the glutathione 
concentration appears to have a minimal effect on the stability of the scFv.  This is not 
unexpected as the VH and VL intradomain disulfide bonds in an Fv fragment are 
buried, thus protecting them from reducing agents.193,58  This experiment demonstrates 
that scFv24, 44 and 77 are still able to bind to Bcl-2/xL after incubation at 24 h at 37 
oC and at high concentrations of glutathione.  Although this assay is a simplified 
model of the intracellular environment it is encouraging that the scFv tested retained 
antigen specificity.  This also suggests that after intracellular delivery the anti-Bcl-2 
and anti-Bcl-xL scFvs will be able to bind to cellular Bcl-2 and Bcl-xL.    
 
2.4 Conclusions  
Neutralising scFvs specific for Bcl-2 and Bcl-xL have been isolated from three naïve 
phagemid libraries (Lib1, Lib2 and Lib3) with several scFvs showing low IC50 values 
in an Alpha screen competition assay for the inhibition of the Bcl-2 and Bcl-xL 
interaction with BID BH3.  Table 2-6 shows the isolated scFvs showing the most 
potent inhibition of Bcl-2 and Bcl-xL.  
   
Table 2-6: A selection of IC50 values determined for the isolated anti-Bcl-2/xL scFv for the inhibition of 
the Bcl-2/xL interaction with BID BH3 in an Alpha screen assay. 
 
scFv # 
IC50, nM VH CDR3 amino acid 
sequence Bcl-xL Bcl-2 
    
44 - 2 DLWELLLADAFDI 
45 - 6 SKFLWFGGRNYFDP 
    
22 21 - TGEYSGYDTSGVEL 
24 2 - DATTAPFYYYMDV 
   
 
61 2 18 ALSQTYWGFFPTYFDS 
67 22 14 SGSSSWYRPDDAFDI 
           contains amber stop codon in VH domain. 
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Neutralising scFvs that cross-selectively inhibit Bcl-2 and Bcl-xL were isolated 
together with scFvs that are specific and neutralising to either Bcl-2 or Bcl-xL only.  
Notably, the lead scFvs showed IC50 values for the inhibition of the Bcl-2/xL 
interaction with BID BH3 lower than that calculated for the small molecule Bcl-2/xL 
inhibitor ABT-737.   
Furthermore, several studies utilising the same libraries that were used in this chapter 
have reported the isolation scFvs with very high affinity to a target antigen.194,31  For 
example, Vaughan et al. (1996) reported the isolation of several scFvs possessing Kd 
values of <10 nM for a particular antigen.31  The fact that high affinity antibodies have 
previously been isolated from the libraries used in this project, and from similarly 
sized naïve scFv libraries, gives promise for the lead anti-Bcl-2 and anti-Bcl-xL scFv 
isolated in this project to also possess high affinities. 
Additionally, the leads scFv24, 44 and 77 show good stability at 37 oC in the presence 
of reduced glutathione (2.5-20 mM).  This suggests that the scFv will be stable in the 
reducing intracellular environment, which is an important requirement for intracellular 
antibodies.   
Finally, in future studies it will be important to verify the specificity of the isolated 
scFv for Bcl-2 and Bcl-xL and also to other members of the Bcl-2 family such as, 
Mcl-1, A1 and Bcl-w.  Nevertheless, a number of isolated antibodies show potent 
inhibition of Bcl-2 and Bcl-xL binding to BID BH3.  Thus, these scFvs are expected to 
induce apoptosis in cells reliant on the overexpression of Bcl-2 and/or Bcl-xL for 
survival. 
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2.5 Materials and Methods  
All agar plates and media were made with 2TY medium (16 g Tryptone, 10 g Yeast 
Extract, 5 g NaCl in 1 litre of H2O), additional regents and antibiotics added to 2TY 
media are as follows; Ampicillin and glucose (2TYAG, 100 µg/ml Ampicillin, 2% 
glucose), Kanamycin (2TYK, 50 µg/ml Kanamycin) and Ampicillin and Kanamycin 
(2TYAK, 100 µg/ml Ampicillin and 50 µg/ml Kanamycin).  E. coli TG1 (Gibson, 
1984) suppressor strain (K12, D (lac-pro), supE, thi, hsd')¶traD36, proA+B+, lacIq, 
lacZDM15) was used for all phage production.  The recombinant human Bcl-2 and 
Bcl-xL used for the phage selections was purchased from R&D systems.  All His-tag 
purified scFv used for high-throughput screening was performed by the high-
throughput expression team at MedImmune (Cambridge, U.K.).  All phage display and 
ELISA protocols described are based on methods described by McCafferty et al. 
(1994)29 and standard protocols established at MedImmune (Cambridge, U.K.).  
Finally, the human scFv naïve phagemid libraries DP47trp (Lib1) BMVtrp (Lib2) and 
CStrp (Lib3) used for all scFv selections are described by Tomlinson et al. (1992)245, 
McCafferty et al. (1994)29, and Lloyd et al. (2004)194, respectively.  Each library was 
generated from non-immunised individuals from isolated spleen and bone marrow 
tissue and estimated to contain 1010 unique scFv sequences.  In all libraries the VL and 
VH domains are linked together by a 15 amino acid (Gly4Ser)3 linker.    
 
2.5.1 Biotinylation of Bcl-2 and Bcl-xL  
EZ-Link Sulfo-NHS-LC-Biotin (sulfosuccinimidyl-6-(biotinamido) hexanoate 50 
(Pierce, Thermo Scientific) was used to non-specifically label primary amines of 
human Bcl-2 (25.4 kDa), and human Bcl-xL (24.4 kDa) purchased from R&D 
systems.  The proteins were supplied in 25 mM HEPES-KOH (pH 7.4), 
0.1 M KCl, 10% Glycerol.  To increase the biotinylation reaction, the buffer pH was 
increased by addition of saturated NaHCO3 to give a final 10% solution. 
A 1 mg/ml solution of sulfosuccinimidyl-6-(biotinamido) hexanoate 50 (1797 
pmol/ml) was added at a 1:4 molar excess to either Bcl-2 or Bcl-xL.  After a 1 h 
incubation at rt the reaction mixture was analysed using MALDI-TOF MS.  If the 
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biotinylation was unsuccessful, further EZ-Link Sulfo-NHS-LC-Biotin was added (1:4 
ratio) until the desired number of biotins (1-2 on average) was added to the protein. 
The proteins were then purified by size exclusion using a PD-10 de-salting column 
(GE Healthcare, Sephadex G-25 Medium, 85-260 µm, exclusion limit Mw 5000) pre-
equilibrated with 30 ml 1x PBS.  Fractions were collected at 0-2.75 ml (dead volume), 
2.75-3.9 ml (protein) and 3.9-4.9 ml (salts and smaller particles).  Fraction 2.75-3.9 ml 
was analysed by MALDI-TOF MS and the percentage of biotinylation was calculated 
from the MS peak intensities. 
Protein concentration was determined using an Eppendorf BioPhotometer at 280 nm.  
The protein integrity and activity was determined using the direct binding ELISA 
protocol.   
 
2.5.2 Direct binding ELISA 
Biotinylated antigens were titrated (2x dilution) starting at 10 µg/ml on a 96-well 
Greiner plate.  50 µl of each dilution was transferred to the corresponding well of 96-
well streptavidin-coated plate (Strepmax, costar 96-well plate, Thermo scientific) to 
give a range of antigen concentrations from 10.00-0.01 µg/ml.  Biotinylated insulin (1 
µg/ml coating concentration) and streptavidin coated wells were also used as negative 
controls to detect non-specific antibody binding. 
Antigen was allowed to bind to the plate overnight at 4 °C or for 30 min at 37 °C.  
Following incubation the plates were washed 3x with PBS to remove unbound 
antigen.  Plates were then blocked using 200 µl/well of 3% (w/v) milk powder in 1x 
PBS (3% MPBS) and incubated for 1 h at rt.  Plates were then washed 3x with PBS, 
followed by the addition of 50 µl of detection antibody, diluted according to 
manuIDFWXUHU¶V UHFRPPHQGDWLRQ LQ  03%6  'HWHFWLRQ DQWLERGLHV XVHG LQFOXGHG
mouse anti-Bcl-2 (Calbiochem, binding to amino acids 41-54 of rhBcl-2, Clone Ab-1) 
and mouse anti-Bcl-xL
 
(Sigma-Aldrich, binding to amino acids 3-14 of rhBcl-xL, 
Clone 2H12).
  
Plates were then washed 3x with PBS/0.1% Tween, followed by the 
addition of 50 µl of goat anti-mouse horse radish peroxidise (HRP) antibody conjugate 
(R&D systems) to each well, which GLOXWHG DFFRUGLQJ WR PDQXIDFWXUHU¶V
recommendation in 3% MPBS. 
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Finally, plates were washed 3x with PBS/0.1% Tween, followed by addition of 50 µl 
of peroxidase substrate 3,3ƍ,5,5ƍ-Tetramethylbenzidine (TMB, Sigma-Aldrich) to each 
well.  The plates were developed for 5-20 min at rt, followed by the addition of 50 µl 
of 0.5 M H2SO4 to each well. Plates were read using an Envision plate reader (Perkin 
Elmer) at 450 nm. 
 
2.5.3 Phage selection protocol 
All naïve scFv libraries were contained in the pCANTAB6 phagemid (Figure 2-13).29 
 
Figure 2-13: Vector map of pCANTAB6. 
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In the first step, 250 ml of 2TY media was inoculated with a single colony of TG1 E. 
coli cells.  The culture was grown at 37 °C until mid-log phase was reached, 
corresponding to OD600 0.5-1.00. 
For the first round of selections naïve antibody phage libraries DP47trp (Lib1) BMVtrp 
(Lib2) and CStrp (Lib3) were used (1010 cfu/ml).  50 µl of the rescued naïve phage 
library was blocked using 450 µl of 3% MPBS for 1 h at rt.  100 µl of streptavidin 
coated magnetic beads (Dynal-280, Invitrogen)  were also blocked using 1 ml of 3% 
MPBS at rt for 1 h, beads were then removed using a magnetic block and resuspended 
in 100 µl of 3% MPBS.  ScFv specific for streptavidin were removed from the phage 
libraries by addition of 50 µl blocked magnetic beads.  Beads were then removed and 
discarded.  Biotinylated Bcl-2 or Bcl-xL was then added to give a concentration of 100 
nM for round 1 (antigen concentration was decreased with each round to increase 
selection stringency).   
After 1 h incubation, 50 µl of beads were added and incubated for a further 5 min.  
Beads were then removed and washed 5 times in 1 ml PBS/0.1% Tween using a 
Kingfisher 96 magnetic particle processor (Thermo Scientific).  Selected phage was 
eluted using 200 µl trypsin solution (10 µg/ml trypsin in 0.1 M sodium phosphate 
buffer, pH 7.4) at 37 °C on an orbital plate shaker at 600 rpm, thus cleaving the phage 
from scFv bound to biotinylated antigen/streptavidin complex. 
Eluted phage was used to infect mid-log phase TG1 E. coli cells at 37 °C for 1 h.  
Phage output titres were calculated by serial dilution of infected TG1s.  Diluted cells 
were plated onto 2TYAG plates at dilutions of 10-2, 10-3, 10-4 and 10-5 and incubated 
overnight at 30 °C.  Colonies were counted on each plate using an ACOLYTE colony 
counter.  Phage output titres were expressed as the number of colony forming units 
(cfu/ml). 
The infected E. coli was also plated on bioassay plates and grown at 30 °C overnight.  
The bacterial lawn was harvested with 10% glycerol 2TY media and either frozen or 
used directly for further phage rescue and selection rounds. 
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2.5.4 Phage rescue for subsequent selection rounds 
In order to carry out subsequent phage display selection rounds, the bacteria collected 
and stored as a glycerol stock (output from previous round) were used to express 
phage particles.  Phage libraries of selection outputs were prepared ready for 
immediate use as they are not suitable for storage. 
25 ml of 2TYAG medium was inoculated with 0.25-0.5 ml of the glycerol stock, from 
the selections, to give a starting culture OD600 of ~ 0.1.  Cultures were grown at 37 qC 
to OD600 = 0.5-1.0.  Cells were then infected with 2.5 µl of M13K07 helper phage 
stock (3x1013 pfu/ml) and slowly shaken (150 rpm) at 37 °C for 1 h.  Cells were then 
harvested at 2000 g for 10 min followed by resuspension in 0.5 ml 2TYAK medium, 
allowing for proliferation of cells containing phagemid (Ampicillin resistant) and 
helper phage (Kanamycin resistant).  The resuspended cells were transferred into a 
clean 250 ml flask containing 25 ml 2TYAK media and grown overnight at 25 qC. 
1 ml of overnight culture was centrifuged for 5 min and the supernatant, containing 
phage, removed and used in selections.  Phage input titres were calculated to 
determine the amount of phage used for each selection round.  This was achieved by 
adding 10 Pl of the input phage stock to 990 Pl of 2TY medium (10-2 dilution).  10 Pl 
of the diluted phage was then added to a second tube containing 990 Pl 2TY medium 
(10-4 dilution), this was mixed thoroughly.  10 Pl of this dilution was then added to a 
96 deep-well plate containing 990 Pl of mid-log phase TG1 E. coli (10-6 dilution). 
Infected cells were incubated for 1 h at 37 qC with shaking (150 rpm).   Cells were 
further diluted to give samples of 10-8, 10-9, 10-10 and 10-11 dilution.  100 µl of cells 
was spread onto 2TYAG petri dishes and grown overnight at 30 qC.  Colonies were 
counted and phage titres calculated to determine phage input. 
 
2.5.5 Analysis of selected phage 
Single colonies from the phage output titre plates were picked into individual wells of 
a Costar 96-well plate containing 100 µl of 2TYAG and grown for 8 h at 37 qC.  
Glycerol was added to each well to give a final 20% glycerol solution to allow storage 
at -70 qC.  Individual colonies (a representative population from each library, 
  
71 
approximately 96 colonies) were used for DNA sequencing using 6DQJHU¶VPHWKRG195, 
by the DNA chemistry team at MedImmune (Cambridge, U.K.) using the primer MYC 
(Appendix II).  ScFv sequences were analysed and annotated using Blaze2 software®.  
96-well plate glycerol stocks were also used for phage ELISA to assess the number of 
antigen specific scFv collected from the selections. 
 
2.5.6 Phage ELISA 
96-well glycerol stocks from selections were used for inoculation of 96-well plates 
containing 900 µl of 2TYAG media, cultures were grown to an OD600 of 0.5-1.0.  
Phage production was started by the infection with helper phage M13K07 (100 µl/well 
of 1.5x1010 pfu/ml solution) for 1 h at 37 qC.   Cultures were then centrifuged at 2000 
g for 10 min, the media was then changed to 500 µl of 2TYAK per well.   Plates were 
then incubated overnight at 25 qC to allow for accumulation of progeny phage in the 
supernatant. 
The following day, 500 µl of 6% MPBS was added to each well and incubated for 1 h 
at rt. Plates were then centrifuged at 2000 g for 5 min.  Biotinylated Bcl-2, Bcl-xL or 
Insulin was coated onto 96-well streptavidin coated plate at a concentration of 1.25 
µg/ml by addition of 50 µl of the protein sample to each well, followed by incubation 
of the plate at 37 oC for 0.5 h, and finally washing of the plate 3x with PBS.  50 µl of 
supernatant from the 96 deep-well plates containing phage was then added to 
corresponding wells on the Bcl-2, Bcl-xL, Insulin or streptavidin plates.  Incubations 
and washes followed that described for Direct binding ELISA.   Anti-M13 mAb HRP 
conjugate (R&D systems) was used as a secondary antibody and diluted by 1:5000 in 
3% MPBS.  50 µl of the secondary antibody was then added to each well, followed by 
incubation for 1 h at rt and then washing of the wells 3x with PBS.  Plates were 
developed and read as previously described in the direct binding ELISA protocol 
(Section 2.5.2).  ScFv which bind specifically to the antigen of interest were defined 
by having at least >3 fold signal over that seen on an irrelevant antigen. 
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2.5.7 High-throughput screening  
All materials were purchased from PerkinElmer and are as follows; OptiPlate-384 
(Prod#6007299), AlphaScreen® FLAG® (M2) Detection Kit, 10000 assay points 
(Prod#6760613M, Donor Streptavidin beads and Acceptor anti-flag beads).  Further 
materials used were; (Biotin)-Bcl-xL (366 µg/ml), BH3-flag (MedImmune, 24 µM 
stock solution, DYKDDDDK-linker-QEDIIRNIARHLAQVGDSMDRSIW), assay 
buffer (100 mM Tris (pH 8), 0.1% BSA, 0.01% Tween-20). 
 
2.5.7.1 Expression of scFv in E. coli periplasm 
96-well glycerol stocks from a selected library were replicated into a 96 deep-well 
plate containing 900 µl of 2TYAG media.  Plates were incubated at 37 oC until 
cultures had an OD600 of ~0.6.  100 µl of IPTG was added to each well at a 
concentration of 1 mM, giving a final well concentration of 0.1 mM.  Plates were 
grown overnight a 30 oC to allow protein expression.  The next day plates were 
centrifuged at 3000 g for 10 min, supernatant was removed and the cell pellets were 
resuspended in 400 µl of MES buffer (50 mM MOPS, 0.5 mM EDTA , 50 mM 
sucrose, pH 7.4), followed by incubation on ice for 30 min.  Plates were again 
centrifuged at 3000 g for 10 min.  The required volume of supernatant was then taken 
for use in high-throughput screening. 
 
2.5.7.2 Alpha Screen Bcl-xL high-throughput screen 
An Alpha screen competition assay was set up to identify scFv that inhibit the binding 
of Bcl-2/xL to BID BH3.  Upon binding of Bcl-2/xL to BH3 a signal is emitted 
allowing for the interaction to be detected.  Upon addition of an inhibiting scFv a loss 
in signal is observed.    
For high-throughput screening, a final assay concentration of 1.95 nM of Bcl-xL and 
0.49 nM of BH3-flag were used.  ScFv library periplasm preparations in 96-well plates 
were transferred onto a 384 Optiphase plates using a Mini track well dispenser, so that 
each well contained one scFv clone.  All other reagent additions were performed using 
a using Multidrop Combi dispenser (Thermo scientific).   
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Controls included non-specific binding (BH3-flag only, no scFv or Bcl-2/xL) and total 
binding (BH3-flag and Bcl-2/xL only, no scFv) wells.  Controls were repeated 6 times 
for each experiment.   
The detection mix was prepared in assay buffer to give a final assay concentration of 
20 µg/ml of both donor and acceptor beads.  The procedure was carried out in a dark 
room under green light. 
Each well contained the reagents added in the following order: 7.5 µl periplasm 
preparations, followed by 7.5 µl of biotinylated Bcl-xL (from a 7.8 nM stock solution).  
The plates were then incubated for 30 min at rt.  Following this step, 5 µl/well of BH3-
flag (from a 2.94 nM stock solution) was added to to the plate and incubated for 60 
min at rt.  Lastly 10 µl of beads (60 µg/ml stock to give a 20 µg/ml final assay 
concentration) were added to each well and incubated for 90 min at rt.  Finally, plates 
were read on an EnVision plate reader (Alpha screen filters and protocols as 
recommended by manufacture¶s guidelines).  Positive hits were defined as < 5% of 
binding compared to the total binding controls. 
 
2.5.7.3 Bcl-2 DELFIA High-throughput screen   
The low sensitivity of the alpha screen Bcl-2 format led to the development of a 
second assay to screen Bcl-2 scFv library outputs.  This was based on a dissociation 
lanthanide fluorescent assay DELFIA assay described by Rega et al. (2007).191  Range 
determining experiments allowed suitable concentrations of reagent to be used.  All 
assay buffers were purchased form Perkin Elmer.  Initially, periplasm samples of scFv, 
selected using Bcl-2, were prepared as previously described (Section 2.5.7.1).    
BID-BH3 biotin (biotin-QEDIIRNIARHLAQVGDSMDRSI, >95% purity, 
synthesised by Pepscan Ltd,) was coated onto 96-well streptavidin coated plates at 37 
qC for 30 min at a concentration of 125 nM.  Plates were then washed 3x with 1x PBS, 
followed by blocking using 3% MPBS for 1 h at rt.  Plates were then washed 3x with 
1x PBS, followed by addition of 25 µl of Bcl-2 (R&D systems, 0.73 mg/ml, 27 kDa) 
at a concentration of 12.5 nM in 6% MPBS.  25 µl/well of periplasm preparations 
were then added to give a single clone in each well.  This gives a final assay Bcl-2 
concentration of 6.25 nM.  Plates were then incubated at rt for 1 h and washed 3x with 
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PBS/0.1% Tween.  50 µl of anti-His-tag antibody conjugated to Eu3+ (Invitrogen) at a 
concentration of 100 ng/ml in DELFIA buffer was added to each well and incubated 
for 1 h at rt.  Plates were then washed 10x with DELFIA buffer followed by addition 
of 50 µl DELFIA enhancement solution.  Plates were finally read on an Envision Plate 
reader at 615 nm.  Positive hits were defined as < 5% of binding compared to the total 
binding controls. 
 
2.5.8  Alpha Screen profiling of His-tag affinity purified scFv. 
All final assay concentrations were the same as that used in the high-throughput screen 
(Section 2.5.7.2).  Titration of His-tag purified scFv was carried out in Grainer 96-well 
plate.  A 1/3 serial dilutions were prepared by the addition of 15 µl scFv (or its 
dilution) into 30 µl assay buffer consecutively on 96-well plate.  Dilutions were 
carried out for each sample in duplicate, 10 µl of scFv dilution was then added to an 
assay well (OptiPlate-384).  The reagents were added in the following order: 10 µl of 
scFv dilution followed by 5 µl of biotinylated Bcl-2 (46.8 nM stock) or Bcl-xL (11.7 
nM stock) and incubated for 30 min at rt.  Following this step, 5 µl/well of BH3-flag 
(Bcl-2 assay: 46.8 nM stock and for Bcl-xL assay: 2.94 nM stock) was added and 
incubated for 60 min at rt.  Lastly, 10 µl of beads (60 µg/ml stock to give a 20 µg/ml 
final assay concentration) were added and incubated for 90 min at rt.  Finally, plates 
were read on an EnVision plate reader (alpha screen filters and protocols as 
recommended by manufactures guidelines required).   
 
2.5.9 scFv binding ELISA in the presence of reduced glutathione 
Purified scFv24, 44 and 77 were diluted to 24 µg/ml into PBS (pH 7.4).  50 µl of the 
diluted scFv were transferred to the required number of wells on a 96-well plate.  To 
these wells was added a 50 µl solution of reduced glutathione (Sigma-Aldrich) in PBS 
at varying concentrations (scFv concentration of 12 µg/ml and glutathione 
concentration of 0, 2.5, 5, 10 or 20 mM).  These samples were then incubated for 24 h 
at 37 oC). 
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Biotinylated Bcl-2 or Bcl-xL (1.25 µg/ml) was coated onto 96-well streptavidin-coated 
plates (Strepmax, costar 96-well plate, Thermo scientific) as previously described 
(Section 2.5.2). A streptavidin coated plate, without added antigen, was used as 
negative control to detected non-specific scFv.  The plates were then washed 3x with 
PBS to remove unbound antigen.  Plates were then blocked with 3% MPBS and 
incubated for 1 h at rt. 
50 µl/well of scFv that had been incubated at the 37 oC for 24 h at a concentration of 
12 µg/ml and in the presence of reduced glutathione (0-20 mM).  The scFv were 
incubated in each well for 1 h at rt.  The plates were then washed 3x with PBS/0.1% 
Tween, followed by the addition of 50 µl/well of anti-myc mAb (9E3) (1 µg/ml) in 3% 
MPBS for 1 h at rt.  Plates were again washed 3x with PBS/0.1% Tween, followed by 
the addition of 50 µl/well of goat anti-mouse mAb HRP conjugate, diluted according 
WRPDQXIDFWXUHU¶VUHFRPPHQGDWLRQLQ03%6)LQDOO\SODWHVZHUHZDVKHG[ZLWK
PBS/0.1% Tween and developed and read as previously described (Section 2.5.2). 
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3  
 
3UHSDUDWLRQDQGFKDUDFWHULVDWLRQRI
VF)Y-&33FRQMXJDWHV 
 
Many biologically active peptides and proteins are unable to internalise into a cell and 
so are ineffective as therapeutics.  A class of peptides called Cell Penetrating Peptides 
(CPPs) have been demonstrated to facilitate the internalisation of macromolecules into 
cells overcoming the cell membrane barrier.196-197    
The use of CPPs for intracellular delivery of proteins has been described extensively 
in the literature.  Of the many CPPs known, the most commonly used are Penetratin 
(Antp)79, HIV Tat 90 and octa-arginine (R8).89  In this chapter, site-specific labelling of 
anti-Bcl-2 and anti-Bcl-xL scFvs with CPPs is described.  The wide number of 
variables that could affect the in vivo properties and efficacy of scFv-CPP conjugates 
such as, the nature of chemical conjugation 70 and influence of the cargo 73 were all 
considered when developing the CPP derivatives.  
The major goals of this chapter are to induce apoptosis in cancer cells by inhibiting 
Bcl-2 and/or Bcl-xL using neutralising anti-Bcl-2 and anti-Bcl-xL scFv-CPP 
conjugates, and to develop methodology that allows for systematic optimisation of a 
scFv-&33¶V cell penetrating capabilities.   
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3.1 Synthetic approaches for scFv-CPP conjugation 
A common approach for the site-specific labelling of proteins is through incorporation 
of an unpaired cysteine residue in the protein construct, thus allowing chemoselective 
labelling using thiol reactive groups.  It was proposed that CPP derivatives modified at 
the N-terminus with either an isobutyryl Cys or maleimido moiety could be conjugated 
to scFv possessing an unpaired cysteine residue (scFv-Cys), thus affording either a 
reversible or non-reversible scFv-CPP conjugate (Figure 3-1). 
 
Figure 3-1: The introduction of a C-terminal cysteine to the scFv construct will allow for site-specific 
labelling through a) disulfide bond formation with the N-terminal cysteine residue of a CPP, or b) 
formation of a thioether bond with a N-maleimido CPP.  A C-terminal His-tag will allow for 
purification of scFv by affinity chromatography and the myc tag (EQKLISEEDL) will allow for 
detection of scFv in ELISA and immunoblotting using anti-myc mAb (9E3). 
Cysteine
pH 7-9 pH 5-7
a) b)
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The first step of the proposed synthesis of scFv-CPP conjugates was the preparation of 
scFv that possess a C-terminally located unpaired cysteine residue.  Additionally, an 
important requirement is a robust method for the medium-scale production of a panel 
of scFv-Cys. E. coli is the most convenient method for the production of scFv due to 
E. coli¶V ZHOO FKDUDFWHULVHG JHQHWLFV DELOLW\ WR JURZ UDSLGO\ WR KLJK GHQVLW\ DQG LV
relatively inexpensive compared to alternative expression systems.198-199  However, 
expression of scFv in E. coli can give marked variations in yield, which is thought to 
be largely dependent on the scFv primary sequence.153   
 
3.2 Expression of scFv-Cys 
The expression of scFv24, 44, 49, 61 and 77 in E. coli was investigated using the 
phagemid vector pUC119MCH (Medimmune, U.K).  Additionally, expression of an 
anti-human carcinoembryonic antigen scFv (Cea6) 31 was also investigated.  It was 
predicted that the high specifity of this scFv for the extracellular carcinoembryonic 
antigen would make this molecule an ideal negative control for biological assays 
investigating the intracellular delivery of the anti-Bcl-2 and Bcl-xL scFvs.  The 
production of scFv using this vector is driven by a lac promoter system.  This vector 
also contains a pelB leader sequence to direct scFv to the oxidising E. coli periplasm, 
thus aiding scFv folding and formation of intradomain disulfide bonds.  The expressed 
scFv construct is illustrated in Figure 3-2. 
 
 
Figure 3-2: The expressed scFv construct from the pUC119MCH vector.  A C-terminal His-tag is 
included for affinity purification, and myc tag for scFv immunodetection using an anti-myc mAb (9E3).  
An unpaired cysteine residue is located between the two C-terminal tags allowing for CPP conjugation. 
 
 
The scFv-encoding DNA was sub-cloned into the pUC119MCH vector by excision of 
scFv DNA from the pCANTAB6 vector used previously for phage display.  This was 
achieved using the restriction endonucleases NotI and SfiI.  The ligation of scFv DNA 
into previously NotI/SfiI digested pUC119MCH vector was then achieved using T4 
Ligase (E.C. 6.5.1.1).  The ligated plasmids were then used to transform competent E. 
coli.  Selection of E. coli colonies possessing the pUC119MCH vector was achieved 
6x HisCysc-myc tagVLVH
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by Ampicillin selection.  A representative population of colonies were cultured and 
used for DNA sequencing to confirm successful and in-frame sub-cloning of the scFv-
encoding DNA into the plasmid.   
In the first instance, the expression of scFv24 and 61 in E. coli was investigated using 
the BL21 E. coli strain on a 400 ml culture scale.  The expression of scFv-Cys was 
induced using 1 mM IPTG when the E. coli culture had reached mid-log phase (OD600 
0.5).  The E. coli cultures were then incubated for 3 h at 37 oC, followed by harvesting 
and lysis of the bacteria using lysozyme and sonication.  The expressed scFv-Cys 
possessing a His-tag were then isolated by affinity purification using a Ni2+ chelating 
column.  The nickel bound scFv-Cys was eluted from the column by increasing the 
imidazole buffer concentration linearly from 40-400 mM.  The eluted scFv-Cys was 
then pooled and analysed by SDS-PAGE.  Unfortunately, the isolated scFv24 and 61 
were of extremely low purity.  Figure 3-3 shows the polyacrylamide gel for purified 
scFv24. 
 
 
Figure 3-3: Reducing SDS-PAGE 15% acrylamide gel of scFv24 after affinity and size exclusion 
purification.  The band corresponding to the scFv is approximately 30 kDa. a) His-tag affinity purified 
scFv24 b) scFv24 after size exclusion chromatography.  
 
In repeated purifications, 20 mM imidazole and 10% glycerol was added to the E. coli 
lysate before loading onto the nickel column to reduce non-specific binding of 
bacterial proteins.  Unfortunately, this had no significant impact on the scFv purity. 
Thus, the partially purified scFv24 was subjected to size exclusion chromatography 
using a Superdex 75 (16/60) column (GE healthcare) to afford a pure sample in a yield 
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of 20% (Figure 3-3, b).  The yields for scFv24 and 61 after the two purification steps 
were between 250-350 µg/L (Table 3-1). 
Table 3-1: Isolation yields for scFv24 and 61 from E. coli expressed from the pUC119MCH vector. 
scFv Expression Yields, µg/L Size exclusion yield  
24 270  20% 
61 340 32% 
 
The expression yields for scFv24 and 61 obtained here are neither remarkably low, nor 
in the top bracket of the yields generally reported in the literature (0.1-20 mg/L).151-152  
However, the low expression of scFv24 and 61 in E. coli using the pUC119MCH 
vector would require large culture volumes to gain useful quantities of scFv. 
In an attempt to improve yields, the T7/lac promoter system was investigated for the 
E. coli expression of scFv-Cys.  High yields of recombinant proteins can be obtained 
when using this promoter system in an E. coli strain possessing the T7 RNA 
polymerase gene (DE3ʄ lysogen).199  
The scFv24 encoding-DNA was sub-cloned into the expression vector p10HISCYS 
(MedImmune, U.K.) using the same method as described for the pUC119MCH vector.  
The p10HISCYS vector possesses a T7/lac promoter system and affords a protein 
construct with a C-terminally located His-tag and unpaired cysteine residue.  
Furthermore, this vector contains the PelB leader sequence to direct scFv to the 
periplasm.  Interestingly, it has been reported that directing scFv to the periplasm 
together with high expression levels can result in leakage of the scFv into the culture 
media.193  This can make purification significantly easier, allowing for efficient 
isolation of scFv in high yields.  Thus, it was hypothesised that the T7/lac promoter 
system will dramatically increase expression levels, both allowing for increased 
isolation of soluble scFv from the periplasm and promote scFv leakage into the culture 
media.  The scFv construct expressed from this vector is illustrated in Figure 3-4.   
 
 
Figure 3-4: ScFv construct resulting from E. coli expression using the p10HISCYS vector; A C-terminal 
His-tag for affinity purification and C-terminal Cys is included for CPP conjugation.  
 
Cys10x HisVLVH
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Initially, the expression of scFv24 in E. coli was performed on a 10 ml scale using 
BL21 (DE3ʄ) E. coli.  Cultures were induced with 1 mM IPTG at mid-log phase 
followed by incubation for 16 h at 25 oC.  The E. coli was harvested and lysed, 
followed by analysis of the bacterial fractions using SDS-PAGE and western blot 
(Figure 3-5). 
 
Figure 3-5: Western blot of scFv24 expressed in BL21 (ȜDE3) from p10HISCYS.  E. coli was induced 
at mid-log using 1 mM IPTG and incubated for 16 h at 25 oC.  The bacteria were fractionated to give 
the whole cell, media, soluble and insoluble fractions.  The nitrocellulose membrane was incubated with 
anti-polyhistidine mAb (R&D systems) followed by incubation with a goat-anti-mouse mAb (R&D 
systems) horseradish peroxidase conjugate and developed using 3,3ƍ,5,5ƍ-Tetramethylbenzidine (TMB). 
 
Unfortunately, no scFv24 was detected in any of the soluble fractions.  However, 
scFv24 was detected in the insoluble fraction using an anti-polyhistidine mAb at 
approximately 28 kDa, as can be seen from the western blot in Figure 3-5. 
The next step was to monitor the expression of scFv24 over 16 h at 16 oC to determine 
an optimum point to harvest E. coli and avoid the formation of inclusion bodies.  After 
inducing the cultures with 1 mM IPTG, a 1 ml aliquot was removed at 1, 3, 6 and 16 h.  
The E. coli was harvested by centrifugation followed by lysis using lysozyme (1 
mg/ml).  The insoluble and soluble fractions were then analysed by reducing SDS-
PAGE (Figure 3-6). 
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Figure 3-6: Time course of E. coli expression of scFv24 using the p10HISCYS vector in BL21 (ȜDE3). 
E. coli was induced at mid-log with 1 mM IPTG and incubated for 16 h at 16 oC with samples being 
taken at specific time points.  a) Bacterial fractions were analysed using a 15% SDS-PAGE gel and 
stained with Coomassie blue  b) after the electoblot, the nitrocellulose membrane was incubated with 
anti-polyhistidine mAb followed by an goat anti-mouse mAb horseradish peroxidase conjugate and 
developed using 3,3ƍ,5,5ƍ-Tetramethylbenzidine (TMB).  
 
Unfortunately, the majority of scFv24 expressed from the pHIS10CYS vector appears 
in the insoluble bacterial fraction at 16 h post-induction (Figure 3-6).  It was decided 
that the p10HISCYS vector was unsuitable for the expression of a panel of scFv in this 
study.  Therefore, an alternative approach to obtain useful quantities of scFv was 
investigated. 
  
3.2.1 Mammalian expression of scFv-Cys 
The expression of lead scFv in a mammalian expression system established at 
MedImmune (Cambridge, U.K) was investigated.  ScFv24, 77, 49 and the controls 
scFv84 63 and Cea6 31 were sub-cloned into the mammalian expression vector 
pEOMCH.  The scFv construct from the pEOMCH vector is identical to that produced 
by the pUC119MCH vector (see Figure 3-2).   
A variant of Chinese Hamster Ovary cells (CHO), called CEP6 were used for the 
expression of scFv-Cys.  Small-scale expression was carried out using a 10-20 ml 
suspension of CEP6 cells (5 x 105 cells/ml).  The transient transfection of CEP6 cells 
with the pEOMCH vector was achieved using the transfection reagent 
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polyethylenimine (PEI).  An aqueous solution of PEI (10 mg/ml) was added in equal 
volume to a solution of purified plasmid (0.25-0.5 mg/ml).  This mixture was then 
transferred to the CEP6 cultures to give a final concentration of 1 µg DNA/ml of cells.  
The transfected cultures were incubated at for 10 days 37 oC with shaking, followed 
by cell harvesting and analysis of the culture media using a western blot to detect 
secreted scFv (Figure 3-7). 
 
Figure 3-7: Western blot of CEP6 expression of scFv24, 77, 61, 84 and Cea6 using the pEOMCH 
vector.  Cells were transiently transfected and incubated for 10 days at 37 oC.  Culture media was 
analysed by western blot using a 4-12% polyacrylamide gel followed by transfer to nitrocellulose 
membrane.  The membrane was incubated with anti-myc mAb (9E3) followed by goat anti-mouse mAb 
horseradish peroxidase conjugate and developed using an acridan-based substrate and read at 440 nm. 
 
The small-scale expression of scFv24, 84 and Cea6 in CEP6 cells was successful.  
However, no detectable expression of scFv61 was observed (Figure 3-7).  Although 
scFv77 was expressed in good levels the observed mass by western blot was ~35 kDa 
(Figure 3-7).  The greater mass observed compared to that calculated for scFv77 (29 
kDa) may be attributable to glycosylation at an N-glycosylation recognition sequon 
(Asn-Xaa-Thr) present in the C-terminus of the scFv (Figure 3-8).200-201  
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Figure 3-8: SDS-PAGE analysis of scFv77 showing a band at ~35 kDa.  scFv77 amino acid sequence 
shows the presence of an Asn-Xaa-Thr sequon.  A 4-12% polyacrylamide gel was used and stained 
using Coomassie blue. 
 
The good expression of scFv77 still makes this a suitable scFv for further 
investigation.  If glycosylation has occurred, the close proximity of the glycosylation 
site to the C-terminal cysteine residue may have a negative effect on both CPP 
conjugation and subsequently cellular internalisation.  Therefore, removal of the N-
glycosylation site by replacing the asparagine with a glutamine residue using site-
direct mutagenesis is required. 
The expression of scFv24, 84 and Cea6 was scaled up to a 0.5 L culture volume.  The 
CEP6 cells were transiently transfected as previously described followed by 
incubation of the culture for 10 days 37 oC. The cells were harvested and the expressed 
scFv possessing a His-tag were isolated from the culture media by affinity purification 
using a Ni2+ chelating column.  The obtained expression yields and SDS-PAGE 
analysis of the purified scFv24, 84 and Cea6 are shown in Figure 3-9.   
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scFv Yields, mg/L 
scFv24 26.2 
Cea6 59.2 
scFv84 26.3 
   
Figure 3-9:  The expression yields from CEP6 cells for scFv24, Cea6 and scFv84 using the pEOMCH 
vectors.  SDS-PAGE analysis shows pure protein with a single band at ~30 kDa. 4-12% polyacrylamide 
gel was used and stained using coomassie blue. 
 
The medium-scale expression of scFv24, 84 and Cea6 in CEP6 cells was successful, 
allowing for isolation of scFv in good yields of 26.2, 59.2 and 26.3 mg/L, respectively.  
These yields are significantly higher than yields achieved in E. coli.  Notably, minimal 
optimisation of the transfection and expression conditions were required to achieve 
high isolation yields for each scFv providing a universal expression system for the 
panel of lead anti-Bcl-2 and anti-Bcl-xL scFv. 
An important requirement from the mammalian expression system is the production of 
active scFv-Cys.  Hence, the ability of purified scFv to inhibit Bcl-2 and Bcl-xL 
binding to the BH3 region of BID was determined using an Alpha screen assay.  The 
inhibition curves for scFv24, 84 and Cea6 are shown in Figure 3-10. 
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  IC50, nM 
  Bcl-2 Bcl-xL 
scFv24 - 6 ± 2 
Cea6 - - 
scFv84  > 4000 153 ± 2 
 
Figure 3-10: The inhibition curves for scFv24, scFv84 and Cea6 in an Alpha screen assay, curves show 
the inhibition of Bcl-2/xL binding to BID-BH3 by a) scFv24, b) scFv84 and c) Cea6.   
 
 
The IC50 values determined for the inhibition of the Bcl-2 and Bcl-xL interaction with 
BH3 for scFv24, 84 and Cea6 corresponded to IC50 values determined for the scFvs 
expressed on a small-scale using the phagemid vector pCANTAB6 (Chapter 2).  The 
purified scFv24 inhibited the binding of Bcl-xL to BH3 with an IC50 value of 6 ± 2 
nM.  Surprisingly, the positive control scFv84 that was isolated from phage display 
libraries by Cohen-Saidon et al. (2003) and demonstrated to inhibit Bcl-2, showed 
only minimal inhibition of Bcl-2 binding to BH3 in the Alpha screen assay.63  
However, this scFv did inhibit Bcl-xL with an IC50 value of 153 ± 2 nM.  This result is 
in contrast to the reported properties of scFv84.63  Finally, Cea6 showed no inhibition 
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of Bcl-2 or Bcl-xL confirming its suitability for use as a negative control in cell based 
assays. 
Mammalian expression of lead scFvs proved successful, with high yields being 
obtained (26-60 mg/L) for scFv24, 84 and Cea6.  The expression conditions required 
minimal optimisation between different scFv constructs, thus addressing the first aim 
of this study.  Additionally, practical quantities of active scFv-Cys were obtained. This 
will allow for the investigation of CPP-mediated cellular delivery of the lead scFv and 
provide material for the envisaged whole cell and in vitro assays.  The next phase of 
the project is described, focussing on the synthesis of CPP derivatives for site-specific 
conjugation to scFv-Cys.   
 
3.3 Fmoc solid-phase peptide synthesis of CPPs 
In the first instance, CPPs that are well established for the cellular delivery of proteins 
were investigated for cellular delivery of lead scFv. Table 3-2 shows the CPP 
sequences that were chosen to be synthesised and conjugated to scFv-Cys. 
 
Table 3-2: Cell penetrating peptides chosen for conjugation to scFv-Cys. 
  
 Derivatives Sequence Reference 
 
  Penetratin  derivatives 
  Antp52-58 RRMKWKK Fischer et al. (2000) 202 
Antp43-58 RQIKIWFQNRRMKKWKK Derossi et al. (1996) 79 
   Polyarginine derivatives:  
  octa-arginine RRRRRRRR Wender et al. (2000) 89 
   HIV Tat derivatives 
  Tat49-57 RKKRRQRRR Vives et al. (1997) 90 
   Polyproline derivatives  
  Pro14 PPPPPPPPPPPPPP Crespo et al. (2002) 95 
 
 
Polyarginine, Penetratin and HIV Tat have been extensively used for the cellular 
delivery of proteins.  Additionally, Crespo et al. (2002) describe the internalisation of 
FAM-(Pro)14-OH 12 into NRK-49F cells.95  Hence, it was proposed that conjugation 
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of (Pro)14 to scFv could enable cell penetration.  This peptide would be an interesting 
alternative to the polycationic CPPs as its non-cationic nature would be expected to 
result in significantly different in vivo properties compared to a cationic CPP.81   
The synthesis of all CPP derivatives was achieved using Fmoc solid-phase peptide 
synthesis (SPPS) 7KH6KHSSDUG¶V)PRFt-Bu SPPS approach utilises the base labile 
9-IOXRUHQ\OPHWK\OR[\FDUERQ\O )PRF JURXS IRU Į-amino protection in conjunction 
with acid-labile side-chain protection of amino acids.203  The general principles of 
Fmoc SPPS are outlined in Scheme 3-1.  
Scheme 3-1: The general principles of Fmoc solid-phase peptide synthesis (SPPS). 
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The first step in Fmoc SPPS is the introduction of a NĮ-Fmoc protected amino acid to 
a solid support via a linker.  The Fmoc group is then removed using 20% piperidine/ 
DMF prior to the addition of the second amino acid which is also in the NĮ protected 
form.  Amide bond formation is achieved by activation of the carboxyl group of the 
NĮ-Fmoc protected amino acid promoting nucleophilic attack by the amino group of 
the peptidyl resin.  The activation of a carboxylic acid can be achieved by substitution 
of the hydroxyl with an electron withdrawing group, thus increasing the 
electrophilicity of the carbonyl.  A common method to activate a carboxyl group is by 
using aminium or phosphonium coupling reagents, such as HATU, HBTU, TBTU or 
PyBOP.204-205  An alternative method is through carbodiimide activation using N,N'-
Diisopropylcarbodiimide (DIC) in the presence of an auxiliary nucleophile, for 
example 1-hydroxy-7-azabenzotriazole (HOAt) 206 to form an activated ester.  After 
introduction of the required amino acids to the peptidyl resin through repeated cycles 
of Fmoc deprotection, carboxyl activation and amide bond formation, the peptide can 
be cleaved and fully deprotected using 90% TFA to afford the desired peptide 
derivative. 
 
3.3.1 Synthetic strategies for CPP derivatives 
A standardised approach to the synthesis and design of CPP derivatives is important 
for the systematic optimisation of scFv-CPP conjugates.  Therefore, a robust method 
for the introduction of thiol reactive groups to CPP derivatives was investigated.  
Another crucial component in this phase of the project is to provide a simple and 
robust method for the qualitative measurement of scFv-CPP cellular internalisation.  
This can be achieved through the addition of a fluorescent probe to the CPP construct.  
The general design of the CPP derivatives is shown Figure 3-11.  
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Figure 3-11: The general design of the CPP derivatives, a C-terminal lysine residue will allow for 
fluorescent labelling of the peptide.  The N-terminus of the peptide will allow for coupling of either a 
maleimidopropionyl or isobutyryl cysteine moiety for site-specific conjugation to scFv-Cys 
 
The CPP construct was designed for the introduction of both thiol reactive groups and 
fluorescent probes.  The C-terminal lysine residue provides a reactive handle for 
modification with a fluorescent probe.  An established method to achieve this is by 
introducing an orthogonally protected lysine residue to the peptidyl resin.  This can 
then be deprotected for regiospecific introduction of a fluorescent probe followed by 
universal cleavage and deprotection to afford the labelled peptidic material.205   
Two established orthogonal protecting groups for side-chain protection of a lysine 
residue are the hydrazine-labile ivDde 204,207 and the acid sensitive methoxytrityl 
(Mmt) protecting groups.208  The ivDde protecting group is stable to 20% piperidine 
and >95% TFA, thus providing orthogonality with the Fmoc group and acid-labile 
protecting groups.207  The Mmt protecting group can be removed from the side-chain 
of Lys using 1% TFA in DCM allowing for deprotection in the presence of the Fmoc 
group and side-chain protecting groups that require >90% TFA for removal.208  Both 
protecting groups provide the orthogonality required for selective deprotection of a C-
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terminal lysine residue, followed by the introduction of a fluorescent probe to the CPP 
derivatives.  
5-Carboxyfluorescein 54 (5-FAM) is a versatile fluorescent probe and is commonly 
used to label peptides for imaging using confocal laser scanning microscopy (CLSM) 
and fluorescence microscopy.  5-FAM can be regioselectively introduced to a peptide 
during solid-phase synthesis.  The coupling of 5-FAM 54 to an orthogonally 
deprotected lysine residue can be achieved using DIC 55 and HOAt 56 to activate the 
5-carboxyl group.  This affords the activated intermediate 57 allowing for the SN2 
substitution at the carbonyl of 57 by the İ-amine of Lys (Scheme 3-2).209  
 
Scheme 3-2: Mechanism of 5-carboxyfluorescein 54 coupling to a primary amine using DIC 55 and 
HOAt 56. 
 
 
 
However, the 5-FAM phenolic groups can also attack the activated carboxyl group of 
5-FAM to form polymeric phenyl esters.  Base-catalysed aminolysis using 20% 
piperidine/DMF can be used to cleave ester bound 5-FAM.210 
The Rink Amide NovaGelTM resin was utilised for the synthesis of the CPP 
derivatives.  Once the peptide has been assembled by step-wise introduction of NĮ-
protected amino acids to resin, the peptidic material is cleaved from the resin and 
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universally deprotected using a solution of TFA-TIPS-H2O (90:2:8) to afford the 
peptide amide.205  The introduction of Fmoc-Lys(ivDde)-OH or Fmoc-Lys(Mmt)-OH 
to the rink amide linker allows for the orthogonal deprotection and regioselective 
modification of the lysine residue prior to the universal cleavage/deprotection step.       
Furthermore, N-terminal functionalization of CPP derivatives with either a maleimido 
moiety or cysteine residue will allow for site-specific conjugation of the CPP to scFv-
Cys.  In the first instance, the synthesis of Antp52-58 derivatives was investigated.  The 
synthesised peptides were functionalised with either an N-terminal isobutyryl Cys or 
maleimido moiety, together with regiospecific labelling with 5-FAM.   
 
3.3.2 Penetratin derivatives 
Penetratin (Antp) is a well characterised CPP and has been demonstrated to deliver 
proteins into cells.  Fischer et al. (2000) 202 showed that the eight amino acid truncated 
Penetratin derivative Antp52-58 (52RRMKWKK58) efficiently penetrates cells and is the 
minimum sequence required for internalisation.  This peptide was synthesised because 
of its simplicity and size, making it an attractive peptide for future studies in terms of 
scale-up synthesis.  Additionally, the originally described full length Antp43-58 
(43RQIKIWFQNRRMKWKK58) 78 was also synthesised.  The proposed synthesis of 
N-isobutyryl Cys Penetratin (Antp52-58) derivatives is shown in Scheme 3-3.   
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Scheme 3-3: Synthesis of the N-isobutyryl Cys Antp52-58 derivatives. 
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The first residue to be introduced to the resin linker was Fmoc-Lys(ivDde)-OH using 
HATU and DIPEA.  All subsequent amino acids were then coupled to the peptidyl 
resin using HATU to afford intermediate 58.  The final Fmoc-Cys(Trt)-OH residue 
was coupled to the peptidyl resin using HOAt and DIC to reduce racemisation.211  This 
was followed by Fmoc deprotection and N-capping with an isobutyryl moiety using 
isobutyric anhydride to yield the peptidyl resin 59 (Scheme 3-3, steps i- iv).   
The next step was the orthogonal deprotection of peptidyl resin 59 by removing the 
ivDde protecting group from the C-terminal lysine residue using 1% Hydrazine/DMF 
to afford intermediate 60 (Scheme 3-3, step v).  The deprotection profile was 
monitored by detection of the chromophoric indazole reaction-product at 290 nm.207   
Intermediate 60, was universally deprotected and cleaved from the resin by acidolysis 
using 90% TFA to afford Antp52-58 derivative 61 (Scheme 3-3, step vi).  Alternatively, 
5-FAM was coupled to 60 via WKHİ-amino group of the deprotected Lys using HOAt 
and DIC to afford intermediate 62 (Scheme 3-3, step vii-viii).  Finally, the full 
deprotection of 62 and cleavage from the resin yielded the 5-FAM labelled Antp52-58 
derivative 63 (Scheme 3-3, step ix).  The crude HPLC traces of the two N-isobutyryl 
cysteinyl Antp52-58 derivatives 61 (tR 3.12 min) and 63 (tR 7.16 min) are shown in 
Figure 3-12 a) and b), respectively.   
 
 
Figure 3-12:  The crude HPLC trace of a) Antp52-58 derivative 61 b) Antp52-58 derivative 63.  Samples 
were run using the method; 10-40% B over 10 min, 3 ml/min.  The column used was an Onyx 
Monolithic analytical C18 column (100 x 4.6 mm). 
 
 
The synthesis of both the Antp52-58 derivatives 61 and 63 was successful, preparative 
HPLC was used to isolate the peptides in a purity of >85% and isolation yields of 51% 
and 46% for 61 and 63, respectivly.  The general concepts outlined for the synthesis of 
a) b)
min min 
A
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61 and 63 were applied to the synthesis of N-maleimido functional Antp52-53 
derivatives. 
It was proposed that introduction of N-maleoyl-ȕ-alanine 64 to the N-terminus of the 
Antp52-58 peptidyl resin following the method described by Hansen et al. (1998) would 
afford the N-maleimidopropionyl Antp52-58 derivative.163  The first step taken was the 
synthesis of N-maleoyl-ȕ-alanine 64 following the literature precedent (Scheme 3-
4).212 
Scheme 3-4: Synthesis of N-maleoyl-ȕ-alanine 64. 
 
 
The condensation of stoichiometric quantities of maleic anhydride 65 DQGȕ-alanine 66 
in AcOH afforded the intermediate 67 at rt as a white precipitate (Scheme 3-4, i).  The 
acid-catalysed intramolecular attack of the carbonyl group by the amide was then 
promoted by reflux of 67 in AcOH to afford the maleimide 64 after silica 
chromatography in a yield of 50% (Scheme 3-4, ii), which was spectroscopically 
identical to the literature.212  A scale-up of the reaction, to gram scale, resulted in no 
decrease in yield or purity.   
The synthesis of N-maleimidopropionyl Antp52-58 derivatives was achieved following 
Scheme 3-5.  The first residue to be introduced to the rink amide resin was Fmoc-
Lys(Mmt)-OH.  The Mmt protecting group was used as an alternative to the 
hydrazine-labile ivDde protecting group.  This was to avoid the potential Michael 
addition of hydrazine to the unsaturated imide of the maleimide moiety. 
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Scheme 3-5: Synthesis of N-maleimidopropionyl Antp52-58 derivatives. 
 
 
 
After the coupling of all the residues to the peptidyl resin, the N-terminal Fmoc group 
was deprotected, followed by introduction of N-maleimide-ȕ-alanine 64 to peptidyl 
resin using HOAt and DIC to afford intermediate 69 (Scheme 3-5, steps i-ii).  The full 
deprotection of 69 and cleavage from the resin using TFA-TIPS-H2O (90:2:8) yielded 
the N-maleimidopropionyl Antp52-58 derivative 70 as the major product (Scheme 3-5, 
step iii).  Following this approach the longer Antp43-58 derivative 75 was also 
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synthesised.  Figure 3-13 shows the crude analytical HPLC of both N-
maleimidopropionyl functional peptides 70 (tR 3.02 min) and 75 (tR 3.23 min). 
 
 
Figure 3-13: The crude HPLC trace of a) Antp52-58 derivative 70 (tR 3.02 min), b) Antp43-58 derivative 75 
(tR 3.23 min).  Peptide 70 was analysed using 20-30% B over 10 min and peptide 75 was analysed using 
20-70% B over 10 min, 3 ml/min and an Onyx Monolithic analytical C18 column (100 x 4.6 mm). 
 
Following successful synthesis of peptides 70 and 75, the introduction of 5-FAM to 
the maleimido functional Antp52-58 derivative was investigated.  In the first instance, 
the Mmt protecting group was removed from N-maleimidopropionyl functionalised 
intermediate 69 using 1% TFA, 1% TIPS in DCM.  This was followed by the 
introduction of 5-FAM to the Lys side-chain using HOAt and DIC, as previously 
described.  However, the final 20% piperidine/DMF step to removal 5-FAM 
polymeric phenolic esters proved problematic.  It became evident that the order of N-
maleoyl-ȕ-alanine and 5-FAM coupling was extremely important.  The final 
piperidine wash resulted in the addition of piperidine to the unsaturated imide of 
maleimide, thus deactivating the functional group.  To overcome this, the Mmt 
deprotection was performed before the removal of the N-terminal Fmoc group, to 
afford intermediate 71 (Scheme 3-5, step iv).  This allowed for the coupling of 5-FAM 
to the Lys side-chain (Scheme 3-5, step v) to yield 72.  Treatment of 72 with 20% 
piperidine/DMF removed the N-terminal Fmoc group allowing for the introduction of 
N-maleoyl-ȕ-alanine using HOAt and DIC to give 73 (Scheme 3-5, steps vi-vii).  
Finally the full deprotection of 73 and cleavage from the resin by acidolysis yielded 
the 5-FAM labelled N-maleimidopropionyl Antp52-58 derivative 74 as the major 
product (Scheme 3-5, step viii).  The crude HPLC trace for 5-FAM labelled Antp52-58 
derivative 74 (tR 4.34 min) is shown in Figure 3-14.  
a) b)c)a) b)
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Figure 3-14: The analytical HPLC trace of crude peptide Antp52-58 derivative 74 (tR 4.34 min) analysed 
using 1-90% B over 10 min, 3 ml/min with an Onyx Monolithic analytical C18 column (100 x 4.6 mm). 
 
 
The synthetic strategies described in this section were applied to the synthesis of octa-
arginine, HIV Tat and (Pro)14 derivatives.   
 
3.3.3 Octa-arginine derivatives 
N-Maleimidopropionyl octa-arginine derivatives 76 and 77 were synthesised following 
the same method described for N-maleimidopropionyl Antp derivatives 70, 74 and 75 
(see Scheme 3-5).   
 
The synthesis of the octa-arginine derivatives was achieved using the coupling reagent 
PyOxim®.213  The acylation reaction for each Fmoc-Arg(Pbf)-OH introduced to the 
peptidyl resin was repeated, before Fmoc deprotection, to insure complete coupling.  
The successful coupling of N-maleoyl-ȕ-alanine followed by cleavage and 
deprotection afforded N-maleimidopropionyl octa-arginine 76 as the major product.  
Alternatively, 5-FAM was introduced to the peptidyl resin followed by cleavage and 
b)
min 
A
U
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deprotection of the peptide to afford the 5-FAM labelled octa-arginine 77 as the major 
product (Scheme 3-5, v-viii).  Figure 3-15 shows the crude HPLC traces for 76 (tR 3.00 
min) and 77 (tR 6.27 min). 
 
 
Figure 3-15: The analytical HPLC trace of crude peptide a) octa-arginine derivative 76 (tR 3.00 min), 1-
90% over 15 min, 3 ml/min b) octa-arginine derivative 77 (tR 6.27 min), 1-50% B over 10 min, 
3ml/min, c) purified 76 (tR 2.72 min), 1-90% B over 10 min, d) purified 77 (tR 3.85 min), 1-90% B over 
10 min .  Both crude and purified peptides were analysed using an Onyx Monolithic analytical C18 
column (100 x 4.6 mm). 
 
 
The relatively unclean synthesis of 76 and 77 is most likely attributable to incomplete 
coupling of Fmoc-Arg(Pbf)-OH.  Nevertheless, the purity and yields achieved after 
a) b)
c)
d)
A
U
A
U
minmin
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d)
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preparative HPLC were suitable for the current study, providing sufficient material for 
conjugation to scFv-Cys. 
 
3.3.4 HIV Tat49-57 derivatives 
The synthesis of HIV Tat49-57 derivative 78 and the 5-FAM labelled derivative 79 was 
achieved using the same method used for the Antp derivatives (see Scheme 3-5). 
 
Initially, synthesis was performed using the coupling reagent HATU and DIPEA.  
However, no major product could be detected by analytic HPLC.  Monitoring of the 
effluent from the Fmoc deprotections at 290 nm gave indication of difficult amino acid 
couplings.  Difficult couplings were signified by a reduced Fmoc deprotection peak, 
notably the glutamine and following arginine residue showed significantly reduced 
Fmoc deprotection profiles.  Based on these observations, the acylation reactions to 
introduce Fmoc-Gln(Trt)-OH and Fmoc-Arg(Pbf)-OH to the peptidyl resin were 
repeated before Fmoc deprotection.  These alterations had little effect on the crude 
peptidic material obtained, with no major species being detected. 
However, repetition of the synthesis using the coupling reagent PyOxim®, together 
with repetition of the acylation reaction for each amino acid was successful affording 
the Tat47-58 derivative 78 as the major product.  Following Scheme 3-5, successful 
introduction of 5-FAM was also achieved to afford the 5-FAM labelled Tat47-58 
derivative 79.  The crude HPLC traces for the Tat47-58 derivatives 78 and 79 are shown 
in Figure 3-16.    
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Figure 3-16: The crude HPLC trace of a) Tat47-58 derivative 78 (tR 3.43 min), 1-30% B over 6 min, 3 
ml/min b) Tat47-58 derivative 79 (tR 5.24), 1-50% B over 10 min, 3 ml/min. c) purified 78 (tR 4.45 min), 
1-90% B over 15 min, d) purified 79 (tR 3.80 min), 1-90% B over 10 min.  Both crude and purified 
peptides were analysed using an Onyx Monolithic analytical C18 column (100 x 4.6 mm).   
 
The analytical HPLC traces of crude 78 and 79 show a major species at 3.43 and 5.24 
min respectively, corresponding to the desired Tat47-58 derivatives.  The synthesis of 78 
and 79 afforded material in yields and purity, after preparative HPLC, suitable for 
conjugation to scFv-Cys.    
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3.3.5 Pro14 derivatives 
The synthesis of N-isobutyryl Cys (Pro)14-Lys amide 80 and N-isobutyryl Cys (Pro)14-
Lys(FAM) amide 81 was investigated to provide a (Pro)14 derivative for conjugation to 
scFv.  The cell penetrating capability of this scFv-(Pro)14 conjugate can then be 
assessed using CLSM.95  The synthesis of the Pro14 derivatives was achieved 
following Scheme 3-3.  
 
After assembly of the peptides and coupling of 5-FAM, the peptidyl resins were 
cleaved from the resin by acidolysis to afford the Pro14 derivatives 80 and 81.  The 
crude HPLC traces for 80 (tR 4.59 min) and 81 (tR 7.33 min) are shown in Figure 3-17. 
  
103 
 
Figure 3-17: Crude HPLC trace of a) Pro14 derivative 80 (tR 4.59 min), b) Pro14 derivative 81 (tR 7.33 
min), both peptides were analysed using 1-60% B over 12 min, 3 ml/min . c) purified 80 (tR 5.00 min), 
1-60% B over 12 min, d) purified 81 (tR 7.37 min), 1-60% B over 12 min .  Both crude and purified 
peptides were analysed using an Onyx Monolithic analytical C18 column (100 x 4.6 mm).   
 
The analytical HPLC of each peptide showed the presence of a major species.  Further 
analysis of the major peak using TOF MS (ES+) showed the presence of a deletion 
sequence corresponding to (Pro)14-Lys and (Pro)14-Lys-(FAM) for 80 and 81, 
respectively.  The separation of these two species could not be achieved on a C8 or C18 
column.  As the deletion sequences will not interfere in the scFv conjugation both 80 
and 81 were used as heterogeneous samples.  
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3.3.6 Summary of CPP derivative synthesis 
A practical and robust synthetic approach for the synthesis of CPP derivatives has 
been developed.  The described approaches allowed for labelling of peptides with 5-
FAM and functionalisation of the N-terminus with either a maleimido or isobutyryl 
Cys moiety (Scheme 3-3 and Scheme 3-5). 
Synthesis of N-maleimidopropionyl Antp derivatives 70, 74 and 75 was high yielding 
with clean crude peptides being obtained.  The synthesis of the arginine rich Tat47-58 
derivatives 78 and 79, and octa-arginine derivatives 76 and 77 did not afford crude 
peptides of good purity.  However, after purification, sufficient quantities of pure 
peptide were isolated for conjugation to scFv-Cys.  The synthesised peptides were all 
purified by preparative RP-HPLC to afford peptides in good purity.  The purity and 
HPLC isolation yields for each CPP derivative are shown in Table 3-3. 
 
Table 3-3:  CPP derivatives synthesised by Fmoc SPPS and purified by RP-HPLC with corresponding 
isolation yields and purity. 
 
 # 
 CPP Sequence Yield Purity* tR/ min 
61 Antp52-58 iBut-C-RRMKWKK-K-[NH2]  51% >85% 3.18 
63 Antp52-58 iBut-C-RRMKWKK-K(FAM)-[NH2] 46% >90% 3.96 
70 Antp52-58 Mal-RRMKWKK-K-[NH2]  69% >90% 3.00 
74 Antp52-58 Mal-RRMKWKK-K(FAM)-[NH2] 43% >95% 4.30 
75 Antp43-58 Mal-RQIKIWFQNRRMKWKK-K-[NH2] 20% >90% 4.60 
76 octa-arginine Mal-(R)8-K-[NH2]   15% >90% 2.72 
77 octa-arginine Mal-(R)8-K(FAM)-[NH2] 30% >95% 3.85 
78 Tat49-57 Mal-RKKRRQRRR-K-[NH2] 19% >95% 2.55 
79 Tat49-57 Mal-RKKRRQRRR-K(FAM)-[NH2] 36% >95% 3.80 
80 Pro14 iBut-C-(P)14-K-[NH2] 30% >90% 4.72 
81 Pro14 iBut-C-(P)14-K(FAM)-[NH2] 28% >90% 5.00 
* Peptide purity determined from intergration of HPLC peaks.   1-90% B over 10 min, 3ml/min, Onyx 
monolithic C18 (100 x 4.6 mm).  
 
The synthesis of four different CPP derivatives possessing either an N-terminal 
maleimido or cysteine residue was successful, thus allowing for conjugation of the 
CPP derivatives to scFv-Cys.  The successful introduction of 5-FAM to the CPP 
derivatives will allow for the investigation of scFv-CPP cell internalisation using 
CLSM or fluorescence microscopy.  
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3.4 Preparation of scFv-CPP conjugates 
It was previously proposed that an anti-Bcl-2/xL scFv-CPP conjugate will be able to 
internalise into cells, allowing for binding and inhibition of Bcl-2 or Bcl-xL.  An 
important aspect of the scFv-CPP preparation is the development of efficient and 
simple methodology allowing for rapid screening of a panel of scFv-CPP conjugates in 
whole cell assays. 
 
3.4.1 Thioether conjugation 
Site-specific conjugation of N-maleimidopropionyl Antp52-58-Lys(FAM) 74 to the 
previously expressed scFv-Cys (scFv24) was achieved following Scheme 3-6. 
 
Scheme 3-6: Mechanism of N-maleimidopropionyl Antp52-58 derivatives conjugation to scFv-Cys. 
 
 
  
106 
The conjugation of 74 to scFv24 was carried out in a sodium acetate buffer (pH 5.5) 
and in the presence of the reducing agent tris(2-carboxyethyl)phosphine (TCEP).    
This was to reduce any scFv-S-S-scFv dimers present, thus increasing the amount of 
scFv available for conjugation to 74.  A range of different TCEP concentrations were 
used to determine the optimum concentration for peptide conjugation.  The scFv 
concentration was kept constant at 0.9 mg/ml in PBS (pH 7.4).   
The first step was the addition of TCEP to scFv24 followed by incubation for 1 h at rt.  
The Antp52-58 derivative 74 was then added at a 10x molar excess relative to the scFv.  
After 1 h, the conjugation of 74 was assessed using MALDI-TOF MS.  Figure 3-18 
shows the effect of the TCEP concentration on the percentage of scFv24-74 formed in 
the conjugation reaction.  The percentage of scFv24-74 was determined from the 
MALDI-TOF MS peak intensities for the [M+H]+ species of scFv24 and scFv24-74 
observed at m/z 29000 and 30689, respectively.  
 
Figure 3-18: The effect of increasing TCEP concentration on maleimide conjugation to scFv-Cys.  The 
percentage coupling was calculated from the peak intensity for the unlabelled and labelled scFv species 
using MALDI-TOF MS (sinapic acid matrix) 
 
A 5x molar excess of TCEP allowed for 75% coupling of 74 to scFv24.  However, an 
increase of TCEP to 10x and 20x molar excess resulted in a dramatic decrease in 
conjugation.  Interestingly, the omission of TCEP resulted in no conjugation of 74 to 
scFv24, thus reduction of the scFv is an important step in this reaction.  Although 
TCEP is advertised as being compatible with the maleimido moiety the findings here 
show that TCEP has a negative effect on the reactivity of the maleimido moiety, this is 
also supported by the similar findings of Getz et al. (1999) and Shafer et al. (2000).214 - 215 
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Moreover, the removal of TCEP by size exclusion, prior to the addition of peptide 74, 
allowed for >95% conjugation of 74 to scFv24.  This was confirmed by MALDI-TOF 
MS revealing a single peak at m/z 30689.0 assigned as [M+H]+ for the scFv24-74 
conjugate.  Figure 3-19 shows the MALDI-TOF MS spectra of the unlabelled scFv24 
before treatment with TCEP, and the MS spectra of scFv24-74. 
 
 
Figure 3-19:  The MALDI-TOF MS traces for  a) scFv24 and b) scFv24-74 conjugate formed after 
treatment of scFv24 with TCEP followed by size exclusion and then addition of 10x molar excess of 
Antp52-58-K(FAM) 74 and incubation for 1.5 h at rt. 
 
In summary, >95% coupling of N-maleimidopropionyl Antp52-58-Lys(FAM) 74 to 
scFv24 was achieved by initially treating the scFv with 5x molar excess of TCEP 
followed by removal, and then addition of a 10x molar excess of CPP.  The method 
developed for conjugation of N-maleimidopropionyl CPPs to scFv24 was applied to 
the panel of synthesised CPP derivatives.     
  
3.4.2 Disulfide conjugation 
It was predicted that conjugation of a CPP derivative to scFv using a disulfide linkage 
would allow for cell internalisation and release of the scFv from the CPP in the 
reducing cellular environment.70,216  The formation of a disulfide bond between the C-
terminally located cysteine residue of scFv24 and the N-terminal cysteine residue of 
iBut-C-(P)14-K(FAM)-[NH2] 81 was investigated as a model reaction. 
The first approach investigated for the conjugation of 81 to scFv24 via a disulfide 
bond was by air oxidation.  In the first step, scFv24 was treated with 5x molar excess 
TCEP to reduce any scFv-S-S-scFv dimers.  The reduced scFv solution was then 
buffer exchanged into deoxygenated PBS buffer (pH 8).  This was followed by the 
addition of 81 at high dilution over 2 h with vigorous stirring until a 20x molar excess, 
29000.8
30689.0
c)
29099.6
a) b)
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relative to scFv24 had been added.  Unfortunately, this approach afforded only ~70% 
labelling of scFv24 with 77. This was not improved with vigorous stirring and 
increased incubation time (24-48 h at rt).  Using this approach, three possible species 
can be formed; CPP-S-S-CPP, CPP-S-S-scFv and scFv-S-S-scFv.  Therefore, the 
formation of these dimers may have resulted in the low conjugation yields achieved.  
To encourage the formation of the scFv-S-S-CPP conjugate the cysteine residue of 81 
was activated with 2,2-dithiodipyridine 82 using a method adapted from Rabanal et al. 
(1996) 217 (Scheme 3-7). 
 
Scheme 3-7: Conjugation of N-maleimidopropionyl CPP derivatives to scFv-Cys using 2,2-
dithiodipyridine 82 .  
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The activation of 81 was achieved using a 5x molar excess of 2,2-dithiodipyridine 82 
in AcOH:H2O (1:3).  The reaction mixture was stirred for 4 h at rt, subsequent 
purification afforded the activated intermediate 83 in a yield of 65% (Scheme 3-7, i).  
The analytical HPLC of 83 showed the presence of one major species and synthesis of 
was confirmed by TOF MS (ES+) with a peak at m/z 1073.4878 being detected and 
assigned as the [M+2H]2+ species.   
ScFv24 was treated with a 10x molar excess of 83 in sodium acetate buffer (pH 5.5) 
for 1.5 h at rt, followed by analysis using MALDI-TOF MS (Figure 3-20).  
 
Figure 3-20: MALDI-TOF MS of scFv24-81 after incubation with 136 for 1.5 h at rt. 
 
Figure 3-20 shows the complete conversion of scFv24 to form a single species at m/z 
30999.0 assigned as the [M+H]+ of scFv24-81.  The activation of 81 with 2,2-
dithiodipyridine 82 provides a simple and efficient method for coupling CPPs to scFv-
Cys via a disulfide bond.  This approach can be applied to the conjugation of other N-
isobutyryl Cys CPP derivatives. 
 
3.4.2.1 ScFv conjugation to a small molecule carrier (SMoC)  
To increase the possibility of achieving cellular internalisation of scFv24 and the 
induction of apoptosis, alternative delivery vectors were also investigated.  Rebstock 
et al. (2008) 98 report the synthesis and application of a delivery vector based on a 
guanidine functionalised biphenyl scaffold.  This small molecule carrier (SMoC) 
demonstrated efficient intracellular delivery of an attached biomolecule into a wide 
variety of cell types with good efficiency.97  For this reason, the SMoC derivative 14 
was conjugated to scFv24 and Cea6.   
30999.015
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The Boc protected SMoC derivative 84 was synthesised by Charnwood Molecular Ltd.  
The Boc deprotection of 84 was achieved by acidolysis using 50% TFA in DCM to 
afford 14 in a quantitative yield (Scheme 3-8, i).98 
 
Scheme 3-8: Synthesis of scFv-SMoC conjugate scFv24-14. 
 
 
 
The conjugation of 14 to scFv24 and Cea6 was achieved using the method described 
by Okuyama et al. (2007).97  Briefly, a 10x molar excess of 14 was added to the scFv 
(3 mg/ml) in sodium acetate buffer (pH 5.5) (Scheme 3-8, ii).  After 1.5 h at rt the 
reaction was analysed by MALDI-TOF MS (Figure 3-21).  
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Figure 3-21: The MALDI-TOF MS trace for scFv24-14 after incubation with SMoC 14 for 1.5 h at rt. 
 
The successful conjugation of 14 to scFv24 and Cea6 was achieved with >95% 
conversion of the scFv to the scFv24-14 and Cea6-14 conjugate.  ScFv24-14 and 
Cea6-14 were purified by size exclusion to afford the pure scFv conjugate in yields of 
54% and 37%, respectively. 
 
3.4.3 Summary of scFv-CPP conjugate preparation 
The optimised conjugation methods allow for >90% conjugation of CPP derivatives to 
scFv.  After the formation of scFv-CPP conjugates, unreacted CPP was removed by 
size exclusion using a +L3UHSGHVDOWLQJFolumn (GE healthcare).   
Table 3-4 shows the percentage conjugation of CPP derivatives to scFv24 and Cea6 
together with the yields achieved after the conjugation and purification steps.  The 5-
FAM labelled CPP derivatives were also conjugated to scFv24 for determination of 
scFv24-CPP internalisation using fluorescence microscopy and CLSM. 
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Table 3-4: Summary of scFv-CPP conjugates purified by size exclusion. 
 
scFv 
conjugate Peptide Yield  
% of scFv 
labelled 
with 
peptide 
MALDI-TOF MS, 
m/z [M+H]+ 
Calc. Obs. 
scFv24-74 Mal-RRMKKWKK-K(FAM)-[NH2] 31% >95% 30696 30689 
scFv24-76 Mal-(R)8-K-[NH2] 78% >95% 30573 30578 
Cea6-76 Mal-(R)8-K-[NH2] 33% >95% 30423 30454 
scFv24-77 Mal-(R)8-K(FAM)-[NH2] 32% >95% 30931 30928 
scFv24-79 Mal-RKKRRQRRR-K(FAM)-[NH2] 34% >95% 31004 31007 
scFv84-79 Mal-RKKRRQRRR-K(FAM)-[NH2] 37% ~20%* 30142 n.d 
Cea6-79 Mal-RKKRRQRRR-K(FAM)-[NH2] 32% ~35%* 30855 n.d 
scFv24-81 iBut-C-(P)14-K(FAM)-[NH2] 34% >95% 31064 30999 
scFv24-14 SMoC 54% >95% 29621 29623 
Cea6-14 SMoC 37% >95% 29554 29553 
*determined only from absorbance of 5-FAM using eq. 3.   The observed m/z for all scFv-CPP 
conjugates is within <0.2% error of the calculated m/z. 
 
The successful conjugation of the CPP derivatives to scFv24 was confirmed by 
MALDI-TOF MS revealing [M+H]+ peaks for all of the scFv24-CPP conjugates 
(Table 3-4).  A slightly lower yield for the scFv-CPP(FAM) conjugates was achieved 
compared to the scFv-CPP conjugates.  This is attributable to greater precipitation of 
the scFv during the conjugation reactions when using the FAM labelled peptides.  It is 
possible that the 5-FAM destabilised the protein upon conjugation, resulting in greater 
protein precipitation.  The conjugation of 5-FAM labelled Tat47-58 derivative 79 to 
scFv84 and Cea6 was also successful, however, MALDI-TOF MS did not detect the 
scFv84-79 and Cea6-79 conjugates.  Thus, the successful conjugation of 79 to the 
scFv was confirmed from the absorbance ratio of the scFv and 5-FAM using eq. 3.  
The percentage conjugation was significantly lower than that achieved for the 
conjugation of 79 to scFv24.  This may be attributable to the observed instability of 
these scFv compared to scFv24, resulting in greater protein precipitation during the 
conjugation reaction.  Further investigation into the CPP conjugation conditions for 
scFv84 and Cea6 are required to increase yields and the percentage of CPP 
conjugation.  
Fluorophore/protein ratio =  
୅ౣ౗౮୭୤୪ୟୠୣ୪୪ୣୢ୮୰୭୲ୣ୧୬கכ୮୰୭୲ୣ୧୬ୡ୭୬ୡୣ୬୲୰ୟ୲୧୭୬ሺ୑ሻ כ     (eq. 3) 
Amax =  Absorbance of sample measured at the wavelength PD[LPXPȜmax) for the dye molecule İ =  Molar extinction coefficient of 5-FAM (M-1 cm-1) 
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The activity of scFv-CPP conjugates was confirmed by ELISA.  The retention of the 
scFv specificity for Bcl-2 and Bcl-xL is essential for the envisaged studies using these 
scFv-CPP conjugates.  Figure 3-22 shows the positive binding of the scFv24-CPP 
conjugates to Bcl-xL, and scFv84-79 binding to Bcl-2, determined using a direct 
binding ELISA.  
 
Figure 3-22: Analysis of scFv-CPP binding to Bcl-xL and Bcl-2 using a binding ELISA.  Biotinylated 
Bcl-xL or Bcl-2 was coated onto streptavidin 96-well plates, followed by incubation with the 
corresponding scFv-CPP.  After washing, bound scFv was detected using anti-myc mAb (9E3) and goat 
anti-mouse HRP conjugate, and finally developed with TMB.  The plate was then read on an Envision 
plate reader at 450 nm. a) scFv24, scFv24-CPP and Cea6 binding to Bcl-xL.  b) scFv84, scFv84-79 and 
Cea6 binding to Bcl-2.   
 
The antigen specificity of all of the scFv-CPP conjugates was retained, with similar 
binding to Bcl-2 and Bcl-xL being observed as the unconjugated scFv.  Overall, the 
optimised methods for the preparation of scFv-CPP conjugates has allowed for >90% 
conjugation of the CPP derivatives to the purified scFv-Cys.  Importantly, the antigen-
binding of the scFv was retained after CPP conjugation, allowing for investigation into 
the cell internalisation and the biological effects of the scFv-CPP conjugates. 
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3.5 Cellular delivery of scFv-CPP(FAM) conjugates  
The CPP mediated delivery of proteins can be determined using a variety of methods, 
for example flow cytometry 218, immunoprecipitation 63 and radiolabelling.69  The 
most common approach is through attachment of a fluorophore to the CPP allowing 
for detection of cell internalised CPP using fluorescence microscopy or confocal laser 
scanning microscopy (CLSM).63, 65  
When investigating the internalisation of CPP conjugates using fluorescent probes it is 
important to ensure that false positives are not obtained and that the limitations of the 
technique used are taken into account.  Cationic CPPs will adhere to the negatively 
charged cell membrane, which can lead to the overestimation of CPP internalisation.99  
The possibility of artefacts is also increased when using fixed cells, as this can 
permeabilise the cell membrane resulting in increased CPP uptake, leading to 
overestimation of CPP internalisation.99  Thus, in this study only live cells were used 
to minimise the potential for artefacts.   
 
3.5.1 Fluorescence microscopy  
Fluorescence microscopy was used to assess the internalisation of scFv-CPP 
conjugates and to compare the effectiveness of each CPP derivative.  Using 
fluorescence microscopy it is not possible to discriminate between membrane 
associated and intracellular fluorescence.  However, removing membrane adsorbed 
peptides before fluorescence microscopy can avoid artefacts. A simple method to 
remove membrane bound CPPs described by Kameyama et al. (2007) is to wash cells 
treated with CPPs with an acidic buffer (3 M glycine, pH 3) before imaging.219   
The internalisation of the scFv-CPP(FAM) conjugates into HeLa cells was 
investigated by incubation  of the cells with a 10 µM solution of scFv-CPP(FAM) for 
30 min at 37 oC.  Following incubation, the medium was removed and the cells were 
washed twice with an acid wash buffer (3 M Glycine, pH 3), twice with PBS (pH 7.4) 
and finally left in Hanks balanced salt solution (HBSS buffer) containing the 
membrane permeable nuclear stain Hoechst 33342.  The fluorescence microscopy 
images for HeLa cells treated with 10 µM of scFv24 labelled with Antp52-58 (scFv24-
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74), octa-arginine (scFv24-77) and Tat49-57 (scFv24-79) are shown in Figure 3-23.  
The nuclei are shown in blue and the scFv24-CPP conjugates are shown in green. 
 
a)   
b)        
c)        
        d)          
 
Figure 3-23: Fluorescence microscopy of HeLa cells treated with scFv-CPP(FAM) (Green) for 30 min 
at 37oC  a) vehicle only control b) scFv24-77, 10 µM c) scFv24-79, 10 µM d) scFv24-74, 10 µM.   The 
cells were also incubated with the nuclear stain Hoechst 33342 (blue).  The magnifications shown for 
each image are the objective magnification used. 
X 10  
X 10 
X 10  
X 20 
X 20 
X 10 X 20 
X 5 
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The image of untreated HeLa cells (Figure 3-23, a) shows no auto-fluorescence, thus 
acting as a control for comparison to cells treated with scFv-CPP(FAM) conjugates.  
Figure 3-23 b) shows cells treated with the scFv-octa-arginine conjugate scFv24-77, 
the cell associated fluorescence of scFv24-77 is of greater intensity than the other 
scFv-CPP conjugates and appears to be uniformly distributed throughout the cells.  
ScFv24 labelled with Tat49-57 (scFv24-79) and Antp52-58 (scFv24-74) (Figure 3-23, c 
and d) shows very different fluorescent localisation compared to scFv24-77.  The 
punctate fluorescence of the HeLa cells treated with scFv24-79 appears to be cell 
associated, suggesting localisation of the scFv in cellular vesicles.  However, it is not 
possible using fluorescence microscopy to firmly determine if this fluorescence is 
membrane bound or intracellular.  Notably, there is little cell associated fluorescence 
seen for the scFv-Antp52-58 conjugate scFv24-74.  Thus, it was concluded that Antp52-
58 was not a suitable for the intracellular delivery of scFv into HeLa cells.   
 
3.5.2 Confocal Laser Scanning Microscopy (CLSM)  
CLSM was used to confirm that the scFv-octa-arginine conjugate scFv24-77 and the 
scFv-Tat49-57 conjugate scFv24-79 are internalised into cells.  CLSM allows for in-
focus imaging at selected depths of a sample by using a point source of light and 
pinhole to reject light that is not incident from the focal plane.220  In the context of this 
study this allows for focussing within the cell, distinguishing between membrane 
bound and cell internalised scFv-CPP conjugates, avoiding the possibility of artefacts 
associated with membrane adsorbed CPPs.  
HeLa or Rat Basophilic Leukaemia (RBL-2H3) cells were incubated for 30-90 min at 
37 oC with 10 µM of either scFv24-77 or scFv24-79.  After incubation, the cells were 
washed with PBS and incubated with 5 µM of the nuclear stain Draq5 (Ex 646 nm/ 
Em 681 nm).  The unfixed live cells were then imaged using an inverted x63 oil 
immersion lens.  Figure 3-24 shows the confocal images taken at selected depths 
within the cell (z-sectioning) after HeLa cells were incubates with a 10 µM solution of 
scFv24-77 for either 30 or 90 min at 37 oC. 
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a) 30 min             b)  90 min 
             
  
Figure 3-24: Z-sectioning using confocal microscopy of HeLa cells treated with 10 µM  of scFv24-77 
(Green) for a) 30 min at 37 oC and b) 90 min at 37 oC.  Draq5 was used as a nuclear stain (Purple).   
 
The punctate co-localisation of scfv24-77 in the HeLa cells after 30 and 90 min 
incubate (Figure 3-24 a and b) is indicative of endosomal entrapment of a CPP 99, z-
sectioning of the cells also confirmed that the fluorescence observed is intracellular, 
suggesting that scFv24-77 is internalised into HeLa cells by an endocytic route.  The 
z-sectioning of RBL-2H3 cells incubated with scFv24-77 for 30 min is shown in 
Figure 3-25. 
       
  
 
Figure 3-25: Z-sectioning using confocal microscopy of RBL-2H3 cells treated with 10 µM of scFv24-
77 (Green) for 30 min at 37 oC.  Draq5 was used as a nuclear stain (Purple).  
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Interestingly, RBL-2H3 cells incubated with scFv24-77 show very different 
localisation compared to the HeLa cells.  The uniform fluorescence of the whole cell 
suggests cytoplasmic localisation of scFv24-77.  This encouraging data suggests that 
the scFv24-77 conjugate will be able bind to Bcl-2 and Bcl-xL in RBL-2H3 cells.  
Figure 3-26 a) shows the z-sectioning of HeLa and RBL-2H3 cells incubated for 30 
and 90 min with a 10 µM solution of the Tat49-57 conjugate scFv24-79 at 37 oC. 
a)           b) 
       
c)          d)  
             
Figure 3-26: CLSM z-sectioning of HeLa and RBL-2H3 cells treated with 10 µM of the scFv-Tat49-57 
conjugate scFv24-79 (Green) a) HeLa cells, 10 µM scFv24-79, 30 min at 37 oC b) HeLa cells, 10 µM 
scFv24-79, 90 min at 37 oC, c) RBL-2H3 cells, 10 µM scFv24-79, 30 min at 37 oC, d) RBL-2H3 cells, 
10 µM scFv24-79, 90 min at 37 oC.  After incubation with scFv24-79 the cells were incubated with 5 
µM Draq5 to stain the cell nuclei (Purple). 
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After incubation of scFv24-79 with HeLa and RBL-2H3 cells for 30 min there was no 
significant cell associated fluorescence observed (Figure 3-26, a and c).  After 
incubation of scFv24-79 for 90 min with HeLa cells, single points of intense 
fluorescence are seen (Figure 3-26, b and d).  This fluorescence appears to be 
intracellular and possibly a result of scFv localising in cellular vesicles.   The 
incubation of RBL-2H3 cells with scFv24-79 for 30 min gave similar results to that 
observed with HeLa cells.  However, after 90 min the fluorescence intensity was 
significantly greater (Figure 3-26, d).  The punctate fluorescence seen after incubation 
of scFv24-79 with RBL-2H3 cells again suggests co-localisation of the scFv-CPP in 
cellular vesicles.   
The distinctly different localisations seen for scFv24-74 and scFv24-79 after 
incubation with HeLa and RBL-2H3 cells suggests that the scFv-CPP conjugates are  
internalised by different mechanisms.  A number of studies have reported that CPP 
internalisation varies dependant on the CPP, cell type, exposure time, temperature, 
peptide concentration and treatment of cells (un-fixed and fixed).99,82,221  Therefore, 
the differences in cellular localisation observed for scFv24-74 and scFv24-79 is 
possibly a result of both the cell line and the CPP used (i.e. octa-arginine and Tat47-59).  
Further investigation of scFv24-77 cellular internalisation using a wider panel of cell 
lines would provide insight into the general cellular localisation of scFv24-77.  
Nonetheless, the octa-arginine derivative 77 proved to be the most promising CPP 
investigated here for the intracellular delivery of scFv.   
  
3.5.2.1 Cellular internalisation of scFv24-Pro14 conjugate 
It was proposed that conjugation of Pro14 derivative iBut-C-(P)14-K(FAM)-[NH2] 81 to 
scFv24 would enable cellular internalisation of the scFv.  Thus, HeLa cells were 
incubated with scFv24-81 at a concentration of 10 µM for 90 min at 37 oC, followed 
by imaging using CLSM (Figure 3-27, a). 
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                         a) scFv24-81, 10 µM, 90 min 
 
b) 81, 10 µM, 90 min  c)  81, 50 µM, 90 min        cd) 81, 100 µM, 90 min         
            
Figure 3-27: Z-sectioning using confocal microscopy of HeLa cells treated with a) scFv24-81 (Green) 
for 90 min at 37 oC, 10 µM b) treated with iBut-C-(P)14-K(FAM)-[NH2] 81 at 10 µM, c) 50 µM and d) 
100 µM for 90 min at 37 oC.  Draq5 was used as a nuclear stain (Purple). 
 
It is clear that no cell associated fluorescence scFv24-81 is observed after incubation 
for 90 min with HeLa cells (Figure 3-27, a).  In a further experiment, cells were also 
incubated with iBut-C-(P)14-K(FAM)-[NH2] 81 at 10, 50 and 100 µM for 90 min at 37 
oC, followed by CLSM (Figure 3-27, b, c and d).  At 10 and 50 µM no cell associated 
fluorescence for 81 was observed, minimal cell associated fluorescence was seen at 
100 µM suggesting internalisation of 81 at very high concentrations.  The contrast 
between the results for 81 seen here compared to those seen by Crespo et al. (2002) 
are most likely attributable to the techniques employed.95  CLSM of live cells avoids 
artefacts associated with membrane adhered peptide and permeabilisation of the cell 
membrane through cell fixing.  However, Crespo et al. (2002), utilised fluorescence 
microscopy with paraformaldehyde fixed cells increasing the likelihood of 
overestimating cellular internalisation of the peptide.99  Therefore, it was concluded 
that iBut-C-(P)14-K(FAM)-[NH2]  81 was not a suitable delivery vector for scFv. 
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3.5.3 Summary of scFv-CPP cell internalisation 
The cellular internalisation of scFv24 was successful.  The octa-arginine derivative 77 
proved the most efficient CPP to enable intracellular delivery of scFv, with apparent 
cytoplasmic delivery being achieved in RBL-2H3 cells.  A summary of the cell 
internalisation of the scFv-CPP conjugates is shown in Table 3-5. 
 
Table 3-5: scFv-CPP(FAM) internalisation and localisation; summary of CLSM and Fluorescence 
microscopy  
 
scFv-CPP CPP Sequence 
Localisation of scFv-CPP 
conjugate 
HeLa RBL-2H3 
scFv24-77 octa-arginine Mal-(R)8-K(FAM)-[NH2] cellular vesicles cytoplasm  
scFv24-79 Tat49-57 Mal-RKKRRQRRR-K(FAM)-[NH2] Minimal internalisation, cellular vesicles 
scFv24-74 Antp52-58 Mal-RRMKKWKK-K(FAM)-[NH2] Minimal cell internalisation n.d 
scFv24-81 Pro14 iButyl-C-(P)14-K(FAM)-[NH2] extracellular n.d 
 
 
The comparison of the CPPs ability to deliver proteins into HeLa cells has been 
reported previously.  Moosmeier et al. (2010) conclude that the order of efficiency for 
the internalisation of streptavidin by the CPPs used here is Antp52-58 < Tat49-57 < octa-
arginine.222  Although this is in agreement with the findings here, there are significant 
differences between the co-localisation of HIV Tat49-57 (scFv24-79) and octa-arginine 
(scFv24-77) scFv conjugates that should be taken into account and could be influential 
on the biological effect of internalised scFv. 
In conclusion, octa-arginine appears to be the most suitable CPP for delivering scFv24 
into cells, thus it will be used to investigate the ability of scFv24 to induce apoptosis 
by inhibition of Bcl-xL. 
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3.6 Biological activity of scFv-CPP conjugates   
Previously in Chapter 2, anti-Bcl-2 and Bcl-xL scFv were demonstrated to inhibit Bcl-
2 and Bcl-xL binding to the BH3 region of BID in an in vitro Alpha screen 
competition assay.  In a cellular context, cancer cells relying on the overexpression of 
Bcl-2 family members for cell survival will undergo apoptosis by inhibition of Bcl-
2/xL.  The pro-apoptotic proteins (BAK and BAX) are then able to induce downstream 
effector proteins, leading to the onset of apoptosis.169   
 
 
 
 
Figure 3-28: The intrinsic and extrinsic apoptosis pathways.  In healthy cells, Bcl-2/xL forms a 
heterodimer with BAX/BAK stopping the activation of apoptosis.  Activation of the BH3-only proteins 
by cellular stress leads to displacement of Bcl-2/xL from the dimer allowing for BAX/ BAK to initiate 
the onset of apoptosis.  Overexpression of Bcl-2/xL deregulates this pathway.  Bcl-2/xL inhibitors act 
by inhibiting Bcl-2/xL heterodimer formation with BAX and BAK. 
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The comparison of the biological effect of anti-Bcl-2/xL scFv-CPP conjugates to the 
small molecule Bcl-2/xL inhibitor ABT-737 will provide insight into the effectiveness 
of the scFv-CPP conjugates to be internalised into a cell and inhibit Bcl-2/xL.  The 
viability of cells after treatment with either ABT-737 or scFv-CPP conjugates was 
assessed using a luciferase-based ATP assay (Cell Titre Glo®, Promega).  The 
concentration of ATP has a direct relationship to the number of viable cells and a 
linear relationship with increasing cell numbers, thus making it a suitable marker to 
assess the effect of the scFv-CPP conjugates on cell viability.  The principle of this 
assay is shown in Scheme 3-9.223 
Scheme 3-9: The principle of the luciferase-based ATP cell viability assay, the reaction of luciferin with 
ATP is catalysed by luciferase  in the presence of Mg2+. 
 
 
 
Jurkat cells have previously been reported to be sensitive to Bcl-2/xL inhibition by 
ABT-737 224-225 and also cell penetrable BH3 peptides.178  Therefore, Jurkat cells were 
seeded at 3 x 103 cells/well in 96-wells plates and treated for 48 h at 37 oC with either 
ABT-737 (Figure 3-29, a) or the Bcl-xL neutralising scFv24-octa-arginine conjugate 
scFv24-76 (Figure 3-29, b). 
 
 
 
 
Figure 3-29: a) ABT-737 and b) scFv24-76 effect on Jurkat cell viability. Negative controls included 
Cea6-76, vehicle control, time 0 and cells only control. 
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The EC50 calculated for ABT-737 with Jurkat cells was 14.0 ± 0.6 µM, this is slightly 
higher than the literature EC50 value of 5 µM.225  However, this difference could be 
related to cell line variability and experimental error.  Unfortunately, the viability of 
the Jurkat cells was unaffected after incubation with 40 µM of scFv24-76.  
Unexpectedly, the non-specific scFv-octa-arginine conjugate Cea6-76 did reduce the 
number of viable Jurkat cells, with a similar luminescence signal to time 0 wells being 
observed, thus suggesting that Cea6-76 has a cytostatic effect on Jurkat cells.  This is 
most likely a result of a non-specific interaction by Cea6 as this scFv is not specific for 
an intracellular target.31  Further investigations using Cea6-76 are required to confirm 
the mechanisms involved in this apparent cytostatic effect. 
 
3.6.1 The effect of scFv-CPP constructs on Rat basophilic leukaemia 
cell (RBL-2H3) viability 
Cohen-Saidon et al. (2003) reported the isolation of an anti-Bcl-2 scFv and 
demonstrated that the scFv-Tat fusion protein was able to internalise in a rat basophilic 
leukaemia cell line (RBL-2H3) and induce apoptosis.63  Using a trypan blue dye 
exclusion assay the authors observe a 50% decrease in cell viability after incubation 
with anti-Bcl-2 scFv (15 µg/ml, 0.5 µM) compared to untreated cells and cells treated 
with a non-specific scFv.63  This experiment was repeated using the same anti-Bcl-2 
scFv (scFv84).  In this study, however, scFv84 was conjugated to the 5-FAM labelled 
Tat49-57 derivative 79 by a thioether bond to afford scFv84-79.  RBL-2H3 cells were 
incubated with scFv84-79 (25 µg/ml, 0.83 µM) for 48 h followed by determination of 
cell viability using the Cell Titre Glo® assay (Figure 3-30). 
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Figure 3-30: The effect on RBL-2H3 cell viability after incubation with scFv84-79 for 48 h.  Negative 
controls included Cea6-79, sample buffer and cells only control. 
 
The viability of the RBL-2H3 cells was unaffected by treatment with scFv84-79 over 
48 h.  This is contradictory to the findings reported by Cohen-Saidon et al. (2003) 63 
using a scFv-Tat47-57 (47YGRKKRRQRRR57) fusion protein, however, the 5-FAM 
labelled Tat49-57 derivative 79 was conjugated to scFv84 by a thioether bond in this 
study.  It is possible the results seen with scFv84-79 could be related to the position 
and nature of the peptide conjugation and the presence of 5-FAM.   
The treatment of RBL-2H3 cells with ABT-737 (Figure 3-31, a) and the octa-arginine 
conjugates scFv24-76 and Cea6-76 (Figure 3-31, b) at 40 µM had no effect on cell 
viability.  
Log [ABT-737] /M
Lu
m
in
e
se
n
ce
 
(R
LU
)
-6 -5 -4
0
200000
400000
600000
Lu
m
in
e
se
n
ce
 
(R
LU
)
MP
sc
fv2
4.7
6, 
40
 
MP
ce
a6
.
76
 
40
 
ce
lls 
on
ly 
sa
m
ple
 
bu
ffe
r
tim
e 
0
0
500000
1000000
1.5u100 6
a) b)
 
  EC50 , µM 
RBL-2H3 12 ± 2  
 
Figure 3-31: a) ABT-737 and b) scFv24-76 effect on RBL-2H3 cell viability.  Negative controls 
included Cea6-76, vehicle and cells only control.  
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The EC50 value calculated for ABT-737 using RBL-2H3 cells was 12 ± 2 µM, thus 
having similar sensitivity to ABT-737 as Jurkat cells.  This suggests that cells may not 
be sensitive enough to Bcl-2/xL knockout for a 40 µM solution of scFv24-76 to 
induce apoptosis.  
 
3.7 Conclusions  
In the first phase of this study a mammalian expression system was used to produce 
usable quantities of scFv-Cys.  This allowed for site-specific conjugation of a range of 
CPP derivatives to the C-terminally located cysteine residue of the scFv.  The 
optimised conjugation conditions and high levels of scFv obtained from the 
mammalian expression system will allow for rapid screening of a panel of scFv-CPP 
conjugates without time consuming sample preparation in future studies.  
Furthermore, it was demonstrated that conjugation of the octa-arginine derivative 77 to 
scFv24, affording the scFv24-77 conjugate, enabled internalisation into HeLa and 
RBL-2H3 cells.  Although the conjugate clearly localises in cellular vesicles of HeLa 
cells, in RBL-2H3 cells the conjugate appears to be localised in the cytoplasm, 
however this could also be an artefact of membrane bound scFv conjugate.  In 
contrast, the Tat49-57 conjugate scFv24-79 showed minimal internalisation into HeLa 
and RBL-2H3 cells, furthermore, the internalised protein appeared to localise in 
cellular vesicles in both cell lines.  Intracellular delivery of a protein using CPPs has 
been previously reported to result in endosome entrapment.99  Additionally, 
Tünnemann et al. (2006) demonstrated that TAT fusion proteins (>50 amino acids) 
were taken up largely into cytoplasmic vesicles.73  Cytoplasmic delivery of the scFv-
CPP conjugates is necessary for scFv binding and inhibition of the targets Bcl-2 and 
Bcl-xL.  Therefore, based on the CLSM imaging, it was concluded that scFv 
conjugated to the octa-arginine derivative 76 or the 5-FAM labelled 77 were the most 
suitable constructs for the cell viability assay. 
Unfortunately, preliminary cell viability studies did not suggest induction of apoptosis 
by scFv24-76.  In this assay the small molecule Bcl-2/xL inhibitor ABT-737 was used 
as a positive control with EC50 values of 12 ± 2 µM and 14.0 ± 0.6 µM being 
calculated for Jurkat and RBL-2H3 cells, respectively.  The low sensitivity of the two 
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cells lines to ABT-737 prompted the use of high concentration of scFv24-76 to be 
used (40 µM).  Incubation of scFv24-76 for 48 h with both RBL-2H3 and Jurkat cells 
showed no effect on cell viability.  It is possible that the absence of a biological 
response is due to the low sensitivity of these cell lines to Bcl-2/xL inhibition.  In 
order to induce cell apoptosis, significant amounts of scFv would be required to be 
internalised into the cells.  Thus, it is possible that internalisation efficiency and 
endosomal entrapment of the scFv-CPP may be a limiting factor.  This is also 
supported by the in vitro data that shows scFv24 to be a more potent inhibitor of Bcl-
xL than ABT-737.  Of equal importance, is that scFv24 is specific to Bcl-xL only, thus 
the sensitivity of the RBL-2H3 and Jurkat cells to Bcl-xL inhibition has to be 
considered. 
A number of reports have investigated the sensitivity of different cell lines to ABT-
737, thus using a cell line that displays high sensitivity to ABT-737 will increase the 
possibility of observing a biological effect for the scFv24-76 conjugate (Table 3-6). 
 
Table 3-6: EC50 values for ABT-737 with a selection of cell lines. 
 
Cell Line  
EC50, µM 
Reference Culture conditions 
10% FBS Reduced FBS (%) 
HL-60 >10 - 
High et al. (2010) 225 
K562 >10 - 
Nalm6 >10 - 
Jurkat 5.00 - 
Molt4 0.92 - 
REH 0.68 - 
CEM 0.30 - 
Hal-01 0.19 - 
DoHH2  0.13 0.001 (3%) 
Bruncko et al. (2007) 226 RS11380 0.15 0.014 (3%) 
SUDHL-4 0.85 0.220 (3%) 
NCI-H146 0.09 0.015 (0%) 
Shoemaker et al. (2006) 227 
A549 22.3 5.2 (0%) 
 
The design of the CPP derivatives will allow for further optimisation of scFv delivery.  
The C-terminal lysine residue could be used to incorporate endosomolytic peptides, a 
selection of peptides demonstrated to possess endosomolytic properties are shown in 
Table 3-7. 
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Table 3-7: A selection of endosomolytic peptides. 
 
 
Endosomolytic peptide Reference 
18 HA2; GLFGAIAGFIEGGWTGNIDGWYG Wadia et al. (2004) 111 
19 H5WYG; GLFHAIAHFIHGGWHGLIGGWGYG Pichon et al. (2001) 112 
20 10HIS; HHHHHHHHHH Lo et al. (2008) 113 
21 43E; LAELLAELLAEL Ohmori et al. (1997) 114 
 
These endosomolytic peptides have been demonstrated to increase endosome escape 
of cargo internalised through CPP mediated delivery.  Introducing one of these 
peptides to a scFv-CPP conjugate could increase the quantity of scFv being delivered 
into the cytoplasm, resulting in a larger quantity of scFv being able to inhibit Bcl-2/xL 
and induce apoptosis.  
In summary, investigation into obtaining a sufficiently sensitive cell line to Bcl-2/xL 
knockout is required to increase the possibility of observing a biological response 
induced by scFv24-CPP conjugates.  Future directions after this first objective should 
then be both focussed on optimising the cellular delivery and biological effect of the 
lead anti-Bcl-2 or Bcl-xL scFv-CPP conjugates. 
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3.8 Materials and Methods  
All agar plates, culture media and buffers used are described in Chapter 2, unless 
otherwise stated. All vectors were kindly supplied by MedImmune, Cambridge. All 
DNA manipulations were performed using plasmid purified using a QIAgen plasmid 
purification kiW4,$*(1DFFRUGLQJWRWKHPDQXIDFWXUH¶VJXLGHOLQHVDQGusing either 
TG1 (K12, D (lac-pro), supE, thi, hsd')¶traD36, proA+B+, lacIq, lacZDM15) or 
Novablue (endA1 hsdR17 (rK12± mK12+) supE44 thi-1 recA1 gyrA96 relA1 lac 
)ƍ>SUR$+B+ lacIq=ǻ07Q@ 7HWR)) E. coli strains.  All protein concentrations 
were determined from the sample absorbance at A280 using a NanoDrop 
spectrophotometer (Thermo Scientific).   
 
3.8.1 SDS-PAGE and western blot analysis 
SDS-PAGE was utilised to assess the purity of protein samples.  5 µl of NuPAGE® 
LDS Sample Buffer (Invitrogen) and 1 µl of 1 M TCEP were added to 10 µl of protein 
sample.  The samples were heated for 2 min at 95 oC and then loaded onto either a 
15% SDS polyacrylamide gel or a 2-12% NuPAGE® Bis-Tris gel (Invitrogen), 
submersed in running buffer (0.1% SDS, 25 mM Tris, 192 mM glycine).  The samples 
were then separated using 180 V until the loading buffer reached the bottom of the gel.   
The gel was then washed with 20 ml of H2O, followed by staining with Coomassie 
blue stain (1% Coomassie brilliant blue R-250, 10% AcOH, 40% isopropanol, 50% 
H2O) for 1 h at rt.  The gel was then destained using destain solution (20% 
isopropanol, 10% AcOH and 70% H2O) until the protein bands were visible.  
For western blot analysis gels were used before fixing and staining.  Protein bands 
were electroblotted to a nitrocellulose membrane (Hybond C, 0.45µm, GE Healthcare) 
using transfer buffer (20% MeOH, 25 mM Tris, 192 mM glycine) as the transfer 
medium at 100 V for 2 h.  The membranes were washed using 20 ml of 1x PBS and 
then blocked with 3% MPBS for 2 h at rt. All primary and secondary antibodies used 
are shown in Table 3-8 with corresponding concentrations used for the western blot. 
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  Table 3-8: Primary and secondary antibodies used for western blotting 
Antibody Concn  Supplier 
Primary 
  Anti-Myc mAb (9E3) 1 µg/ml AbD Serotec 
Anti-polyhistidine mAb (AD.1.1.10) 1 µg/ml R&D systems 
   Secondary 
  
Goat Anti-Mouse IgG HRP conjugate 
Used as a 
1:1000 dilution  R&D systems 
 
The primary and secondary antibodies were diluted into 3% MPBS.  Membranes were 
incubated with a primary antibody for 1 h at rt (10 ml of antibody dilution), followed 
by washing of the membrane with 20 ml of wash buffer (1xPBS/0.1% Tween v/v).  
This wash step was repeated 3x before the addition of a secondary antibody (10 ml of 
antibody dilution).  After incubation, the membranes were washed as before and then 
developed using 1.5 ml of thH SHUR[LGDVH VXEVWUDWH ƍƍ-tetramethylbenzidine 
liquid substrate system for membranes (TMB, Sigma-Aldrich).  The reaction was 
stopped by washing the membrane with PBS. 
 
3.8.2 General sub-cloning procedure  
All enzymes and buffers were purchased from New England Biolabs. All pCANTAB6 
and pUC119MCH plasmid were purified using QIAgen midi plasmid purification kit, 
following manufacture¶s guidelines. 
 
3.8.2.1 Digestion of scFv DNA and vector  
The design of phagemid pCANTAB6 allows for the isolation of the scFv-encoding 
DNA from the vector using restriction enzymes NotI and NcoI or alternatively NotI 
and SfiI. For the vector pUC119MCH and pEOMCH, restriction enzymes SfiI and 
NotI were used to clone scFv DNA and for pHIS10CYS enzymes NotI and NcoI were 
used.  
ScFv DNA and plasmid concentrations were determined using an Eppendorf 
BioPhotometer and agarose gel electrophoresis (1.5% agarose gel at 120 V).  The 
following components were combined and performed in duplicate.    
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For the digestion of vector DNA and isolation of scFv DNA with the restriction 
enzymes NotI and NcoI each sample contained, ~2 µg of DNA, 1 µl of both NotI (10 
U/ µl) and NcoI (10 U/µl), 5 µl of 10x restriction buffer 3, 0.5 µl of 10 mg/ml bovine 
serum albumin (BSA) and nuclease-free water to make the final reaction volume up to 
50 µl.  Samples were then incubated for 2-4 h at 37 qC. 
Alternatively, for the digestion of DNA with the restriction enzymes SfiI and NotI, 
each sample contained ~5 µg of DNA, 1 µl of SfiI (10 U/µl), 5 µl of 10x restriction 
buffer 2, 0.5 µl BSA (10 mg/ml) and nuclease-free water to make the final reaction 
volume up to 50 µl.  Samples were then incubated for 1.5 h at 50 qC.  After 
incubation, 5 µl of 10x restriction buffer 2, 0.5 µl BSA (10 mg/ml), 2 µl of NotI (10 
U/µl) and nuclease-free water to make the final reaction volume up to 100 µl was 
added, followed by incubation for 1.5 h at 37 qC. 
Following all incubation steps, the digested DNA was analysed using gel 
electrophoresis on a 1.5% agarose gel at 120 V.  The scFv inserts were identified at 
approximately 850 bp through comparison to a 1 kb marker.  The DNA was purified 
from the agarose gel using a QIAgen gel purification kit following manufactures 
guidelines.  
 
3.8.2.2 Ligation of inserts and vectors 
For a typical ligation ~100 ng vector and ~100 ng of insert (approx. 5:1 molar ratio of 
insert ends: vector ends) is required.  To each ligation reaction, 2 µl of cut vector (at 
50 ng/µl, i.e. ~100 ng or ~3 x 1010 molecules) and 5 µl cut insert (at 20 ng/µl, i.e. ~100 
ng or ~1011 molecules) was added to 3 µl 10x T4 ligation buffer, 1 µl T4 DNA ligase 
and 19 µl nuclease-free water.  Samples were then incubated overnight at 16 qC. 
 
3.8.2.3 Transformation of ligated DNA into E. coli 
Initially, chemically competent E. coli was thawed on ice.  10 µl of each ligation 
reaction was added into 100 µl competent cells and incubated for 30 min on ice.  A 
positive and a negative transformation control were included by mixing 100 µl of E. 
coli with 10 ng undigested vector or no DNA.  This was followed by heat shock of the 
  
132 
FHOOVIRUVHFDWÛ&XVLQJDSUHKHDWHGWKHUPDOF\FOHU$IWHUKHDWVKRFNFHOOVZHUH
incubated on ice for 2 min followed by addition of 900 µl 2TYG media.  The E. coli 
was then incubated IRUKDWÛ&with shaking at 120 rpm. 
Cells were centrifuged at 2000 g for 10 min and resuspended in 200 µl of 2TY media.  
Cells suspension was then spread onto pre-dried 2TYAG bioassay plates for 
pCANTAB6 or 2TYK bioassay plates for pUC119MCH. 
 
3.8.3 Expression of scFv-Cys in E. coli with pUC119MCH vector 
ScFv-encoding DNA was excised from purified pCANTAB6 vector containing the 
desired scFv DNA sequence using the restriction enzymes NotI and SfiI as previously 
described (Section 3.8.2.1).  Purified scFv-encoding DNA was then ligated into 
SfiI/NotI digested pUC119MCH vector (Figure 3-32).  Successful sub-cloning was 
confirmed by DNA sequencing of the pUC119MCH vector using the PUC_R primer 
(Appendix II).  Purified pUC119MCH containing scFv24-encoding DNA was used to 
transform competent E. coli BL21 (IKX$>ORQ@RPS7JDO>GFP@ǻKVG6). 
 
 
Figure 3-32:  Vector map of pUC119MCH vector, the scFv constructs are sub-cloned into the vector 
using NotI and SfiI restriction sites. 
 
 
A single colony of E. coli containing the pUC119MCH vector was used to inoculate 
400 ml of TYK media.  Cultures were incubated at 37 °C with shaking at 380 rpm.  At 
an OD600 between 0.5-1 cultures were induced using 1 mM IPTG followed by 
incubation of the culture at 37 oC with shaking at 380 rpm for 16 h.  Bacteria were 
pUC119MCH 
4.5 kb 
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harvested by centrifugation at 4 °C, 3000 g for 15 min.  Pellets were snap frozen and 
stored at -80 °C until further use.   
Approximately 3 g of E. coli pellet was suspended into 20 ml of lysis buffer (2xPBS, 
Roche protease Inhibitor cocktail (EDTA free), 1 mg/ml lysozyme (Sigma-Aldrich), 
pH 7.4) and incubated for 5 min at rt.  The bacterial suspension was then sonicated at 
75 W intermittently for 10 seconds, with 30 second intervals on ice.  The lysate was 
centrifuged at 10000 g for 10 min at 4 oC, the supernatant was then removed and 
filtered through a 0.45 µm filter. 
Affinity purification was carried out using a 5 ml HitrapTM FF crude nickel chelate 
column (GE Healthcare).  The bacteria lysates were loaded onto the column using a 
peristaltic pump (0.5-1.0 ml/min) at 4 oC.  All following wash steps were then 
SHUIRUPHGRQDQb.7$SULPHSXULILFDWLRQV\VWHPZLWKDIORZUDWHRIPl/min and 
a pressure limit of 0.3 MPa.  Columns were washed with  10 column volumes (CV) of 
2 x PBS, 10 CV of 40 mM imidazole (2x PBS) and eluted using a linear gradient 10 
CV from 40 to 400 mM imidazole over 10 CV with the collection of 5 ml fractions.  
All fractions were analysed using SDS-PAGE and western blot.  Fractions containing 
scFv were pooled and concentrated using a VivaspLQFHQWULIXJDOFRQFHQWUDWRU000 
Mw cut off).  Protein concentrations were determined from absorbance at A280 using a 
NanoDrop spectrophotometer (Thermo Scientific). 
Protein samples were purified by size exclusion using a 16/60 Superdex 75 column 
GE Healthcare) pre-equilibrated using 2x PBS (pH 7.4) on an ÄKTA purifier at a flow 
rate of 0.3 ml/min with 0.5 ml fraction collection.  Fractions were analysed by SDS-
PAGE, the fractions corresponding to the scFv were pooled and concentration using a 
9LYDVSLQFHQWULIXgal concentrator (Mw cut off <5000).  Samples were snap frozen 
and stored at -20 oC.  
 
3.8.4 Expression of scFv-Cys in E. coli with p10HISCYS vector 
ScFv24-encoding DNA was sub-cloned into p10HISCYS vector (Figure 3-33) using 
the restriction enzymes NotI and NcoI as previously described.  Successful sub-
cloning was confirmed by DNA sequencing of the p10HISCYS vector using the T7 
forward primer (Appendix II). Purified p10HISCYS containing scfv24-encoding DNA 
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was used to transform competent E. coli BL21 (IKX$>ORQ@RPS7JDOȜ'(>GFP@
¨KVG6).    
 
 
Figure 3-33: Vector map of p10HISCYS vector.  ScFv constructs are sub-cloned into the vector using 
NotI and SfiI restriction sites 
 
 
A single transformed E. coli colony possessing the pHIS10CYS vector containing the 
scfv24-encoding DNA was cultured in 10 ml of 2TYAG media at 37 oC.  This was 
then transferred to 16 oC when the culture reached OD600 0.4.  At OD600 0.5-0.6 the 
culture was induced with 1 mM IPTG.  At 1, 2, 4, 6 and 16 h a 1 ml sample was 
removed from the culture.  The bacteria were harvested by centrifugation at 3000 g 
and 4 oC.  Supernatant was used making the media fraction.  The E. coli fractions were 
DQDO\VHGXVLQJDPRGLILHGPHWKRGGHVFULEHG LQ WKH ,QYLWRJHQ4,$H[SUHVVLRQLVW228  
Briefly, the pellet was suspended into 100 µl of lysis buffer (2x PBS, Roche protease 
Inhibitor cocktail (EDTA free), 1 mg/ml lysozyme (Sigma-Aldrich), pH 7.4) and 
incubated on ice for 30 min.  The bacterial lysate was then centrifuged at 13,000 g at 4 
oC.  The supernatant (i.e. soluble fraction) was transferred to a fresh sample tube.  The 
bacterial pellet was resuspended into 100 µl of 1x PBS to form the insoluble fraction.  
A 20 µl aliquot from each sample was added to 5 µl of NuPAGE® LDS Sample Buffer 
(Invitrogen) and 1 µl of 1 M TCEP and heated for 15 min at 95 oC.  These samples 
were analysed by SDS-PAGE and western blotting as previously described. 
 
p10HISCYS 
5.5 kb 
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3.8.5 Transient expression of scFv-Cys in Cep6 cells with pEOMCH 
vector 
ScFv constructs were sub-cloned into pEOMCH vector (Figure 3-34) using the 
restriction enzymes NotI and SfiI as previously described.  Successful sub-cloning was 
confirmed by DNA sequencing of the pEOMCH vector using the two primers AR138 
and AR142 (Appendix II).  The pEOMCH vector containing the desired scFv 
construct were purified using a QIAGEN plasmid Giga prep kit according to the 
manufacturer¶V protocol. 
 
Figure 3-34: Vector map of pEOMCH vector.  ScFv constructs are sub-cloned into the vector using 
NotI and SfiI restriction sites. 
 
The CEP6 cells were sub-cultured by the tissue culture team at MedImmune 
(Cambridge, U.K.), 24 h before transfection the Cep6 cells were seeded at 5 x 105 
viable cells/ml in 500 ml in CD-CHO medium, thus on the day of transfection it was 
assumed that the cell number would be approximately 1 ± 0.5 x 106 viable cells/ml.  
Before transfection, the cultures were inoculated with penicillin (100 µg/ml) and 
streptomycin (100 µg/ml). 
The purified pEOMCH-scFv plasmid was added to polyethylenimine (PEI, 10 mg/ml) 
at a 1:1 (v/v) ratio.  The quantity of plasmid used was calculated so that it would give 
a final culture concentration of 1 µg DNA/ml of cells at 1.0 ± 0.5 x 106 cells/ml.  For 
example, using a 500 ml culture; 10 ml of purified plasmid at 0.5 mg/ml was added to 
pEOMCH 
9.8 kb 
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10 ml of PEI (10 mg/ml), the 20 ml solution would then be added to the culture, thus 
resulting in approximately 1 µg DNA/ml of cells. 
Before addition of the PEI/DNA mixture to the cultures the solution was vortexed for 
10 seconds followed by incubation for 1 min at rt, this solution was then added to the 
cell culture.  The cultures were supplemented with 50 ml of M20A feed (MedImmune, 
U.K. containing amino acids, vitamins, recombinant human insulin and plant 
hydrolysates) and 10% glucose.  The cultures were incubated for approximately 10 
days and supplemented every 2-3 days with 50 ml M20A feed and 10% glucose.  After 
10 days the cells were harvested by centrifugation at 3000 g for 30 min at 4 oC.  
Supernatants were then filtered through a 0.22 µm filter (Millipore, Stericup® Filter 
Units).  The culture supernatants containing the secreted scFv were stored at 4 oC 
overnight before affinity purification. 
Histidine purification was carried out using a 5 ml Hitrap FF crude column (GE 
Healthcare).  The filtered media was loaded onto a column using a peristaltic pump at 
1 ml/min.  The loaded column was then washed with 5 CV of 2x PBS, 5 CV of 40 mM 
imidazole in 2x PBS and scFv eluted using 400 mM imidazole in 2x PBS with 2 ml 
fraction being collected.  Figure 3-35 shows the SDS-PAGE analysis of a typical 
purification for scFv24, 84 and Cea6.   
 
Figure 3-35: Reducing 2-12% SDS polyacrylamide gel of samples from affinity purification of a) 
scFv24 b) Cea6 and c) scFv84 from pEOMCH.  Fractions shown include cell culture media before 
purification, flow through of media after loading onto 5 ml HitrapTM FF crude nickel column, column 
washes followed by elution of scFv using 400 mM imidazole in 2x PBS.  The gel was stained with 
coomassie blue. 
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The fraction were then analysed using SDS-Page.  Fractions containing protein were 
pooled and buffer exchanged using a PD-10 column (GE Healthcare) into sodium 
acetate buffer (pH 5.5).  The eluent was then concentrated to ~2 mg/ml using a 
9LYDVSLQFHQWULIXJDOFoncentrator (5000 Mw cut off) and stored at -80 oC.  
 
3.8.6 Preparation of scFv-CPP conjugates 
Unless stated, all buffers were filtered through a 0.22 µm filter and degassed.  
Standard buffers used are as previously described.  All scFv-Cys used were purified 
from Cep6 cells using the pEOMCH vector. 
All reagent used for CPP conjugations were purchased from Sigma-Aldrich unless 
stated.  Both N-maleimidopropionyl and N-isobutyryl cysteinyl CPPs were synthesised 
as described in Chapter 6 and used as 10 mg/ml solutions in deionised water.  All 
scFv-Cys (1-4 mg/ml) used for conjugations were treated with 10x molar excess of 
TCEP for 1 h at rt.  For example, to 15 ml of scFv24 (1.47 mg/ml, 0.74 µmol) was 
added TCEP (2.1 mg, 7.34 µmol) followed by incubation for 1 h at rt.  The sample 
was then desalted into a deoxygenated sodium acetate buffer (pH 5.5) using a 
+L3UHS  'HVDOWLQJ &ROXPQ -10 ml/min, GE Healthcare) on an ÄKTA 
purifier at a flow rate of 8-10 ml/min with 2 ml fraction collection.  Fractions 
corresponding to the scFv were pooled and concentrated to 2 mg/ml using a Vivaspin 
centrifugal concentrator (Mw cut off < 5,000). 
 
3.8.6.1 Conjugation of N-maleimidopropionyl CPPs to scFv-Cys 
The synthesised N-maleimidopropionyl CPPs were reconstituted into deionised water 
to a final concentration of 10 mg/ml.  To a solution of 1 ml of scFv-Cys (2 mg/ml, 2 
mg, 67 nmol) was added 10x molar excess of N-maleimidopropionyl CPP (670 nmol).  
The reaction was incubated for 1.5 h at rt or overnight at 4 oC.  Samples were analysed 
for successful conjugation using MALDI-TOF MS using a Bruker Daltonics Ultraflex 
instrument and sinapic acid (50% MeCN/ H2O) matrix.  The data were processed 
using Bruker Daltonics FlexanalysisTM software. If the coupling was incomplete a 
further 10x excess of peptide was added to the reaction and incubated for a further 1.5 
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KDWUWIROORZHGE\DQDO\VLV6DPSOHVZHUHSXULILHGXVLQJD+L3UHS'HVDOWLQJ
Columns (8-10 ml/min, GE Healthcare) on an ÄKTA purifier using sodium acetate 
buffer (pH 5.5) at flow rate of 8-10 ml/min with 2 ml fraction collection.  A typical 
purification trace is shown in Figure 3-36, the major peak at 13.09 min corresponds to 
the scFv-CPP conjugate and the minor peaks are the elution of excess unreacted 
peptide. 
 
 
 
 
Figure 3-36:  A typical elution trace obtained for the purification of scFv-CPP conjugates using a 
+L3UHS'HVDOWLQJ&ROXPQV-10 ml/min, GE Healthcare) on an ÄKTA purifier.  
 
 
Fractions corresponding to the scFv-CPP conjugate were pooled and concentrated 
using D9LYDVSLQFHQWULIXJDOFRQFHQWUDWRU0ZFXWRII5000) to approximately 12 
mg/ml.  All scFv samples were then stored at -20 oC until further use. 
 
3.8.6.2 Conjugation of peptide 136 and SMoC 14 to scFv-Cys. 
The pyridyl disulfide activated N-isobutyryl cysteinyl peptide 136 or the small 
molecule carrier (SMoC) 14 was conjugated to scFv-Cys using the same protocol used 
for N-maleimidopropionyl CPPs (Section 3.8.6.1).  Samples were again purified by 
VL]H H[FOXVLRQ XVLQJ D +L3UHS  'HVDOWLQJ &ROXPQV DQG FRQFHQWrated using a 
9LYDVSLQFHQWULIXJDOFRQFHQWUDWRU0ZFXWRII5000) to approximately 12 mg/ml.  
Each sample was then analysed using MALDI-TOF MS as previously described. 
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3.8.6.3 Direct binding ELISA ± scFv-CPP antigen specificity 
The specificity of the scFv-CPP conjugates for Bcl-2 or Bcl-xL was determined using 
the direct binding ELISA protocol (Section 2.5.2).  Biotinylated Bcl-2 or Bcl-xL (1.25 
µg/ml) was coated onto 96-well streptavidin-coated plates (Strepmax, costar 96-well 
plate, Thermo scientific) as previously described (Section 2.5.2). A streptavidin coated 
plate, without added antigen, was used as negative control to detect non-specific scFv.  
After coating, the plates were washed 3x with PBS to remove unbound antigen.  Plates 
were then blocked using 200 µl/well of 3% MPBS and incubated for 1 h at rt. 
Plates were then washed 3x with PBS, followed by the addition of 50 µl/well of scFv-
CPP (1.6, 0.7 or 0.4 µg/ml) in 3% MPBS to the Bcl-xL, Bcl-2 and streptavidin only 
coated plates.  The scFv-CPP was then incubated for 1 h at rt.  The plates were then 
washed 3x with PBS/0.1% Tween, followed by the addition of 50 µl/well of mouse 
anti-Myc mAb (9E3) (1 µg/ml) in 3% MPBS followed by incubation at rt for 1 h.  The 
plates were then washed 3x with PBS/0.1% Tween.  50 µl/well of mouse anti-mouse 
horse radish peroxidise (HRP) antibody conjugate (R&D systems), diluted according 
WRPDQXIDFWXUHU¶V UHFRPPHQGDWLRQ LQ03%6ZDV WKHQDGGHGDQG LQFXEDWHGDW UW
for 1 h.  Finally, plates were washed 3x with PBS/0.1% Tween and developed and the 
absorbance at 450 nm read as previously described (Section 2.5.2). 
 
3.8.7 General cell culture protocol  
All buffers used were either filtered through 0.2 µm filters or autoclaved.  Standard 
buffers used are as follows; HBSS buffer (0.55 M Glucose, 0.137 M NaCl, 5.4 mM 
KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM 
NaHCO3, pH 7), Acid wash buffer (0.3 M Glycine, 150 mM NaCl, pH 3), Phosphate 
buffered saline (PBS; 2.67 mM potassium chloride, 1.47 mM potassium phosphate 
monobasic, 137.93 mM sodium chloride, 8.1 mM sodium chloride, pH 7.4).  
Jurkat and RBL-2H3 cells were maintained by static culture in RPMI-1640 (Sigma-
Aldrich) medium supplemented with 10% fetal bovine serum (FBS).  HeLa cells were 
maintained in Eagle's Minimum Essential Medium (Sigma-Aldrich) supplemented 
with 10% FBS.  All cell culture manipulations were performed in a Class II 
microbiological safety cabinet that was cleaned with 70% IMS prior to use.  All FBS 
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used was heat inactivated (55-59 oC) for 30 min to denature complement proteins prior 
to use.  The cells were cultured in a humidified incubator containing 5% CO2 at 37 °C.  
The cell lines were sub-cultured into 75 ml Costar tissue culture flasks until 
confluence reached approximately 80%.   
Sub-culturing of suspension cells was achieved by a 1/6 dilution of confluent cells into 
fresh culture media.  For adherent cells, the media was aspirated and the cells were 
washed with 2 ml of sterile PBS.  The cells were then treated with ~0.5 ml of 0.25% 
(w/v) trypsin 0.53 mM EDTA solution at 37 oC for 5 min or until all cells were visibly 
detached from the flask.  To the suspended cells ~5 ml of culture media was added.  
The cells were then diluted into fresh culture media once more at approximately 1/6 
dilution.  Each cell line was sub-culture no more than 30 times before disposal.  
 
3.8.8 Fluorescence microscopy 
All fluorescence microscopy was carried out using a Nikon Eclipse 90i Fluorescent 
Microscope.  HeLa cells were seeded at 1 x 105 cells/well in a 12-well cell culture 
plate (Nunc) and allowed to adhere at for 16 h at 37 oC.  500 µl of scFv-CPP(FAM) 
conjugates at 10 µM in RPMI-1640 media were then added to cells, and incubated for 
30 min at 37 oC followed by aspiration of the media.  Cells were then washed 3x with 
1 ml of acid wash buffer (3 M glycine, pH 3) to remove membrane adsorbed scFv-
CPP conjugates, followed by washing 3x with 1 ml PBS.  The cells were then left in 2 
ml of HBSS buffer containing Hoechst 33342 (0.5 µg/ml, Sigma-Aldrich, Prod# 
B2261) to stain cell nuclei.  Cells were then imaged either at x5, x10 or x20 
magnification.  The Hoechst 33342 stain was imaged by UV absorbance using a 
mercury lamp.  
 
3.8.9 Confocal scanning laser microscopy 
All CSLM was carried out using a Zeiss LSM510 META Confocal Imaging System 
and Zeiss LSM510 operating software.  Cells were imaged using an inverted 63x oil 
objective and Argon (458, 477, 488, 504 nm) and He-Ne 633 nm lasers, Z-sectioning 
was performed using the Zeiss LSM510 operating software.   
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Live-cell imaging was performed using a method adapted from that described by 
Chazotte et al. (2011).229  HeLa or RBL-2H3 cells were seeded at 1 x 105 cells/well 
using a 6-well cell culture plate (Nunc) containing glass coverslips.  The cells were 
allowed to adhere at for 14 h at 37 oC.  The scFv-CPP(FAM) conjugates were diluted 
into RPMI-1640 media to give a concentration of 10 µM.  The media in each well was 
removed followed by addition of 1 ml/well of the diluted scFv-CPP(FAM) samples.  
The cells were then incubated for 30 or 90 min at 37 oC.  After incubation, the media 
was removed and the cells were washed 3x with 2 ml of PBS.  The cells were then 
incubated with the nuclear stain Draq5® (5 µM, 500 µl, New England Biolabs) for 5 
min at rt. Cells were again washed 2x with 2ml of PBS before the coverslips removed 
and placed onto cover slides with the cells facing down.  To prevent the cells from 
drying out, 50 µl of HBSS buffer was applied onto glass slides prior to placing the 
coverslip cells down, the coverslip was then held in place by application of nail 
varnish around the edges.  The cells were then imaged and z-sections were taken using 
the Zeiss LSM510 operating software.  
 
3.8.10 Biological activity of scFv-CPP conjugates - Cell Titre Glo 
assay® 
The biological activities of the scFv-CPP conjugates and ABT-737 were assessed 
using an ATP/Luciferase based assay (Cell Titre Glo assay®, Promega).  Jurkat cells 
were seeded on the day of dosing in 96-well cell culture plates (Costar) at 3 x 103 
cells/well in 20 µl of fresh media.  Alternatively, RBL-2H3 cells were seeded at 3 x 
103 cells/well in 100 µl of fresh media and given 16 h to adhere at 37 oC.  After the 
cells were attached, 80 µl of media was removed from each well to leave the cells in 
20 µl of media/well.     
ScFv-CPP constructs (12-15 mg/ml, 0.4-0.5 mM stock solution) in sodium acetate 
buffer (pH 5.5) were diluted into RPMI-1640 media to give a working concentration 
of 50 µM.  The diluted sample was then filtered through a sterile 0.22 µm syringe 
filter (PVDF, Millipore).  80 µl of the filtered sample was then added to each well to 
give a final assay concentration of 40 µM and well volume of 100 µl.   
Alternatively, ABT-737 (1.63 mg/ml, 2 mM stock in DMSO) was diluted into RPMI-
1640 media to give a stock solution of 25 µM, which was then further diluted to give 
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the serial dilutions; 12.50, 6.25, 3.13, 1.56 and 0.78 µM in RPMI-1640 media.  80 µl 
of each dilution was added to each well to give final ABT-737 concentrations of 0.63-
20 µM in a well volume of 100 µl.   
Each sample dilution was tested in triplicate.  Negative controls included wells 
containing only 100 µl of RPMI-1640 media and wells containing RPMI-1640 media 
and sample vehicle.  Additionally, a time 0 control plate containing 3 x 103 cells/well 
in 100 µl RPMI-1640 media was analysed, using the Promega Cell Titre Glo® protocol 
described below, at the time of dosing the cells. 
Cells were incubated with the samples for 48 h at 37 oC.  The cell viability of each 
well was then determined using the Promega Cell Titre Glo® protocol.  The first step 
was the addition of 100 µl of luciferase/ATP assay solution to each well followed by 
agitation of the plate using an orbital plate shaker at 600 rpm for 2 min.  Cells were 
then transferred to a white walled 96-well plate and incubated for a further 6 min at rt.  
Plates were read on a PerkinElmer Envision plate reader measuring the relative 
luminescence units (RLU).   
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4  
 
Controlled unmasking of a cationic 
cell penetrating peptide for 
intracellular delivery 
 
The highly basic nature of the arginine side-chain plays a major role in the cell 
penetrating capability of arginine rich CPPs.89  Although CPPs have shown promise 
for the intracellular delivery of macromolecules they have had limited in vivo success.  
The conjugation of a cationic CPP to a protein results in non-specific uptake into 
almost all tissues together with rapid blood clearance.119  This wide-spread tissue 
uptake often means that relatively high doses (mg/kg) of CPP conjugates are required 
to induce a biological effect.  As previously mentioned there have been a number of 
reported approaches that aim to reduce the non-specific uptake of CPPs using targeted 
delivery or targeted activation of CPP internalisation.  A novel alternative to these 
methods is investigated in this chapter.   
The aim of the research presented in this chapter is to control the cellular 
internalisation of a CPP by masking the cationic arginine residues with hydrolytically 
and/or enzymatically labile protecting groups.  It is predicted that after i.v. 
administration of the CPP, the cationic charge will then be gradually unmasked by 
breakdown of the protecting groups by hydrolysis or deprotection by serum esterases.  
This slow unmasking will then allow for the CPP to interact with cell membranes 
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leading to internalisation.  Figure 4-1 illustrates the principle of the approach 
investigated in this chapter.   
 
 
Figure 4-1: The protected guanidine functionalities of the CPP result in inhibition of cell internalisation.  
Slow hydrolysis of the protecting groups or deprotection by the activity of serum esterases then exposes 
the guanidine moieties allowing for internalisation of the peptide. 
 
This approach could prolong the circulation time of a protein-CPP conjugate, allowing 
for organ uptake and reducing peripheral tissue uptake.  The advantage of this method 
is that the activation step is separate from the targeting mechanism.  Therefore, this 
approach could be used in conjunction with a range of cargo and tissue targeting 
molecules.   
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The research aims of this chapter are: 
 
1. Proof-of-concept: does carbamate protection of the guanidine functionality of 
octa-arginine inhibit cell penetration? 
 Synthesis of 5-FAM labelled octa-ornithine derivatives. 
 In-solution guanidinylation of octa-ornithine derivatives to afford 
carbamate protected octa-arginine derivatives. 
 Cell internalisation studies comparing the protected and unprotected octa-
arginine derivatives using confocal laser scanning microscopy (CLSM). 
2. The application of esterase and hydrolytically sensitive carbamate protecting 
groups for the protection of octa-arginine.  
 Investigate the application of acyloxymethyl (AM) and acyloxy (AO) 
carbonyl groups for the side-chain protection of arginine. 
 Evaluate the esterase-sensitivity and hydrolytic stability of the AM and 
AO groups at the monomer level using a HPLC based assay. 
 Investigate the application of esterase-sensitive AM/AO groups for the 
protection of the guanidine functionality of octa-arginine.  
 
The overall goal of this chapter is to establish if guanidine protection with labile 
protecting groups is a feasible and effective approach to modulating cell 
internalisation of the CPP octa-arginine. 
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4.1 Proof-of-concept: Inhibition of CPP cell internalisation 
by carbamate protection of the guanidine moieties 
Carbamate protection of the guanidine functionality of octa-arginine was investigated 
as a method to inhibit its cell penetration.  It was proposed that protected octa-arginine 
could be accessed by the in-solution guanidinylation of an octa-ornithine derivative 
using carbamate protected guanidinylating agents.  Therefore, the initial step was the 
synthesis of 5-FAM labelled octa-ornithine derivatives to provide material for use in 
the rest of this study.  Importantly, the regioselective labelling of the peptides with 5-
FAM would provide a robust method to assess the cellular uptake of the octa-arginine 
derivatives using CLSM.  Table 4-1 shows the peptides that will be used in this 
chapter. 
 
Table 4-1: Octa-ornithine derivatives to be synthesised  
 
# Peptide Reference 
 
octa-ornithine derivatives 
 
85 FAM-(Orn)8-[NH2]  
86 FAM-(Orn-Ahx)8-[NH2]  
 
  
 
octa-arginine derivatives 
 87 FAM-(Arg)8-[NH2] Wender et al. (2000) 89 
88 FAM-(Arg-Ahx)8-[NH2] Rothbard et al. (2002) 218 
 
The 5-FAM labelled octa-ornithine derivative 85 was chosen based on the CPP octa-
arginine 87.  This CPP is widely used for the intracellular delivery of a wide range of 
cargo.89  Additionally, the 6-aminohexanoic acid (Ahx) spaced octa-ornithine 
derivative 86 was chosen.  The corresponding spaced octa-arginine derivative 88 was 
reported by Rothbard et al. (2002) to possess superior cell penetrating ability 
compared to octa-arginine.218  Moreover, octa-ornithine derivative 86 may be more 
suitable for the introduction of multiple protected guanidine moieties due to the 
spacing between the amino acid residues and flexibility of the peptide backbone 
relative to 85.   
The synthesis of octa-ornithine 85 was achieved using standard Fmoc solid-phase 
peptide synthesis (Fmoc SPPS) on a Rink amide NovaGel® resin.  The first residue to 
be introduced to the resin was Fmoc-Orn(Boc)-OH using four equivalents of amino 
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acid and the carboxyl-activation mixture HATU and DIPEA, relative the resin loading 
(0.1 mmol).  All subsequent amino acid residues were introduced to the peptidyl resin 
after repeated steps of Fmoc deprotection using 20% piperidine in DMF followed by 
coupling of Fmoc-Orn(Boc)-OH.  This was repeated until a total of eight ornithine 
residues were introduced to the peptidyl resin to afford intermediate 89 (Scheme 4-1, 
i-ii).   
 
Scheme 4-1: Synthesis of the 5-FAM labelled octa-ornithine derivative 85. 
 
 
 
 
 
In the next step of the synthesis, 89 was Fmoc deprotected using 20% piperidine in 
DMF.  5-FAM was then introduced to the peptidyl resin using the coupling reagents 
HOAt and DIC (Scheme 4-1, iii-iv).  The reaction mixture was stirred intermittently 
for 16 h at rt.  The resin was then washed with DMF to remove excess reagents.  
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Subsequent washing of the resin with 20% piperidine/ DMF removed any 5-FAM 
polymeric phenyl esters by base-catalysed aminolysis to afford peptidyl resin 90 
(Scheme 4-1, v).210  The final step of the synthesis involved treatment of 90 with TFA-
TIPS-H2O (90:2:8) to furnish the FAM labelled octa-ornithine derivative 90 in good 
yield and purity (>80%).  Figure 4-2 shows the crude analytical trace of 85 (tR 3.12 
min). 
 
 
 
Figure 4-2: Analytical HPLC of crude FAM-(Orn)8-[NH2] 85 (tR 3.12 min) analysed using a 1-90% B 
over 10 min, 3ml/min method on an Onyx Monolithic C18 column (100 x4.6 mm). 
  
 
 
The successful synthesis of 85 was confirmed by TOF MS (ES+) with a peak at m/z 
644.8573 being detected and assigned as the [M+2H]2+ species together with a single 
major product being observed by analytical HPLC (see Figure 4-2).  The 
aforementioned synthetic approach was applied to the synthesis of the Ahx spaced 
octa-ornithine derivative 86.  
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Scheme 4-2: Synthesis of the Ahx spaced 5-FAM labelled octa-ornithine derivative 86. 
 
 
 
Preparative HPLC of crude peptide 86 gave a peptide of good purity (>95%) and in an 
isolation yield of 46%.  Figure 4-3 shows the analytical HPLC trace for the crude 
peptide 86 (tR 2.77 min).  
 
 
Figure 4-3: Analytical HPLC of crude FAM-(Orn-Ahx)8-[NH2] 86 (tR 2.77 min) analysed using 1-100% 
B over 10 min, 3ml/min method on an Onyx Monolithic C18 column (100 x 4.6 mm).  
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The successful synthesis of 86 was confirmed by TOF MS (ES+) with peaks at m/z 
1097.6907 and 732.1321 being observed and assigned as [M+2H]2+ and [M+3H]3+, 
respectively.  The reduced yield of 86 was the result of incomplete coupling of the 
final ornithine residue, possibly due to aggregation of the peptide hindering access to 
WKHĮ-amine, thus reducing the efficiency of the residue coupling.  Table 4-2 shows the 
synthesised octa-ornithine derivative and the corresponding yields.   
 
 
Table 4-2: Isolation yields and purity of FAM-(Orn)8-[NH2] 85 and FAM-(Orn-Ahx)8-[NH2] 86. 
 
  
Sequence Yield Purity* tR/ min 
  
85 FAM-(Orn)8-[NH2] 71% >80% 3.12 
86 FAM-(Orn-Ahx)8-[NH2] 46% >95% 3.45 
 *Peptide purity determined from intergration of HPLC peak.  
 1-90% B over 10 min, 3ml/min, Onyx monolithic C18 (100 x 4.6 mm).  
 
The two octa-ornithine derivatives 85 and 86 were used for subsequent reactions 
investigating the in-solution guanidinylation of the ornithine side-chain to afford 
protected octa-arginine derivatives. 
In this context, the reported procedure by Wender et al. (2001) utilises pyrazole-1-
carboxamidine 93 to guanidinylate a trifluoroacetamide protected octa-ornithine 
derivate 94 affording the octa-arginine derivative 95 in a yield of 50% (Scheme 4-
3).230  
 
Scheme 4-3: Synthesis of octa-arginine 95 by guanidinylation of trifluoroacetamide protected octa-
ornithine derivate 94. 
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Overall, the octa-arginine was synthesised in 10 steps starting from the 
trifluoroacetamide protected ornithine monomer in an overall yield of 29%.  
Alternatively, a milder approach for introducing guanidine moieties to a molecule is 
the application of protected isothioureas such as, N,N'-bis(tert-butoxycarbonyl)-S-
methylthiourea 96 and N,N'-bis(benzyloxycarbonyl)-S-methylthiourea 97.231   
 
 
 
Usually, the conversion of an isothiourea to a guanidine requires an activation step.  
This can be achieved under mild conditions using the Lewis acid mercuric 
chloride.232,233  The guanidinylation reaction proceeds by Hg(II) bonding with the 
thioether of 96, resulting in polarisation of the carbon-sulfur bond, which promotes the 
SN2 substitution of the methyl thioether by an amine.  The proposed mechanism for 
this reaction is illustrated in Scheme 4-4. 
 
Scheme 4-4: The proposed mechanism for the guanidinylation of an amine with N,N'-bis(tert-
butoxycarbonyl)-S-methylthiourea 96 in the presence of HgCl2. 
 
 
 
This strategy was employed to introduce di-Boc protected guanidine moieties to an 
octa-ornithine derivative to afford the corresponding protected octa-arginine.  The 
protected peptide will then be used to determine if cell internalisation is inhibited by 
protecting the guanidine moieties of arginine.  
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The guanidinylation of the octa-ornithine derivatives 85 and 86 using N,N'-bis(tert-
butoxycarbonyl)-S-methylthiourea 96 and mercuric chloride was investigated.  The 
Ahx spaced octa-ornithine derivative 86 was used to determine optimum reaction 
conditions.  Peptide 86 was dissolved in water and treated with 10 eq. of DIPEA to 
scavenge TFA salts.  Separately, 96 was dissolved into MeCN and pre-activated using 
a stoichiometric amount of mercuric chloride.  Peptide 86 was then added dropwise to 
the activated guanidinylating agent (Scheme 4-5). 
 
Scheme 4-5: Synthesis of  FAM-(R(di-Boc)-Ahx)8-[NH2] 98. 
 
 
 
 
The reaction was stirred for a further 2 h, followed by removal of the solvent in vacuo.  
The orange residue was suspended in MeCN and centrifuged at 13000 g for 20 min.  
This resulted in a white pellet and clear orange supernatant.  The supernatant was then 
analysed by HPLC.  The synthesis of FAM-(R(di-Boc)-Ahx)8-[NH2] 98 was 
successful.  Analysis by TOF MS (ES+) revealed peaks at m/z 1378.1024, 1033.8420 
and 827.2668 that were assigned as the multiple ions [M+3H]3+, [M+4H]4+ and 
  
153 
[M+5H]5+, respectively.  Additional peaks corresponding to sequential loss of Boc 
groups were also detected, suggesting fragmentation of the peptide in the MS.  
Preparative HPLC was used to isolate 98 in a yield of 57%.  Surprisingly, subsequent 
analysis of the purified peptide by analytical HPLC indicated that the NG-Boc 
protected peptide was unstable in aqueous conditions, indicated by the presence of 
four major peaks in the HPLC chromatogram (Figure 4-4).  
 
 
Figure 4-4:  Analytical HPLC of purified FAM-(R(di-Boc)-Ahx)8-[NH2] 98 analysed using 1-100% B 
over 10 min, 3ml/ min method on an Onyx Monolithic C18 column (100 x4.6 mm).  
 
To confirm that the observed species seen in the HPLC were due to the loss of Boc 
groups peptide 98 was NG-Boc deprotected by acidolysis (Scheme 4-6).  Additionally, 
this would provide the unprotected octa-arginine derivative to be used as a positive 
control in the cell internalisation studies.   
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Scheme 4-6: Synthesis of FAM-(R-Ahx)8-[NH2] 88. 
 
 
FAM-(R(di-Boc)-Ahx)8-[NH2] 98 was NG-Boc deprotected in a solution of TFA-TIPS-
H2O (90:2:8) with stirring for 2 h at rt.  The TFA was then removed in vacuo to afford 
an orange residue.  This residue was triturated with diethyl ether followed by 
lyophilisation.  The resulting orange solid was analysed using analytical HPLC (Figure 
4-5). 
 
 
Figure 4-5: Analytical HPLC of crude FAM-(R-Ahx)8-[NH2] 88 (tR 3.88 min) analysed using 1-90% B 
over 10 min, 3ml/ min method on an Onyx Monolithic C18 column (100 x 4.6 mm).  
 
 
AU
-0.05
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
6.46
3.88
2.32
12.42
min
A
U
3.64
  
155 
The major peak at 3.88 min (Figure 4-5) was isolated by preparative HPLC to afford 
88.  Notably, purified 88 was stable unlike the Boc protected peptide 98.   The 
successful isolation of 88 was confirmed by MALDI-TOF MS.  A major species at m/z 
2531.397 was observed, which is in agreement with the calculated value for the 
[M+H]+ species of the fully deprotected octa-arginine derivative 88.  
Interestingly, the Boc deprotection of 98 resulted in one major species.  This suggests 
that the multiple species seen in the analytical HPLC of 98 are due to hydrolysis of the 
Boc groups.   TOF MS (ES+) analysis of peptide 98 showed the presence of a number 
of species with different numbers of Boc groups, however it must be noted that this 
fragmentation may also occur due to ES ionisation.  Nevertheless, comparison of the 
internalisation capabilities of the partially protected FAM-(R(di-Boc)-Ahx)8-[NH2] 98  
and the unprotected FAM-(R-Ahx)8-[NH2] 88  should still be insightful.   
The guanidinylation of octa-ornithine derivative 85 was achieved using the same 
method used for the synthesis of 98 (Scheme 4-5), however, at rt no reaction occurred.  
Alternatively, heating of the reaction to 50 oC with stirring for 2 h resulted in complete 
guanidinylation of peptide 85 to give the NG-Boc protected octa-arginine 99 (Scheme 
4-7). 
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Scheme 4-7: Synthesis of FAM-(R(di-Boc))8-[NH2] 99 and FAM-(R)8-[NH2] 87. 
 
 
 
The successful synthesis of 99 was confirmed by TOF MS (ES+) revealing a peak at 
m/z 807.4263 that was assigned at the [M+4H]4+ species.  Preparative HPLC of the 
crude peptide afforded 99 in good purity and a yield of 23%.  Interestingly, peptide 99 
displayed greater stability under aqueous conditions compared to FAM-(R(di-Boc)-
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Ahx)8-[NH2] 98.  This difference could be a result of 98 adopting a more compact 
conformation in solution compared to the Ahx spaced peptide 98, thus protecting the 
Boc groups from hydrolysis.  
The NG-Boc deprotection of 98 was achieved using TFA-TIPS-H2O (90:2:8) (Scheme 
4-7, ii).  The TFA was then removed in vacuo after 4 h and the resulting orange 
residue was triturated with diethyl ether.  FAM-(R)8-[NH2] 87 was then isolated by 
preparative HPLC in good purity and an isolation yield of 40%.  The successful 
synthesis of 87 was confirmed by MALDI-TOF MS with a peak at m/z 1625.86 being 
detected and assigned as the [M+H]+ species.  Table 4-3 shows the yields and purity of 
both the synthesised NG-protected and unprotected octa-arginine derivatives. 
 
Table 4-3: Synthesised NG-Boc protected and unprotected octa-arginine derivatives. 
 
# Sequence Yield Purity*  tR / min  
98 FAM-(R(di-Boc)-Ahx)8-[NH2]  57% n.d 6.76, 7.09, 7.42, 7.76 
88 FAM-(R-Ahx)8-[NH2]  56% >95% 3.88 
99 FAM-(R(di-Boc))8-[NH2]  23% >80% 8.95 
87 FAM-(R)8-[NH2]  40% >95% 3.47 
*Peptide purity determined from integration of HPLC peak.  1-90% B over 10 min, 3ml/min, Onyx 
monolithic C18 (100 x 4.6 mm).  Multiple peaks for 98 due to sequential NG-Boc deprotection.  
 
 
In summary, the in-solution guanidinylation of the octa-ornithine derivatives 85 and 
86 was successful.  Guanidinylation using the Boc protected isothiourea 96 afforded 
the NG-Boc protected octa-arginine derivatives 95 and 99.  Notably, peptide 99 
displays greater stability under aqueous conditions compared to the protected Ahx 
spaced octa-arginine 98.  Thus, peptide 99 is perhaps a more suitable peptide for 
CLSM studies comparing the cell internalisation of the protected and unprotected 
octa-arginine derivatives.  
 
4.1.1 Cell internalisation of protected octa-arginine derivatives 
The cell internalisation of the prepared peptides was assessed using CLSM.  By 
comparing the cellular internalisation of the protected and unprotected octa-arginine 
derivatives the effect of protecting the guanidine functionality of an octa-arginine can 
be assessed.  The unprotected octa-arginine derivatives FAM-(R)8-[NH2] 87 and 
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FAM-(R-Ahx)8-[NH2] 88 were used as positive controls.  These peptides were 
compared to the protected peptide FAM-(R(di-Boc)8-[NH2] 99 and the partially 
protected FAM-(R(di-Boc)-Ahx)8-[NH2] 98 (Figure 4-6). 
 
 
Figure 4-6:  The cell internalisation of the a) unprotected and b) carbamate protected octa-arginine 
derivatives will be compared to determine if protection of the arginine side-chains inhibits 
internalisation.  The peptides are labelled with 5-FAM allowing for internalised peptide to be imaged 
using CLSM.  
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HeLa cells were treated with either the NG-Boc protected or the unprotected octa-
arginine derivative at 10 µM for 30 min at 37 oC.  After incubation, cells were washed 
with PBS and incubated with 5 µM of the nuclear stain Draq5 (Ex 646 nm/Em 697 
nm).  Finally, the live cells were imaged using an inverted x63 oil immersion lens.  Z-
sectioning using CLSM allowed for focusing within the cell, distinguishing between 
membrane and intracellular associated fluorescence.  The prepared peptides all possess 
an N-terminal fluorescein (Ex 494 nm/Em 518 nm) allowing for detection of the 
peptide.  Figure 4-7 shows HeLa cells treated with FAM-(R-Ahx)8-[NH2] 88  (Figure 
4-7, b) and FAM-(R(di-Boc)-Ahx)8-[NH2] 98  (Figure 4-7, c).   
 
 
 
 
Figure 4-7:  Cell internalisation of octa-arginine derivatives.  HeLa cells treated with 10 µM of 5-FAM 
labelled peptide (green), for 30 min at 37 oC.  Cells were then washed and incubated with the nuclear 
stain Draq5 (purple) and imaged using CLSM with an inverted x63 oil immersion lens a) untreated 
cells, b) FAM-(R-Ahx)8-[NH2] 88  and  c) FAM-(R(di-Boc)-Ahx)8-[NH2] 98.  
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The partial protection of the arginine side-chains appears to inhibit cell internalisation 
of the Ahx spaced octa-arginine 98 (Scheme 4-7, c).  However, the FAM-(R-Ahx)8-
[NH2] 88 does not show intense cell associated fluorescence, suggesting that this 
peptide is not efficiently internalised into HeLa cells (Scheme 4-7, b).  Despite this, 
there is still a difference between the cell internalisation of the partially protected 98 
and unprotected peptide 88. 
The cell internalisation of the FAM-(R)8-[NH2] 87 and FAM-(R(di-Boc)8-[NH2] 99 
was investigated using the same method as previously described.  Figure 4-8 shows 
the CLSM images of HeLa cells treated with 10 µM of peptide (green) for 30 min, 
again the cell nucleus was stained with Draq5 (purple).  
 
Figure 4-8:  Cell internalisation of octa-arginine derivatives.  HeLa cells treated with 10 µM of 5-FAM 
labelled peptide (green), for 30 min at 37 oC.  Cells were then washed and incubated with the nuclear 
stain Draq5 (purple) and Z-sections of the cells were taken using CLSM with an inverted x63 oil 
immersion lens a) untreated cells, b) FAM-(R)8-[NH2] 87 and  c) FAM-(R(di-Boc))8-[NH2] 99.      
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FAM-(R)8-[NH2] 87 is clearly internalised, with uniform cellular fluorescence being 
observed (Figure 4-8, b).  In contrast, minimal fluorescence is seen for the NG-Boc 
protected peptide FAM-(R(di-Boc)8-[NH2] 99 (Figure 4-8, b). 
In summary, the inhibition of the cellular internalisation of octa-arginine was 
successfully achieved by protection of the guanidine moieties of the arginine side-
chains using the Boc protecting group.  The difference observed in the CLSM images 
is very significant.  FAM-(R)8-[NH2] 87 shows the most efficient cellular uptake with 
intense cell associated fluorescence being observed.  This cellular uptake was almost 
completely inhibited through NG-Boc protection, demonstrated by treatment of cells 
with FAM-(R(di-Boc))8-[NH2] 99.  CLSM of cells treated with 99 showed no cell 
associated fluorescence, thus suggesting no cellular uptake of the peptide.   
 
4.2 Protection of arginine side-chain with hydrolytic and 
esterase-labile protecting groups 
The aforementioned findings clearly demonstrated that CPP side-chain protection 
decreases cellular uptake.  Thus, the use of hydrolytically or catalytically labile 
protecting groups was investigated.  The protection of an octa-arginine derivative with 
labile protecting groups is predicted to result in unmasking of the cell penetrating 
properties of the peptide in vivo.       
An established method for the protection of amine and guanidine moieties in drug 
molecules is the application of the esterase-sensitive acyloxymethyl carbonyl (AM) 
protecting group.146  Therefore, this class of protecting group may be suitable for the 
protection of an octa-arginine derivative.  Upon enzymatic cleavage of the ester 
moiety by serum esterases, the protecting group is removed to leave the unprotected 
amine (Scheme 4-8).146, 234-235 
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Scheme 4-8: Enzymatic cleavage of an acyloxymethyl carbonyl (AM) protected amine by an esterase to 
afford the unprotected amine.146 
 
 
 
There are several examples of AM moieties being used in prodrugs.  For example, 
Cundy et al. (2004) reported the synthesis of XP13512 100, a prodrug of Gabapentin, 
which is used for the treatment of neuropathic pain.  This prodrug showed better 
bioavailability than the parent drug and was rapidly converted after absorption.236  
Additionally, Gangwar et al. (1997) report the application of an AM group for the 
synthesis of the peptide prodrug 101.  Upon enzymatic cleavage of the ester, the linear 
peptide is produced.237  The half-life of the cyclic peptide in human blood plasma was 
132 ± 4 min.   
 
Of relevance to the aims of this chapter, Saulnier et al. (1994) demonstrated the 
application of AM groups for the protection of guanidine moieties.  The authors 
utilised several AM groups to protect the guanidine moiety of the model compound N-
benzylguanidine 102.  This was achieved by guanidinylation of benzyl amine 103 
using an 11¶-bis(acyloxymethoxycarbonyl)-S-methylisothiourea that was pre-
activated with sulfuryl chloride (Scheme 4-9). 
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Scheme 4-9: Guanidinylation of benzyl amine 103 with a thiourea using sulfuryl chloride. 
 
 
Initially, the isothiourea was pre-activated with sulfuryl chloride to afford the reactive 
intermediate 104.  This pre-activation step improved the chemoselectivity of the 
reaction by reducing the nucleophilic attack at the ester carbonyl of the isothiourea.  
The reported half-lives (t1/2) of the protected guanidine moieties in rat blood plasma 
were 1.12 min and 0.13 min for the 105 and 106 respectively.  Experiments using pig 
liver esterase (PLE) also confirmed that the deprotection of these groups was mediated 
by esterases.147 
Alternatively, acyloxycarbonyl (AO) protecting groups can also be used to mask 
amine and guanidine moieties.  These simple carbamates have shown less promise for 
the protection of amines in drug molecules because of the relative chemical and 
enzymatic stability compared to AM group.146  However, the application of AO 
protecting groups will be investigated in this chapter for the protection of an octa-
arginine, primarily as a more stable alternative to the AM groups. 
It was proposed that assessment of the hydrolytic and esterase-sensitivity of AM and 
AO protecting groups at the monomer level will give insight into their suitability for 
the protection of an octa-arginine derivative (Scheme 4-10).  
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Scheme 4-10: The proposed synthesis of AO and AM protected ornithine residue and either hydrolytic 
or enzymatic deprotection to give the unprotected argnine residue.  
 
 
It is envisaged that the protected arginine monomers will provide material for stability 
assays to investigate the breakdown of the protecting groups in different aqueous 
conditions and in the presence of esterases using a HPLC based assay. 
 
4.2.1 Synthesis of protected isothioureas 
Initially a number of isothiourea starting materials needed to be synthesised.  It was 
proposed that these intermediates could be accessed by a previously reported 5-step 
synthesis.147,238  For example, the synthesis of isobutanoyloxymethyl and 
pivaloyloxymethyl protected isothioureas is outlined in Scheme 4-11.   
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Scheme 4-11: Synthesis outline for 11¶-bis(acyloxymethoxycarbonyl)-S-methylisothiourea.  
 
 
In the first step of the proposed synthesis 237, an ethereal solution of ethanethiol 107 
and chloromethyl chloroformate 108 was stirred for 16 h at rt.  Subsequent purification 
of the crude reaction mixture afforded O-chloromethyl-S-ethyl carbonothioate 109 in a 
98% yield (Scheme 4-11). 
 
Scheme 4-12: Synthesis of O-(chloromethyl)-S-ethyl ester 109.  
 
 
 
 
The spectroscopic data for 109 was identical to that reported in the literature.238  To 
avoid nucleophilic attack at the carbonyl of 109, the alkyl chloride was converted to an 
alkyl iodide by a Finkelstein reaction (Scheme 4-13). 
 
Scheme 4-13: Synthesis of O-(iodomethyl)-S-ethyl carbonothioate 110. 
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Compound 109 was added to a solution of sodium iodide in acetone with stirring for 4 
h at 40 oC.  Subsequent work-up of the crude reaction mixture afforded the reactive 
intermediate O-(iodomethyl)-S-ethyl carbonothioate 110 in a yield of 88%.  Exchange 
of the chloride for an alkyl iodide was confirmed by 1H NMR with a slight downfield 
shift of the adjacent methylene protons from į 5.77 to 5.98 ppm being observed, which 
was also in agreement with the literature.238 
The next step of the synthesis involved the addition of 110 to a solution of either 
sodium isobutyrate or sodium pivalate in dry DMF at -20 oC.  The solution was then 
warmed to rt and stirred for 16 h.  The reaction proceeded by a SN2 substitution of the 
alkyl iodide by the carboxylate anion to furnish the esters 111 and 112 in yields of 
79% and 82%, respectively (Scheme 4-14).     
  
 Scheme 4-14: Synthesis of acyloxymethyl-S-ethyl carbonothioate 111 and 112. 
 
 
 
 
 
Successful synthesis of the 111 and 112 was confirmed using 1H NMR with a slight 
upfield shift of the methylene protons from į 5.98 ppm for 110 to 5.80 ppm for both 
111 and 112 being observed.  Additionally, FTIR showed the presence of two 
carbonyl peaks between 1720 and 1760 cm-1 that are in agreement with the 
literature.238  The penultimate step of the synthesis involved the chlorination of 111 
and 112 using sulfuryl chloride (Scheme 4-15).   
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Scheme 4-15: Synthesis of acyloxymethyl carbonochloridate 113 and 114. 
 
 
Sulfuryl chloride (1.3 eq.) was added to 111 or 112 at 4 oC with stirring.  The reaction 
mixture was allowed to warm to rt and stirred for 1 h.  The by-product of the reaction, 
ethylsulfenyl chloride, was largely removed in vacuo.  However, further purification 
was required by Kugelrohr distillation to afford the pure acyloxymethyl 
carbonochloridate 113 and 114 in yields of 27% and 60%, respectively.  Successful 
chlorination of the esters was confirmed using FTIR with a change in the absorption of 
the carbonyl at 1720 cm-1 for 111 and 112 to approximately 1790 cm-1 for 113 and 114 
being observed.  Additionally, 1H NMR showed the loss of a triplet at į 1.32 ppm and 
quartet at į 2.89 ppm, confirming substitution of the ethanthio moiety.  
The successful synthesis of the acyloxymethyl carbonochloridate intermediates 
allowed for the synthesis of the 11¶-bis(acyloxymethoxycarbonyl)-S-
methylisothioureas following the procedure described by Saulnier et al. (1994) 
(Scheme 4-16).147   
 
Scheme 4-16: Synthesis of 11¶-bis(acyloxymethoxycarbonyl)-S-methylisothioureas 116 and 117.  
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In this final step, 2-methyl-2-thiopseudourea hemisulfate 115 was reacted with either 
acyloxymethyl carbonochloridate 113 or 114 using Schotten-Baumann conditions.  
115 was dissolved in saturated NaHCO3 followed by dropwise addition of 2.5 
equivalents of the carbonochloridate in DCM followed by rigorous stirring for 24 h.  
Formation of the mono-protected 2-methyl-2-thiopseudourea was seen as a minor 
product.  Silica chromatography allowed for isolation of the di-protected 2-methyl-2-
thiopseudourea 116 and 117 in reasonable yields.  Successful synthesis was confirmed 
by TOF MS (ES+) with molecular ion peaks detected at m/z 379.1197 and 407.1324 
assigned as [M+H]+ for 116 and 117, respectively. 
It was proposed that the AO protected isothioureas could be accessed following a 
previously reported one-step synthesis.239 The intermediates N,N'-bis-
(ethyloxycarbonyl)-S-methylthiourea 118 and N,N'-bis-(isopropyloxycarbonyl)-S-
methylthiourea 119 isothiourea were synthesised following the proposed synthetic 
route shown in Scheme 4-17.  
 
Scheme 4-17: Synthesis of N,N'-bis-(acyloxycarbonyl)-S-methylthioureas 118 and 119. 
 
 
 
 
Thus, 2-methyl-2-thiopseudourea 115 was dissolved in DCM followed by the addition 
of 3 equivalents of either ethyl chloroformate or isopropyl chloroformate.  Subsequent 
work-up and purification afforded 118 and 119 in yields of 76% and 44%, 
respectively.  The successful synthesis of 118 and 119 was confirmed by TOF MS 
(ES+) with molecular ions at m/z 235.0838 and 263.1097 being detected and assigned 
as the [M+H]+ species, respectively. 
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4.2.2 The stability of acyloxycarbonyl and acyloxmethyoxy carbonyl 
protected arginine 
To investigate the stability of the AM and AO protecting groups, a simple model 
system that utilised an ornithine monomer was developed.  The first step in setting up 
the model system was the synthesis of AM and AO protected arginine derivatives.  
The guanidinylation of two different ornithine monomers, Fmoc-Orn-OH 120, N-
acetyl ornithine 121 and the dipeptide N-acetyl ornithyl phenylalanine amide 122 
using the prepared protected isothioureas was investigated.   
 
 
 
Initially, the guanidinylation of Fmoc-Orn-OH 120 was investigated, as the 
absorbance of the Fmoc group would allow for detection of small quantities of the 
compound and deprotected species in a HPLC assay. The guanidinylation of 120 using 
11¶-bis-((pivaloyloxy)methyloxycarbonyl)-S-methylthiourea 117 was achieved 
following the procedure described by Saulnier et al. (1994) (Scheme 4-18).147 
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Scheme 4-18: Synthesis of AM protected Fmoc-Arg-OH 124. 
  
 
 
 
 
The first step involved the pre-activation 117 using sulfuryl chloride to afford the 
reactive intermediate 123.  The excess sulfuryl chloride
 
and the sulfenyl chloride were 
then removed in vacuo (Scheme 4-18, i).  Without purification, 2 equivalents of 123 
were added to a solution of Fmoc-Orn-OH 120 in DCM and 4 equivalents of DIPEA 
(Scheme 4-18, ii).  The reaction was stirred for 1 h at rt followed by purification by 
silica chromatography to afford 124 in a yield of 22%.  The successful guanidinylation 
of 124 was confirmed by TOF MS (ES+) with a base peak at m/z 713.2806 being 
detected, which was assigned as [M+H]+. 
Unfortunately, 124 was only sparingly soluble in aqueous solvents, thus could not be 
used to assess the hydrolytic or esterase stability of the AM protecting groups in 
aqueous buffers.  This insolubility is possibly a result of the organic nature of the 
Fmoc group.      
Alternatively, guanidinylation of N-acetyl ornithine was investigated.  It was predicted 
this would yield an ornithine derivative with improved water solubility.  The 
conditions used for the synthesis of 125 were applied to the guanidinylation of N-
acetyl ornithine 121 (Scheme 4-19). 
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Scheme 4-19: Attempted synthesis of AM protected Fmoc-Arg-OH 125. 
 
 
N-acetyl ornithine was insoluble in DCM, thus alternative solvents and reaction 
conditions were investigated for the synthesis of 125.  The conditions that were 
investigated for this reaction are outlined in Table 4-4. 
 
Table 4-4: Unsuccessful attempts to synthesise 125. 
 
Solvent  Base Temperature Result 
DMF DIPEA rt No reaction 
DMF DIPEA 50 oC No reaction 
DMF DIPEA 80 oC, 1 h Inseparable mixture 
THF DIPEA rt, 16 h No reaction, partial solubility of N-acetyl ornithine, 
THF/ H20 DIPEA rt, 16 h No reaction 
 
By heating the reaction at 80 oC in DMF it is possible that the rate of the desired 
reaction was increased.  However, the rate of nucleophilic substitution at the ester 
carbonyl of 123 would have also increased leading to product decomposition, 
explaining the inseparable mixture obtained using these conditions. 
Thus, an alternative scaffold was investigated, in an attempt to obtain an arginine 
derivative of suitable solubility for both the guanidinylation reaction and application in 
an enzyme based assay using aqueous buffers.  The dipeptide N-acetyl ornithyl 
phenylalanine amide 122 was investigated for this application.  Additionally, this 
dipeptide was synthesised with the rational that the phenylalanine side-chain would 
increase the UV absorbance of the dipeptide, thus enabling detection of small 
quantities of the compound in a HPLC based assay.  The synthesis of 122 is outlined 
in Scheme 4-20.  
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Scheme 4-20:  Proposed synthesis of N-acetyl ornithyl phenylalanine amide 122. 
 
 
In the first step of the proposed synthesis, thionyl chloride was added dropwise to a 
methanolic solution of phenylalanine 126 at 0 oC.240  The reaction mixture was 
warmed to rt followed by refluxing for 3 h (Scheme 4-21). 
 
Scheme 4-21: Synthesis of phenylalanine methyl ester 127. 
 
 
 
Re-crystallisation of phenylalanine methyl ester 127 from the crude reaction mixture 
using methanol and diethyl ether was achieved in a yield of 92% which was 
spectroscopically identical to the literature.240 
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In the next step, compound 127 was coupled to Fmoc-Orn(Boc)-OH 128 by amide 
bond formation.  A stoichiometric amount of 128 was added to the coupling reagent 
HATU 131 and DIPEA in DMF with stirring, to form the activated ester intermediate 
132.  0.5 equivalents of 127 was then added to this solution followed by stirring at rt 
for 3 h.  The reaction proceeded by the mechanism shown in Scheme 4-22.205 
 
Scheme 4-22: Mechanism of amide bond formation using the coupling reagent HATU 131.  
 
 
 
 
 
Subsequent purification of the crude reaction mixture afforded 129 in a yield of 78%.  
In the next step, the Fmoc group of 129 was removed using diethylamine (DEA) in 
DCM (Scheme 4-23, i). 
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Scheme 4-23: Synthesis of N-acetyl(N'-(tert-butoxycarbonyl)ornithyl)phenylalanine methyl ester 130.  
 
  
 
The intermediate 133 was isolated by removal of the reaction solvent and DEA in 
vacuo.  A solution of 133, DIPEA and acetic anhydride in DCM was stirred for 16 h at 
rt (Scheme 4-23, ii).  Subsequent work-up and purification of the reaction mixture 
furnished 130 in a yield of 54%.   
In the penultimate step, the methyl ester of 130 was modified by aminolysis.  This was 
achieved by dissolving 130 in a methanolic solution of 7 N ammonia and  stirring of 
the reaction mixture for 16 h at rt followed by removal of the reaction solvent in vacuo 
(Scheme 4-24, i).  
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Scheme 4-24: Synthesis of N-acetyl ornithyl phenylalanine amide 122. 
 
 
 
In the final step, 134 was Boc deprotected by acidolysis using a 50% solution of TFA 
in DCM for 3 h at rt.  Trituration of the resulting residue with diethyl ether afforded N-
acetyl ornithyl phenylalanine amide 122 in a yield of 97% (Scheme 4-24, ii).  
Successful synthesis of 122 was confirmed by 1H NMR with a loss of a singlet at į 
1.42 and 3.69 ppm being observed, which corresponded to the Boc and methyl ester 
protons, respectively.  Further confirmation was provided by TOF MS (ES+) revealing 
a base peak at m/z 321.1889, which was assigned as the [M+H]+ species.  
The successful synthesis of 122 using established chemistry supplied a compound that 
could then be used for the synthesis of AM and AO protected arginyl derivatives.  The 
model reaction shown in Scheme 4-25 was investigated to determine the optimum 
condition for the guanidinylation of 122.  The guanidinylating agent 118 was used as it 
was predicted that the AO protecting groups would be more stable than the AM 
groups, thus being more suitable for initial reactions investigating different conditions. 
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Scheme 4-25: Synthesis of AO protected N-acetyl argninyl phenylalanine amide derivative 135. 
 
 
Initial attempts focused on using sulfuryl chloride
 
to activate the guanidinylating agent 
118 as previously described.  However, this proved unsuccessful, thus several 
alternative conditions were investigated.  Table 4-5 outlines the conditions used for the 
synthesis of 135.  
  
Table 4-5: Conditions investigated for the synthesis of 135. 
 
Solvent  Base Reagent Temperature Result 
DCM DIPEA SO2Cl2 rt 122 insoluble  
DCM DIPEA SO2Cl2 40 oC 122 insoluble 
DMF DIPEA SO2Cl2 rt, 1 h No reaction 
DMF DIPEA HgCl2 rt, 6 h Product formation 
MeCN/H20 (1:1) DIPEA HgCl2 rt, 6 h Product formation 
 
The pre-activation of 118 with sulfuryl chloride was not successful in DCM or DMF.  
Alternatively, isothiourea 118 was dissolved in DMF followed by the addition of a 
stoichiometric amount of mercuric chloride and DIPEA.   The dipeptide 122 was then 
added to this solution followed by stirring of the reaction mixture for 6 h.  Subsequent 
analysis of the crude reaction mixture by TOF MS (ES+) detected a peak at m/z 
535.2875 that corresponded to the calculated value for the [M+H]+ species of 135.  
Thus, activation of 118 with mercuric chloride proved successful.  The synthesis of 
135 was carried out on a larger scale using DMF as a reaction solvent.  Preparative 
HPLC of the crude reaction mixture allowed for isolation of 135 in a yield of 45%.  
These conditions were then applied to the synthesis of several NG-protected N-acetyl 
arginyl phenylalanine analogues using the previously prepared AM and AO protected 
isothioureas.  Table 4-6 shows the synthesised analogues and their corresponding 
yields. 
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R protecting group Yield TOF MS (ES
+), 
m/z [M+H]+ 
136 CH2OCOCH(CH3)2 22% 651.2841 
137 CH2OCOC(CH3)3 23% 679.3285 
135 CH2CH3 45% 507.2562 
138 CH(CH)3 29% 535.2875 
139 C(CH3)3 70% 563.3188 
 
Table 4-6: The synthesised protected N-acetyl arginyl phenylalanine derivatives. 
 
 
 
The 11¶-bis(acyloxymethoxycarbonyl)-S-methylisothioureas 116 and 117 were 
successfully activated using mercuric chloride and used to guanidinylate the ornithine 
side-chain of 122.  Notably, this activation method did not result in breakdown of the 
AM protecting groups.   
 
4.2.2.1 Hydrolytic stability of the AM and AO protecting groups 
The prepared AM and AO protected dipeptides were used in a HPLC based assay to 
assess the hydrolytic stability of the AM and AO protecting groups.  It was predicted 
that the AM protecting groups may break down to give the unprotected arginine 
residue in aqueous buffers.  Thus, to provide a positive control for the HPLC assay, 
the NG-Boc protected N-acetyl arginyl phenylalanine amide 139 was deprotected by 
acidolysis using TFA to afford 140 (Scheme 4-26). 
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Scheme 4-26: Synthesis of N-acetyl argnine phenylalanine amide 140. 
 
 
Analytical HPLC of the AM and AO protected N-acetyl arginyl phenylalanine amide 
analogues showed one major peak before being used in the stability assay.  Table 4-7 
shows the retention times for the unprotected dipeptide 140 and the AO (135 and 138) 
and AM (136 and 137) protected dipeptides. 
 
  R group tR/ min* 
140 - 3.10 
136 CH2OCOCH(CH3)2 6.34 
137 CH2OCOC(CH3)3 6.97 
135 CH2CH3 4.85 
138 CH(CH3)3 5.41 
      
Table 4-7:  Analytical HPLC chromatograms for the AO and AM protected dipeptides before use in the 
stability assays. *1-90% B over 10 min, 3 ml/min (Onyx Monolithic C18, 100 x 4.6 mm). 
 
The stability of the protected dipeptides was assessed at pH 5.0, 7.4 and 9.0.  Using a 
Britton±Robinson buffer 241, a 0.2 mM solution of the protected dipeptides was 
prepared with a pH of 5.0 and 9.0, a PBS buffer was used to prepare the pH 7.4 
sample.  Each sample was then incubated at 37 oC and at specific time points an 
aliquot was removed and analysed by analytical HPLC.  Further analysis of the major 
peaks using TOF MS (ES+) confirmed the identity of the deprotected dipeptide 
species.  Figure 4-9 and Figure 4-10 show the HPLC traces of the AM protected 
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dipeptides 136 and 137 after incubation for 1 h and 12 h at 37 oC at pH 5.0, 7.4 and 
9.0.  
 
 
 
Figure 4-9:  HPLC chromatograms of the AM protected dipeptide 136 after incubation at 37 oC in 
aqueous buffer with a) pH 5.0 , b) pH 7.4 and c) pH 9.0 over 12 h.  Peaks 1, 2 and 3 were identified 
using HRMS TOF MS (ES+).  The HPLC method used was 1-90% B over 10 min, 3 ml/min (Onyx 
Monolithic C18, 100 x 4.6 mm). 
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Figure 4-10: HPLC chromatograms of the AM protected dipeptide 137 after incubation at 37 oC in 
aqueous buffer with a) pH 5.0, b) pH 7.4 and c) pH 9.0 over 12 h.  Peaks 1, 2 and 3 were identified 
using HRMS TOF MS (ES+).  The HPLC method used was 1-90% B over 10 min, 3 ml/min (Onyx 
Monolithic C18, 100 x 4.6 mm). 
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A summary of the stability of the AM and AO protected dipeptides after incubation in 
in an aqueous buffer at either pH 5.0, 7.4 or 9.0 at 37 oC is summarised in Table 4-8.  
 
Table 4-8: The time range of AM and AO deprotection from the AM and AO protected dipeptides after 
incubation at 37 oC in aqueous buffer at pH 5.0, 7.4 and 9.0.  
  
  
Stability 
# R protecting group pH 5.0 pH 7.4 pH 9.0 
136 COCH2OCH(CH3)2 < 12 h > 12 h < 1 h 
137 COCH2OC(CH3)3 > 12 h > 12 h < 1 h 
135 CH2CH3 
> 24 h 
138 CH(CH3)2 
 
 
The two AM protected dipeptides 136 and 137 are deprotected over 12 h in aqueous 
buffer to initially give the mono-protected dipeptide and then finally the unprotected 
arginine residue 140.  At pH 5.0, 7.4 and 9.0 the isobutanoyloxymethyl carbonyl 
protected dipeptide 137 (Figure 4-9) is deprotected to 140 to a greater extent than the 
pivaloyloxymethyl carbonyl protected dipeptide 131 (Figure 4-10).  Moreover, 136 is 
deprotected to a greater extent at pH 9.0 and pH 5.0 compared to at pH 7.4.  In 
contrast, the AO protected dipeptides 136 and 137 showed no detectable deprotection 
over 24 h at pH 5.0, 7.4 and 9.0 at 37 oC. 
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4.2.2.2 Esterase-mediated deprotection of the protected arginine 
derivatives 
The esterase-mediated deprotection of the AO and AM protecting groups was also 
investigated.  Previous studies by Gogate et al. (1987) and Saulnier et al. (1994) have 
focussed on the kinetics of AM breakdown using pig liver esterase (PLE, E.C.3.1.1.1), 
human blood plasma and in aqueous buffers.147, 234-235  Scheme 4-27 shows the 
esterase-mediated deprotection of an AM protected N-acetyl arginyl phenylalanine 
amide derivative to afford the unprotected arginine residue 140. 
 
Scheme 4-27: Deprotection of AM protected N-acetyl arginyl phenylalanine amide derivative by pig 
liver esterase (PLE). 
 
 
 
The stability of the AO and AM protected dipeptides in the presence of PLE was 
investigated.  Thus, 0.2 mM solutions of the protected dipeptides in PBS (pH 7.4) 
were treated with PLE to give final concentration of 1 U/ml followed by incubation at 
37 oC.  At specified time points an aliquot was removed and added to an equal volume 
of MeCN to stop the reaction.  Each time point was then analysed using analytical 
HPLC and each peak identified by TOF MS (ES+).  The chromatograms for the AM 
protected analogues 136 and 137 are shown in Figure 4-11. 
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Figure 4-11:  HPLC trace of AM protected dipeptides a) 137 and b) 136.  Samples were incubated at 0.2 
mM in PBS (pH 7.4) with 1 U/ ml porcine liver esterase (PLE) at 37 oC.  Aliquots were taken at certain 
time points and analysed using 1-90% B over 10 min, 3 ml/min (Onyx monolithic C18 column 100 x 4.6 
mm).  Analysis of each peak using TOF MS (ES+) allowed for the identification of each dipeptide 
species. 
    
Both the isobutoxymethyl carbonyl and the pivolyloxymethyl carbonyl protected 
dipeptides are deprotected by PLE.  The starting molecule is deprotected to give the 
mono-acetylated product within the first 5 min of incubation.  Over the next 30 min 
the mono-acylated product is further deprotected to the N-acetyl arginyl phenylalanine 
amide 140.  The stability of 136 and 137 at pH 7.4 in PBS has previously been shown 
(Figure 4-9 and Figure 4-10) confirming that the AM deprotection observed is esterase 
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driven.  The AO protected dipeptides 135 and 138 showed no significant deprotection 
after incubation with PLE at for 24 h at 37 oC.  Table 4-9 summarises the qualitative 
data for the AM and AO protected dipeptides incubated with 1 U/ml of PLE. 
 
Table 4-9: The time range of AM and AO deprotection from the AM and AO protected dipeptides after 
incubation at 37 oC with PLE (1 U/ml) in PBS (pH 7.4). 
 
# R protecting group Stability, t1/2 (1 U PLE/ml) 
136 COCH2OCH(CH3)2 < 0.5 h 
137 COCH2OC(CH3)3 < 0.5 h 
135 CH2CH3 > 24 h 
138 CH(CH3)2 > 24 h 
 
Based on the esterase and hydrolytic stability assays it is clear that the AO protected 
arginine residues 135 and 138 are not deprotected in the presence of PLE or in an 
aqueous buffer at pH 5.0, 7.4 or 9.0.  Thus, these protecting groups are not suitable for 
the labile protection of the guanidine functionality of an octa-arginine derivative.  
However, the AM protected arginine residues of 136 and 137 were deprotected to 
afford the desired unprotected arginine residue upon treatment with 1 U/ml of PLE 
(<0.5 h) and also deprotected at pH 5.0 and pH 9.0, and to a lesser extent at pH 7.4.  
Thus, the AM protecting groups were deemed suitable for the NG-protection of an 
octa-arginine derivative.  
 
4.2.3 Synthesis of an acyloxymethyl carbonyl protected octa-arginine 
derivative  
The guanidinylation of octa-ornithine derivatives 85 and 86 using the AM protected 
isothiourea N,N'-bis-((isobutanoyloxy)methyloxycarbonyl)-S-methylthiourea 116 was 
investigated using the same method as described for the synthesis of the NG-Boc 
protected FAM-(R(di-Boc)-Ahx)8-[NH2] 98.   
The first step was the pre-activation of isothiourea 116 (10 eq.) with HgCl2 (10 eq.) in 
DMF.  A solution of 85 (1 eq.) and DIPEA (10 eq.) in H2O (1 ml) was then added 
dropwise to the activated isothiourea, followed by stirring at rt (Scheme 4-28). 
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Scheme 4-28: Synthesis of AM protected octa-arginine derivative 143. 
 
 
 
After stirring of the reaction mixture at rt for 2 h, the solvent was removed in vacuo.  
The resulting orange residue was suspended in MeCN and centrifuged at 13000 g for 
20 min.  The supernatant was analysed by HPLC, which revealed a major product at tR 
8.85 min (Figure 4-12). 
 
 
Figure 4-1210:  Analytical HPLC chromatogram for the crude reaction mixture for synthesis of the AM 
protected octa-arginine derivative 143. The HPLC method used was 1-90% B over 10 min, 3 ml/min 
(Chromolith Semi-prep C18, 100 x 10 mm).  
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The major peak at 8.85 min was isolated and analysed by TOF MS (ES+).  The 
fragmentation pattern of this HPLC fraction is shown in Figure 4-13 with the 
corresponding structures. 
 
 
 
Figure 4-123:  HRMS TOF MS (ES+) spectra of the 8.85 min peak from the HPLC analysis of the 
reaction mixture of the AM protected octa-arginine derivative 143.  The corresponding peptide 
fragments and calculated masses are also shown. 
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Isolation of the peak at 8.85 min using preparative HPLC afforded 143 in a yield of 
33%.  However, further analysis of the isolated sample using TOF MS (ES+) at a lower 
mass range revealed a peak at m/z 379.1175 corresponding to the [M+H]+ species of 
isothiourea 116 (see Scheme 4-28).  This suggests that the isolated material is a 
mixture of both protected peptide 143 and isothiourea 116.  Further purification using 
a number of RP-HPLC methods could not resolve this mixture.  
Nevertheless, preliminary studies investigating the stability of the protected peptide 
143 were performed using the peptide 143/isothiourea 116 mixture.  Hence, a 0.1 mM 
solution of the peptide reagent 143 in PBS (pH 7.4) was treated with 5 U/ml of PLE at 
37 oC (Scheme 4-29). 
Scheme 4-29:  Deprotection of AM protected octa-arginine derivative 143 by pig liver esterase (PLE). 
 
 
 
At specified time points, an aliquot from the reaction mixture was removed and added 
to an equal volume of MeCN.  This sample was then analysed using analytical HPLC.  
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Figure 4-14 shows the HPLC chromatograms for the AM protected octa-arginine 143 
after incubation for 15 min and 30 min with PLE (10 U/ml). 
 
 
 
 
Figure 4-14:  HPLC chromatograms of a 0.1 mM solution of the AM protected octa-arginine 143 after 
incubation at 37 oC with PLE (5 U/ ml) for a) 0 min, b) 15 min, c) 30 min and d) incubation at 37 oC 
without PLE for 30 min.  The HPLC method used was 1-90% B over 10 min, 1.2 ml/min (Onyx 
Monolithic C18, 100 x 3.00 mm). 
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After 15 min (Figure 4-14, b) there are a number of species detected, suggesting that 
PLE is removing the AM protecting groups of 143.  Interestingly, after 30 min there 
are no detectable species and no peak corresponding to 143 (tR 8.59 min) (Figure 4-14, 
c).   
To confirm that the deprotection of 143 was esterase catalysed, 143 was also incubated 
at 37 oC in PBS (pH 7.4) for 30 min in the absence of PLE (Figure 4-13, d).  In the 
absence of PLE it is clear that there is no detectable deprotection of 143, suggesting 
that the fragmentation pattern seen in Figure 4-14, b) is due to the activity of PLE.  
Two further controls were also performed, Figure 4-15 a) shows the HPLC 
chromatogram for the unprotected FAM-(Arg)8-[NH2] 87.  Figure 4-15 b) shows the 
chromatogram of a 0.2 mM solution of isothiourea 116, after treatment with PLE (1 
U/ml) for 2 min. As mentioned earlier, analysis of 143 using TOF MS (ES+) detected 
remaining isothiourea 116 in the sample.  The identity of each peak in Figure 4-15, b) 
was determined using TOF MS (ES+). 
 
Figure 4-15:  HPLC chromatograms of a) the unprotected octa-arginine 87 (tR 4.22 min) and b) the 
isothiourea 116 (tR 8.75 min) after incubation at 37 oC with PLE (1 U/ ml) for 5 min.  The HPLC 
method used was 1-90% B over 10 min, 1.2 ml/min (Onyx Monolithic C18, 100 x 3.00 mm). 
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Importantly, Figure 4-15 b) shows the PLE-mediated deprotection of isothiourea 116 
to form the mono-protected isothiourea 144 at tR 3.90 min.  Comparing this to the 
chromatogram of the AM protected octa-arginine 143 after incubation with PLE for 15 
min (Figure 4-14 b) it is clear that the fragmentation patterns are significantly 
different.  However, Figure 4-15 a) shows the chromatogram for the unprotected octa-
arginine derivative 87.  This single peak at 4.22 min is not seen in the chromatograms 
of 143 after incubation with PLE for 15 or 30 min (Figure 4-14, b and c).  Thus, 
suggesting that 143 is either completely digested by PLE or partially deprotected to 
form many different deprotected peptide species.  If the number of deprotected species 
is vast then it is possible that they would not be detected by absorbance using HPLC.   
It was predicted that the octa-arginine species observed after incubation of 143 with 
PLE may internalise into cells.  Thus, in a preliminary experiment, a 10 µM solution 
of 143 was treated with PLE (1 U/ml) at 37 oC.  After 2.5 min and 15 min aliquots 
were removed and added to an equal volume of MeCN to stop the reaction.  Samples 
were then lyophilised, reconstituted into RPMI-1640 media and then added to HeLa 
cells.  Cells were incubated with the samples for 30 min at 37 oC, followed by removal 
of the media, washing of the cells with PBS and finally imaging using CLSM.  Figure 
4-16 shows the z-sectioning of HeLa cells incubated with 10 µM of 143 (green) after 
incubation with PLE (1 U/ml).  Cells were also incubated with the nuclear stain Draq5 
(purple). 
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a) 143, 10 µM, 0 min PLE                           b) 143, 10 µM, 5 min PLE 
                                       
          
   c)  143, 10 µM, 15 min PLE 
     
 
Figure 4-16: Cell internalisation of the AM protected octa-arginine derivative 143.  HeLa cells treated 
with 10 µM of 135 that had been pre-incubated with PLE (1 U/ml) at 37 oC for a) 0 min b) 5 min and c) 
15 min.  After incubation of HeLa cells with the PLE treated PLE for 30 min at 37 oC the cells were 
then washed with PBS and incubated with the nuclear stain Draq5 (purple) followed by z-sectioning 
using CLSM with an inverted x63 oil immersion lens. 
 
Figure 4-16 a) shows HeLa cells after incubation with octa-arginine 143, before 
incubation with PLE.  It is clear that the AM protecting groups inhibit internalisation 
of the octa-arginine, as no cell associated green fluorescence is observed (Figure 4-16, 
a).  After 2.5 min incubation of 143 with PLE (1 U/ml) there is still no internalisation 
into HeLa cells detected (Figure 4-16, b).  Interestingly, cell associated fluorescence is 
seen for HeLa cells incubated with 143 after incubation of the peptide with PLE (1 
U/ml) for 15 min.  This suggests that the AM protected octa-arginine 143 is 
deprotected by PLE enabling cellular internalisation.  However, the green fluorescence 
seen in Figure 4-16 c) is only minimal, suggesting that only a small amount of the 
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peptide is able to internalise into HeLa cells and that 143 may not be significantly 
deprotected by PLE after 15 min incubation. 
   
4.1 Conclusions  
The major aim of this chapter was to develop a novel method to mask the cationic 
charge and control the cell penetrating capabilities of the CPP octa-arginine.  In the 
initial phase of the study it was demonstrated that NG-Boc protection of an octa-
arginine derivative successfully inhibited its cell entry capabilities.  Thus, further 
investigations focussed on the protection of the guanidine functionality of octa-
arginine using the esterase-sensitive acyloxymethyl carbonyl (AM) protecting groups.   
The synthesis of the AM protected octa-arginine derivative 143 was deemed 
successful and confirmed by TOF MS (ES+) with a number of fragments 
corresponding to 143 being detected (see Figure 4-13).     
 
 
Incubation of 143 with PLE showed a complex deprotection pattern, however, no fully 
unprotected octa-arginine 87 species was detected. This suggests that a large number 
of deprotected species are formed after incubation with PLE.  Incubation of PLE 
treated 143 with HeLa cells allowed for detection of cell associated fluorescence using 
CLSM, thus suggesting that the AM protected octa-arginine 143 is deprotected 
sufficiently to enable internalisation of the peptide into the HeLa cells.   
Further CLSM studies investigating the cell penetration capabilities of the AM 
protected octa-arginine after PLE treatment are required. Studies using a panel of cell 
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lines together with treatment of the 143 with PLE over a longer time course will 
provide greater insight into the effectiveness of this approach for the controlled 
activation of octa-DUJLQLQH¶V FHOO SHQHWUDWLQJ FDSDELOLWLHs.  The quantification of 
internalised AM octa-arginine after PLE treatment will be important for detailed 
assessment of the octa-arginine deprotection and subsequent cell internalisation.  
Robust quantification of the internalised octa-arginine could be achieved using 
MALDI-TOF MS using a modified method based on that described by Burlina et al. 
(2005).242  A schematic for this proposed approach is outlined in Figure 4-17. 
 
 
 
Figure 4-17:  Quantification of internalised octa-arginine using MALDI-TOF MS using the method 
described by Burlina et al. (2005).242   
 
The application of a biotinylated AM protected octa-arginine would enable isolation of 
internalised octa-arginine using streptavidin coated beads.  Subsequent elution of the 
peptide from the beads will then allow for analysis of the peptide using MALDI-TOF 
MS.  This method could be used to quantitatively monitor the amount of AM protected 
octa-arginine that is internalised into cells in the presence of PLE.    
Overall, this proof-of-principle study has provided compelling evidence that the cell 
penetrating properties of the CPP octa-arginine can be inhibited through carbamate 
Cell
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biotinylated peptides using 
magnetic streptavidin 
coated beads, followed by 
elution from the beads
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protection of the guanidine functionality.  The study also presents preliminary data on 
the protection of an octa-arginine derivative with esterase and hydrolytically labile 
protecting groups.  These results suggest that the esterase-sensitive AM protecting 
groups are suitable for the inhibition of octa-arginine cellular internalisation.  Further 
studies to confirm the exact deprotection and activation mechanism of an AM 
protected octa-arginine derivative are required.  However, the data presented in this 
chapter suggests that this is a promising approach to controlling the cell penetrating 
activity and masking the cationic charge of octa-arginine.   
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4.2 Materials and methods 
The HPLC stability assays were performed using a Waters 2525 pump, Waters 2487 
Detector, Waters 2767 Fraction collector and autosampler.  An Onyx Monolithic C18, 
(100 x 4.00 mm) analytical column was used for all experiments using the following 
solvents: solvent A ± H2O, 0.06% TFA and solvent B ± 90% MeCN, 10% H2O, 0.06% 
TFA.  The standard method used for all assays was a linear gradient of 1-90% B over 
10 min, 3 ml/min.  The injection volume for each run was 100 µl.  This was achieved 
by using a 100 µl injection loop.  To ensure reproducibility between runs, 120 µl of 
sample was injected into the injection loop for each run.  The detector was set-up to 
record the absorbance of the effluent at 214 nm. 
 
4.2.1 Hydrolytic stability assay 
Test compounds were dissolved in methanol followed by addition to a Britton-
Robinson buffer (0.04 M H3BO3, 0.04 M H3PO4 and 0.04 M CH3COOH) 241 prepared 
at either pH 5.0 or 9.0 to give a 2% methanol/buffer solution and a final dipeptide 
concentration of 0.2 mM.  For samples tested at pH 7.4 a PBS buffer was used.  The 
samples were then incubated at for 24 h at 37 oC and at specified time points (0, 1, 12 
and 24 h) a 120 µl aliquot was removed for analytical HPLC analysis using the 
standard method previously described.   
 
4.2.2 Esterase assay 
Pig liver esterase (PLE, 165 U/mg, Sigma-Aldrich) was used for all of the esterase 
assays.  Test compounds were dissolved in methanol followed by addition of 1x PBS 
(pH 7.4) to give a final 2% methanol/PBS solution and a final dipeptide concentration 
of 0.2 mM.  Enzyme reactions were initiated by addition of PLE to give a final 
concentration of 1 U PLE/ml unless otherwise stated.  Reactions were incubated at 37 
oC and at specified time points a 60 µl aliquot was removed and added to an equal 
volume of ice cold MeCN.  Samples were then analysed using the standard HPLC 
previously described. 
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4.2.3 Confocal scanning laser microscopy 
All CLSM was carried out using the same instrument and general method described in 
Section 3.8.9.  HeLa cells were seeded at 1 x 105 cells/well in 6-well plates containing 
glass coverslips, and allowed to adhere for 24 h at 37 oC.  5-FAM labelled peptides 
dissolved in DMSO at 40-100 µg/ml were added to RPMI-1640 media to give a final 
peptide concentration of 10 µM (>1% total DMSO content). 2 ml/well of the peptide 
solution was then added to the cells, followed by incubation for 30 min at 37 oC.  After 
incubation, the media was removed and the coverslips were washed 3x with 2 ml of 
PBS followed by incubation of the cells with 500 µl of the nuclear stain Draq5® (5 
µM, New England Biolabs) for 5 min at rt. The coverslips were then washed 3x with 2 
ml of PBS.  The coverslips were then removed and placed onto a cover slide.  To 
prevent the cells from drying out, 50 µl of HBSS buffer was applied onto glass slides 
prior to placing coverslip cells down.  The coverslip was then held in place by 
applying nail varnish around the edges.  Cells were then imaged and z-sections taken 
using the Zeiss LSM510 operating software.  
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5  
 
Conclusions and future directions 
 
 
A systematic approach to modifying antibody fragments with CPPs to enable cellular 
penetration has been developed, together with a novel method to control the in vivo 
properties of a CPP.  This methodology will allow for optimisation of the cell 
penetrating capabilities and in vivo properties of a transbody (i.e. an antibody 
delivered into a cell), thus providing a gateway to unlocking the immense potential of 
therapeutic transbodies. 
In the initial phase of the project, specific scFv towards the anti-apoptotic proteins 
Bcl-2 and Bcl-xL were isolated from naïve scFv phage display libraries.  This was 
achieved by high-throughput screening of enriched scFv libraries selected against Bcl-
2 and Bcl-xL using an in vitro competition assay for the interaction of Bcl-2 and Bcl-
xL with BID BH3.  Table 5-1 shows the IC50 values of the most potent neutralising 
anti-Bcl-2/xL scFv isolated from the scFv libraries. 
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Table 5-1: A selection of IC50 values determined for the isolated anti-Bcl-2/xL scFv for the inhibition of 
the Bcl-2/ xL interaction with BID BH3 in an Alpha screen assay 
 
scFv # 
IC50, nM VH CDR3 amino acid 
sequence Bcl-xL Bcl-2 
    
44 - 2 DLWELLLADAFDI 
45 - 6 SKFLWFGGRNYFDP 
    
22 21 - TGEYSGYDTSGVEL 
24 6 ± 2 - DATTAPFYYYMDV 
    
61 2 18 ALSQTYWGFFPTYFDS 
67 22 14 SGSSSWYRPDDAFDI 
    
 
The isolated scFv showed IC50 values in the low nanomolar range.  Moreover, scFv 
that specifically inhibit either Bcl-2 or Bcl-xL, or cross inhibitors of both proteins 
were isolated.   In future studies, it will be important to verify the specificity of the 
lead scFv for other Bcl-2 family members.  This will be possible by using a binding 
ELISA and a panel of Bcl-2 family members such as, Mcl-1, A1 and Bcl-w.  
Nonetheless, the scFv isolated in this project are significantly more potent inhibitors of 
Bcl-2 and Bcl-xL than the previously reported anti-Bcl-2/xL scFv (scFv84) 63 and the 
small molecule Bcl-2/ xL inhibitor ABT-737 48 (Table 5-2).227 
 
Table 5-2: IC50 values determined for scFv84 and ABT-737 48 for the inhibition of the Bcl-2/xL 
interaction with BID BH3 in an Alpha screen assay. 
 
scFv # 
IC50, µM VH CDR3 amino acid 
sequence Bcl-xL Bcl-2 
scFv84 0.152 ± 0.002 > 4 YGYTFDY 
 
1.2 ± 0.3 0.5 ± 0.2 
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The next stage of the project was to modify the lead scFv with a CPP to enable cell 
penetration.  A systematic approach to modifying the isolated scFv with CPPs was 
developed to enable cell penetration.  The CPP construct design is shown in Figure 5-
1. 
 
Figure 5-1: The general design of CPP derivatives, a C-terminal lysine residue will allow for fluorescent 
labelling of the peptide,  The free N-terminus will allow for coupling of either a maleimidopropionyl or 
isobutyryl cysteine moiety for site-specific conjugation to scFv-Cys. 
 
This CPP construct allowed for regioselective labelling with 5-carboxyfluorescein (5-
FAM) to the C-terminal lysine residue.  Additionally, the introduction of either N-
maleimidopropionyl or N-isobutyryl cysteinyl moieties allowed for the site-specific 
conjugation of the CPP to lead scFv via a C-terminally located cysteine residue in the 
protein.   
CPP derivatives possessing the aforementioned functionality were successfully 
synthesised using standard Fmoc solid-phase peptide synthesis (Fmoc SPPS).  
Regioselective labelling of the C-terminal lysine residue was achieved by introducing 
an orthogonally protected lysine residue to the peptidyl resin.  Subsequent 
deprotection of the orthogonal protecting group from the peptidyl resin then allowed 
for regioselective introduction of 5-FAM to the CPP.  Scheme 5-1 and Scheme 5-2 
show the synthetic procedures for the synthesis of N-maleimidopropionyl and N-
isobutyryl cysteinyl CPPs.  
  
200 
Scheme 5-1: Synthesis of the N-isobutyryl Cys CPP derivatives 
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Scheme 5-2: Synthesis of N-maleimidopropionyl CPP
 
derivatives. 
 
 
This strategy provided a robust method for the synthesis of a panel of CPP derivatives.  
Four different 5-FAM labelled CPP derivatives were then conjugated to scFv24 and 
the cell penetrating capabilities of these conjugates were determined using Confocal 
Laser Scanning Microscopy (CLSM) (Table 5-3). 
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Table 5-3: scFv-CPP(FAM) internalisation and localisation; summary of CLSM and Fluorescence 
microscopy.  
 
scFv-CPP CPP Sequence 
Localisation of scFv-CPP 
conjugate 
HeLa RBL-2H3 
 
    
scfv24-77 octa-arginine Mal-(R)8-K(FAM)-[NH2] cellular vesicles cytoplasm 
 
    
scfv24-79 Tat49-57 Mal-RKKRRQRRR-K(FAM)-[NH2] Minimal internalisation, cellular vesicles 
 
    
scFv24-74 Antp52-58 Mal-RRMKKWKK-K(FAM)-[NH2] Minimal cell internalisation n.d 
 
    
scFv24-81 Pro14 iButyl-C-(P)14-K(FAM)-[NH2] extracellular n.d 
 
Based on the CLSM studies it was clear that scFv24-77 possessed the most efficient 
cellular penetration capabilities.  A summary of the preparation of scFv24-77 and 
subsequent cellular internalisation is shown in Figure 5-2. 
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Figure 5-2: Z-sectioning using confocal microscopy of a) HeLa cells and b) RBL-2H3 cells treated with 
scFv24-77  (Green) for 30 min at 37 oC, 10 µM and 90 min at 37 oC, 10 µM.  Draq5 was used to stain 
cell nuclei (Purple). 
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Investigation into the biological effect of scFv24-77 was achieved using a cell 
viability assay.  Table 5-4 shows the EC50 for the positive control ABT-737 48 for the 
two cell lines used in the study. 
 
Table 5-4:  EC50 value of ABT-737 for RBL-2H3 and Jurkat cells.  
 
 
Cell line EC50, µM 
 
RBL-2H3 12 ± 2 
Jurkat 14.0 ±  0.6 
 
 
Unfortunately, treatment of both cell lines with 40 µM of scFv24-77 did not affect cell 
viability.  This is likely due to insufficient quantities of scFv being delivered into the 
cytoplasm of the cells to induce a biological effect.  There are many studies that 
demonstrate CPP-cargo conjugates being retained in cellular vesicles.99, 73  Thus, it is 
possible that entrapment of the scFv-CPP in cellular vesicles is an influential factor in 
this study.  Of equal importance is that scFv24 is specific to Bcl-xL only, thus the 
sensitivity of the RBL-2H3 and Jurkat cells to Bcl-xL inhibition has to be considered.  
For this reason, screening of a wider range of cell lines with scFv that are specific to 
Bcl-2 and Bcl-xL only and also cross-selective should be performed.  The use of cell 
lines that have been tested with ABT-737 will give guidance to the sensitivity of the 
cell to Bcl-2/xL inhibition.  Table 5-5 shows a selection of cell lines and the EC50 
values for ABT-737 reported in the literature. 
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Table 5-5: EC50 of cell lines to ABT-737 treatment 
 
Cell Line  
EC50, µM 
Reference Culture conditions 
10% FBS Reduced FBS (%) 
HL-60 >10 - 
High et al. (2010) 225 
K562 >10 - 
Nalm6 >10 - 
Jurkat 5.00 - 
Molt4 0.92 - 
REH 0.68 - 
CEM 0.30 - 
Hal-01 0.19 - 
DoHH2  0.13 0.001 (3%) 
Bruncko et al. (2007) 226 RS11380 0.15 0.014 (3%) 
SUDHL-4 0.85 0.220 (3%) 
NCI-H146 0.09 0.015 (0%) 
Shoemaker et al. (2006) 227 
A549 22.3 5.200 (0%) 
 
 
In addition to screening a wider panel of cell lines, it is also proposed that by 
introducing endosomolytic peptides to the CPP construct the quantity of scFv in the 
cytoplasm could be increased, thus increasing the quantity of scFv available to inhibit 
Bcl-2 and Bcl-xL.  Table 5-6 shows a selection of peptides that have been reported to 
promote endosomal escape of an attached cargo.   
 
Table 5-6: A selection of endosomolytic peptides 
 
# Endosomolytic Peptides Reference 
18 HA2; GLFGAIAGFIEGGWTGNIDGWYG Wadia et al. (2004) 111 
19 H5WYG; GLFHAIAHFIHGGWHGLIGGWGYG Pichon et al. (2001) 112 
20 10HIS; HHHHHHHHHH Lo et al. (2008)113 
21 43E; LAELLAELLAEL Ohmori et al. (1997) 114 
 
The screening of a panel of scFv conjugated to different CPPs and endosomolytic 
peptides will allow for determination of the most effective peptides for efficient 
cytoplasmic delivery.   
Nevertheless, we have successfully developed methodology for the systematic 
modification of a scFv to enable cellular internalisation.  The optimisation of CPP 
conjugation to lead scFv via a C-terminal cysteine allowed for efficient preparation of 
scFv-CPP conjugates.  This will allow for future screening of a wider panel of scFv 
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and CPP combinations to determine the most suitable CPP for intracellular delivery.   
Further screening of the neutralising scFv specific for Bcl-2 and Bcl-xL scFv in a 
wider range of cell lines together with comparison with the small molecule Bcl-2/xL 
inhibitor ABT-737 will allow for rational optimisation of the scFv-CPP conjugate.     
Complementary to the preparation of scFv-CPP conjugates, a novel method for 
controlling the in vivo properties of the CPP octa-arginine has been developed.  In the 
first stage of this proof-of-principle study, it was demonstrated that masking the 
guanidine functionality of octa-arginine inhibits its cellular internalisation (Figure 5-
3).   
 
 
Figure 5-3: HeLa cells treated with 10 µM of 5-FAM labelled peptide (green), for 30 min at 37 oC.  
Cells were then washed and incubated with the nuclear stain Draq5 (purple) and Z-sections of the cells 
were taken using CLSM with an inverted x63 oil immersion lens a) FAM-(R(di-Boc))8-[NH2] 99 and b) 
FAM-(R)8-[NH2] 87.   
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The inhibition of octa-arginine is most likely a result of masking the positive charge of 
the peptide, similar studies by Jiang et al. (2004) support this inference.  In this study, 
the authors completely inhibit the cellular penetration of nona-arginine by masking the 
cationic charge with the anionic nona-glutamate.138 
This principle was then expanded to using the esterase and hydrolytically sensitive 
acyloxymethyl carbonyl (AM) protecting groups to mask octa-arginine.  A preliminary 
study investigating the masking of the guanidine functionality of an octa-arginine 
derivative with AM protecting groups was deemed successful.  Scheme 5-3 illustrates 
the approach taken to introduce AM protected guanidine moieties to the octa-ornithine 
derivative 85 affording the AM protected octa-arginine derivative 143. 
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Scheme 5-3: : Synthesis of AM protected octa-arginine derivative 143 and subsequent deprotection with 
pig liver estease (PLE). 
 
 
Studies using analytical HPLC confirmed that the AM protected octa-arginine was 
deprotected by pig liver esterase (PLE).  Further CLSM studies investigating the cell 
penetrating capabilities of the AM protected octa-arginine 143 after treatment with 
PLE, incubation in aqueous buffers and most importantly in blood plasma are 
required.  Additionally, robust quantification of octa-arginine internalisation would 
provide insight into the effectiveness of the controlled unmasking of the AM protected 
octa-arginine 143 and subsequent cellular internalisation.  Quantification of 
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internalised octa-arginine after treatment with PLE could be achieved using MALDI-
TOF MS using a modified method based on that described by Burlina et al. (2005). 242 
This proof-of-concept study afforded compelling evidence that esterase-labile AM 
protecting groups could be used to mask the cationic charge of octa-arginine.  The 
potential of the NG-masking approach to modulate the cell penetrating capabilities of a 
CPP are numerous.  For example, this approach is predicted to increase the circulation 
time of the CPP and reduce widespread non-specific tissue uptake.  Moreover, the 
activation of the CPP is reliant on hydrolytic and/or esterase unmasking of the cationic 
charge.  This separation between the tissue targeting and CPP activation mechanism is 
in contrast to the other approaches described for modulating the activity of a 
CPP.138,137  Therefore, this approach could be used in conjunction with different tissue 
targeting molecules and different macromolecular cargo.  
The major goal of this project was to define rules for the modification of antibody 
reagents to possess cell penetrating capabilities whilst retaining suitable in vivo 
properties.  This thesis aimed to achieve this by taking a systematic approach to 
modifying scFv with CPPs.  The development of efficient methodology to produce 
scFv-CPP conjugates has been achieved and will allow for rapid screening of a panel 
of scFv-CPP conjugates in future studies.  Moreover, the design of the CPP construct 
and development of a novel guanidino-masking technique to controlling the cell 
penetrating capabilities of a CPP will allow for optimisation of the in vivo properties 
of a scFv-CPP conjugate.    
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6  
  
 
Experimental  
 
6.1 Materials and Instrumentation 
All solvents used of were high grade and purchased from Fischer Scientific 
(Loughborough, UK) and used as received. All amino acids were purchased from 
Novabiochem (Nottingham, UK) and all other commercial reagents were purchased 
from Sigma-Aldrich and were used as received without further purification.   
Analytical thin-layer chromatography (TLC) was performed on Merck silica gel 0.25 
mm silica gel 60 F254 plates. TLC plates were visualised using UV absorbance at 254 
nm, or by staining with potassium permanganate dip.  Flash chromatography was 
performed using Merck silica gel (200-400 mesh).   
Analytical RP-HPLC was carried out using a Waters setup, comprised of two 510 
pumps, a 486 detector and MilleniumTM software.  The detector was set-up to record 
the absorbance of the effluent at 214 nm. The systems used were;  
x System 1: 1-90% B over 10 min, 3 ml/ml, Onyx analytical C18 (100 x 4.6 mm) 
x System 2: 1-90% B over 10 min, 1 ml/min, Ace analytical C8 (5 µm, 50 x 3 mm) 
x System 3: 1-100% B over 10 min, 3 ml/min, Onyx analytical C18 (100 x  4.6 mm) 
x System 4: 1-90% B over 10 min, 1.2 ml/min, Onyx analytical C18 (100 x 3.00 mm) 
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Preparative RP-HPLC was performed on a Waters Setup comprising of two Waters 
2525 pumps, a Waters 2487 Detector and a Waters 2767 Fraction collector.  The 
detector was set-up to record the absorbance of the effluent at 214 nm.  Standard 
solvents used for both analytical and preparative HPLC were: 100% H2O, 0.06% TFA 
(Solvent A) and 90% MeCN, 10% H2O and 0.06% TFA (Solvent B). 
1H and 13C NMR spectra were acquired on a Bruker-AV 400 spectrometer operating at 
400 and 100 MHz respectively and processed using Bruker TopSpin NMR 3.0 
software.  Deuterated solvents used were CDCl3 (Cambridge Isotope Laboratories 
Inc.) and CD3OD (Sigma-$OGULFK&KHPLFDOVKLIWVįDUHUHFRUGHGLQSSPUHODWLYHWR
TMS and coupling constants (J) recorded in Hz.  Abbreviations used in the description 
of specta are; s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublet), t 
(triplet), q (quartet) and m (multiplet). 
Mass spectra were recorded on a High Resolution Time of Flight (TOF) electrospray 
ionisation (ES) system comprising of a Waters 2795 Separations module and 
0LFURPDVV /&7 GDWD ZDV SURFHVVHG XVLQJ 0DVV/\Q[ VRIWZDUH  $OWHUQDWLYHO\
spectra were recorded by Matrix Assisted Laser Desorption Ionisation TOF MS 
(MALDI-TOF MS) using a Bruker Daltonics Ultraflex instrument.  The data was 
processed using Bruker Daltonics FlexanalysisTM software.    
FTIR spectra were recorded using a Pierce ThermoScientific Nicolet IR200 FTIR and 
the data processed using OMNICTM software.  Samples were prepared using either 
KBr powder or NaCl plates.  Melting points were recorded on a Gallenkamp melting 
point apparatus.   
Confocal imaging of live cells was performed using a Zeiss LSM510 META Confocal 
Imaging System and Zeiss LSM510 operating software.  Cells were imaged using an 
inverted 63x oil objective and Argon (458, 477, 488, 504 nm) and He-Ne 633 nm 
lasers. 
 
6.1.1 General method for Fmoc solid-phase peptide synthesis of 
CPPs 
All solvents used were of HPLC grade and purchased from Fischer Scientific unless 
otherwise stated.  DMF was of peptide synthesis grade, purchased from Rathburn 
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Chemicals Ltd.  All peptides were chemically synthesized by 9-
ÀXRUHQ\OPHWKR[\FDUERQ\O)PRFVROLG-phase synthesis on a Rink Amide NovaGelTM 
resin (Novabiochem, Prod# 855031, 0.67 mmol/g-1) on a 0.1 (150 mg resin) or 0.2 
mmol (300 mg resin) scale, unless otherwise stated.  The coupling reagent HATU; 2-
(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate was 
purchased from Fluorochem Ltd and Pyoxim®; O-[(1-cyano-2-ethoxy-2-
oxoethylidene)amino]-oxytri(pyrrolidin-1-yl) phosphonium hexafluorophosphate 213  
were purchased from Novabiochem.  All amino acid residues introduced to the 
peptidyl resin were standard NĮ-Fmoc protected derivatives with acid-labile side-chain 
protecting groups, unless otherwise stated.  Table 6-1 shows the NĮ-Fmoc-amino acids 
used for each peptide synthesis. 
 
Table 6-1: Standard NĮ-Fmoc amino acids with acid-labile side-chain protecting groups used in Fmoc 
SPPS 
  Mw 
Fmoc-Arg(Pbf)-OH 648.8 
Fmoc-Asn(Trt)-OH 596.7 
Fmoc-Cys(Trt)-OH 585.7 
Fmoc-Gln(Trt)-OH 610.7 
Fmoc-Ile-OH 353.4 
Fmoc-Lys(Boc)-OH 468.5 
Fmoc-Met-OH 371.5 
Fmoc-Orn(Boc)-OH 454.5 
Fmoc-Phe-OH 387.4 
Fmoc-Pro-OH 337.4 
Fmoc-Trp(Boc)-OH 526.6 
 
All acylations were carried out in DQ2PQLILWFRQWLQXRXVIORZJODVVFROXPQ[
10 mm), and all wash steps were performed using a NOVASYN® GEM manual 
peptide synthesiser, unless otherwise stated.  The UV absorbance of the effluent was 
measured at 290 nm using a LKB Biochrom Ultrospec II spectrometer, and recorded 
using a LKB Bromma 2210 recorder. 
All amino acid residues, for a 0.2 and 0.1 mmol scale synthesis, were introduced to the 
peptidyl resin using the following reaction mixture unless otherwise stated; Fmoc-
amino acids (4 equivalents), HATU (3.9 equivalents), DIPEA (8 equivalents) in DMF 
(~1.5 ml).  This reaction mixture was added to the resin, followed by intermittent 
stirring for 3 h at rt.   
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After 3 h the peptidyl resin was washed with DMF to remove excess amino acid and 
coupling reagents, followed by Fmoc deprotection using 20% piperidine/DMF (2.8 
ml/min, 10 min).  The Fmoc deprotection was monitored by UV absorbance of the 
effluent at 290 nm.  Finally, peptidyl resins were washed with DMF (2.8 ml/min, 10 
min) to remove remaining piperidine before the next amino acid coupling.  
After the introduction of the required amino acid residues to the peptidyl resin the 
peptidic material was cleaved from the resin and universally deprotected by 
suspending the peptidyl resin in a solution of trifluoroacetic acid (TFA, 9 ml), 
triisopropylsilane (TIPS, 0.2 ml) and H2O (0.8 ml) for 3-5 h at rt.  The suspension was 
filtered and the filtrate evaporated to dryness in vacuo.  The resulting residue was 
triturated with cold diethyl ether (3 x 10 ml) to afford the crude peptidic material.  
Preparative HPLC was used to isolate the desired peptide followed by lyophilisation.  
The peptide purity was then determined by analytical HPLC. 
 
6.2 Experimental for Chapter 3 
N-[2, 3, 2', 3'-tetra(2-guanidino-ethyloxy)-biphenyl-4-ylmethyl]-3-[2-
pyridyl)dithio]propionamide trifluoroacetate salt, (14) 97-98 
N¶-Bis(tertbutoxycarbonyl) guanidino]-
ethyloxy]-biphenyl-4-ylmethyl]-3-[2-
pyridyl)dithio]-propionamide 84 (106 mg, 
0.067 mmol) was Boc deprotected by 
acidolyisis using 50% TFA/DCM (10 ml). 
The reaction was stirred for 2 h at rt followed 
by removal of reaction solvent in vacuo.  The 
resulting residue was triturated with cold 
diethyl ether to afford the title compound as a 
clear solid (80 mg, 97%) that was 
spectroscopically identical to the literature 
precedent.98  1H NMR (400 MHz, CDCl3): įSSP+WJ= 6.8 Hz), 3.11 (2H, 
t, J= 6.8 Hz), 3.23-3.30 (4H, m), 3.60-3.71 (4H, m), 3.89 (2H, m), 3.97 (2H, m), 4.22 
(4H, m), 4.48 (2H, s), 6.87 (1H, m), 7.02 (1H, d, J= 7.8 Hz), 7.10-7.20 (4H, m), 7.22 
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(2H, m), 7.80-7.87 (2H, m). HRMS TOF (ES+): m/z calcd. for C33H50N14O5S22+ 
[M+2H]2+ 393.1760 found 393.1749.   
N-Isobutyryl cysteinyl arginyl arginyl methionyl lysyl lysyl tryptophyl 
lysyl lysyl lysyl amide; Antp52-57 derivative, (61) 
Rink Amide NovaGelTM resin (300 mg, 
0.2 mmol) was swollen using DMF (1.5 
ml) at rt for 1 h,  The resin was then 
washed using a NOVASYN® GEM 
manual peptide synthesiser with 20% 
piperidine/DMF (2.8 ml/min, 10 min), followed by DMF (2.8 ml/min, 10 min).  Fmoc-
Lys(ivDde)-OH (460 mg, 0.8 mmol) was pre-activated using HATU (297 mg, 0.79 
mmol) and DIPEA (207 mg, 278.7 µl, 1.6 mmol) in DMF (~ 1.5 ml).  This coupling 
mixture was added to the resin and stirred intermittently for 6 h at rt.  The peptidyl 
resin was then washed with DMF (2.8 ml/min, 5 min) to remove excess reagents, 
followed by treatment with 20% piperidine/DMF (2.8 ml/min, 10 min) and finally 
washed with DMF (2.8 ml/min, 10 min).  All subsequent Fmoc-amino acids (0.8 
mmol) were pre-activated using HATU (297 mg, 0.79 mmol), DIPEA (207 mg, 279 
µl, 1.6 mmol) in DMF (~ 1.5 ml) for 3 h at rt with intermittent stirring before Fmoc 
deprotection.  All amino acids were coupled by repeated cycles of coupling and 
deprotection to yield peptidyl resin 58.  
Fmoc deprotection of 58 was achieved as previously described.  Fmoc-Cys(Trt)-OH 
(469 mg, 0.8 mmol) was pre-activated using HOAt (109 mg, 0.8 mmol) and DIC (100 
mg, 124 µl, 0.8 mmol) in DMF (~ 1 ml) and added to the peptidyl resin for 3 h with 
intermittent stirring.  This was followed by washing with DMF and Fmoc deprotection 
as described.  The peptidyl resin was then treated with isobutyric anhydride (126.5 mg, 
133 µl, 0.8 mmol) and DIPEA (207 mg, 279 µl, 1.6 mmol) for 1 h followed by 
washing of resin with DMF (2.8 ml/min, 10 min) to afford peptidyl resin 59. 
Peptidyl resin 59 was treated with 2% Hydrazine/DMF (2.8 ml/min, 15 min) with 
monitoring of the reaction by absorbance of the effluent at 290 nm.  Upon reaction 
completion the resin was washed with DMF (2.8 ml/min, 10 min).  
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The peptidyl resin was then transferred to a Buchner funnel and washed with DMF (20 
ml), DCM (20 ml), hexane (20 ml), and dried in vacuo for 3 h to afford peptidyl resin 
60 (623 mg, 77%).  Approximately 1/3 of peptidyl resin 60 (0.07 mmol) was 
suspended in trifluoroacetic acid (TFA, 9 ml), triisopropylsilane (TIPS, 0.2 ml) and 
H2O (0.8 ml) for 4 h.  The suspension was filtered and the filtrate evaporated to 
dryness in vacuo.  The resulting residue was triturated with cold diethyl ether (3 x 10 
ml) to afford an off white residue (34 mg, 50%).  The residue was dissolved in H2O 
and lyophilised to afford Antp52-57 derivative 61.  Preparative HPLC (Onyx Semi-prep 
Monolith C18 column, 100 mm x 10 mm, 10-40% B over 10 min, tR; 3.12 min) of 20 
mg crude peptide 61 gave 10 mg (51%) of the title compound as a white solid.  
HPLC: system 1; tR 1.38 min (purity >85%); HRMS TOF (ES+): m/z calcd. for 
C59H107N21O10S22+ [M+2H]2+ 666.8970 found 666.7127, calcd. for C59H108N21O10S23+ 
[M+3H]3+ 444.9338 found 444.9823. 
N-isobutyryl cysteinyl arginyl arginyl methionyl lysyl lysyl tryptophyl 
lysyl lysyl (N'-fluorescein-5-carbonyl) lysyl amide, Antp52-57 
derivative, (63) 
The title compound was 
synthesised using approximately 
1/3 (0.07 mmol) of the ivDde 
deprotected resin 60.  5-FAM (75 
mg, 0.2 mmol) was pre-activated 
using HOAt (27 mg, 0.2 mmol) 
and DIC (25 mg, 31 µl, 0.2 
mmol) in DMF (1 ml) and added to the peptidyl resin, followed by intermittent stirring 
for 16 h at rt.  The resin was then washed with DMF (2.8 ml/min, 10 min), followed 
by treatment with 20% piperidine/ DMF (2.8 ml/min, 20 min) and finally DMF (2.8 
ml/min).  The peptidyl resin was then collected and washed with DMF, DCM and 
hexane, and dried in vacuo (208 mg, 72%).  The peptide was cleaved from the resin 
and deprotected as previously described using TFA-TIPS-H2O (90:2:8) for 3 h at rt 
followed by removal of the TFA in vacuo.  Subsequent trituration of the remaining 
residue using diethyl ether afforded an orange residue (52 mg, 89%).  Preparative 
HPLC (Chromolith Semi-prep C18 column, 100 mm x 10 mm, 10-40% B over 8 min, 
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tR 4.52 min) of 23.1 mg of crude peptide afforded 11 mg (46%) of the title compound 
as an orange solid.  HPLC: system 1; tR 3.96 min (purity >85%).  HRMS TOF (ES+): 
m/z calcd. for C80H117N21O16S22+ [M+2H]2+ 845.9209 found 845.5109, calcd. for 
C80H118N21O16S23+ [M+3H]3+ 546.2830 found 546.2165, calcd. for C80H119N21O16S24+ 
[M+4H]4+ 423.4641 found 423.5317. 
N-Maleoyl-ȕ-alanine, (64) 212 
0DOHLF DQK\GULGH  J  PPRO DQG ȕ-alanine (1.35 g, 
1.2 mmol) were dissolved in 25 ml glacial acetic acid (AcOH) 
at rt.  The reaction mixture was then refluxed for 16 h with 
stirring.  AcOH was removed in vacuo giving a light brown 
residue.  The residue was dissolved in toluene (25 ml) and the solution evaporated to 
dryness in vacuo.  This process was repeated three times.  N-Maloeyl-ȕ-alanine was 
isolated using silica chromatography (SiO2, 10% MeOH/ DCM Rf; 0.34) as a white 
solid (1.28 g, 50%).  1H NMR (400 MHz, DMSO-d6): įSSP+WJ= 7.3 Hz, 
CH2CH2), 3.61 (2H, t, J= 7.3 Hz, CH2CH2), 7.01 (2H, s), 12.35 (1H, s).  13C NMR 
(100 MHz, DMSO-d6): įSSP  CH2), 33.76 (CH2), 134.56 (CH), 172.00 
(C=O), 170.69 (C=O).  HRMS TOF (ES-): m/z calcd. for C7H6NO4- [M-H]- 168.0302 
found 168.0191.  FTIR (KBr): 3458 (CH2), 3093 (CH2), 2633 (CH), 1704 (C=O).  
M.pt: 95-97 oC (lit.212 92±94°C) 
N-maleimidopropionyl arginyl arginyl methionyl lysyl lysyl 
tryptophyl lysyl lysyl lysyl amide, Antp52-57 derivative, (70) 
Fmoc-Lys(Mmt)-OH (513 mg, 0.8 
mmol) was pre-activated using HATU 
(297 mg, 0.79 mmol) and DIPEA (207 
mg, 279 µl, 1.6 mmol, DIPEA) in 
DMF (~1.5 ml) and added to the 
NovaGelTM Rink Amide resin (300 mg, 0.2 mmol) for 6 h with intermittent stirring at 
rt.  All subsequent amino acids were coupled and deprotected as previously described 
to afford peptidyl resin 68.  Approximately ½ of peptidyl resin 68 (0.1 mmol) was 
Fmoc deprotected as previously described using 20% piperidine/DMF.  N-maleoyl-ȕ-
alanine (67 mg, 0.4 mmol) was pre-activated with HOAt (109 mg, 0.4 mmol) and DIC 
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(25 mg, 30 µl, 0.4 mmol) in DMF (~1.5 ml) and added to the resin followed by 
intermittent stirring of the resin for 3 h at rt followed by washing of the resin with 
DMF (2.8 ml/min, 10 min).  The peptidyl resin was then collected and washed with 
DMF, DCM and hexane, and dried in vacuo (345 mg, 90%).  The peptide was cleaved 
from the resin and deprotected as previously described for 61 using TFA-TIPS-H2O 
(90:2:8) for 3 h at rt followed by removal of the TFA in vacuo.  Subsequent trituration 
of the remaining residue using diethyl ether afforded an off white residue (98 mg, 
90%).  Preparative HPLC (Phenomenex Luna C18 column, 5 µm, 50 x 21.2 mm, 20-
27% B over 8 min, 20.41 ml/min, tR 4.06 min) of 22 mg crude peptide gave 15 mg 
(69%) of the title compound as a white solid.  HPLC: system 1; tR 3.00 min (purity 
>90 %).  HRMS TOF (ES+): m/z calcd. for C59H101N21O11S2+ [M+2H]2+ 655.8850 
found 655.8702, calcd. for C59H102N21O11S3+ [M+3H]3+ 437.5924 found 437.5938. 
N-maleimidopropionyl arginyl arginyl methionyl lysyl lysyl 
tryptophyl lysyl lysyl (N'-fluorescein-5-carbonyl) lysyl amide, Antp52-
57 derivative, (74) 
The Mmt protecting group of 
peptidyl resin 68 (~0.1 mmol) 
was removed using 1% TFA/1% 
TIPS/DCM.208  This was carried 
RXW XVLQJ DQ 2PQLILW
continuous flow glass column 
(150 x 10 mm).  Firstly, the resin 
was washed with DCM (20 ml) to remove any residue DMF, the resin was then treated 
with the 1% TFA/1% TIPS/DCM (~100 ml) by allowing the cleavage mixture to 
slowly flow through the column, this was continued until no orange eluent was 
observed.  To remove remaining TFA, the resin was washed with DCM (25 ml) 
followed by DMF (25 ml). 
5-FAM was then coupled to the deprotected Lys by pre-activation of 5-FAM (75 mg, 
0.2 mmol) using HOAt (27 mg, 0.2 mmol) and DIC (25 mg, 31 µl, 0.2 mmol) in DMF 
(1 ml).  This mixture was then added to the peptidyl resin, followed by intermittent 
stirring for 16 h at rt.  The resin was then washed with DMF (2.8 ml/min, 10 min), 
followed by treatment with 20% piperidine/DMF (2.8 ml/min, 20 min) and finally 
  
218 
DMF (2.8 ml/min).  N-maleoyl-ȕ-alanine (67 mg, 0.4 mmol) was then pre-activated 
with HOAt (109 mg, 0.4 mmol) and DIC (25 mg, 30 µl, 0.4 mmol) in DMF (~ 1.5 ml) 
and added to the resin followed by intermittent stirring of the resin for 3 h at rt 
followed by washing of the resin with DMF (2.8 ml/min, 10 min).    The peptidyl resin 
was collected and washed with DMF, DCM and hexane, and dried in vacuo (293.3 
mg, 74%).  The peptide was cleaved from the resin and deprotected as previously 
described using TFA-TIPS-H2O (90:2:8) for 3 h at rt followed by removal of the TFA 
in vacuo, subsequent trituration of the remaining residue using diethyl ether afforded 
an orange residue (102 mg, 83%).  Preparative HPLC (Hichrom semi-prep C18, 50 x 
21.2 mm, 25-40% B over 20 min, 4.0 ml/min, tR 9.74 min) of 6 mg crude peptide gave 
2.6 mg (43%) of the title compound as an orange solid.  HPLC: system 1; tR 4.30 min 
(purity >85%), system 2; tR 5.47 min (purity >85%)   HRMS TOF (ES+); m/z calcd. 
for C80H111N21O17S2+ [M+2H]2+ 834.9089 found 835.0024, calcd. for 
C80H111N21O17S3+ [M+3H]3+ 556.9417 found 556.8813.  
N-maleimidopropionyl arginyl glutaminyl isoleucyl lysyl isoleucyl 
tryptophyl phenylalanyl glutaminyl arginyl arginyl methionyl lysyl 
tryptophyl lysyl lysyl lysyl amide, Antp52-57 derivative, (75) 
 
The synthesis of the title compound was achieved as described for peptide 70 on a 0.1 
mmol scale (152 mg, 0.1 mmol).  However, all amino acids after residue eight were 
coupled for 6 h with each coupling step being repeated before Fmoc deprotection and 
introduction of the next amino acid residue.  Following addition of all of the residues, 
N-maleoyl-ȕ-alanine was introduced to approximately ½ of the resin (~0.05 mmol) as 
previously described for 70.  The resin was then collected and washed with DMF, 
DCM and hexane, and dried in vacuo (279 mg, 67%).  The peptidyl resin was cleaved 
and deprotected as previously described using TFA-TIPS-H2O (90:2:8) for 5 h at rt, 
followed by removal of the TFA in vacuo.  Subsequent trituration of the remaining 
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residue using diethyl ether afforded a white residue (84 mg, 105%).  Preparative 
HPLC (Chromolith Semi-prep C18 column, 100 mm x 10 mm, 20-50% B over 10 min, 
7.0 ml/min, tR 4.09 min) of 25.6 mg crude peptide gave 5.1 mg (20%) of the title 
compound as a white solid.  HPLC: system 1; tR 4.60 min (purity >85%) HRMS 
TOF (ES+); m/z calcd. for C117H188N38O23S2+ [M+2H]2+ 1263.2227 found 1263.2030, 
calcd. for C117H189N38O23S3+ [M+3H]3+ 842.4842 found 842.4617, calcd. for 
C117H190N38O23S4+ [M+4H]4+ 632.1150 found 632.0976. 
N-maleimidopropionyl (arginyl)8 -lysyl amide, octa-arginine 
derivative, (76) 
Synthesis of the title compound was 
performed on a 0.2 mmol scale (300 
mg of resin) and achieved following 
the method described for peptide 70 
with slight modification. In the first 
step, Fmoc-Lys(Mmt)-OH (513 mg, 
0.8 mmol) was pre-activated using HATU (297 mg, 0.79 mmol) and DIPEA (207 mg, 
279 µl, 1.6 mmol, DIPEA) in DMF (~ 1.5 ml) and added to the NovaGelTM Rink 
Amide resin (300 mg, 0.2 mmol) for 6 h with intermittent stirring at rt.  Each 
subsequent coupling of Fmoc-Arg(Pbf)-OH (230 mg, 0.4 mmol) was achieved by pre-
activation using O-[(1-cyano-2-ethoxy-2-oxoethylidene)amino]-oxytri(pyrrolidin-1-yl) 
SKRVSKRQLXP KH[DÀXRURSKRVSKDWH 3\2[LP® 213 (211 mg, 0.4 mmol) and DIPEA 
(103 mg, 139 µl, 0.8 mmol) in DMF (~1 ml).  This mixture was then added to the resin 
followed by intermittent stirring for 1 h at rt.  Each amino acid coupling was carried 
out twice before Fmoc deprotection.  Approximately ½ (~0.1 mmol) of the resin was 
Fmoc deprotected followed by coupling of N-maleoyl-ȕ-alanine (67 mg, 0.4 mmol) 
using HOAt (109 mg, 0.4 mmol) and DIC (25 mg, 30 µl, 0.4 mmol) in DMF (~1.5 
ml).  This mixture was added to the resin and stirred intermittently for 3 h at rt.  The 
peptidyl resin was then collected and washed with DMF, DCM and hexane, and dried 
in vacuo (391 mg, 77%).  The peptide was then cleaved and deprotected as previously 
described using TFA-TIPS-H2O (90:2:8) for 5 h at rt followed by removal of the TFA 
in vacuo.  Subsequent trituration of the remaining residue using diethyl ether afforded 
a white residue (64 mg, 53%).  Preparative HPLC (Chromlith Semi-prep C18 column, 
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100 mm x 10 mm, 1-25% B over 6 min, tR 4.43 min) of 32 mg crude peptide gave 5 
mg (15%) of the title compound as a white solid.  HPLC: system 1; tR 2.72 min 
(purity >85%), system 2; tR 4.14 min (purity >85 %). HRMS TOF (ES+): m/z calcd. 
for C61H119N36O123+ [M+3H]3+ 515.9931 found 515.9893, calcd. for C61H119N36O124+ 
[M+4H]4+ 387.2466 found 387.2472. 
N-maleimidopropionyl (arginyl)8 -(N'-fluorescein-5-carbonyl) lysyl 
amide, octa-arginine derivative, (77) 
Approximately ½ of the Fmoc 
protected resin from 76 (~0.1 
mmol) was treated with 1% 
TFA/1% TIPS/DCM (100 ml) to 
remove the Mmt protecting group 
as described for 74.  To remove 
remaining TFA, the resin was 
washed with DCM (25 ml) followed by DMF (25 ml).  5-FAM was then coupled to 
peptidyl resin as previously described for 74, followed by washing of the resin with 
20% piperidine/DMF.  N-maleoyl-ȕ-alanine was then introduced to the peptidyl resin 
as previously described for 74.  The peptidyl resin was then collected and washed with 
DMF, DCM and hexane, and dried in vacuo (332 mg, 61%).  The peptide was cleaved 
from the resin and deprotected as previously described using TFA-TIPS-H2O (90:2:8) 
for 5 h at rt, followed by removal of the TFA in vacuo.  Subsequent trituration of the 
remaining residue using diethyl ether afforded an orange residue (61 mg, 52%).  
Preparative HPLC (Chromolith Semi-prep C18 column, 100 mm x 10 mm, 1-50% B 
over 10 min, tR 5.95 min) of 37 mg crude peptide gave 11 mg (30%) of the title 
compound as an orange solid.  HPLC: system 1; tR 3.85 min (purity >95 %), system 
2; tR 5.30 min (purity >95%).  HRMS TOF (ES+): m/z calcd. for C82H129N36O183+ 
[M+3H]3+ 635.3423 found 635.6711, calcd. for C82H130N36O184+ [M+4H]4+ 476.7586 
found 477.0062. 
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N-maleimidopropionyl arginyl lysyl lysyl arginyl arginyl glutaminyl 
arginyl arginly arginyl lysyl amide, Tat49-58 derivatives, (78) 
 
Synthesis of the title compound 
was achieved following the same 
method as described for 76 on a 
0.2 mmol scale (300 mg of 
resin). After coupling of all of 
the amino acids, approximately ¼ of the resin (~0.05 mmol) was Fmoc deprotected.  
N-Maleoyl-ȕ-alanine was then introduced to the peptidyl resin as previously described.  
The peptidyl resin was then collected and washed with DMF, DCM and hexane, and 
dried in vacuo (165 mg, 62%).  The peptide was cleaved from the resin and 
deprotected as previously described using TFA-TIPS-H2O (90:2:8) for 5 h at rt 
followed by removal of the TFA in vacuo.  Subsequent trituration of remaining residue 
using diethyl ether afforded a white residue (33 mg, 66%).  Preparative HPLC 
(Chromolith Semi-prep C18 column, 100 mm x 10 mm, 1-50 B over 10 min, tR 3.64 
min) of 8.6 mg crude peptide gave 1.6 mg (19%) of the title compound as a white 
solid.  HPLC: system 1; tR 2.55 min (purity >90%). HRMS TOF (ES+): m/z calcd. 
for C66H127N34O143+ [M+3H]3+ 540.3430 found 540.0051, calcd. for C66H128N34O144+ 
[M+4H]4+ 405.2582 found 405.2563. 
N-maleimidopropionyl arginyl lysyl lysyl arginyl arginyl glutaminyl 
arginyl arginly arginyl (N'-fluorescein-5-carbonyl) lysyl amide, Tat49-
58 derivatives, (79) 
Approximately 0.07 mmol of 
Fmoc protected resin from the 
synthesis of 78 was Mmt 
deprotected using 1% TFA/1% 
TIPS/DCM (100 ml) as 
described for 74.  To remove 
remaining TFA, the resin was 
washed with DCM (25 ml) 
followed by DMF (25 ml).  5-FAM was then coupled to peptidyl resin as previously 
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described for 74, followed by washing of the resin with 20% piperidine/DMF.  N-
Maleoyl-ȕ-alanine was then introduced to the peptidyl resin as previously described.  
The peptidyl resin was then collected and washed with DMF, DCM and hexane, and 
dried in vacuo (315 mg, 86%).  The peptide was cleaved from the resin and 
deprotected as previously described using TFA-TIPS-H2O (90:2:8) for 5 h at rt, 
followed by removal of the TFA in vacuo.  Subsequent trituration of the remaining 
residue using diethyl ether afforded an orange residue (114 mg, 68%).  Preparative 
HPLC (Chromolith Semi-prep C18 column, 100 mm x 10 mm, 15-50 B over 10 min, tR 
3.72 min) of 23 mg crude peptide gave 8 mg (36%) of the title compound as an orange 
solid.  HPLC: system 1; tR 3.80 min (purity >95 %), system 2; tR 5.63 min (purity >95 
%). HRMS TOF (ES+): m/z calcd. for C87H137N34O203+ [M+3H]3+ 659.3577 found 
659.6850, calcd. for C87H138N34O204+ [M+4H]4+ 494.7701 found 495.0150. 
N-isobutyryl cysteinyl (prolyl)14 lysyl amide, Pro14 derivative, (80) 
Synthesis of 80 was achieved following the 
same method as described for 61 a 0.2 
mmol scale (300 mg of resin). Proline 
residues were introduced to the peptidyl 
resin using Fmoc-Pro-OH (270 mg, 0.8 
mmol), HATU (297 mg, 0.79 mmol) and DIPEA (207 mg, 279 µl, 1.6 mmol) in DMF 
(~ 1.5 ml).  This reaction mixture was added to the peptidyl resin as stirred 
intermittently for 3 h.  Approximately ½ of the peptidyl resin (0.1 mmol) was 
collected and then cleaved from the resin as previously described using TFA-TIPS-
H2O (90:2:8) for 3 h at rt followed by removal of the TFA in vacuo.  Subsequent 
trituration of remaining residue using diethyl ether afforded a white residue (64 mg, 
88%).  Preparative HPLC (Onyx Semi-prep Monolith C18 column, 100 mm x 10 mm, 
10-35% B over 10 min, tR 5.00 min) of 25.3 mg crude peptide gave 10.9 mg (43%) of 
the title compound as a white solid. HPLC: system 1; tR 4.72 min (purity >80%). 
HRMS TOF (ES+): m/z calcd. for C83H125N18O17S+ [M+H]+ 1678.9196 found 
1678.8091, calcd. for C83H125N18O17S2+ [M+2H]2+ 839.4629 found 839.3392. 
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N-isobutyryl cysteinyl (prolyl)14 -(N'-fluorescein-5-carbonyl) lysyl 
amide, Pro14 derivative, (81) 
Synthesis of 81 was achieved following the 
same general method as described for 63.  
Approximately ½ of the peptidyl resin from 
80 (~0.1 mmol) was labelled with 5-FAM 
as described for 63.  The peptide was then 
cleaved from the resin as previously 
described using TFA-TIPS-H2O (90:2:8) 
for 3 h at rt followed by removal of the TFA in vacuo.  Subsequent trituration of 
remaining residue using diethyl ether afforded an orange residue (61 mg, 93%).  
Preparative HPLC (Onyx Semi-prep Monolith C18 column, 100 mm x 10 mm, 10-60% 
B over 10 min, tR 7.50 min) of 52 mg crude peptide gave 14 mg (28%) of the title 
compound as an orange solid.  HPLC: system 1; tR 5.39 min (purity >90%), system 2; 
tR 6.24 min (purity >90%). HRMS TOF (ES+): m/z calcd. for C104H136N18O23S2+ 
[M+2H]2+ 1018.9885 found 1018.9812, calcd. for C104H137N18O23S3+ [M+3H]3+ 
679.6614 found 679.6570. 
N-isobutyryl-S-2-pyridylthio-cysteinyl-(prolyl)14-(N'-fluorescein-5-
carbonyl) lysyl amide, Pro14 derivative, (83) 
To a stirred solution of 81 (3 mg, 1.79 
µmol) in AcOH:H2O (2 ml, 3:1 v/v) was 
added 2,2'-dithiodipyridine (2 mg, 8.95 
µmol).  After stirring for 3 h at rt the solvent 
was evaporated to dryness in vacuo.  The 
orange residue was dissolved in H2O (2 ml) 
followed by washing with diethyl ether (3x 
2 ml) to remove all unreacted 2,2'-dithiodipyridine and the by-product 2-
mercaptopyridine to afford the title compound as an orange solid (2.5 mg, 65%).  
HPLC: system 1; tR 5.80 min (purity >75%); HRMS TOF (ES+): m/z calcd. for 
C109H139N19O23S22+ [M+2H]2+ 1073.4716 found 1073.4878, calcd. for 
C109H140N19O23S23+ [M+3H]3+ 715.9842 found 715.9943. 
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6.3 Experimental for Chapter 4 
FAM-(Orn)8-[NH2], (85) 
Rink amide NovaGelTM resin (300 
mg, 0.2 mmol) was swollen using 
DMF (1.5 ml) at rt for 1 h,  The 
resin was then washed using a 
NOVASYN® GEM manual 
peptide synthesiser with 20% 
piperidine/ DMF (2.8 ml/min, 10 
min), followed by DMF (2.8 ml/min, 10 min).  Fmoc-Orn(Boc)-OH (364 mg, 0.8 
mmol) was pre-activated using O-[(1-cyano-2-ethoxy-2-oxoethylidene)amino]-
oxytri(pyrrolidin-1-yl) phosphoniuPKH[DÀXRURSKRVSKDWH3\2[LP® 213 (422 mg, 0.8 
mmol) and DIPEA (207 mg, 279 µl, 1.6 mmol) in DMF (~ 1.5 ml).  The coupling 
mixture was added to the resin and stirred intermittently for 6 h at rt.  The peptidyl 
resin was then washed with DMF (2.8 ml/min, 5 min) to remove excess reagents, 
followed by treatment with 20% piperidine/ DMF (2.8 ml/min, 10 min) and finally 
washed with DMF (2.8 ml/min, 10 min).  This is repeated eight times to afford 
peptidyl resin 89.  
Fmoc deprotection of 89 was achieved using 20% piperidine/ DMF (2.8 ml/min, 10 
min) followed by washing the peptidyl resin with DMF (2.8 ml/min, 10 min).  The 
next step involved the pre-activation of 5-FAM (150 mg, 0.4 mmol) using HOAt (54 
mg, 0.4 mmol) and DIC (50 mg, 62 µl, 0.4 mmol) in DMF (1 ml) this mixture was 
then added to the peptidyl resin and stirred intermittently at rt for 16 h.  The peptidyl 
resin was then washed with DMF (2.8 ml/min, 10 min), followed by treatment with 
20% piperidine/ DMF (2.8 ml/min, 20 min) and finally DMF (2.8 ml/min) to afford 
peptidyl resin 90.   
Peptidyl resin 90 was transferred to a Buchner funnel and washed with DMF (20 ml), 
DCM (20 ml), hexane (20 ml), and dried in vacuo for 3 h.  The resin was then 
suspended in TFA (9 ml), TIPS (0.2 ml) and H2O (0.8 ml) for 4 h at rt.  The 
suspension was filtered and the filtrate evaporated to dryness in vacuo.  The resulting 
residue was triturated with cold diethyl ether (3 x 10 ml) to afford the title compound 
as an orange solid (182.2 mg, 71%).  Analytical RP-HPLC of the lyophilised peptide 
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showed a crude peptide of good purity (>80%), thus peptide 85 was used without 
further purification.  HPLC; system 1: tR 3.12 min (purity >80%), system 2: tR 5.55 
min (purity >80%), HRMS TOF (ES+); m/z calcd. for C61H95N17O142+ [M+2H]2+ 
644.8617 found 644.8573. 
FAM-(Orn-Ahx)8 ±[NH2], (86) 
Rink amide NovaGelTM resin 
(151 mg, 0.1 mmol) was 
swollen using DMF (1.5 ml) at 
rt for 1 h,  The resin was then 
washed using a NOVASYN® 
GEM manual peptide 
synthesiser with 20% 
piperidine/ DMF (2.8 ml/min, 10 min), followed by DMF (2.8 ml/min, 10 min). Fmoc-
6-aminohexanoic acid (141 mg, 0.4 mmol) was pre-activated using HATU (148 mg, 
0.39 mmol) and DIPEA (104 mg, 140 µl, 0.8 mmol) in DMF (~ 1.5 ml).  The coupling 
mixture was added to the resin and stirred intermittently for 6 h at rt.  The peptidyl 
resin was then washed with DMF (2.8 ml/min, 5 min) to remove excess reagents, 
followed by treatment with 20% piperidine/ DMF (2.8 ml/min, 10 min) and finally 
washed with DMF (2.8 ml/min, 10 min).  The second amino acid to introduced to the 
peptidyl resin was Fmoc-Orn(Boc)-OH (182 mg, 0.4 mmol) was pre-activated using 
HATU (148 mg, 0.39 mmol) and DIPEA (104 mg, 140 µl, 0.8 mmol) in DMF (~ 1.5 
ml).  Again the activated amino acid was added to the resin a stirred for 3 h at rt.  The 
aforementioned couplings were repeated until a total of eight ornithine residues had 
been added to the resin to afford peptidyl resin 91. 
Fmoc deprotection of 91 was achieved using 20% piperidine/DMF (2.8 ml/min, 10 
min) followed by washing the peptidyl resin with DMF (2.8 ml/min, 10 min).  The 
next step involved the pre-activation of 5-FAM (75 mg, 0.4 mmol) using HOAt (27 
mg, 0.2 mmol) and DIC (25 mg, 31 µl, 0.2 mmol) in DMF (1 ml) this mixture was 
then added to the peptidyl resin and stirred intermittently at rt for 16 h.  The peptidyl 
resin was then washed with DMF (2.8 ml/min, 10 min), followed by treatment with 
20% piperidine/DMF (2.8 ml/min, 20 min) and finally DMF (2.8 ml/min) to afford 
peptidyl resin 92. 
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Peptidyl resin 92 was transferred to a Buchner funnel and washed with DMF (20 ml), 
DCM (20 ml), hexane (20 ml), and dried in vacuo for 3 h.  The resin was then 
suspended in TFA (9 ml), TIPS (0.2 ml) and H2O (0.8 ml) for 4 h at rt.  The 
suspension was filtered and the filtrate evaporated to dryness in vacuo.  The resulting 
residue was triturated with diethyl ether as previously described followed by 
lyophilisation of the remaining residue to afford the title compound as an orange solid 
(227 mg, 111%).  The crude peptide was purified using preparative HPLC 
(Chromolith semi-prep C18 column, 100 mm x 10 mm, 15-25% B over 15 min, 7 
ml/min, tR 3.42 min) 22 mg of crude peptide gave 10 mg (46 %) of the title compound 
as an orange solid.  HPLC: system 1; tR 3.45 min (purity >95 %).  HRMS TOF 
(ES+): m/z calcd. for C109H183N25O222+ [M+2H]2+ 1097.6996 found 1097.6907, calcd. 
for C109H184N25O223+ [M+3H]3+ 732.1355 found 732.1321, calcd. for C109H185N25O224+ 
[M+4H]4+ 549.3535 found 549.3470. 
FAM-(Arg)8-[NH2], (87) 
To FAM-(Arg(di-Boc))8-[NH2] 15 
(2 mg, 0.62 mmol) was added TFA 
(1.3 ml), TIPS (50 µl) and H2O (160 
µl).  The reaction mixture was 
stirred for 2 h at rt.  The TFA was 
removed in vacuo to give an orange 
residue.  The residue was triturated 
with cold diethyl ether followed by 
purification using preparative HPLC (Chromolith Semi-prep C18 column, 100 mm x 
10 mm, 1-50% B over 10 min, tR; 5.17 min) to yield an orange solid (401 µg, 40%).  
HPLC; system 1: tR 3.47 min (purity >90 %), system 2: tR 4.85 (purity >90 %). 
MALDI-TOF MS (sinapic acid): m/z calcd. for C69H110N33O14+  1624.89 [M+H]+  
found 1625.86. 
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FAM-(Arg-Ahx)8-[NH2], (88) 
To FAM-(Arg(di-Boc)-
Ahx)8-[NH2] 98 (1 mg, 0.242 
mmol) was added TFA (1.3 
ml), triisopropylsilane (50 µl) 
and water (160 µl).  The 
reaction mixture was stirred 
for 4 h at rt.  The TFA was 
removed in vacuo to give an 
orange residue.  The residue 
was triturated with cold diethyl ether followed by purification using preparative HPLC 
(Chromolith Semi-prep C18 column, 100 mm x 10 mm, 5-70% B over, 7 ml/min, tR; 
4.49 min) to afford the title compound as an orange residue (390 µg, 56%).  HPLC: 
System 1: tR 3.88 min (purity >70 %), MALDI-TOF MS (sinapic acid); m/z calcd. 
for C117H198N41O22+ [M+H]+ 2530.57 found 2531.30.  
FAM-(Arg(Di-Boc)-Ahx)8-[NH2], (98) 
N,N'-bis(tert-butoxycarbonyl)-
S-methylthiourea 96 (5.08 mg, 
17.48 µmol) was pre-activated 
with HgCl2 (4.8 mg, 17.48 
µmol) in MeCN (1 ml).  A 
solution of DIPEA (7.6 µl, 
43.7 µmol) and FAM-(Orn-
Ahx)8-[NH2] 86 (4 mg, 1.82 
µmol) in 1 ml H2O was added 
dropwise to this solution 
followed by stirring at rt for 2 h.  The reaction solvents were evaporated to dryness in 
vacuo to afford an orange residue.  This residue was dissolved into MeCN (2 ml) and 
centrifuged at 13000 g for 20 min to give a white pellet and orange supernatant.  The 
title compound was isolated from the supernatant using preparative HPLC 
(Chromolith Semi-prep C18 column, 100 mm x 10 mm, 50-90% B over 10 min, 7 
ml/min, tR 5.99 min) and lyophilised to afford the title compound as an orange residue 
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(4.3 mg, 57%).  HPLC; System 3: tR 6.76, 7.09, 7.42, 7.76 min (purity n.d.), HRMS 
TOF (ES+); m/z calcd. for C197H328N41O543+ [M+3H]3+ 1378.1024 found 1378.1410, 
calcd. for C197H329N41O544+ [M+4H]4+ 1033.8576 found 1033.8420, calcd. for 
C197H330N41O545+ [M+5H]5+ 827.2875 found 827.2668, calcd. for C192H322N41O525+ 
[M+5H-Boc]5+ 807.2771 found 807.2635, calcd. for  C187H314N41O505+ [M+5H-
2Boc]5+ 787.2666 found 787.2573, calcd. for  C182H306N41O485+ [M+5H-3Boc]5+ 
767.0554 found 767.0530.    
FAM-(Arg(di-Boc))8 ±[NH2], (99) 
N,N'-bis(tert- 
butoxycarbonyl)-S- 
methylthiourea 96 (25.3 
mg, 87.2 µmol) was pre-
activated by the addition 
of HgCl2 (23.7 mg, 17.48 
µmol) in MeCN (5 ml).  
A solution of DIPEA 
(30.4 µl, 174.4 µmol) and 
FAM-(Orn)8-[NH2] 88 (12.0 mg, 9.10 µmol) in 5 ml H2O was added dropwise to the 
pre-activated isothiourea, followed by stirring at 50 oC for 2 h.  The reaction mixture 
was then evaporated to dryness in vacuo to afford an orange residue.  This residue was 
dissolved in MeCN (3 ml) and centrifuged at 13000 g for 20 min.  The supernatant 
was then purified using preparative HPLC (Chromolith Semi-prep C18 column, 100 
mm x 10 mm, 50-100% over 10 min, 7 ml/min, tR 8.92 min) to afford the title 
compound as an orange residue (6.8 mg, 23%).  HPLC: system 2: tR 8.95 min (purity 
>70 %), system 3: tR 9.29 min (purity >70%). HRMS TOF (ES+); m/z calcd. for 
C149H241N33O464+  [M+4H]4+ 807.4386 found 807.4263. 
 
O-(Chloromethyl)-S-ethyl ester, (109) 238 
A solution of ethanethiol (5.45 ml, 4.7 g, 78 mmol) and DIPEA 
(13.7 ml, 9.05 g, 78 mmol) in diethyl ether (20 ml) was added 
dropwise to an ethereal solution (60 ml) of chloromethyl 
chloroformate (3.6 ml, 40 mmol) at 0-4 oC with stirring.  The reaction was then 
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allowed to warm to rt and stirred for 16 h.  The reaction mixture was firstly filtered 
and the filtrate evaporated to dryness in vacuo.  The crude oil was then purified by 
passage through a silica plug (SiO2, 50% petroleum ether/ 50% ethyl acetate, Rf; 0.63) 
to afford the title compound as a clear colourless oil (11.8g, 98%), which was 
spectroscopically identical to that described in the literature.238,243  1H NMR (400 
MHz, CDCl3): įSSP+W&+2CH3, J= 7.5 Hz), 2.93 (q, 2H, CH2CH3 J= 7.3 
Hz), 5.77 (s, 2H, CH2Cl); 13C NMR (100 MHz, CDCl3): įSSP&+3), 25.71 
(CH2), 70.25 (ClCH2), 170.38 (C=O). FTIR (NaCl disc); 2976 (CH), 1723 (C=O) cm-
1
. 
O-(Iodomethyl)-S-ethyl carbonothioate (110) 238 
A solution of O-(chloromethyl)-S-ethyl ester 109 (11 g, 71 
mmol) in acetone (50 ml) was added dropwise to a solution of 
sodium iodide (21.14 g, 142 mmol) and sodium bicarbonate 
(613 mg, 7.1 mmol) in acetone (150 ml) with stirring at rt.  The reaction mixture was 
then heated to 40 oC and stirred for 4 h.  The reaction mixture was filtered and the 
precipitated sodium chloride was washed with acetone (2 x 10 ml).  The filtrate was 
evaporated to dryness in vacuo.  The resulting deep purple oil was dissolved in H2O 
(50 ml) and extracted with hexane (4 x 50 ml).  The organic phase was then washed 
with 5% NaHCO3 (1 x 50 ml), 1% Na2S2O3 (2 x 50 ml) and dried over NaSO4.  
Finally, the solvent was evaporated to dryness in vacuo to yield the title compound as 
a colourless, clear liquid (14.98 g, 88%), which was spectroscopically identical to that 
described in the literature.238,243  1H NMR (400 MHz, CDCl3): įSSP  +, t, 
CH2CH3, J= 7.5 Hz), 2.92 (2H, q, CH2CH3 J= 7.5 Hz), 5.98 (2H, s, CH2I); 13C NMR 
(100 MHz, CDCl3): įSSP CH3), 25.55 (CH2), 31.46 (CH2I) 169.90 (C=O).  
FTIR (NaCl disc); 2976 (CH), 1721 (C=O) cm-1. 
 
Isobutanoyloxymethyl-S-ethyl carbonothioate, (111) 238 
To a solution of sodium isobutyrate (4.01 g, 36 mmol) in dry 
DMF (50 ml), was added dropwise a solution of iodomethyl-
S-ethyl carbonothioate 110 (7.00 g, 28 mmol) in dry DMF 
(10 ml) at -20 oC with stirring.  The reaction mixture was allowed to warm to rt and 
stirred for 16 h.  The reaction mixture was then filtered to remove precipitated sodium 
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chloride.  The precipitate was washed with DMF (10 ml) and diethyl ether (100 ml).  
H2O (60 ml) was added to the filtrate, followed by extraction of the title compound 
with diethyl ether (4 x 40 ml).  The organic layer was isolated and washed with 5% 
NaHCO3 (50 ml), H2O (50 ml), 0.1 M HCl (50 ml), brine (50 ml) and finally dried 
over Na2SO4.  The solvent was evaporated to dryness in vacuo to afford the title 
compound as a colourless clear oil (4.57 g, 79%), which was spectroscopically 
identical to that described in the literature.243  1H NMR (400 MHz, CDCl3): įSSP
1.17 (6H, d, J= 7.0 Hz, CH(CH3)2), 1.31 (3H, t, J= 7.3 Hz, CH2CH3), 2.59 (1H, sept, 
J= 7.0 Hz, CH(CH3)2), 2.88 (2H, q, J= 7.3 Hz, CH2CH3), 5.79 (2H, s, OCH2O); 13C 
NMR (100 MHz, CDCl3): įSSP  CH3CH2), 18.54 (CH(CH3)2), 25.33 
(CH3CH2), 33.67 (CH(CH3)2), 80.27 (OCH2O), 170.60 (C=O), 175.41 (C=O).  FTIR 
(NaCl disc): 2976 (CH), 1760 (C=O), 1722 (C=O) cm-1. 
 
Pivaloyloxymethyl-S-ethyl carbonothioate, (112) 238 
To a solution of sodium pivaloate (9.68 g, 78 mmol) in 
dry DMF (80 ml) was added a solution of iodomethyl-
S-ethyl carbonothioate 110 (14.7 g, 60 mmol) in dry 
DMF (10 ml) was dropwise at -20 oC.  The reaction was allowed to warm to rt and 
stirred for 16 h.  The reaction mixture was then filtered to remove precipitated sodium 
chloride.  The precipitate was washed with DMF (20 ml) and diethyl ether (100 ml).  
H2O (60 ml) was added to the filtrate, followed by extraction of the title compound 
with diethyl ether (4 x 40 ml).  The organic layer was isolated and washed with 5% 
NaHCO3 (50 ml), H2O (50 ml), 0.1 M HCl (50 ml), brine (50 ml) and finally dried 
over Na2SO4.  The solvent was evaporated to dryness in vacuo to give the title 
compound as a clear, colourless oil (10.7 g, 82%), which was spectroscopically 
identical to that described in the literature.238,243  1H NMR (400 MHz, CDCl3): įSSP
1.20 (9H, s, C(CH3)3), 1.31 (3H, t, J= 7.4 Hz, CH2CH3), 2.88 (q, 2H, J= 7.4 Hz, 
CH2CH3), 5.79 (2H, s, OCH2O);  13C NMR (100 MHz, CDCl3):  įSSP 
(CH3CH2), 25.33 (CH3CH2), 26.75 (C(CH3)3), 38.73 (C(CH3)3), 80.50 (OCH2O), 
170.55 (C=O), 176.84 (C=O).  FTIR (NaCl disc): 2975 (CH), 1757 (C=O), 1724 
(C=O) cm-1.   
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Isobutanoyloxymethyl carbonochloridate, (113) 238  
Sulfuryl chloride (337 µl, 628 mg, 4.7 mmol) was added 
dropwise to O-(isobutanoyloxy)methyl-S-ethyl carbonothioate 
111 (770 mg, 3.9 mmol) at 0 oC with stirring.  The reaction 
mixture was then allowed to warm to room temperature with stirring for 1 h.  
Unreacted sulfuryl chloride and the by-product sulfenyl chloride were removed in 
vacuo. The crude liquid was purified using a Kugelrohr distillation apparatus.  The 
title compound was isolated at approximately 75-80 oC and 15 mbar as a light yellow 
oil with a pungent odour (190 mg, 27%), which was spectroscopically identical to that 
described in the literature.243  1H NMR (400 MHz, CDCl3): įSSP+GJ= 
7.0 Hz, CH(CH3)2), 2.60 (1H, sept, J= 7.0 Hz, CH(CH3)2), 5.82 (2H, s, OCH2O); 13C 
NMR (100 MHz, CDCl3): įSSP  &+CH3)2), 33.84 (CH(CH3)2), 80.76 
(OCH2O), 174.50 (C=O), 175.62 (C=O).  FTIR (NaCl disc): 2980 (CH), 1789 (C=O), 
1762 (C=O) cm-1. 
Pivaloyloxymethyl carbonochloridate, (114) 238 
Sulfuryl chloride (6.83 g, 4.1 ml, 50 mmol) was added to 
O-(pivaloyloxy)methyl-S-ethyl carbonothioate 112 (10.2 g, 
0.46 mol) at 0 oC.  The reaction was then allowed to warm 
to room temperature with stirring for 1 h.  The by-products 
were removed in vacuo.  The crude liquid was then purified by Kugelrohr distillation.  
The title compound was isolated at approximately 85-90 oC at 15 mbar as a clear 
yellow liquid with a pungent odour (5.34 g, 60%), which was spectroscopically 
identical to that described in the literature.238,243  1H NMR (400 MHz, CDCl3): įSSP
1.23 (s, 9H, C(CH3)3), 5.81 (s, 2H, CH2).  FTIR (NaCl disc): 2978 (CH), 1791 
(C=O), 1761 (C=O) cm-1. 
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N,N'-bis-((isobutanoyloxy)methyloxycarbonyl)-S-methylthiourea, 
(116) 147 
To a vigorously stirred solution of 2-
methyl-2-thiopseudourea hemisulfate (70 
mg, 0.5 mmol) in saturated NaHCO3 (10 
ml) was added isobutanoyloxymethyl 
carbonochloridate 111 (180 mg, 1 mmol) 
in DCM (10 ml).  After stirring at rt for 24 h the organic phase was evaporated to 
dryness in vacuo.  The crude reaction mixture was then purified by silica 
chromatography (SiO2, 30% ethyl acetate/petroleum ether, Rf; 0.30) to afford the title 
compound as a colourless clear oil (80 mg, 23%).  1H NMR (400 MHz, CDCl3): 
įSSP  + G J= 7.1 Hz, CH(CH3)2), 2.44 (3H, s, SCH3), 2.61 (2H, m, 
CH(CH3)2), 5.82 (4H, s, OCH2O), 11.73 (1H, br s, NH); 13C NMR (100 MHz, 
CDCl3): įSSP6CH3), 18.76 (CH(CH3)2), 33.88 (CH(CH3)2), 80.72 (OCH2O), 
81.30 (OCH2O), 150.33 (CSCH3), 159.69 (C=O), 159.78 (C=O), 174.47 (C=O), 
175.59 (C=O).  HRMS TOF (ES+): m/z calcd. for C14H23N2O8S+ [M+H]+ 379.1170 
found 379.119.  FTIR (KBr): 3425 (CH), 3188 (CH), 2977 (CH), 2935 (CH), 1759 
(C=O), 1661 (C=O), 1573 (C=O) cm-1. 
 
11¶-bis-((pivaloyloxy)methyloxycarbonyl)-S-methylthiourea, (117)147 
 To a vigorously stirred solution of 2-
methyl-2-thiopseudourea hemisulfate 
(1.81 g, 13 mmol) in saturated NaHCO3 
(30 ml) was added pivaloxymethyl 
carbonochloridate 114 (5 g, 26 mmol) in DCM (20 ml).  After stirring at rt for 24 h the 
organic phase was evaporated to dryness in vacuo.  The crude reaction mixture was 
purified by silica chromatography (SiO2, 20% ethyl acetate/ petroleum ether, Rf; 0.35) 
to afford the title compound as an oil that solidified on standing to give a white solid 
(2.9 g, 55%).  1H NMR (400 MHz, CDCl3): įSSPV+&&H3)3), 2.45 (s, 
3H, SCH3), 5.82 (s, 4H, OCH2O), 11.73 (br s, 1H, NH). 13C NMR (100 MHz, 
CDCl3): įSSP  6CH3), 27.02 (C(CH3)3), 38.98 (C(CH3)3), 81.17 (OCH2O) 
174.41 (C=O) 177.08 (C=O).  HRMS TOF (ES+): m/z calcd. for C16H27N2O8S+ 
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[M+H]+ 407.1483 found 407.1324.  FTIR (KBr): 3178 (CH), 2977 (CH), 2935 (CH), 
2875 (CH), 1770 (C=O), 1752 (C=O), 1733 (C=O), 1678 (C=O) cm-1. 
N,N'-bis-(ethyloxycarbonyl)-S-methylthiourea, (118) 239  
To a solution of 2-methyl-2-pseudothiourea hemisulfate 
(5.89 g, 43 mmol) in dry dichloromethane (40 ml) and 
DIPEA (16.67 g, 22.46 ml, 130 mmol) was added ethyl 
chloroformate (14 g, 12.29 ml, 130 mmol) dropwise with stirring at 0 oC.  The reaction 
mixture was then allowed to warm to rt and stirred for 16 h.  The reaction solvent was 
evaporation to dryness in vacuo to afford a yellow oil.  This crude oil was dissolved in 
DCM (50 ml) and washed with saturated NaHCO3 (3 x 50 ml), water (3 x 50 ml), 
brine (3 x 50 ml) and the dried over MgSO4.  The title compound was purified by 
silica chromatography (SiO2, 20% ethyl acetate/petroleum ether, Rf; 0.39) to afford a 
colourless clear oil (7.62 g, 76%).  1H NMR (400 MHz, CDCl3): įSSP+W
J= 7.3 Hz, CH2CH3), 2.88 (3H, s, SCH3), 5.78 (4H, q, J= 7.3 Hz, CH2CH3); 13C NMR 
(100 MHz, CDCl3): įSSP(SCH3), 18.62 (CH2CH3), 80.33 (CH2CH3), 170.66 
(C=O), 175.52 (CSCH3). HRMS TOF (ES+): m/z calcd. for C8H15N2O4S+ [M+H]+ 
235.0748 found 235.0838.  FTIR (NaCl disc): 3132 (CH), 2987 (CH), 2931 (CH), 
1752 (C=O), 1649 (C=O) cm-1. 
N,N'-bis-(isopropyloxycarbonyl)-S-methylthiourea, (119) 
To a solution of 2-methyl-2-pseudothiourea hemisulfate 
(2.65 g, 19 mmol) in dry dichloromethane (50 ml) and 
DIPEA (7.37 g, 9.9 ml, 130 mmol) was added a solution 
of 1 M isopropyl chloroformate in toluene (57 ml, 57 
mmol) at 0 oC with stirring over 30 min.  The reaction mixture was then allowed to 
warm to rt and stirred for 16 h.  The reaction solvent was evaporation to dryness in 
vacuo to afford yellow oil.  This crude oil was dissolved in DCM (50 ml) and washed 
with saturated NaHCO3 (3x 50 ml), water (3x 50 ml), brine (3x 50 ml) and the dried 
over MgSO4.  The title compound was purified by silica chromatography (SiO2, 0.5% 
MeOH/ DCM, Rf; 0.74) to afford a white solid (2.2 g, 44%).  1H NMR (400 MHz, 
CDCl3): įSSP  (6H, d, J=  6.4 Hz, CH(CH3)2), 1.32 (6H, d, J=  6.4 Hz, 
CH(CH3)2), 2.41 (3H, s, SCH3), 4.97 (2H, m, CH(CH3)2), 11.79 (1H, br s, NH); 13C 
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NMR (100 MHz, CDCl3): įSSP  6CH3), 22.15 (CH(CH3)2), 31.01 
(CH(CH3)2), 70.05 (CH(CH3)2), 71.10 (CH(CH3)2), 151.50 (C=O), 161.11 (C=O), 
172.53 (CSCH3).  HRMS TOF (ES+): m/z calcd. for C10H19N2O4S+ [M+H]+ 263.1061 
found 263.1097.  FTIR (KBr): 3145 (CH), 2981(CH), 2933 (CH), 1746 (C=O), 1644 
(C=O) cm-1.  M.pt: 45-47 oC. 
N-Fmoc-N',N''-bis((pivaloyloxy)methyloxycarbonyl)arginine, (124) 
To a solution of isothiourea 117 
(104 mg, 0.26 mmol) in DCM (1 
ml) was added sulfuryl chloride 
(52 mg, 50 µl) dropwise at 0 oC 
with stirring.  The reaction 
mixture was warmed to rt and 
stirred for 1 h.  The reaction 
solvent was then evaporated to dryness in vacuo.  The crude residue (102 mg) was 
then dissolved into DCM (0.5 ml) and added dropwise to a solution of Fmoc-Orn-OH 
(78 mg, 0.22 mmol), DIPEA (74 mg, 100 µl, 0.57 mmol) in DCM (1 ml) at 0-4 oC 
with stirring.  The reaction mixture was then warmed to rt and stirred for 16 h.  The 
reaction solvent was evaporated to dryness in vacuo followed by purification of the 
crude residue by silica chromatography (SiO2, 5% MeOH/DCM, Rf: 0.33) to afford 
the title compound as an off white solid (120.7 mg, 77%).  1H NMR (400 MHz, 
CDCl3): įSSP  + V &&+3)3), 1.67 (9H, s, C(CH3)3), 1.42-1.86 (4H, m, 
CH2CH2), 3.25-3.50 (2H, m, CH2NH), 4.16 (1H, t, J= 6.9, CH Fmoc), 4.36 (2H, d, J= 
6.9 Hz, CH2 Fmoc), 4.64 (1H, br s, CHĮ), 5.46 (4H, s, OCH2O), 7.24-7.76 (8H, m, 
Fmoc), 7.87 (1H, br s, NH), 8.45 (1H, br s, NH).  13C NMR (100 MHz, CDCl3): 
įSSP  &+2), 26.82 (C(CH3)3), 27.08 (C(CH3)3), 29.68 (CH2), 38.80 (CH2), 
47.10 (CH2CH Fmoc), 53.79 (ĮCH), 67.18 (CH2CH Fmoc), 80.48 (OCH2O), 119.98 
(CH Fmoc), 120.33 (CH Fmoc), 125.09 (CH Fmoc), 127.09 (CH Fmoc), 127.74 (CH 
Fmoc), 141.30 (quaternary C), 143.62 (quaternary C), 149.58 (quaternary C), 152.86 
(quaternary C), 156.56 (quaternary C), 177.06 (C=O), 177.51 (C=O).  HRMS TOF 
(ES+): m/z calcd. for C35H45N4O12+ [M+H]+ 713.3029 found 713.2852.  FTIR (KBr): 
3359 (CH), 2974 (CH), 1752 (C=O), 1710 (C=O).  M.pt: 79-82oC.  
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Phenylalanine methyl ester hydrochloride salt, (127) 240 
Thionyl chloride (3.87 g, 2.34 ml, 32.5 mmol) was added 
drop wise to a solution of phenylalanine (4.13 g, 25.0 
mmol) in methanol (30 ml) at 0-4 oC.  Once the addition 
was complete, the reaction was refluxed for 1 h with 
stirring.  All solvent was then removed and the product 
recrystallized from methanol/diethyl ether (2:1) to afford the title compound as white 
crystals (4.78 g, 89%).  1H NMR (400 MHz, CDOD3): įSSP-3.03 (2H, m, CH2 
benzyl), 3.78 (3H, s, OCH3), 4.33 (1H, m, CHĮ), 7.25-7.40 (5H, m, phenyl), 13C NMR 
(100 MHz, CDOD3): įSSP (CH2 benzyl), 53.53 (OCH3), 55.16 (ĮCH), 128.89 
(CH Phenyl), 130.10 (CH Phenyl), 130.40 (CH Phenyl), 135.26 (ipsoC Phenyl), 170.35 
(C=O).  HRMS TOF (ES+): m/z calcd. for C10H14NO2+ [M+H]+ 180.1019 found 
180.0858.  FTIR (KBr): 3405.95 (CH), 2855.77 (CH), 1746.91 (C=O).  M.pt: 156-
158 oC (lit.244 158-162 oC). 
N-Fmoc(N'-(tert-butoxycarbonyl)ornithyl)phenylalanine methyl ester, 
(129) 
Phenylalanine methyl ester 127 (460 mg, 2.13 mmol) 
in DMF was added dropwise to a solution of Fmoc-
Orn(Boc)-OH (1.46 g, 3.2 mmol), HATU (1.21 g, 3.2 
mmol) and DIPEA (1.13 ml, 6.39 mmol) in DMF.  The 
reaction was stirred vigorously at rt for 16 h.  DMF was 
removed in vacuo followed by precipitation of the 
desired dipeptide using ethyl acetate (30 ml).  The 
precipitate was isolated by filtration and washed with 
ethyl acetate followed by drying in vacuo to afford the title compound as a white solid 
(1.02 g, 78%).  1H NMR (400 MHz, CDCl3): įSSP+V&&H3)3), 1.47-1.93 
(4H, m, CH2CH2), 2.97-3.35 (4H, m, CH2NH, CH2 benzyl), 3.69 (3H, s, CH3O), 4.19 
(1H, m, CH2CH Fmoc), 4.25-4.44 (3H, m, CH2CH Fmoc, CHĮ Orn), 4.39 (1H, m, CHĮ 
Orn), 4.72 (1H, br s, NH), 4.80 (1H, m, CHĮ Phe), 5.60 (1H, br s, NH), 6.81 (1H, br s, 
NH), 7.08-7.80 (13H, m, phenyl, Fmoc).  13C NMR (100 MHz, CDCl3): įSSP
(CH2), 28.41 (C(CH3)3), 30.00 (CH2), 37.70 (CH2), 47.09 (CH2), 52.29, 53.35 (ĮCH), 
53.70 (ĮCH), 67.02 (CH2CO), 79.30 (C(CH3)3), 119.94 (CH) ,125.09 (CH), 125.97 
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(CH), 127.07 (CH), 127.69 (CH), 128.66 (CH), 129.19 (CH), 135.78 (ipsoC phenyl), 
141.27 (quaternary C), 143.81 (quaternary C), 156.13 (C=O), 156.46 (C=O), 171.54 
(C=O), 171.69 (C=O).  HRMS (TOF ES+): m/z calcd. for C35H42N3O7+ [M+H]+ 
616.3018 found 616.2902.  FTIR (KBr): 3342 (CH), 3062 (CH), 2970 (CH), 1740 
(C=O), 1684 (C=O), 1650 (C=O) cm-1.  M.pt: 180-182 oC. 
N-Acetyl(N'-(tert-butoxycarbonyl)ornithyl)phenylalanine methyl 
ester, (130)  
To a solution of 129 (914 mg, 1.5 mmol) in 10 ml DCM 
was added diethylamine (2 ml, 19 mmol) followed by 
stirring at rt for 3 h.  The reaction solvent and DEA were 
then evaporated to dryness in vacuo.  The crude residue 
was then dissolved into DCM (50 ml) and filtered.  To the 
filtrate was added DIPEA (10 ml, 58 mmol) and acetic 
anhydride (2.8 ml, 30 mmol), followed by stirring at rt for 
3h.  Again the reaction solvent was evaporated to dryness 
in vacuo.  The crude residue was dissolved into DCM and washed with Sat. NaHCO3 
(3 x 25 ml), 0.01 M HCl (3 x 25 ml), brine (3 x 25 ml) and dried over MgSO4.  The 
desired compound was purified by silica chromatography (SiO2, 3% MeOH/DCM, Rf; 
0.3) to afford the title compound as an off white solid (348 mg, 54%).  1H NMR (400 
MHz, CDCl3): įSSP+V&&H3)3), 1.39-1.56 (2H, m, CH2CH2), 1.71-1.81 
(2H, m, CH2CH2), 1.96 (3H, s, COCH3), 2.92-3.25 (4H, m, CH2NH, CH2 benzyl), 3.71 
(3H, s, CH3O), 4.45 (1H, m, CHĮ Orn), 4.72 (1H, m, NH), 4.73 (1H, m, CHĮ Phe), 
6.38 (1H, br m, NH), 6.87 (1H, br s, NH), 7.04-7.25 (5H, m, Phenyl). 13C NMR (100 
MHz, CDCl3): įSSP&22CH3), 26.39 (CH2), 28.40 (C(CH3)3), 29.62 (CH2), 
37.68 (CH2 phenyl), 39.47 (CH2), 52.08 (COOCH3), 52.37 (ĮCH), 53.46 (ĮCH), 79.47 
(C(CH3)3), 127.77 (CH phenyl), 128.58 (CH phenyl), 129.20 (CH phenyl), 136.83 
(ipsoC phenyl), 156.62 (C=O), 170.17 (C=O), 171.633 (C=O), 171.74 (C=O).  HRMS 
TOF (ES+): m/z calcd. for C22H33N3NaO6+ [M+Na]+ 458.2267 found 458.2262.  FTIR 
(KBr): 3344 (CH), 2983 (CH), 1740 (C=O), 1684 (C=O), 1650 (C=O) cm-1.  M.pt: 
162-164 oC. 
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N-acetyl ornithyl phenylalanine amide trifluoroacetate salt, (122) 
N-Acetyl-Orn(Boc)-Phe methyl ester 130 (340 mg, 
0.78 mmol) was dissolved into a 7 N ammonia in 
methanol (10 ml) and stirred for 16 h at rt.  The 
ammonia was then removed by blowing nitrogen 
onto the reaction mixture.  The reaction solvent was 
then evaporated to dryness in vacuo.  The crude 
residue was then Boc deprotected using 50% TFA in 
DCM (10 ml) with stirring at rt for 3 h.  The TFA and 
solvent were then evaporated to dryness in vacuo.  
The resulting residue was triturated with diethyl ether (3 x 10 ml) and the resulting 
residue lyophilised to afford the title compound as an off white residue (327 mg, 
97%).  1H NMR (400 MHz, CD3OD): įSSP-1.79 (4H, m, CH2CH2), 1.96 (3H, 
s, COCH3), 2.84-2.97 (3H, m, CH2NH, CHH benzyl), 3.16 (1H, dd, J=  5.6, 13.9 Hz, 
CHH benzyl), 4.30 (1H, m, CHĮ Orn), 4.62 (1H, dd, J=  5.6, 8.7 Hz, CHĮ Phe),  7.16-
7.32 (5H, m, phenyl); 13C NMR (100 MHz, CD3OD): įSSPCH3CO), 23.39 
(CH2), 28.20 (CH2),  37.40 (CH2),  38.72 (CH2), 52.62 (ĮCH), 54.15 (ĮCH),  126.39 
(CH
 
phenyl), 128.05 (CH phenyl), 128.96 (CH phenyl) 138.352 (ipsoC phenyl), 
173.424 (C=O), 173.607 (C=O), 175.992 (C=O).  HRMS TOF (ES+): m/z calcd. for 
C16H25N4O3+ [M+H]+ 321.1922 found 321.1732.  FTIR (KBr): 3275 (CH), 1681 
(C=O), 1640 (C=O), 1543 (C=O) cm-1.   
General Procedure for synthesis of NG-protected N-acetyl ornithyl 
phenylalanine amide (135-139) 
The isothiourea (0.07 mmol) was pre-activated with HgCl2 (16 mg, 0.06 mmol) in 
DMF (2 ml).  A solution of DIPEA (40 µl, 0.24 mmol) and N-acetyl ornithyl 
phenylalanine amide 122 (25 mg, 0.06 mmol) in 1 ml of H2O was added dropwise to 
this solution followed by stirring for 2h at rt.  The reaction solvents were then 
evaporated to dryness in vacuo to afford a white residue.  This residue was dissolved 
into MeCN:H2O (1:1, 2 ml) and centrifuged at 13000 g for 20 min to give a white 
pellet and clear supernatant.  The title compound was isolated from the supernatant 
using preparative HPLC unless otherwise stated. 
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N-Acetyl(N',N''-bis-(ethyloxycarbonyl)arginyl)phenylalanine amide, 
(135)  
The title compound was prepared according to the 
above procedure using N-acetyl-ornithyl 
phenylalanine amide 122 (25 mg, 0.06 mmol) and 
N,N'-bis-(ethyloxycarbonyl)-S-methylthiourea 118 
(14 mg, 0.06 mmol) in 3 ml DMF/H2O (3:1, v/v).  
The crude residue was purified by preparative HPLC 
(40-75%B over 10 min, 7 ml/min, Chromolith Semi-
prep C18 column, 100 mm x 10 mm, tR 5.47 min) to 
afford a white residue (13 mg, 45%).  1H NMR (400 
MHz, CD3OD): įSSP  + W J= 7.3 Hz, CH3CH2), 1.33 (3H, t, J= 7.3 Hz, 
CH3CH2), 1.41-1.70 (4H, m, CH2CH2), 1.97 (3H, s, CH3CO), 2.94 (1H, dd, J= 9.3, 
13.9 Hz, CHH benzyl), 3.20 (1H, dd, J= 5.1, 13.9 Hz, CHH
 
benzyl), 3.33 (2H, m, 
CH2NH), 4.12 (2H, q, J= 7.1 Hz, CH3CH2), 4.19 (1H, dd, J= 5.3, 7.5 Hz, CHĮOrn), 
4.27 (2H, q, J= 7.1 Hz, CH3CH2), 4.61  (1H, m, CHĮ Phe), 7.15-7.29 (5H, m).  HRMS 
TOF (ES+): m/z calcd. for C23H35N6O7+ [M+H]+ 507.2562 found 507.2606.  HPLC: 
system 1; tR 4.85 min. 
N-acetyl-(N',N''-bis-((isobutanoyloxy)methyloxycarbonyl)-arginyl)-
phenylalanine amide, (136) 
The title compound was prepared according to the 
above procedure using N-acetyl-ornithyl 
phenylalanine amide 122 (25 mg, 0.06 mmol) and 
N,N'-bis-((isobutanoyloxy)methyloxycarbonyl)-S-
methylthiourea 116 (22 mg, 0.06 mmol) in 3 ml 
DMF/ H2O (3:1, v/v).  The crude residue was 
purified by preparative HPLC (40-56% B over 5 
min, 7 ml/min, Chromolith Semi-prep C18 column, 
100 mm x 10 mm, tR 7.22 min) to afford the title 
compound as a white residue (9 mg, 22%). 1H 
NMR (400 MHz, CD3OD): įSSP+G&+&H2)3), 1.48 (2H, m, CH2CH2), 
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1.53-1.70 (2H, m, CH2CH2), 1.96 (3H, s, CH3CO), 2.54-2.67 (2H, m, 2x CH(CH2)3), 
2.93 (1H, dd, J= 9.2, 13.9 Hz, CHH benzyl), 3.23 (1H, dd, J= 5.6, 13.9 Hz, CHH 
benzyl), 3.37 (2H, t, J= 7.0 Hz, CH2NH), 4.20 (1H, dd, J= 5.9, 8.0 Hz, CHĮOrn), 4.62 
(1H, m, CHĮ Phe),  5.76 (2H, s, OCH2O), 5.85 (2H, s, OCH2O), 7.16-7.30 (5H, m, 
phenyl). HRMS TOF (ES+): m/z calcd. for C29H43N6O11+ [M+H]+ 651.2752 found 
651.2841.  HPLC: system 1; tR 6.34 min. 
N-Acetyl-(N',N''-bis-((pivaloyloxy)methyloxycarbonyl)-arginyl)-
phenylalanine amide, (137) 
The title compound was prepared according to 
the above procedure using N-acetyl-ornithyl 
phenylalanine amide 122 (25 mg, 0.06 mmol) 
and 11¶-bis-((pivaloyloxy) 
methyloxycarbonyl)-S-methylthiourea 117 (24 
mg, 0.06 mmol) in 3 ml DMF/ H2O (3:1, v/v).  
The crude residue was purified by preparative 
HPLC (40-64%B over 8 min, 7 ml/min, 
Chromolith Semi-prep C18 column, 100 mm x 
10 mm, tR 5.52 min) to afford the title 
compound as a white residue (10 mg, 23%).  1H 
NMR (400 MHz, CD3OD): įSSP+V&&H3)3), 1.22 (9H, s, C(CH3)3), 1.49 
(2H, m, CH2CH2), 1.59 (2H, m, CH2CH2), 2.73 (3H, s, CH3CO), 2.94 (1H, dd, J= 9.3, 
13.8 Hz, CHH benzyl), 3.20 (1H, dd, J= 5.5, 13.8 Hz, CHH benzyl), 3.36 (2H, t, J= 
7.29 Hz, NHCH2), 4.20 (1H, dd, J= 5.3, 8.6 Hz, CHĮ Orn), 4.64 (1H, m, CHĮ Phe), 
5.77 (2H, s, OCH2O), 5.86 (2H, s, OCH2O), 7.16-7.29 (5H, m, phenyl).  HRMS TOF 
(ES+): m/z calcd. for C31H47N6O11+ [M+H]+ 679.3298 found 679.3285.  HPLC: 
system 1; tR 6.97 min 
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N-acetyl-(N',N''-bis-(isopropyloxycarbonyl)-arginyl)phenylalanine 
amide, (138) 
The title compound was prepared according to the 
above procedure using N-acetyl-ornithyl 
phenylalanine amide 122 (25 mg, 0.06 mmol) and 
N,N'-bis-(isopropyloxycarbonyl)-S-methylthiourea 
119 (19 mg, 0.06 mmol) in 3 ml DMF/H2O (3:1, 
v/v).  The crude residue was purified by preparative 
HPLC (40-90%B over 10 min, 7 ml/min, 
Chromolith Semi-prep C18 column, 100 mm x 10 
mm, tR 6.24 min) to afford the title compound as a 
white residue (11 mg, 29%).  1H NMR (400 MHz, CD3OD): įppm; 1.29 (6H, d, J= 
6.7 Hz, CH(CH3)2), 1.33 (6H, d, J= 6.7 Hz, CH(CH3)2), 1.44-1.54 (2H, m, CH2CH2), 
1.55-1.70 (2H, m, CH2CH2), 1.97 (3H, s, SCH3), 2.94 (1H, dd, J= 9.3, 13.9 Hz, CHH  
benzyl), 3.20 (1H, dd, J= 5.4, 13.9 Hz, CHH
  
benzyl), 3.36 (2H, t, J= 7.2 Hz, NHCH2), 
4.21 (1H, dd, J= 5.9, 7.9 Hz CHĮ Orn), 4.62 (1H, m, CHĮ Phe), 4.93-5.05 (2H, m, 
CH(CH3)2, CH(CH3)2), 7.16-7.30 (5H, m, phenyl).  HRMS TOF (ES+): m/z calcd. for 
C25H39N6O7+ [M+H]+ 535.2875 found 535.2783.  HPLC; system 1: 5.41 min 
N-Acetyl-(N',N''-bis(tert-butoxycarbonyl)arginyl)phenylalanine 
amide, (139) 
The title compound was prepared 
according to the above procedure using 
N-acetyl-ornithyl phenylalanine amide 
122 (100 mg, 0.23 mmol) and  
N,N'-bis(tert-butoxycarbonyl)-S- 
methylthiourea 96 (70 mg, 0.24 mmol) 
in MeCN/H2O (1:1, v/v).  The crude 
residue was purified by silica chromatography (SiO2, 3% MeOH/DCM, Rf: 0.1 used to 
elute non-polar impurities, followed by elution of compound using 10% MeOH/DCM) 
to afford the title compound as a white residue (104 mg, 70%).  1H NMR (400 MHz, 
CD3OD): įSSP  + P &H2CH2), 1.48 (2H, m, CH2CH2), 1.54 (9H, s, 
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C(CH3)3), 1.69 (9H, s, C(CH3)3), 1.97 (3H, s, COCH3), 2.94 (1H, dd, J= 9.1, 13.8 Hz, 
CHH
 
benzyl), 3.16-3.31 (3H, m, CHH
  
benzyl, NHCH2CH2), 4.18 (1H, dd, J= 5.8, 7.8 
Hz, CHĮOrn), 4.60 (1H, dd, J= 5.2, 8.9 Hz, CHĮPhe), 7.16-7.29 (5H, m, phenyl); 13C 
NMR (100 MHz, CD3OD): įSSP CH3CO), 26.43 (CH2), 28.27 (C(CH3)3), 
28.40 (CH2 benzyl), 28.58 (C(CH)3), 29.59 (CH2), 41.28 (CH2), 55.27 (ĮCH) 55.50 
(ĮCH), 80.43 (C(CH3)3, 84.52 (C(CH3)3), 127.74 (CH phenyl), 129.45 (CH phenyl), 
130.34 (CH
 
phenyl), 138.60 (CH phenyl), 154.17 (C=O), 157.64 (C=O), 164.57 
(NHCNH2N), 173.99 (C=O), 175.93 (C=O).  HRMS TOF (ES+): m/z calcd. for 
C27H43N6O7+ [M+H]+ 563.3188 found 563.2790.  FTIR (KBr): 3321 (CH), 1672 
(C=O), 1544.  
 N-acetyl arginyl phenylalanine amide trifluoroacetate salt, (140) 
N-Acetyl-(N',N''-bis(tert-butoxycarbonyl)arginyl) 
phenylalanine amide 139 (20 mg, 0.036 mmol) was Boc 
deprotected by acidolysis using 50% TFA in DCM.  The 
reaction was stirred for 6 h at rt.  TFA and solvent were 
removed in vacuo, the resulting residue was then 
triturated with cold diethyl ether (3 x 10 ml) followed by 
lyophilisation of the remaining residue to afford the title 
compound as a white solid (10 mg, 67%).  1H NMR (400 MHz, CD3OD): įSSP
1.50 (2H, m, CH2CH2), 1.54-1.76 (2H, m, CH2CH2), 1.97 (3H, s, COCH3), 2.93 (1H, 
dd, J= 9.0, 14.2 Hz, CHH
 
benzyl), 3.13 (2H, t, J= 7.4 Hz, NHCH2), 3.18 (1H, dd, J= 
5.3, 14.2 Hz, CHH
 
benzyl), 4.26 (1H, m, CHĮOrn), 4.60-4.67 (1H, m, CHĮ Phe), 7.17-
7.38 (5H, m, phenyl). 13C NMR (100 MHz, CD32'įSSP 22.49 (CH3CO), 25.99 
(CH2), 29.84 (CH2), 38.87 (CH2 benzyl), 41.88 (NHCH2), 54.52 (ĮCH), 55.43 (ĮCH), 
127.81 (CH Phenyl), 129.45 (CH Phenyl), 130.33 (CH Phenyl), 138.43 (ipsoC Phenyl), 
145.47 (NHCNH2N), 173.63 (C=O), 176.02 (C=O).  HRMS TOF (ES+): m/z calcd. 
for C17H27N6O3+ [M+H]+ 363.2140 found 363.2146.  FTIR (KBr): 2977 (CH), 1770 
(C=O), 1752 (C=O), 1733 (C=O), 1539, 1431 cm-1.  HPLC: system 1: tR 3.10 min. 
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N-FAM-((N',N''-bis-((isobutanoyloxy)methyloxycarbonyl)-arginyl)8 
amide, (143) 
 
N,N'-bis-((isobutanoyloxy)methyloxycarbonyl)-S-methylthiourea 116 (10 mg, 26.21 
µmol) was pre-activated with HgCl2 (7 mg, 26 µmol) in DMF (3 ml).  To this solution 
was added a mixture of FAM-(Orn)8 ±[NH2] 87 (6 mg, 2.73 µmol) and DIPEA (24 µl, 
32.3 µmol) dropwise, followed by stirring of the reaction mixture at rt for 2 h.  The 
reaction solvent was then evaporated to dryness in vacuo to afford an orange residue.  
This residue was then dissolved into MeCN (2 ml) and centrifuged at 13000 g for 20 
min to give a white pellet and orange supernatant.  The title compound was isolated 
from the supernatant using preparative HPLC (Onyx Semi-prep Monolith C18 column, 
100 mm x 10 mm, 50-80% B over 6 min, 7 ml/min, tR 4.07 min) and the collected 
HPLC fraction lyophilised to afford an orange residue (3.5 mg, 33%).  HPLC: system 
1: tR 7.85 min (>85%), system 2: tR 8.97 min (>85%), HRMS TOF (ES+); m/z (%); 
719.2104 (33), 749.2119 (100), 779.1939 (47), 914.6830 (43), 1012.8709 (27), 
1251.4883 (33), 1371.5160 (63), 1393.5126 (40), 1404.5098 (20).    
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Appendix I 
 
The integrity of biotinylated human Bcl-2 (rhBcl-2) and human and mouse Bcl-xL 
(rhBcl-xL and rmBcl-xL) was determined using a standard binding ELISA and anti-
Bcl-2 and anti-Bcl-xL mAbs.  Additionally, the ability of Bcl-2 and Bcl-xL to bind to 
BID BH3 was determined using the standard phage ELISA protocol using phage 
displaying BID BH3.  The results of the binding ELISA are shown below.   
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Figure 2 15: Calibration curve for Biotinylated human Bcl-2, human Bcl-xL and 
mouse Bcl-xL.  ELISAs carried out on 96 Costar 200 µl streptavidin coated plate. a) 
incubation with anti-Bcl-2, b) incubation with anti-Bcl-xL and c) incubation with 
phagemid BH3pC6. 
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Appendix II 
 
The primers used in this thesis were synthesised by the DNA sequencing team at 
MedImmune (Cambridge, U.K). 
 
Primers: 
 
0<&¶&$$$$$&7&$7&7&$*$$*$*¶ 
 
389B5¶$*&**$7$$777&$&$&$**¶ 
 
T7 Forward: ¶7$$7$&*$&7&$&7$7$***¶ 
 
$5¶*&&*&&$&&$7*&7&7**¶ 
 
$5¶**&&****&&$7&&$*$&$7*¶ 
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Appendix III 
 
The amino acid sequences of the isolated anti-Bcl-2 and anti-Bcl-xL scFv: 
 
Cea6 
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNSPINWLRQAPGQGLEWMGSIIP
SFGTANYAQKFQGRLTITADESTSTAYMELSSLRSEDTAVYYCAGRSHNYELY
YYYMDVWGQGTMVTVSGGGGSGGGGSGGGGSDIQMTQSPSTLSASIGDRVT
ITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLT
ISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIKRAAA 
 
ScFv19 
EVQLVQSGAEARRPGSSVKVSCKASGGALRGFAINWVRQAPGQGLEYLGGIIP
LFGTTKLAQKFQDRVTVAADESTNTAYMELTGLTSEDTAVYYCARDGLQFDI
DAFDMWGRGTLVTVSGGGGSGGGGSGGGGSQSVLTQPPSVSAAPGQKVTISC
SGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGI
TGLQTGDEADYYCAAWDDSLNGWVFGGGTKLTV 
 
ScFv20 
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGII
PIFGTGNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAAYYCARENSNYDA
FDIWGQGTLVTVSGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQRVTISCSGS
SSNIGSNTVNWYQRLPGAAPQLLIYNNDQRPSGIPDRFSGSKSGTSGSLVISGL
QSEDEADYYCASWDDSLNGRVFGGGTKLTV 
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ScFv21 
EVQLVQSGGDVKKPGSSVTVSCTASGVAFSSYGISWVRQAPGQRLEWMGWII
RICSTGNYAQKLQGRVTITADESTSTAYMDMSSLTSEDTAAYYCARENSKYD
ACICGAEGQWSGGGGSGGGGSGGGGSPQJLLNQPPSPSGTPAQRVTIWSSGSS
SNIGSNTANWYQRLPGAAPQLVIYNNDQRPSGIPDRFSGSKSGTSGSLVISGLQ
SEDEADYYCASWDDSGNRGVFGGGTKLTVLEIKRAAA 
 
ScFv23 
QVQLVQSGGGVVQPGRSLRLSCAASGFTFSNYGMNWVRQAPGKGLEWVAVI
SYNGETKYYADSVQGRFTVSRDNSKNTLYLQMNSLRTEDTAMYYCAKVAGD
TPIDYWGRGTLVTVSGGGGSGGGGSGGGGSYELTQPPSASGTPGQRVTISCSG
SSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSRSGTSASLAISG
LQSEDEADYYCATWDDSLNTWPFGGGTKLTVLEIKRAAA 
 
 ScFv24 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDATTAP
FYYYMDVWGQGTMVTVSGGGGSGGGGSGGGGSAQAVLTQPSSASGTPGQR
VAISCFGSSSNIETNSVSWFQQFPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSA
SLAIRGLQSDDEADYYCAAWDDSLSGWVFGGGTKLTVLGAAA 
 
ScFv25 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARATGDPS
GYNWFDPWGRGTLVTVSGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQRVTI
SCSGSRFNIGSNTVHWYQHLPGMAPKLLIYSNNQRPSGVPDRFSGSKSGTSAS
LAISGLQSEDEADYYCAVWDDILNSWLFGGGTKLTV 
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ScFv26 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRDCSSVG
CYTSLDYWGQGTMVTVSGGGGSGGGGSGGGGSQSVLTQPPSVSGAPGQRVTI
SCTGTTSNIGAGYDVHWYQHLPGAAPKLLIYDSTNRPSGVPDRFSGSKSGTSA
SLAITGLQAEDEADYYCQSYDTRLAYVFGTGTKLTV 
 
ScFv28 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDMIRLD
WGDLSIDNWFDPWGQGTMVTVSGGGGSGGGGSGGGGSQSVLTQPPSASGTP
GQRVTISCSGGSSNIGSNTVNWYQQLPGTAPKLLIYSNNLRPSGVPDRFSGSKS
GTSASLALSELQSEDETDYYCAAWDDSLNAYVFGTGTKVTV 
 
ScFv29 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDFGNW
NYYYYYYYGMDVWGKGTMVTVSGGGGSGGGGSGGGGSLPVLTQPPSASGT
PGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSK
SGTSASLAISGLQSEHEADYFCAAWDDTLDGWVFGGGTKVTV 
 
ScFv30 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSWGA
GGVDAFDVWGRGTLVTVSGGGGSGGGGSGGGGSQAVLTQPSSVSGAPGQRV
TISCTGSSSNIGAGYDVHWYQQLPGSAPKLLIFGNNNRPSGVPDRFSGSKSGTS
VSLAITGLQAEDEADYYCQSYDNSLRGSVFGGGTKLTV 
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ScFv31 
EQQLMEYVRGLDQRGGSRRLSCSAJVFTASSOATSSIYQTTGMGQEPVSGINGI
JGSTYYADSAKGGFSMSRDNSMNRENLKNNSDRQEDTARYDYARQDRYGSG
TSCYYEQYFDVGGGRATVTVSGGGGSGGGGSGGGGSQSFLKQPPSPSRTPGQ
RVTIQSSGNRVNIGSNNAHWYQHIPGKAPNLLIYSNNQRPSGVPDRFSGSKSD
ASASLTISGVQSEDEADYYCTVWEDIENSWLFGGGTKVTV 
 
ScFv32 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRLEWL
GINYYYGMDVWGKGTMVTVSGGGGSGGGGSGGGGSQAVLTQPSSVSVAPG
KTARITCGGTDIGSKSVHWYQQKPGQAPVLVVYYDRDRPSGIPERFSGSNSGN
TATLTISRVEAEDEADYYCQVWHTVDDFRCLRRKGPKLTV 
 
ScFv42 
GVQLVQSGAEVKKPGSSVKVSCKSSGGSLRQYDISWLRQAPGQGPEWMGGIS
PSLGPANYAQKFQGRITITADEATTTVYMQLDSLTSEDTAVYFCARDPLSLYP
YFDSWGQGTMVTVSGGGGSGGGGSGGGGSQSVLTQPASVSGSPGQSITISCTG
TSSDVGGYNYVSWYQQHPGKAPKLMIYEGSKRPSGIPDRFSGSSSGNTASLTIT
GAQAEDEADYYCHSRDSSGNHVLFGGGTKLTVEIKRAAA 
 
ScFv43 
QVQLVQSGGGLVKPGGSLRLSCAACGFTFSDYYMSWIRQAPGKGLEWVSYIS
SSSSYTNYADSVKGRFTISRDNAKNSLYLQMNSVRAEDTAVYYCASWDYSSA
FDIWGRGTLVTVSGGGGSGGGGSGGGGSQSVLTQPPSVSAAPGQKVTISCSGS
TSNIGNNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNSASLDISG
LQYEEEDDYYCAAWDDSMSEFLFGTGTKLTV 
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ScFv44 
QVQLLQSAAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQGLEWMGGII
PIFGTANYAQKFQGRVTITADGSTSTAYMELSSLRSEDTAVYYCARDLWELLL
ADAFDIWGRGTLVTVSSSSGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQRV
TISCSGSSSNIGSNTVNWYQRLPGAAPQLLIYNNDQRPSGIPDRFSGSKSGTSGS
LVISGLQSEDEADYYCASWDDSLNGRVFGGGTKLTV 
 
ScFv45 
QVQLQQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGG
FDPEDGQTTYAQKFQGRVIMTEDTSTDTAYMELSRLRSEDTAVYYCATSKFL
WFGERNYFDPWGRGTLVTVSGGGGSGGGGSGGGGSSSELTQDPAVSVALGR
TVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNT
ASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTV 
 
ScFv46 
EVQLVQSGAEVKKSGESLKISCSGSGYSFATHWIGWARQLPGKGLEWVGIVFP
GDADTKYSPSFEGQVTISVDKSIGTAYLQWRSLKASDSAKYFCARLGTSGWPF
YYHYYYMDVWGRGTTVTVSGGGGSGGGGSGGGGSSSELTQDLAVSVALGQ
TVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNT
ASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTV 
 
ScFv49 
EVQLVQSGAEVKKPGSSVRVSCKASGGSLTTFPISWVRQAPGQGLEWMGRIV
PLLDITNYAQKFRGRVTLTADKSTNTVYMDVNSLTSEDTAVYYCARPSYDYW
SAYPQRNYFYHGMDVWGQGTLVTVSGGGGSGGGGSGGGGSALSSELTQDPA
VSVALGQTVRITCQGDSLRSDSANWFQQKPGQAPVLVIYGKDRRPSGIPDRIS
GSSSGNTASLTITGAHAEDEADYYCNSRDSSDTHLELFGGGTKLTVLCAAA 
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ScFv53 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSRHMSD
FWGSYLLPSGFFDVWGQGTMVTVSGGGGSGGGGSGGGGSELTQDPAVSVAL
GQTVRITCQGDSLRSYYVSWYQQKPGQAPVVVIYDKNIRPSGIPDRFSGSRSG
NTASLTITGAQAEDEADYYCSSRDSSGNFVVFGGGTKLTVEIKRAAA 
 
ScFv54 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIDCIGDF
CDSGSSSFDYWGRGTLVTVSGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQR
VTISCSGSYSNIGSNYVYWYQQLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTS
ASLAITGLQAEDEADYYCQSYDSGLWVFGGGTKLTV 
 
ScFv55 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREDCGGT
TCLGADSWGQGTMVTVSGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQRVTI
SCSGSSSNIGDNFVYWYQHLPGTAPKLLIYRDDQRPSGVPDRFSGSKSGTSVSL
AVSGLRSEDEADYYCATWDDSVRGYVFGTGTKLTV 
 
ScFv56 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESQHIV
GAAYLDYWGRGTMVTVSGGGGSGGGGSGGGGSELTQDPAVSVALGQTVRIT
CQGDSLRRYYARWYQQKPGQAPVVVMYGEKNRPSGIPDRFSGSSSGNTASLT
ITGAQADDEADYYCNSRGSSGNYLVFGGGTKLTV 
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ScFv57 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDQWLA
PFDYWGKGTTVTVSGGGGSGGGGSGGGGSYVLTQPPSASGTPGQRVTISCSG
SRSHIAGNFVYWYQHLPGTAPKLLIYQNDRRPSGVPDRFSGSQSGTSASLVISG
LRSEDEGDYYCAAWDDSLDGPVFGGGTKVTV 
 
ScFv59 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGHSGSG
WYWDHYFDHWGRGTLVTVSGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQ
RVTISCSGGGSNIGRNSVSWYQQLPGTAPKLILYSNDQRPSGVPDRFSGSKSGT
SASLAISGLRSEDEALYYCAAWDDSLTGLCLRRGTKLTV 
 
ScFv60 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGVSATY
YEPYYFDFWGRGTLVTVSGGGGSGGGGSGGGGSQAVLTQPSSVSGAPGQRV
TISCTGNISNIGAGYDVHWYQQLPGTAPKLLIFGYNNRPSGVPDRFSGSKSGTS
ASLAITGLHPEDEADYYCQSFDSSVSGSWVFGGGTKVTV 
 
ScFv61 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALSQYT
YWTGFFPTYFDSWGRGTMVTVSGGGGSGGGGSGGGGSDIQLTQSPSSLSASV
GDRVTITCRASQVIGSYLAWYQQKAGLAPKLLIYRASTLQSGVPSRFSGSGSG
TDFTLTISSLQPEDFGTYYCQQVNSYPITFGQGTRLEI 
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ScFv65 
QVQLLQSEAEVKKPGASVTVSCKASGYSFGSYAIHWLRQAPGQRLEQMGWID
VGDGSTKYSQKFQGRVTITRDTSATTAYMDLSRMRSDDTAIYYCARDSNTFW
RGFWGYYFNVWGQGTLVTVSGGGGSGGGGSGGGGSHVILTQPPSVSGAPGQ
KVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKS
GTSASVAITGLQADDEDDYYCQSYDSSMSGVVFGGGTKLTVEIKRAAA 
 
ScFv67 
QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSIS
SSSSYTYYADSVKGRFTISRDNAKNSLYLQMNNLRAEDTAVYYCARSGSSSW
YRPDDAFDIWGQGTMVTVSGGGGSGGGGSGGGGSQPVLTQPPSASGTPGQR
VIISCSGSGFNIGRNSVNWYQQLPGTAPKLLVYSDKYRPSGVPDRFSGSKSGTS
ASLAISGLQSEDEADYYCATWDDSVNAWVFGKRDPAHP 
 
ScFv68 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
GSGGSTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARGVSGFT
LPFDSWGRGTLVTVSGGGGSGGGGSGGGGSELTQDPAVSVALGQTVRITCQG
DSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLAITGA
QAEDEADYYCNSRDSSGNHVVFGGGTKVTVEIKRAAA 
 
ScFv69 
GVQLVQSGGGLVRPGESLTLSCTASGFIFNTYSMNWVRQAPGKGLEWVASAS
SSGSFKYYGDSVEDRFTISRDNAKNALFLHMNGLTAEDTAMYYCVRASYQHF
DWSPLGVDSKGTMVTVSGGGGSGGGGSGGGGSELTQDPAVSVALGQTVRIT
CQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTIT
GAQAEDEADYYCSSTGQPVVTVVFGGGTKLTV 
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ScFv70 
QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGII
PIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARETGYYDA
FDLWGRGTMVTVSGGGGSGGGGSGGGGSQSVLTQPPSASGTPGQRVTISCSG
SSSNIGSNTVNWYQRLPGAAPQLLIYNNDQRPSGIPDRFSGSKSGTSGSLVISGL
QSEDEADYYCASWDDSLNGRVFGGGTKLTV 
 
ScFv73 
GAQMVQCGAEVKKPGSSVKVSFKNFGGAFSRYGINQVRQAHGQGIEWMGGII
TIYVTGNYEQKIQDRVTMTTEESANSASMELSSVRCGDTGGYCCVRENSEYD
SVDMWGRGSLVSVSGGGGSGGGGSGGGGSLCMTQPPSAFGAPGQRVTIFCFG
RRSNLGSNNVNWYQRLPGGAPQLLFYQKINNGPQGCPGGFFCSNQGTSGSLVI
RGVQLOEEGDYYCATSEDSMNSRVFGGGNKMTV 
 
ScFv74 
AEQLVQSGGVVVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSLI
SWDGGSPYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTALYYCAKDLNY
DFWSGTGMDVWGKGTLVTVSGGGGSGGGGSGGGGSQSVLTQPASVSGSPGQ
SITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKS
GNTASLTISGLQAEDEADYYCSSYTTRSTRVFGGGTKLTV 
 
ScFv77 
QVQLVQSGGEVKRPGASVKVSCKASGYTFTTYDITWVRQAPGRGLEWMGWI
NTYNGNTKYAQTVQGRVTMSTDTSTGTAYLDLTSLRPDDTAVYYCARVSKW
DRPGYLDYWGQGTLVTVSGGGGSGGGGSGGGGSQAVLTQPSSVSGAPGQRV
TISCTGSSSNIGAGYDVQWYQQIPGTAPKVLIYNNNNRPSGVPDRFSGSKSGTT
GSLAITGLQTEDEAVYYCQSFDRRLNTMSSQSGTQLTK 
 
  
274 
scFv84 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIS
ASGTSTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYGYTFD
YWGQGTLVTVSGGGGSGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRA
SQSISSYLNWYQQKPGKAPKLIYSASALQSGVPSRFSGSGSGTDFTLTISSLQPE
DFATYYCQQYSNYPLTFGGGTKLEIKRAAA 
 
 
 
 
 
 
 
 
 
